


PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION
2001 ANNUAL MEETING



New Orleans, LA ■ May 5-10, 2001

2001 SCIENTIFIC PROGRAM COMMITTEE



Seated (left to right): Drs. McDowell, Ordorica, Butterfield, Muskin, Mega, Shafii. **1st Row Standing (left to right):** Dr. Blake, Mrs. Foulks, Drs. Ruiz, Taylor, Judge, Jayaram, Levin, Crone, Goldfinger, Cheong, Casey. **2nd Row Standing (left to right):** Drs. Dawkins, D'Alli, Wint, Foulks, Stabinsky, Groves, Cutler, Blinder, Stangler, Alessi, Spitz, Pandya, Dudley.

May 5, 2001

Dear Colleagues and Guests:

Welcome to the 154th Annual Meeting of the American Psychiatric Association, the first in the new century. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care into the future.

This year's Annual Meeting theme is "Mind Meets Brain: Integrating Psychiatry, Psychoanalysis, Neuroscience." Many sessions throughout the week will highlight an important aspect of the theme. Please make a special effort to attend the Monday afternoon Presidential Symposium, from 2:00 p.m.-5:00 p.m., entitled, "The Royal Road Revisited: Dreams in the 21st Century."

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in New Orleans. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation on Monday night at 7:30 p.m., where we will honor all those being inducted as fellows and those receiving awards from the APA. A special treat will be the William C. Menninger Convocation Lecture, presented this year by Mr. Harrison H. Schmitt, former astronaut and former Senator from New Mexico. His lecture is entitled, "A Trip to the Moon and Beyond."


Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Philip R. Muskin and the members of the Scientific Program Committee, Dr. Edward F. Foulks and Mrs. Janice Foulks and the members of the Local Arrangements Committee, and to the APA staff who work on the Annual Meeting.

Welcome to New Orleans 2001.

Sincerely,

A handwritten signature in dark ink that reads "Daniel B. Borenstein, M.D." The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

Daniel B. Borenstein, M.D.
President





American Psychiatric Association

1400 K Street, N.W.
Washington, DC 20005
Telephone 202.682.6237
Fax 202.682.6345
E-mail: apa@psych.org

May 5, 2001

154th Annual Meeting New Orleans, LA May 5-10, 2001

President

Daniel B. Borenstein, M.D.

Scientific Program Committee 2000-2001

Philip R. Muskin, M.D., *Chairperson*

Marian I. Butterfield, M.D.

Vice-Chairperson

Robert W. Baker, M.D.

David A. Casey, M.D.

Andrew J. Cutler, M.D.

Karon Dawkins, M.D.

Richard G. Dudley, M.D.

Javier I. Escobar, M.D.

Geetha Jayaram, M.D.

Sheila Judge, M.D.

Saul M. Levin, M.D.

David M. McDowell, M.D.

Lestly T. Mega, M.D.

Patricia I. Ordorica, M.D.

Regina Pally, M.D.

Pedro Ruiz, M.D.

Mohammad Shafii, M.D.

David H. Taylor, M.D.

Consultants

Lesley M. Blake, M.D.

Barton J. Blinder, M.D.

Pamela Y. Collins, M.D.

K. Roy MacKenzie, M.D.

Anand Pandya, M.D.

Edmond H.T. Pi, M.D.

Deborah Spitz, M.D.

Harvey Stabinsky, M.D., J.D.

Subcommittee on Media

Richard E. D'Alti, M.D.

Chairperson

Subcommittee on

Telecommunications

Norman E. Alessi, M.D.

Chairperson

Committee on Commercial Support

Stephen M. Goldfinger, M.D.

Chairperson

Office to Coordinate Annual Meetings

Cathy L. Nash, *Director*

(202) 682-6237

Hope Ball-Mann

Registrar

(202) 682-6092

Frank Berry

Administrative Assistant

(202) 682-6849

Vernetta V. Copeland

CME Course Coordinator

(202) 682-6836

Kendra W. Grant

Scientific Program Coordinator

(202) 682-6191

Gwynne S. Jackson

Administrator, Commercially-

Supported Activities

(202) 682-6172

Sheena L. Majette

Administrative Assistant

(202) 682-6170

Celeste M. Mele

Operations Manager

(202) 682-6237

Renee Wright-Brown

Administrative Assistant

(202) 682-6365

Dear APA Members and Guests:

Welcome to New Orleans, LA, and the 154th Annual Meeting of the American Psychiatric Association. This exciting city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the *Program Book*, you will notice a number of sessions related to the theme "Mind Meets Brain: Integrating Psychiatry, Psychoanalysis, Neuroscience," chosen by our President, Dr. Daniel B. Borenstein. Let me draw your attention to just a few of the many exciting sessions presented this week. Eric R. Kandel, M.D., one of the recipients of the 2000 Nobel Prize for Medicine, will present the Marmor Award Lecture on Monday at 9:00 a.m. Later that day, we will present the Presidential Symposium entitled, "The Royal Road Revisited: Dreams in the 21st Century." Steven E. Hyman, M.D., Director of NIMH, will present the Adolf Meyer Award Lecture on Wednesday at 9:00 a.m. He will discuss how research will approach the mind/brain integration for psychiatric diagnosis as we prepare for *DSM-V*. Drs. Gerald M. Edelman, Michael Gershon, Edithe London, Robert Sapolsky, Mark L. Solms, and Nicholas Tononi will be speaking throughout the week. A finale to the meeting will be a session not to be missed. On Thursday at 9:00 a.m., Ray Kurzweil, writer and inventor, will present a lecture that promises to collide present ideas with future technology. I encourage you to take advantage of the tremendous variety of topics and speakers over the next week.

The Local Arrangements Committee, under the excellent guidance of its Co-Chairpersons, Dr. Edward Foulks and Mrs. Janice Foulks, have developed a wide array of activities that will help you take advantage of New Orleans. You will notice that a number of activities are designed especially for families and children.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. The Convocation will begin Monday, May 7, at 7:30 p.m.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

You will note in the *Program Book* that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting.

Once again, welcome to New Orleans. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Philip R. Muskin, M.D.

Chairperson

Scientific Program Committee



APA 154th ANNUAL MEETING

New Orleans, LA ■ May 5-10, 2001

KEY LOCATIONS - CONVENTION CENTER

Administrative Office	Room 242, Level 2
<i>American Journal of Psychiatry</i>	APA Resource Center
APA Communications Center	Lobby Level
APA Resource Center	Exhibit Halls D/E/F, Lobby Level
A/V Preview Room	Room 240, Level 2
CME Course Enrollment	Exhibit Halls D/E/F, Lobby Level
Computerized Evaluation	APA Resource Center
<i>Daily Bulletin</i>	Rooms 244/245, Level 2
Education Office	Room 255, Level 2
Exhibit Office	Lobby Level
Information/Locator Center	Lobby Level
Lost & Found	Lobby Level
Meetings Management	Rooms 235/236, Level 2
Message Center	Lobby Level
On-Site Job Bank and Placement Center	APA Resource Center
<i>Psychiatric Services</i>	APA Resource Center
Registration	Exhibit Halls D/E/F, Lobby Level
Scientific Program Office	Room 237, Level 2

FIRST AID

Located on the Lobby Level (across from Exhibit Hall F), Convention Center. Hours of operation: Tuesday, May 1, through Thursday, May 10, opens one hour prior to show opening and closes one hour after the last event of the evening. This station will be manned by Registered Nurses. Information on emergency services may be found on page 4 of the *Leisure Time Activities Brochure*.

COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 5, at approximately 7:30 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule, including nighttime activities, and will conclude on Thursday, May 10, at 6:00 p.m. The Convention Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Services Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page XII for the location of hotels in relation to the Convention Center.

LOCAL ARRANGEMENTS COMMITTEE HOSPITALITY CENTER

Located on the Lobby Level, Convention Center. Hours of operation: Saturday, May 5, 12 noon-5:30 p.m.; Sunday, May 6, to Wednesday, May 9, 9:00 a.m.-5:30 p.m.; and Thursday, May 10, 9:00 a.m.-12 noon. Tickets for leisure time activities will be available at the Tour Desk also located in the Lobby Level, Convention Center.

EXHIBITS

Commercial and educational exhibits are located in Exhibit Halls D/E/F, Lobby Level, Convention Center, along with the Publishers' Bookfair and the APA Resource Center. As a convenience to registrants, the APA Resource Center and Publishers' Bookfair will open on Saturday, May 5, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 6, 11:00 a.m.-4:30 p.m.; Monday and Tuesday, May 7-8, 10:00 a.m.-6:00 p.m., and Wednesday, May 9, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday, May 9. Please refer to the *APA Exhibits Guide* for additional information on participating companies.

INFORMATION/LOCATOR CENTER

Located on the Lobby Level, Convention Center and staffed during registration hours. Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER

Located on the Lobby Level, Convention Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere at the Convention Center. Registrants whose names appear on these monitors should pick up their messages at the Center.

APA RESOURCE CENTER

Located in Exhibit Halls D/E/F, Lobby Level, Convention Center. Hours of operation will be: Saturday, May 5, 10:00 a.m.-5:00 p.m.; Sunday, May 6, 8:00 a.m.-4:30 p.m.; Monday and Tuesday, May 7-8, 10:00 a.m.-6:00 p.m.; and Wednesday, May 9, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, managed care services, APA Job Bank, and APA Periodicals.

APA JOB BANK

Located in the APA Resource Center and open during the Center's hours of operation. The all-new, on-line APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA's Annual Meeting. With new features such as résumé posting, enhanced job searching, and response tracking, the Job Bank provides the best opportunity available for career research and on-site interviews. Candidates and employers are encouraged to activate their resume and jobs postings in advance of the meeting for best results. For more information on the Job Bank go to the APA web site, www.psych.org, and click on the Job Bank icon. You may also contact us by phone (888-884-8242) or e-mail (employers@healthcareers.com) prior to the meeting, or stop by the Job Bank booth on-site.

PRESS OFFICE

Located in the APA Communications Center, Rooms 244/245, Level 2, Convention Center. Hours of operation: Saturday, May 5, 12 noon-5:00 p.m.; Sunday-Wednesday, May 6-9, 8:00 a.m.-6:00 p.m.; and Thursday, May 10, 8:00 a.m.-12 noon.

The Press Office is for the use of registered press only. All Annual Meeting sessions are open to the press except CME Courses, the Business Meeting, Clinical and Continuous Clinical Case Conferences, and Master Educator Clinical Consultations.

DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. Since the issue for Saturday/Sunday is preprinted, information cannot be added on site. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off at the APA Communications Center. The deadlines are 12 noon prior to the date of publication.

CENTER FOR INTERNATIONAL GUESTS

Bienvenidos, Willkommen, Bienvenue, Welcome!

Located in the Ile de France Ballroom, Le Meridien Hotel. Hours of operation: Saturday, May 5, through Wednesday, May 9, 8:00 a.m.-6:00 p.m.; and Thursday, May 10, from 8:00 a.m.-3:00 p.m. All international visitors are invited. These activities are supported by The Pfizer Pharmaceuticals Group.

BUSINESS CENTERS

Convention Center - Rhino Business Center

Location: Lobby F, Lobby Level

Times of operation: Monday-Sunday, 8:00 a.m.-6:00 p.m.

Hilton

Location: 2nd Floor Riverside (Across from Kabby's Restaurant)

Times of operation: Monday-Friday, 7:00 a.m.-8:00 p.m.

Saturday-Sunday, 10:00 a.m.-3:00 p.m.

Marriott

Location: Main Lobby

Times of operation: Monday-Friday, 7:00 a.m.-6:00 p.m.

Saturday-Sunday, 8:00 a.m.-5:00 p.m.

Sheraton

Location: 3rd Floor

Times of operation: Monday-Friday, 7:00 a.m.-6:00 p.m.

Saturday-Sunday, 9:00 a.m.-1:00 p.m.

REGISTRATION

ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE

Located in Exhibit Halls D/E/F, Lobby Level, Convention Center.

Hours of operation: Saturday, May 5, 10:00 a.m.-5:00 p.m.; Sunday, May 6, 7:30 a.m.-5:00 p.m.; Monday-Tuesday, May 7-8, 7:30 a.m.-6:00 p.m.; Wednesday, May 9, 7:30 a.m.-5:00 p.m.; and Thursday, May 10, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

APA MEMBERS

Full-Time Registration.....\$185.00

Members-in-Training (*Member Class MT*) 70.00

Daily Registration..... 95.00

(*all "Member" categories except Medical Students*)

Medical Students *no charge*

NONMEMBERS

Full-Time Registration.....\$650.00

Nonmember Residents, Students, Advocacy

Group Members or Mental Health Chaplains 90.00

Daily Registration (*all "Nonmember"*

categories).....330.00

Medical Students *no charge*

GUEST REGISTRATION

One only per full-time registrant 95.00

Only one guest is allowed to register with each full-time meeting registrant. *The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.*

One-Day Exhibit Hall Only Pass (18 and older) 10.00

On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived **only** for *CME Course Faculty, APA Honorary or Distinguished Fellows (does not include APA Life Fellows or Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present).*

NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS must present documentation of their qualifications to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the *Program Book, APA Exhibits Guide, and New Research Program and Abstracts Books*, and for most categories, a copy of the *Syllabus*.

NAME BADGES

Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Black-Temporary Convention Personnel.

CME COURSE ENROLLMENT

TICKET PURCHASE REQUIRED

FOR CME COURSES

Located in Exhibit Halls D/E/F, Lobby Level, Convention Center. Hours of operation: Saturday, May 5, 10:00 a.m.-5:00 p.m.; Sunday, May 6, 7:30 a.m.-5:00 p.m.; Monday through Wednesday, May 7-9, 7:30 a.m.-6:00 p.m.; and Thursday, May 10, 7:30 a.m.-2:00 p.m.

Tickets for CME Courses not sold by March 30 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 5. You must show your registration badge before you can enroll in courses.

APA ART ASSOCIATION

Located in the APA Resource Center and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

APA AUXILIARY BOOTH

Located on the Lobby Level, Convention Center. Hours of operation: Saturday, May 5, through Wednesday, May 9, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

APA PERIODICALS

Complimentary copies of the latest issues of the *American Journal of Psychiatry, Psychiatric Services, and Psychiatric News* may be obtained at the APA Periodicals Exhibit in the APA Resource Center. Staff of the *American Journal of Psychiatry* and *Psychiatric Services* will be available to answer authors' questions and to receive papers submitted for publication; six copies are required as well as a PC-compatible disk. The *American Journal of Psychiatry* and *Psychiatric Services* publish only original material not published elsewhere in any form and not being considered for publication elsewhere. Staff will also sell subscriptions to all APA journals and demonstrate on-line access for subscribers. Persons who wish to contact editors or reporters of *Psychiatric News* should inquire at the APA Administrative Office, Room 242, Level 2, Convention Center, where an editor can be paged. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

CONTINUING MEDICAL EDUCATION

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for up to 66 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions of the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Forums, Industry-Supported Symposia, most Lectures, some Media Sessions, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, Round Table Discussion, the Presidential Symposium, Review of Psychiatry, Scientific and Clinical Reports, Symposia, Telecommunication sessions, and Workshops. Other program activities are designated Category 2: Research Consultations With, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, some Media Sessions, and some Lectures. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

Please note: APA members are required to maintain their own records of CME hours. Reporting of CME credit is on an honor basis.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the *Certificate of Attendance* found in the front of the *2001 Annual Meeting CME Syllabus & Proceedings Summary Book*. Credit is earned on an hour-for-hour basis.

The *Certificate of Attendance* (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires participation in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Office of Education at the APA. Staff will be available at the Office of Education booth in the APA Resource Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. **BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES.** You can receive a parchment *Certificate of Attendance* at the Annual Meeting by returning your completed form (to the APA Administrative Staff Office, Scientific Program Office, Information/Locator Center or APA Resource Center, all located in the Convention Center) or by completing the computerized general evaluation in the APA Resource Center.

SESSION CAPACITY

We expect "sell out" attendance for many of the scientific sessions. So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Store materials under chairs to maximize seating capacity.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

Thank you for your cooperation.

AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in the Convention Center.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session **except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters.** Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. **Non-media registrants are not permitted to videotape any session** because the intrusive nature of the recording may disrupt the session.

SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.



CHILD CARE SERVICE

Drastically reduced child care costs for APA members. Limited to the first 50 children!

ACCENT on Children's Arrangements, Inc., the official youth program provider for APA, has planned an exciting on-site children's activity program called Camp APA. Camp APA offers both parents and their children a safe, nurturing, and positive experience. ACCENT's professional, specially trained supervisors are certified in both CPR and pediatric first aid. The ACCENT staff are teachers, professional child care providers, or mothers who simply love working with children and have completed ACCENT's specialized training program.

Camp APA is headquartered at the Hilton for the exclusive use of APA registrants and their families. Children aged 6 months to 17 years are welcome and will be provided with developmentally appropriate programs designed specifically for their age group. Activities will take place on site for all children under 6 years old. The older children have the option of uniquely experiencing New Orleans through sure-to-be-talked-about youth tours. On site, children will enjoy arts and crafts projects, active games, and much

more. Youth tours will depart from and return to the on-site Camp APA activity center each day.

ACCENT provides an exceptional caregiver to child ratio: 1:2 for children ages 6 months – 30 months, 1:4 ages 31 months – 4 years, 1:6 ages 4 – 6 years, and 1:8 ages 7 – 17 years.

GUIDE TO THE PROGRAM BOOK

Below, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.**

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Program Office in the Convention Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green ribbons on their badges. Please feel free to direct your questions to them.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

2002 May 18-23	Philadelphia, PA
2003 May 17-22	San Francisco, CA
2004 May 1-6	New York, NY
2005 May 21-26	Atlanta, GA
2006 May 20-25	Toronto, Canada
2007 May 19-24	San Diego, CA
2008 May 3-8	Washington, DC
2009 May 16-21	San Francisco, CA

APA CLINICAL MEETINGS

THE INSTITUTE ON PSYCHIATRIC SERVICES

2001 October 10-14	Orlando, FL
2002 October 9-13	Chicago, IL
2003 October 29-Nov. 2	Boston, MA
2004 October 6-10	Atlanta, GA
2005 October 5-9	San Diego, CA

Tentative program schedules and hotel information for the 2001 Institute on Psychiatric Services are available at the Future Meetings Booth in the APA Resource Center and the Information/Locator Center, both located in the Convention Center.

TABLE OF CONTENTS

Floor Plans for Convention Center, Hilton, Marriott, and Sheraton	VI-XI
City Map	XII
Special Acknowledgments	XIII-XIV
Format Descriptions	XV-XVI
Disclosure Information	XVII-XXIX
Saturday Sessions	1-3
Audiotape Sales Information	4
Sunday Sessions	5-12
Monday Sessions	13-37
Call for 2002 Annual Meeting Papers	38
Tuesday Sessions	39-65
2001 Institute on Psychiatric Services	66
Wednesday Sessions	67-91
Audiotape Sales Information	92
Thursday Sessions	93-107
Topic Index	108-122
Participant Index	123-133
American Psychiatric Publishing Group	134-135
Industry-Supported Symposia	136-159
APA Resource Center	Back Cover

Refer to the *APA Exhibits Guide* for information on: Exhibits, Publishers' Bookfair, Hospitality Lounge, and Dining Facilities in the Convention Center.



The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

©American Psychiatric Association.

The image displays three architectural floor plans of a building, oriented vertically. The top plan is the 'Third Level', showing a long corridor with multiple 'OPEN TO HALL' areas and a 'Ballroom Ceiling' at the bottom. The middle plan is the 'Second Level', featuring a similar layout with 'OPEN TO HALL' areas and a 'Ballroom Ceiling' at the bottom. The bottom plan is the 'Exhibit Area', showing a large hall with various rooms and corridors, including 'Hall A' (102,910 sq. ft.), 'Hall B-1' (53,228 sq. ft.), 'Hall B-2' (66,227 sq. ft.), 'Hall C' (104,862 sq. ft.), 'Hall D' (102,380 sq. ft.), 'Hall E' (137,254 sq. ft.), 'Hall F' (128,687 sq. ft.), 'Hall G' (91,451 sq. ft.), 'Hall H' (109,200 sq. ft.), 'Hall I-1' (50,400 sq. ft.), 'Hall I-2' (41,559 sq. ft.), 'Hall J' (91,080 sq. ft.), and 'Hall K' (128,687 sq. ft.). The 'Exhibit Area' plan also includes a 'PHASE III HEAVY LOAD AREA - 500 lbs. per sq. ft.' and a 'Convention Center Boulevard' at the bottom. The plans are detailed with room numbers, dimensions, and structural elements.

HILTON


#2 Poydras Street
504-561-0500




MARRIOTT

555 Canal Street
504-581-1000

3RD FLOOR BALLROOMS




2ND FLOOR EXHIBIT HALL




MARRIOTT

4TH FLOOR MEETING ROOMS




5TH FLOOR MEETING ROOMS




SHERATON

500 Canal Street
504-525-2500

Second Floor




Third Floor




Fifth Floor

SHERATON



Eighth Floor



[illegible]

DOWNTOWN HOTELS

1. **Bourbon Orleans Wyndham**
2. **Chateau Sonesta Hotel**
3. **Courtyard by Marriott-Conv. Ctr.**
4. **Courtyard by Marriott-St. Charles**
5. **DoubleTree Hotel**
6. **Embassy Suites Hotel**
7. **The Fairmont Hotel**
8. **Hampton Inn Downtown**
9. **Hampton Inn & Suites**
10. **Hilton Riverside New Orleans**
11. **Holiday Inn Select**

12. Hotel Inter-Continental
13. Hotel Monteleone
14. La Quinta Inn Downtown
15. Le Meridien
16. Le Pavillon
17. Marriott New Orleans
18. Omni Royal Orleans
19. Queen & Crescent Hotel
20. Residence Inn by Marriott
21. The Ritz Carlton
22. Sheraton New Orleans
23. Windsor Court Hotel

24. W. New Orleans
25. Wyndham Canal Place Hotel
26. Wyndham Riverfront Hotel

METAIRIE HOTELS

27. Holiday Inn
28. La Quinta Inn
29. Quality Hotel
30. Ramada Limited

SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Breakfast Symposia, "The Impulsive Aggressive Spectrum: Challenging Populations," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the Industry-Supported Symposium, "Plasticity as Efficacy? Neurotrophic Effects of Mood Stabilizers," Wednesday, May 9, 7:00 p.m.; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8 p.m.

Alza Corporation: support of the Industry-Supported Symposium, "Advances in ADHD: Navigating Comorbidity," Wednesday, May 9, 7:00 p.m.; and the registration portfolios.

American Academy of Psychiatry and the Law: co-sponsorship of the Manfred S. Guttmacher Award Lecture, Sunday, May 6, 2:30 p.m.

American Association of Psychiatric Administrators: co-sponsorship of the Administrative Psychiatry Award Lecture, Wednesday, May 9, 9:00 a.m.

American Foundation for Suicide Prevention: co-support of the Industry-Supported Symposium, "Suicide Risk and Bipolar Disorder: Neurobiology and Treatment," Saturday, May 5, 7:00 p.m.

American Psychiatric Foundation: co-support of the APA Award for Research in Psychiatry; and support of the Disaster Psychiatry Fellowship.

Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Monday, May 7, 9:00 a.m.

Association of Women Psychiatrists: support of the joint AWP/APA Women's Career reception and meeting.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, "Atypical Antipsychotic Drugs: How Do They Work?" Sunday, May 6, 1:30 p.m.; "Men, Women, and Schizophrenia: Does Anatomy Determine Destiny?" Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Comparing Atypical Antipsychotic Therapies: Making Sense of the Data," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the APA/AstraZeneca Fellowship and reception; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.

Aventis: support of the Women Residents Travel Program and Luncheon, Monday, May 7, 1:00 p.m.; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.

Bristol-Myers Squibb: support of the Industry-Supported Symposia, "Treating Psychotic Disorders: What Is the State of the Art?" Sunday, May 6, 1:30 p.m.; "Everyday Challenges in Managing Patients on Psychotropic Medications," Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Optimizing Treatment Outcomes in Patients with Chronic Depression," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the Solomon Carter Fuller Award Lecture, Tuesday, May 8, 9:00 a.m.; the Reception for the Solomon Carter Fuller Award Recipient; and the President's Dessert and Reception.

Center for Mental Health Services: sponsorship of the APA/CMHS Minority Fellowship Program; support of Practice Research Network (PRN) Annual Meeting activities; and training activities of the AIDS Education Project.

Center for Substance Abuse and Treatment: partial support of the Course, "Office-Based Treatment of Opiate Dependent Patients," Sunday, May 6, 8:00 a.m.; and support of the Practice Research Network data analysis being presented at the Annual Meeting.

Cephalon Inc.: support of the Industry-Supported Symposium, "Excessive Daytime Sleepiness: Evaluation and Management in Psychiatry," Wednesday, May 9, 7:00 p.m.

Eisai Inc., Pfizer Inc.: support of the Industry-Supported Symposium, "Recognition and Treatment of Alzheimer's Disease: Practical Lessons from New Research," Tuesday, May 8, 7:00 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, "Advances in the Treatment of Depression in Women: Beyond Clinical Lore," Saturday, May 5, 7:00 p.m.; "Critical Decisions in the Lifetime Treatment of Schizophrenia," Sunday, May 6, 8:00 a.m.; co-support of the Industry-Supported Symposium, "Providing Complete Treatment for Patients with Bipolar Disorder," Sunday, May 6, 1:30 p.m.; support of the Industry-Supported Breakfast Symposia, "Depression: Gender, Age, and Special Populations," Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the Adolf Meyer Award Lecture, Wednesday, May 9, 9:00 a.m.; the APA/Lilly Resident Research Awards; partial support of the *New Research Abstracts* and *New Research Program Books*; co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.; and support of the Daniel Freedman Congressional Fellowship.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, "The New Biology of Depression and Antidepressant Treatment," Saturday, May 5, 7:00 p.m.; "Men Over 50: An Endangered Species," Sunday, May 6, 8:00 a.m.; support of the Industry-Supported Breakfast Symposia, "Women's Mental Health: Antidepressant Therapy During the Childbearing Years," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; and co-support of the American Psychiatric Foundation Benefit Evening, Saturday, May 5, 8:00 p.m.

Glaxo Wellcome Inc.: support of the Industry-Supported Symposia, "Issues in the Long-Term Treatment of Depression," Sunday, May 6, 8:00 a.m.; "Responding to the Challenge of Treating Bipolar Disorder," Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Weighing the Options for Managing Bipolar Depression," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; and the APA/Glaxo Wellcome Fellowship Program and reception.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Monday, May 7, 9:00 a.m.

International Academy for Biomedical and Drug Research: support of the Industry-Supported Symposium, "Bipolar Spectrum Disorders: U.S. and European Perspectives," Wednesday, May 9, 7:00 p.m.

Ittleson Foundation, Inc.: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, "Glucose Control and Diabetes Mellitus During Antipsychotic Treatment," Saturday, May 5, 7:00 p.m.; "Chemical Restraints: Clinical, Research, and Ethical Implications," Sunday, May 6, 1:30 p.m.; "Psychosis of Alzheimer's Disease: New Knowledge, New Treatment Strategies," Sunday, May 6, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "A New Era for Managing

SPECIAL ACKNOWLEDGMENTS

Psychosis: Rebuilding Lives for Patients and Families," Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the American Psychiatric Institute for Research and Education/Janssen Research Scholars on Severe Mental Illness Program; and the International Leadership Dinner, Wednesday, May 9, 6:00 p.m.

Lilly Research Laboratories, a division of Eli Lilly & Company: support of the APA/Lilly Psychiatric Research Fellowship.

John D. and Catherine T. MacArthur Foundation: support of Practice Research Network (PRN) Annual Meeting activities.

Merck & Co., Inc.: support of the William C. Menninger Memorial Convocation Lecture, Monday, May 7, 7:30 p.m.; and an unrestricted educational grant in support of various scientific sessions.

National Depressive and Manic-Depressive Association: co-support of the Industry-Supported Symposium, "Providing Complete Treatment for Patients with Bipolar Disorder," Sunday, May 6, 1:30 p.m.

National Institute of Mental Health: co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Monday, May 7, 11:00 a.m.; APA Office of Research Annual Meeting activities for research trainees; and the Program for Minority Research Training in Psychiatry (PMRTP).

National Institute on Drug Abuse: support of the APA Office of Research/Research Training activities and the Drug Abuse Research Scholars in Psychiatry Program (DARSPP).

Novartis Pharmaceuticals Corporation: support of the Industry-Supported Symposia, "Meeting the Challenge of Schizophrenia and Co-Occurring Addictions," Sunday, May 6, 8:00 a.m.; and "Off-Label on the Table: Using New Pharmacological Agents," Tuesday, May 8, 7:00 p.m.

Organon Inc.: support of the Industry-Supported Symposia, "Advances in the Treatment of Geriatric Depression," Sunday, May 6, 1:30 p.m.; and "Neurobiology, Depression, and the Specificity of Treatment Response," Sunday, May 6, 7:00 p.m.

Ortho-McNeil Pharmaceuticals: support of the Industry-Supported Symposium, "An Evidence-Based Medicine Approach to Pediatric Psychiatry," Wednesday, May 9, 7:00 p.m.

Professional Risk Management Services, Inc.: support of the Manfred S. Guttmacher Award Lecture, Sunday, May 6, 2:30 p.m.

Pfizer Inc.: support of the Industry-Supported Symposia, "PTSD: Clinical Characteristics and Treatment Options," Saturday, May 5, 7:00 p.m.; "Alcoholism and Bipolar Disorder: Treatment Options Circa 2001," Sunday, May 6, 8:00 a.m.; "Moving Towards a More Comprehensive Management of Patients with Schizophrenia," Sunday, May 6, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Clinical Challenges in Anxiety," Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 7, 7:00 a.m.; the "Abstracts-On-Disk" Program; the Psychiatric Services Achievement Awards; and the APA *Daily Bulletin* newspaper.

The Pfizer Pharmaceuticals Group: support of the International Hospitality Suite, a daily visitor center for international delegates.

Pharmacia Corporation: support of the Industry-Supported Symposia, "To Switch or Augment? Contemporary Approaches to Resistant Depression," Saturday, May 5, 7:00 p.m.; "Treatment-Resistant Depression Across the Life Span," Sunday, May 6, 7:00 p.m.

Sanofi-Synthelabo, Inc.: support of the Industry-Supported Symposium, "Current and Future Management of Insomnia and Psychiatric Illnesses," Tuesday, May 8, 7:00 p.m.

Sheppard Pratt Health System: support of the Warren Williams Speaker's Awards.

SmithKline Beecham Pharmaceuticals: support of the Industry-Supported Symposia, "To Work and to Love: Focus on Quality of Life in Mood and Anxiety Disorders," Sunday, May 6, 8:00 a.m.; "Images of Anxiety: A New Look at GAD and PTSD," Tuesday, May 8, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Mood and Anxiety Disorders in Understudied Populations," Monday, May 7 and Tuesday, May 8, 7:00 a.m.; the annual contribution to the APA Presidential Fund; and the APA/SmithKline Beecham Young Faculty Award for Research Development in Biological Psychiatry.

Solvay Pharmaceuticals, Inc.: co-support of the Industry-Supported Symposium, "Suicide Risk and Bipolar Disorder: Neurobiology and Treatment," Saturday, May 5, 7:00 p.m.; support of the Industry-Supported Symposium, "Management of Anxiety: An International Perspective," Sunday, May 6, 7:00 p.m.; and the beverage service in the exhibit hall.

Somerset Pharmaceuticals, Inc.: support of the Industry-Supported Symposium, "MAOIs Revisited," Sunday, May 6, 1:30 p.m.

van Ameringen Foundation, Inc.: support of the Division of Research Annual Meeting activities for research trainees and health services researchers.

Wyeth-Ayerst Laboratories: support of the Industry-Supported Symposia, "Sleep: A Window on Mind and Brain," Saturday, May 5, 7:00 p.m.; "Symptomatic and Functional Recovery: Attainable Goals in Treating Depression?" Sunday, May 6, 8:00 a.m.; "Critical Questions in Anxiety Disorders," Sunday, May 6, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Treatment of Depression in Women: From Acute Remission to Sustained Recovery," Wednesday, May 9 and Thursday, May 10, 7:00 a.m.; the Reception to launch the Jeanne M. Spurlock Congressional Fellowship, Monday, May 7, 5:30 p.m.; the APA/Wyeth-Ayerst M.D./Ph.D. Psychiatric Research Fellowship; the Women's Resource Center and Display; the newsletter *Psychiatric Practice and Managed Care*; and the daily in-house TV program, "APA News Network."

FORMAT DESCRIPTIONS

ADVANCES IN RESEARCH

This two-hour session is traditionally chaired by the Chairperson of the Council on Research and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers presented the latest developments in four different, clinically-relevant areas of research.

CLINICAL CASE CONFERENCES

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

CONTINUOUS CLINICAL CASE CONFERENCES

The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday, beginning at 9:00 a.m.). Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

DISCUSSION GROUPS

This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS

These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

MEDIA SESSIONS

In these sessions, a videotape of educational value is shown. Videotapes may illustrate innovation in: patient assessment, diagnosis, treatment, and education; practice management, medical records, information systems, and research; professional education; public awareness and education; psychiatric interpretations of meaning in media; assessment of the biopsychosocial effects of media on individuals; social/cultural issues and mental health/illness; and the human spirit as seen in the arts and humanities.

MEDICAL UPDATES

These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH

This format allows for presentation of the very recent findings obtained from ongoing research. The three types of presentations include: Posters, which are visual, self-explanatory presentations; and Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE

This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH

This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY

There will be five, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

ROUNDTABLE

This 90-minute format is designed to establish a dialogue between psychiatrists and other citizens about controversial issues of special interest to our profession. The moderator presents a panel of experts with hypothetical scenarios that highlight controversial and problematic situations with which psychiatrists interface.

FORMAT DESCRIPTIONS

SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports (formerly Paper Sessions) are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

TELECOMMUNICATION SESSIONS

These three-hour sessions are presented in a computer software demonstration format (i.e., on computer and LCD projector provided for projection on a large screen), or a "hands-on" format limited to 30 participants. Topic areas include telepsychiatry, virtual reality, internet, electronic medical records, and information technology.

SYMPOSIA

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this *Program Book*.

WORKSHOPS

Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.



AMERICAN PSYCHIATRIC ASSOCIATION

CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if AV equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter's name, the manufacturer's name, and the page number(s) the presenter appears on in this *Program Book* are listed below:

Presenter	Manufacturer(s)	Program Page #
Gene G. Abel, M.D.	Abel Screening, Inc.	69
Hagop S. Akiskal, M.D.	International Academy for Biomedical and Drug Research	56, 86, 90, 104
Mark J. Albanese, M.D.	Janssen Pharmaceutica and Research Foundation	60
George S. Alexopoulos, M.D.	Pharmacia Corporation; Eli Lilly and Company; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Wyeth-Ayerst Laboratories; National Institute of Mental Health	11
Jonathan E. Alpert, M.D.	GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Organon Inc.; Wyeth-Ayerst Laboratories	6, 63
Steven I. Altchuler, M.D.	Psychiatrists Mutual Insurance Company	2
Lori L. Altshuler, M.D.	Abbott Laboratories; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb	9, 13, 39
Xavier Amador, Ph.D.	Novartis Pharmaceuticals Corporation	30
Michael G. Aman, Ph.D.	Ortho-McNeil Pharmaceutical; Janssen Pharmaceutica and Research Foundation	90
Jay D. Amsterdam, M.D.	Somerset Pharmaceuticals, Inc.	9, 55
Kimberly A. Arlinghaus, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals	73
Moe Armstrong, M.B.A.	Peer Educator, Project Vinfe (employee)	51
Evelyn Attia, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	58, 84
Peter M. Aupperle, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company	15
Claudia Baldessano, M.D.	GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories	13
Ross J. Baldessarini, M.D.	Solvay Pharmaceuticals, Inc.; Eli Lilly and Company	3
James C. Ballenger, M.D.	Sandoz Pharmaceuticals; Bristol-Myers Squibb; Hoffman-LaRoche; Abbott Laboratories; Pharmacia Corporation; Forest Laboratories, Inc.; Eli Lilly and Company; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Ciba Geigy Corporation, Pharmaceutical Division; Orion Pharma	64
Nigel M. Bark, M.D.	Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer, Inc.; Sanofi Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation	29
Barbara D. Bartlik, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; UroMetrics	20
Rhonda J.R. Beale, M.D.	Blue Cross/Blue Shield of Michigan	96
Ruth M. Benca, M.D.	Sanofi-Synthelabo, Inc.; Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Merck & Co., Inc.; Searle	64
Laura Berman, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc.; Proctor and Gamble; Solvay Pharmaceuticals, Inc.; UroMetrics	20
Sally A. Berry, M.D.	Janssen Pharmaceutica and Research Foundation	9
Joseph Biederman, M.D.	Alza Pharmaceuticals; Shire Richwood Pharmaceuticals; Gliatec, Inc.; Cephalon, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	77, 90
Bernard J. Biermann, M.D.	GlaxoSmithKline	18, 25
Renee L. Binder, M.D.	Janssen Pharmaceutica and Research Foundation	9, 27, 43
Pierre Blier, M.D.	Forest Laboratories, Inc.; Somerset Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Organon Inc.; Eli Lilly and Company; Pierre Fabre Medicaments	3, 9
Sandra L. Bloom, M.D.	Universal Health Services, Inc. (employer)	44
J. Alexander Bodkin, M.D.	Somerset Pharmaceuticals, Inc.	9
Michael J. Bohn, M.D.	Drug Abuse Sciences; Central Pharma	25

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Howard E. Book, M.D.	American Psychological Association Press Inc.	8
Soo Borson, M.D.	Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	67
Charles L. Bowden, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; National Institute of Mental Health; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; R.W. Johnson Pharmaceutical Institute; Sanofi Pharmaceuticals, Inc.; Stanley Foundation; UCB Pharma, Inc.	29
Theron C. Bowers, Jr., M.D.	Cadeus Medical Software	63
Kathleen T. Brady, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company	3, 32, 93, 103
Alan F. Breier, M.D.	Eli Lilly and Company (employer)	106
Richard P. Brown, M.D.	Pharmavite Corporation	41
Thomas E. Brown, Ph.D.	American Psychiatric Press Inc.; The Psychological Corporation; Novartis Pharmaceuticals Corporation; Shire Richmond Pharmaceuticals; GlaxoSmithKline	7, 27, 40
Peter F. Buckley, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica	64
Gregory C. Bunt, M.D.	Pass the Boards, Inc.	7, 24
Vivien K. Burt, M.D.	Forest Laboratories, Inc.	13, 69
Marian I. Butterfield, M.D.	Organon Inc.; Eli Lilly and Company; GlaxoSmithKline	32, 50, 51, 81, 100
Daniel J. Buysse, M.D.	Sanofi-Synthelabo, Inc.; Searle; Wyeth-Ayerst Laboratories; Cephalon	64
Joseph R. Calabrese, M.D.	GlaxoSmithKline; National Institute of Mental Health; Abbott Laboratories; Ciba Geigy Corporation, Pharmaceutical Division; Merck & Co., Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; MacArthur Foundation; National Alliance for Research in Schizophrenia and Affective Disorders; Parke-Davis, Division of Warner-Lambert Company; Robert Wood Johnson Pharmaceutical Research Institute; Sandoz Pharmaceuticals Corporation; Stanley Foundation; TAP Pharmaceuticals; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; UCB Pharma	27, 64
Mary A. Carskadon, Ph.D.	Cephalon, Inc.	90
Diana Carter, M.B.	GlaxoSmithKline	8
Daniel E. Casey, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation	11, 12, 39
David Castle, M.D.	Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation	61, 103
Dennis S. Charney, M.D.	Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Comprehensive Neuroscience; Cyberonics, Inc.; Dov Pharmaceutical; Infosciber; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Merck & Co., Inc.; Mindsense; Mitsubishi Chemical; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation GlaxoSmithKline; Solvay Pharmaceuticals, Inc.	3, 52, 62
K.N. Roy Chengappa, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	9
James C.Y. Chou, M.D.	Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Otsuka Pharmaceuticals; Bristol-Myers Squibb; Merck & Co., Inc.; Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pass the Boards, Inc.	7
Henry Chung, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company	58
Leslie L. Citrome, M.D.	Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Novartis Pharmaceuticals Corporation	49, 103
Gordon H. Clark, Jr., M.D.	Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.	88
Cathryn M. Clary, M.D.	U.S. Pharmaceuticals, Pfizer Inc. (employer)	20
Anita L.H. Clayton, M.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Bristol-Myers Squibb	6, 35, 99
Paula J. Clayton, M.D.	Merck & Co., Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.	48
Thomas G. Cobb, M.D.	GlaxoSmithKline	18
Emil F. Coccaro, M.D.	Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Abbott Laboratories	87
Lee S. Cohen, M.D.	Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Solvay Pharmaceuticals, Inc.; Organon Inc.	2, 30, 62, 67, 93
Jeremy D. Coplan, M.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb	32, 64
Leonardo Cortese, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.	1
Paul T. Costa, Jr., Ph.D.	Psychological Assessment Resources, Inc.	105
Francine Cournos, M.D.	Norton and Penguin-Plum Publishers	31, 47, 60

Presenter	Manufacturer(s)	Program Page #
M. Lynn Crismon, Pharm.D. Harry A. Croft, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc. U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Pharmacia Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Forest Laboratories, Inc.; Searle	34 55
Jeffrey L. Cummings, M.D.	Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Sanofi Pharmaceuticals, Inc.	63
Glenn W. Currier, M.D.	Janssen Pharmaceutica and Research Foundation	9
Amarendra Das, M.D.	GlaxoSmithKline	72
Jonathan R.T. Davidson, M.D.	Wyeth-Ayerst Laboratories; Warner-Lambert; Parke-Davis; Bristol-Myers Squibb; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.; Pharmacia Corporation; Hoffman-LaRoche; Lichtwer Pharma; Organon Inc.; Solvay Pharmaceuticals, Inc.	10
Jonathan S. Davine, M.D.	Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Lundbeck Canada; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Wyeth-Ayerst Laboratories	20
Mary H. Davis, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline	18, 99
Ian C. Dawe, M.D.	GlaxoSmithKline; Eli Lilly and Company	34, 97
Deborah Deas, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; GlaxoSmithKline	25
Charles DeBattista, M.D.	Pharmacia Corporation	3
Jose de Leon, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	45
Pedro L. Delgado, M.D.	Organon Inc.; National Institute of Mental Health; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Otsuka Pharmaceuticals; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Boehringer Ingelheim; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals	11
Davangere P. Devanand, M.D.	Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation	63
Mantosh J. Dewan, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.	40, 104
Lisa B. Dixon, M.D.	Novartis Pharmaceuticals Corporation	5, 44
Karl Doghramji, M.D.	Cephalon; Lorex; Devilbiss	90
Rachelle S. Doody, M.D.	Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.	63
P. Murali Doraiswamy, M.D.	GlaxoSmithKline; Merck & Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Eisai; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Bayer Corporation, Pharmaceutical Division	6
Robert E. Drake, M.D.	Novartis Pharmaceuticals Corporation	5
Wayne C. Drevets, M.D.	Pharmacia Corporation; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company	3, 71
Roxanne Dryden-Edwards, M.D.	Abbott Laboratories	25
Jacques M. Dubuis, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	102
David L. Dunner, M.D.	Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Mitsubishi; Cyberonics	67, 93
Donard S. Dwyer, Ph.D.	Janssen Pharmaceutica and Research Foundation	3
Stuart J. Eisendrath, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	19
Graham J. Emslie, M.D.	Eli Lilly and Company; Bristol-Myers Squibb; Forest Laboratories, Inc.; Organon Inc.; GlaxoSmithKline; Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	34, 67
Jean Endicott, Ph.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Boehringer-Ingelheim; Abbott Laboratories; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation	5
Elias Eriksson, Ph.D.	Forest Laboratories, Inc.; Lundbeck; GlaxoSmithKline; Bristol-Myers Squibb	13
Milton K. Erman, M.D.	Wyeth-Ayerst Laboratories; Searle; Cephalon; Takeda Pharmaceuticals; Ancile; Sanofi Pharmaceuticals, Inc.; Neurocrine Biosciences; Orphan Medical	2
Javier I. Escobar, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Bayer Corporation, Pharmaceutical Division; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; GlaxoSmithKline; Bayer Corporation, Pharmaceutical Division	78, 102, 103
Dwight L. Evans, M.D.	GlaxoSmithKline; Abbott Laboratories; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; TAP Pharmaceuticals; Wyeth-Ayerst Laboratories	39
Raymond A. Faber, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company	26, 40

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Stephen V. Faraone, Ph.D.	Alza Pharmaceuticals; Shire Richwood Pharmaceuticals; Wyeth-Ayerst Laboratories; Eli Lilly and Company	77, 90
Larry R. Faulkner, M.D.	American Board of Psychiatry and Neurology, Inc.	19
Maurizio Fava, M.D.	GlaxoSmithKline; Pharmacia Corporation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Organon Inc.; Bristol-Myers Squibb; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Lundbeck; Knoll Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals; Abbott Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Pharmavite; Lorex Pharmaceuticals; Sanofi Synthelabo Pharmaceuticals; Lichtwer Pharma	6, 11
Jan A. Fawcett, M.D.	Solvay Pharmaceuticals, Inc.	11, 33
Joel S. Feiner, M.D.	Eli Lilly and Company	56, 95
Jacqueline M. Feldman, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Zenith Goldline Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	80, 88
Stephen J. Ferrando, M.D.	Merck & Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company	31, 96
Donna Festa, C.S.W.	Westchester Medical Center-Behavioral Health Center (employer)	19
Robert L. Findling, M.D.	Ortho-McNeil Pharmaceutical; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Organon Inc.; Abbott Laboratories; Somerset Pharmaceuticals, Inc.; Shire Richwood Pharmaceuticals; Medeva; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Eli Lilly and Company	90
Lois T. Flaherty, M.D.	Merck & Co., Inc.	18
Lyle B. Forehand, Jr., M.D.	GlaxoSmithKline	18
Richard J. Frances, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Charter Behavioral; Merck & Co., Inc.; Forest Laboratories, Inc.; Human Genome Services; Schering-Plough; Aventis; Abbott Laboratories	60, 74, 97
Ellen Frank, Ph.D.	GlaxoSmithKline; McArthur Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Pfrizer Italiana; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company;	39
Frances R. Frankenburg, M.D.	Abbott Laboratories; Eli Lilly and Company	60
Matthew J. Friedman, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	62
Mark A. Frye, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline	6, 27, 55, 56
Glen O. Gabbard, M.D.	Merck & Co., Inc.	15, 51, 61
Sara K. Gardiner, M.D.	Bristol-Myers Squibb	50
David R. Gastfriend, M.D.	Bristol-Myers Squibb; Dupont Pharma; Earley Corp.	74, 87
Alan J. Gelenberg, M.D.	Bristol-Myers Squibb; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Merck Sharp & Dohme; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Hoechst Marion Roussel; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Janus Pharmaceuticals; Best Practice; Novartis Pharmaceuticals Corporation; Scios Nova Pharmaceuticals	55
Mark S. George, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Dupont Pharma; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Parke-Davis, Division of Warner-Lambert Company	15
Hertzel C. Gerstein, M.D.	Janssen Pharmaceutica and Research Foundation	3
S. Nassir Ghaemi, M.D.	Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.	33, 55, 93
Leslie H. Gise, M.D.	Merck Medco Managed Care	22, 50
Alexander H. Glassman, M.D.	Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Eli Lilly and Company	11
William M. Glazer, M.D.	Novartis Pharmaceuticals Corporation; Eli Lilly and Company; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb	5, 63
Ira D. Glick, M.D.	Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Johnson and Johnson; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb	26, 67, 93
Donald C. Goff, M.D.	Cortex Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	83
Robert M. Goisman, M.D.	GlaxoSmithKline	1
Joseph F. Goldberg, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Shire Richwood Pharmaceuticals; Pharmacia Corporation	6, 9, 55, 100
Robert N. Golden, M.D.	Bristol-Myers Squibb; Carolina Behavioral Health Alliance, LLC; Foundation of Hope for Research and Treatment of Mental Illness; National Depressive and Manic-Depressive Association; National Institute of Mental Health; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Searle; U.S. Pharmaceuticals, Pfizer Inc.	8

Presenter	Manufacturer(s)	Program Page #
David B. Goldenberg, M.D.	Dupont Pharma	101
Stephen M. Goldfinger, M.D.	Eli Lilly and Company; Zenith Goldline Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	80
Patricia S. Goldman-Rakic, Ph.D.	AstraZeneca Pharmaceuticals	9
R. Jeffrey Goldsmith, M.D.	Schering-Plough; Roche Laboratories, a member of the Roche Group; GlaxoSmithKline; Wyeth-Ayerst Laboratories	19, 46
Jill M. Goldstein, Ph.D.	AstraZeneca Pharmaceuticals	64
Karl Goodkin, M.D.	Pharmacia Corporation; GlaxoSmithKline; Merck & Co., Inc.; Advance Immunet; Phylomed	101
Frederick K. Goodwin, M.D.	Solvay Pharmaceuticals, Inc.; Abbott Laboratories; GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Scios Nova Pharmaceuticals	3, 55, 81, 104
Guy M. Goodwin, M.D.	Eli Lilly and Company; GlaxoSmithKline; International Academy for Biomedical and Drug Research; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lundbeck; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pierre Fabre	64, 90
Jack M. Gorman, M.D.	Wyeth-Ayerst Laboratories; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; National Institute of Mental Health; NARSAD; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Lundbeck; Solvay Pharmaceuticals, Inc.; Merck & Co., Inc.; Synthelabo; International Academy for Biomedical and Drug Research	5, 30, 64
Tana A. Grady-Weliky, M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	32, 44
Kevin F. Gray, M.D.	Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation	26, 63
John F. Greden, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; World Heritage Foundation; MIRA	16, 29, 106
Alan I. Green, M.D.	Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Otsuka Pharmaceuticals	5
Michael F. Green, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc.	12
David J. Greenblatt, M.D.	Sanofi Pharmaceuticals, Inc.; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Searle; Lorex	64
Laurence L. Greenhill, M.D.	Alza Pharmaceuticals; Shire Richwood Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Medeva	77, 85
John H. Greist, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Organon Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Boehringer Ingelheim; Sanofi Pharmaceuticals, Inc.	106
Carlos M. Grilo, Ph.D.	National Institute of Mental Health; National Institutes of Health; Eli Lilly and Company; Donaghue Medical Research Foundation	83
Mark S. Groves, M.D.	GlaxoSmithKline	18
Goran Hajak, M.D.	Sanofi-Synthelabo, Inc.	64
Uriel Halbreich, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Berlex	49
Robert E. Hales, M.D.	Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation	13, 39
Ellen Haller, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	19, 68
Thomas E. Hansen, M.D.	Sanofi Pharmaceuticals, Inc.; Abbott Laboratories; Hoechst Marion Roussel; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	8
David J. Hellerstein, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.; Dista Products; Wyeth-Ayerst Laboratories	48
David C. Henderson, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	3
Victoria Hendrick, M.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company; National Depressive and Manic-Depressive Association; Forest Laboratories, Inc.	39
Robert M.A. Hirschfeld, M.D.	Bristol-Myers Squibb; Abbott Laboratories; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation	13, 39, 57
Jimmie C. Holland, M.D.	Eli Lilly and Company	36
Eric Hollander, M.D.	Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; Eli Lilly and Company	11, 14, 39
Ron Honberg, J.D.	Eli Lilly and Company	25
Douglas H. Hughes, M.D.	Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.	9, 72
Michael Y. Hwang, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company	102
Steven E. Hyman, M.D.	Forest Laboratories, Inc.	3, 70
Richard S. Jackson, M.D.	Bristol-Myers Squibb; Forest Laboratories, Inc.; Organon Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	40, 104
Kay R. Jamison, Ph.D.	Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Eli Lilly and Company	2, 18, 45, 81

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Philip G. Janicak, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.; Genotech	1
James W. Jefferson, M.D.	Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Forest Laboratories, Inc.; GlaxoSmithKline; Eli Lilly and Company; Organon Inc.; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Warner-Lambert; Novartis Pharmaceuticals Corporation; Scios Nova Pharmaceuticals; TAP Pharmaceuticals; Searle; Pharmacia Corporation; Wyeth-Ayerst Laboratories; Healthcare Technology Systems, LLC	8, 67, 93
Dilip V. Jeste, M.D.	Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation	8, 64
David C. Jimerson, M.D.	Knoll Pharmaceutical Company	7, 105
Hadine Joffe, M.D.	Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Society for Women's Health	2, 30
Russell T. Joffe, M.D.	GlaxoSmithKline; Eli Lilly Canada; Wyeth-Ayerst Laboratories; Lundbeck Canada	13, 104
Lewis L. Judd, M.D.	International Academy for Biomedical and Drug Research; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company	90
Jeffrey P. Kahn, M.D.	Work Psych. Associates, Inc.	88
Eric R. Kandel, M.D.	Memory Pharmaceuticals	16
John M. Kane, M.D.	Abbott Laboratories; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company	30
Shitij Kapur, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	9
Roger G. Kathol, M.D.	Cartesian Solutions	16
Ira R. Katz, M.D.	Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Bristol-Myers Squibb; Sanofi Pharmaceuticals, Inc.; Eli Lilly and Company; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	11
Walter H. Kaye, M.D.	Biogenesis U.S., Ltd.	31, 84, 105
Terence M. Keane, Ph.D.	Janssen Pharmaceutica and Research Foundation	9
Paul E. Keck, Jr., M.D.	Abbott Laboratories; Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation	8, 9, 56, 63
Richard S.E. Keefe, Ph.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	5
Gabor I. Keitner, M.D.	GlaxoSmithKline; Organon Inc.; Wyeth-Ayerst Laboratories; Merck & Co., Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Abbott Laboratories	6
Martin B. Keller, M.D.	Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories; Merck & Co., Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; Pharmacia Corporation; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Mitsubishi Pharmaceuticals; Scirex	13
Ronald C. Kessler, Ph.D.	Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline	10
Terence A. Ketter, M.D.	Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company	8, 27, 90
Steven A. King, M.D.	Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Purdue	53
Brian Kirkpatrick, M.D.	Novartis Pharmaceuticals Corporation; Eli Lilly and Company	83
Herbert D. Kleber, M.D.	Schering-Plough	7, 32, 60
Richard Kogan, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb	18, 46, 58
Robert Kohn, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Organon Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.	22
Rebecca A. Kornbluh, M.D.	GlaxoSmithKline	18
Susan G. Kornstein, M.D.	Eli Lilly and Company; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Pharmacia Corporation; Forest Laboratories, Inc.; Mitsubishi-Tokyo; Biovail Laboratories; Wyeth-Ayerst Laboratories; Berlex	2, 35, 39
Thomas R. Kosten, M.D.	Schering Pharmaceuticals	7
K. Ranga R. Krishnan, M.D.	Forest Laboratories, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Merck & Co., Inc.; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Organon Inc.	6, 63
Meir H. Kryger, M.D.	Wyeth-Ayerst Laboratories	2
John H. Krystal, M.D.	GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company	105
Elisabeth J. S. Kunkel, M.D.	Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.	35

Presenter	Manufacturer(s)	Program Page #
David J. Kupfer, M.D.	Forest Laboratories, Inc.; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	52, 106
Helen H. Kyomen, M.D.	Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation	50
Lawrence A. Labbate, M.D.	GlaxoSmithKline; Eli Lilly and Company; Forest Laboratories, Inc.	55
Raymond W. Lam, M.D.	Pfizer Canada; Eli Lilly Canada; Uplift Canada	8
Timothy Lambert, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Sanofi Pharmaceuticals, Inc.; Lundbeck; Kendall	1
William B. Lawson, M.D.	Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	45, 62
Harold E. Lebovitz, M.D.	Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; GlaxoSmithKline; Aventis; Bayer Corporation, Pharmaceutical Division; Bayer Corporation, Pharmaceutical Division; Amylin; U.S. Pharmaceuticals, Pfizer Inc.	3
Ellen Leibenluft, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories	27, 69
Lydia J. Lewis	Eli Lilly and Company; Abbott Laboratories; Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	9, 50, 59
Jeffrey A. Lieberman, M.D.	Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Hoechst Marion Roussel; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation	5, 8, 106
Michael R. Liebowitz, M.D.	Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Bristol-Myers Squibb; Merck & Co., Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Pharmacia Corporation	11
Michael Linden, M.D.	Janssen-Cilag; Oranon-Akzo-Nobel	59
Jean-Pierre Lindenmayer, M.D.	Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	19
Paul S. Links, M.D.	GlaxoSmithKline	60, 97
Barbara K. Lipska, Ph.D.	AstraZeneca Pharmaceuticals	9
Wilson M. Lit, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Ortho-McNeil; AstraZeneca Pharmaceuticals Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.	45
Lance P. Longo, M.D.	Abbott Laboratories; Bristol-Myers Squibb; Lipha Pharmaceuticals	25
Juan F. Lopez, M.D.	Pharmacia Corporation	3
Constanine G. Lyketsos, M.D.	Dupont Pharma; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Neurologic, Inc.	11, 15, 20, 56, 57
Avram H. Mack, M.D.	Bristol-Myers Squibb	44
Gerald A. Maguire, M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories	5
Mark W. Mahowald, M.D.	Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Cephalon	2
Husseini K. Manji, M.D.	GlaxoSmithKline; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Pharmacia Corporation; AstraZeneca Pharmaceuticals; Organon Inc.; Solvay Pharmaceuticals, Inc.; Merck & Co., Inc.; Millenium; Oxford Glycosides; Chiron	64, 90
J. John Mann, M.D.	Solvay Pharmaceuticals, Inc.	2, 34
Lauren B. Marangell, M.D.	Pharmacia Corporation; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Martek Biosciences; Cyberonics; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.; Bristol-Myers Squibb; Abbott Laboratories; GlaxoSmithKline	3, 5
Donatella Marazziti, M.D.	Solvay Pharmaceuticals, Inc.	1, 11
Stephen R. Marder, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; Lundbeck; Bristol-Myers Squibb	1, 30, 67, 93
John C. Markowitz, M.D.	Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; National Institute of Mental Health; Pritzker Research Network; Basic Books; American Psychiatric Press Inc.; Franco Angeli	6
Charles R. Marmar, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.	3, 32
Randall D. Marshall, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb	23, 32, 52, 53, 74, 102,
Rick A. Martinez, M.D.	Johnson and Johnson	106
Christine E. Marx, M.D.	Eli Lilly and Company	43
Prakash S. Masand, M.D.	Pharmacia Corporation; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Bristol Myers Squibb; Hoechst Marion Roussel; Novartis Pharmaceuticals Corporation; Searle; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	11
Barbara J. Mason, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc.; Lipha Pharmaceuticals; Dupont Pharma	6

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
John D. Matthews, M.D.	Eli Lilly and Company	78
Helen S. Mayberg, M.D.	Forest Laboratories, Inc.; Eli Lilly and Company	3
Laurel Mayer, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	58, 84
Robert W. McCarley, M.D.	Cephalon	90
David M. McDowell, M.D.	Bristol-Myers Squibb; Wyeth-Ayerst Laboratories	32, 33, 75, 102
Susan L. McElroy, M.D.	Wyeth-Ayerst Laboratories; International Academy for Biomedical and Drug Research; Abbott Laboratories; Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Alza Pharmaceuticals	11, 56, 90
Alexander McFarlane, M.D.	GlaxoSmithKline; Solvay Pharmaceuticals, Inc.	84
Patrick D. McGorry, Ph.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	67
Patrick J. McGrath, M.D.	Pharmacia Corporation; GlaxoSmithKline; Drug Abuse Sciences; Somerset Pharmaceuticals, Inc.	11
Jacqueline Melonas, J.D.	Professional Risk Management Services, Inc.; APA-sponsored Professional Liability Program	44, 81
Herbert Y. Meltzer, M.D.	Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Merck & Co., Inc.	3, 5
Alan J. Mendelowitz, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	12, 13
Julien Mendlewicz, M.D.	International Academy for Biomedical and Drug Research	90
Ricardo P. Mendoza, M.D.	Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.	45, 79
Matthew A. Menza, M.D.	Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company	85
Emmanuel Mignot, M.D.	Wyeth-Ayerst Laboratories; Cephalon	2
Alexander L. Miller, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.	34
Jacobo E. Mintzer, M.D.	Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	11, 15, 50, 79
Shaila Misri, M.D.	GlaxoSmithKline; Pharmacia Corporation; Bristol-Myers Squibb Canada	8, 83
James E. Mitchell, M.D.	Knoll Pharmaceuticals; Eli Lilly and Company	7, 31, 105
Perry Molinoff, M.D.	Bristol-Myers Squibb	20
Stuart A. Montgomery, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Lundbeck; Wyeth-Ayerst Laboratories; Orion; Roche Laboratories, a member of the Roche Group; Pharmacia Corporation; Merck & Co., Inc.; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Pierre Fabre; Sanofi Pharmaceuticals, Inc.; Lichtwer Pharma; Innapharra; Almirall	67
Leslie C. Morey, Ph.D.	National Institutes of Health; National Institute of Mental Health	83
Philip Morgan, Ph.D.	GlaxoSmithKline (employer)	20
Charles Muntaner, M.D.	University of Maryland (employer)	72
Greer M. Murphy, M.D.	Organon Inc.	9
Robin M. Murray, M.B.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.	29
Dominique L. Musselman, M.D.	GlaxoSmithKline; National Institutes of Health; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Schering-Plough; Dana Foundation	39
Hugh Myrick, M.D.	Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.	6, 90
Joseph C. Napoli, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline	71
Henry A. Nasrallah, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; National Institute of Mental Health	39, 49, 61, 63
J. Craig Nelson, M.D.	Organon Inc.; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Wyeth-Ayerst Laboratories	9
Charles B. Nemeroff, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Merck & Co., Inc.; Mitsubishi; Neurocrine Biosciences; Otsuka Pharmaceuticals; Solvay Pharmaceuticals, Inc.	9, 56, 63
Eric J. Nestler, M.D.	Forest Laboratories, Inc.	3
John W. Newcomer, M.D.	Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; AstraZeneca Pharmaceuticals	3

Presenter	Manufacturer(s)	Program Page #
Cassandra F. Newkirk, M.D.	Bristol-Myers Squibb; GlaxoSmithKline	96
Donald J. Newport, M.D.	Wyeth-Ayerst Laboratories; Eli Lilly and Company; GlaxoSmithKline	93
Andrew A. Nierenberg, M.D.	Pharmacia Corporation; Somerset Pharmaceuticals, Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; Eli Lilly and Company; Lichtwer Pharma; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	3, 9, 50
Carol S. North, M.D.	GlaxoSmithKline; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company	53, 79
Colleen J. Northcutt, M.D.	Servier Pharmaceutical, France	79
Kristin J. O'Dell, M.D.	GlaxoSmithKline	72
Mark Olsson, M.D.	Wyeth-Ayerst Laboratories; Eli Lilly and Company; GlaxoSmithKline; Freedom From Fear	11
Lewis A. Opler, M.D.	Multi-Health Systems, Inc.	25, 40, 74, 103
Maria A. Oquendo, M.D.	Solvay Pharmaceuticals, Inc.	78, 87
Patricia I. Ordorica, M.D.	Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	46, 60, 99
Michael W. Otto, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Psychological Corp.; Ancile	93
Barbara L. Parry, M.D.	Wyeth-Ayerst Laboratories	2
Robert D. Patterson, M.D.	Mental Health Connections, Inc.	71
Debra Patton, R.N.	Schering-Plough; Roche Laboratories, a member of the Roche Group	46
Teri B. Pearlstein, M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	2
Diana O. Perkins, M.D.	Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Hoechst Marion Roussel; U.S. Pharmaceuticals, Pfizer Inc.	5, 63, 64
Katharine A. Phillips, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Gate Pharmaceuticals; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; GlaxoSmithKline	21, 61, 79, 83
Edmond H.T. Pi, M.D.	Eli Lilly and Company	45, 50
Daniel S. Pine, M.D.	Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories	52, 71, 85
Mark H. Pollack, M.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.	5, 67, 93
Bruce G. Pollock, M.D.	Organon Inc.; National Institute of Mental Health; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Pharmacia Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Lundbeck; Janus Pharmaceuticals	9
Robert M. Post, M.D.	Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Johnson and Johnson; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Pharmacia Corporation; AstraZeneca Pharmaceuticals; Bayer Corporation, Pharmaceutical Division	55, 86, 104
David W. Preven, M.D.	Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	19, 77
Andres J. Pumariega, M.D.	Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.	44, 56, 89
Frederick M. Quitkin, M.D.	Organon Inc.	79
Giorgio Racagni, Ph.D.	International Academy for Biomedical and Drug Research	90
Luis F. Ramirez, M.D.	Otsuka Pharmaceuticals; Organon Inc.; TAP Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company	41
Paul M. Ramirez, Ph.D.	Multi-Health Systems, Inc.	40
Neal G. Ranen, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eisai Inc.; Janssen Pharmaceutica and Research Foundation	85
Mark H. Rapaport, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Sanofi Pharmaceuticals, Inc.; Pharmacia Corporation; Organon Inc.; Wyeth-Ayerst Laboratories	5
Judith H.L. Rapoport, M.D.	Bristol-Myers Squibb; Ortho-McNeil; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Richmond; Novartis Pharmaceuticals Corporation	8, 91
Valerie Davis Raskin, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Merck & Co., Inc.; GlaxoSmithKline	100
William E. Reichman, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb	15, 57
Mark A. Riddle, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Quintiles Pacific; Best Practice; Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Shire Richwood Pharmaceuticals	85
Robert G. Robinson, M.D.	Daichi Pharmaceutical Co.	85
Catherine A. Roca, M.D.	Wyeth-Ayerst Laboratories	58, 93
Mercedes M. Rodriguez, M.D.	AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	22, 100

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Steven P. Roose, M.D.	Forest Laboratories, Inc.; Organon Inc.; GlaxoSmithKline; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Eli Lilly and Company	6, 11, 21
Raymond C. Rosen, Ph.D.	Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; TAP Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company	6
Jerrold F. Rosenbaum, M.D.	Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Eli Lilly and Company; Organon Inc.; Lichtwer Pharma; Wyeth-Ayerst Laboratories; Pharmacia Corporation; Millennium Pharmaceuticals	3, 63
Kenneth P. Rosenberg, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	22
Erik J. Roskes, M.D.	GlaxoSmithKline	96
Barbara O. Rothbaum, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc.	3
David R. Rubinow, M.D.	Thera Tech; Bristol-Myers Squibb; Woman's Pharmacy of Madison Wisconsin; Janus Pharmaceuticals; Berlex Pharmaceuticals	30, 58
A. John Rush, M.D.	Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Abbott Laboratories; Cyberonics; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Robert Wood Johnson Foundation; Meadows Foundation; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Stanley Foundation; AstraZeneca Pharmaceuticals; Merck & Co., Inc.; Mitsubishi Pharmaceuticals; Yamanouchi, Inc.	5, 13, 34, 59, 106
Donna H. Ryan, M.D.	Wyeth-Ayerst Laboratories; Knoll Pharmaceuticals; Boots Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Amgen; Bristol-Myers Squibb; Ergo; GlaxoSmithKline; Parke-Davis, Division of Warner-Lambert Company; Regeneron Pharmaceuticals; Schering-Plough	76
Neal D. Ryan, M.D.	Wyeth-Ayerst Laboratories; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Abbott Laboratories	34
Gary S. Sachs, M.D.	GlaxoSmithKline; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Scios Nova Pharmaceuticals; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Solvay Pharmaceuticals, Inc.; Sanofi Pharmaceuticals, Inc.; Bristol-Myers Squibb; Parke-Davis, Division of Warner-Lambert Company	13, 39, 57, 106
Harold A. Sackeim, Ph.D.	Organon Inc.	11, 71
Martha Sajatovic, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.	41
Cynthia W. Santos, M.D.	Janssen Pharmaceutica and Research Foundation	23
Lawrence D. Scahill, M.D.	Ortho-McNeil	91
Michael A. Scharf, M.D.	GlaxoSmithKline	18
Alan F. Schatzberg, M.D.	Organon Inc.; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; Pharmacia Corporation; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Corcept Therapeutics, Inc.	9, 11
Peter J. Schmidt, M.D.	Thera Tech; Bristol-Myers Squibb; Women's Pharmacy of Madison, Wisconsin; Berlex Pharmaceuticals	30
Lon S. Schneider, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Abbott Laboratories	11, 56
Nina R. Schooler, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation	11, 12, 103
Marcia Scott, M.D.	Prudential Insurance (employer)	72
Mary V. Seeman, M.D.	AstraZeneca Pharmaceuticals	64
Stuart N. Seidman, M.D.	Forest Laboratories, Inc.; U.S. Pharmaceuticals, Pfizer Inc.	6, 22
David Shaffer, M.D.	Solvay Pharmaceuticals, Inc.	3, 76
Zafar Sharif, M.D.	Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.	19
Rajiv P. Sharma, M.D.	Parke-Davis, Division of Warner-Lambert Company; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company	1
Shawn C. Shea, M.D.	GlaxoSmithKline	7
David V. Sheehan, M.D.	Wyeth-Ayerst Laboratories; GlaxoSmithKline; Abbott Laboratories; AstraZeneca Pharmaceuticals; Boehringer Ingelheim; Boots Pharmaceuticals; Bristol-Myers Squibb; Burroughs Wellcome; Charter Hospitals; Ciba Geigy Corporation, Pharmaceutical Division; Dista Products; Eli Lilly and Company; Excerpta Medica Asia; Hospital Corporation of America; Humana; ICI; Kali-Duphar; Marion Merrill Dow; Mc Neil Pharmaceuticals; Mead Johnson; Merck Sharp & Dohme; Organon Inc.; Novo Nordisk; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Rhone-Poulenc Rorer Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Roerig; Sandoz; Schering Corporation; Solvay Pharmaceuticals, Inc.; TAP Pharmaceuticals; TGH-University Psychiatry Center; American Medical Association; Anclote Foundation; Eisai Inc.; Forest Laboratories, Inc.; International Clinical Research; Janssen Pharmaceutica and Research Foundation; National	

Presenter	Manufacturer(s)	Program Page #
Richard C. Shelton, M.D.	Institute of Drug Abuse; National Institutes of Health; Novartis Pharmaceuticals Corporation; Quintiles; Sanofi Pharmaceuticals, Inc.; Warner Chilcott	10, 31, 64
Alan P. Siegal, M.D.	Janssen Pharmaceutica and Research Foundation	93
	Abbott Laboratories; Eisai Inc.; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; AstraZeneca Pharmaceuticals	67
Linmarie Sikich, M.D.	Eli Lilly and Company; Ortho-McNeil Pharmaceutical	5, 91
Kenneth R. Silk, M.D.	Forest Laboratories, Inc.	52, 60, 85
Michael A. Silver, M.D.	Eli Lilly and Company; Zenith Goldline Pharmaceuticals	78
Naomi M. Simon, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	93
Samuel G. Siris, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.	102
Gary W. Small, M.D.	Forest Laboratories, Inc.; Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Searle; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Dupont Pharma; GlaxoSmithKline	6, 63
Michael W. Smith, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Otsuka Pharmaceuticals	52
Joseph M. Smurda, M.D.	GlaxoSmithKline	18
Lionel P. Solursh, M.D.	U.S. Pharmaceuticals, Pfizer Inc.	97
Steven M. Southwick, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation	3
Thomas J. Spencer, M.D.	Alza Pharmaceuticals; Medeva; GlaxoSmithKline; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Richwood Pharmaceuticals	35, 90
Stephen M. Stahl, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Boehringer Ingelheim; Yamanouchi; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Roche Laboratories, a member of the Roche Group; Ciba Geigy Corporation, Pharmaceutical Division; Pharmacia Corporation; Hoechst Marion Roussel; Abbott Laboratories; Organon Inc.; Sanofi Pharmaceuticals, Inc.; Pierre Fabre; Lorex; Sumitomo; Watson Laboratories, Inc.; Neurocrine; Lundbeck; Sanao; Searle; Solvay Pharmaceuticals, Inc.; Takeda Pharmaceuticals; Fabre-Kramer; AstraZeneca Pharmaceuticals	20
Dan J. Stein, M.D.	MRC Unit on Anxiety Disorders (employer)	32
Murray B. Stein, M.D.	Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Hoffman-LaRoche; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Pharmacia Corporation	11, 57
Hans Steiner, M.D.	Abbott Laboratories; U.S. Pharmaceuticals, Pfizer Inc.	39
Donna E. Stewart, M.D.	Eli Lilly and Company	21, 50, 53, 83
Nada L. Stotland, M.D.	Solvay Pharmaceuticals, Inc.; U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; Procter & Gamble	15, 26, 45, 72, 79, 100
Zachary N. Stowe, M.D.	Forest Laboratories, Inc.; GlaxoSmithKline; Eli Lilly and Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.; Warner-Lambert	13, 39, 62
James J. Strain, M.D.	Compumco, 1000	44
Stephen M. Strakowski, M.D.	Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Otsuka Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline	14
David L. Sultzer, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation	15
Patricia Suppes, M.D.	Abbott Laboratories; Bristol-Myers Squibb; U.S. Pharmaceuticals, Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pharmaceutica; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Pharmaceutical Research Institute	6, 34, 57, 64
Alan C. Swann, M.D.	Abbott Laboratories; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Pharmacia Corporation; Shire Richwood Pharmaceuticals; Robert Wood Johnson	14, 63, 99
Holly A. Swartz, M.D.	GlaxoSmithKline; Ortho-McNeil Pharmaceutical, Inc.	5
Robert M. Swift, M.D.	Dupont Pharma; U.S. Pharmaceuticals, Pfizer Inc.; Lipha Pharmaceuticals; OY Contral Pharma.	25
Rajiv Tandon, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.	1, 13, 39
Rosemary Tanneck, Ph.D.	Eli Lilly and Company	35

DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Pierre N. Tariot, M.D.	Eisai Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Pharmacia Corporation; Eli Lilly and Company; Berlex; Schwabe; AstraZeneca Pharmaceuticals; Bayer Corporation, Pharmaceutical Division; Lundbeck; Sanofi Pharmaceuticals, Inc.	15, 63, 90
David H. Taylor, M.D.	GlaxoSmithKline	41, 19
Clifton R. Tennison, Jr., M.D.	Eli Lilly and Company; GlaxoSmithKline; AstraZeneca Pharmaceuticals	87
Michael E. Thase, M.D.	Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Organon Inc.; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Wyeth-Ayerst Laboratories; Lipha Pharmaceuticals, Inc.; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Sanofi Pharmaceuticals, Inc.	5, 14, 57, 64, 106
Troy L. Thompson II, M.D.	GlaxoSmithKline	70
Jean L. Tignol, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline	22
Martin G. Tracy, J.D.	Professional Risk Management Services, Inc.	44
Madhukar H. Trivedi, M.D.	Abbott Laboratories; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Johnson and Johnson; Mead Johnson; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Solvay Pharmaceuticals, Inc.	19, 34, 59
L. Lee Tynes, M.D.	Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline	41
Amy M. Ursano, M.D.	GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.	18
Bessel A. Van Der Kolk, M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.	52, 84
Sanjeev Venkataraman, M.D.	Organon Inc.; Forest Laboratories, Inc.	40
Adele C. Viguera, M.D.	Wyeth-Ayerst Laboratories; Eli Lilly and Company	67, 93
Benedetto Vitiello, M.D.	Solvay Pharmaceuticals, Inc.	11, 85
Karen D. Wagner, M.D.	GlaxoSmithKline; Bristol-Myers Squibb; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.	13, 39, 63
John T. Walkup, M.D.	GlaxoSmithKline; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation	13, 85
B. Timothy Walsh, M.D.	Eli Lilly and Company; Knoll Pharmaceuticals	84, 105
Maralee Walsh, Ph.D.	Westchester Medical Center-Behavioral Health Center (employer)	19
Lynn Wecker, Ph.D.	Somerset Pharmaceuticals, Inc.	9
Peter J. Weiden, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation	12, 39
Daniel R. Weinberger, M.D.	AstraZeneca Pharmaceuticals	9
Richard D. Weiner, M.D.	Melta Corporation	14
Margaret D. Weiss, M.D.	SmithKline Beecham Pharmaceuticals; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Checkmate Plus; Celgene	7, 27, 40
Myrna M. Weissman, Ph.D.	Guilford Press (Publisher); Basic Books (Publisher)	34, 79
Diane K. Whitney, M.D.	Eli Lilly and Company; Bristol-Myers Squibb	45
Timothy E. Wilens, M.D.	Alza Pharmaceuticals; Medeva; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; U.S. Pharmaceuticals, Pfizer Inc.; Shire Richwood Pharmaceuticals; Wyeth-Ayerst Laboratories	35, 90
Daniel Wilson, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company	59
Rodgers M. Wilson, M.D.	Janssen Pharmaceutica and Research Foundation; Johnson and Johnson	73
John W. Winkelman, M.D.	Cephalon; Eli Lilly and Company; Wyeth-Ayerst Laboratories	90
Daniel K. Winstead, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; CoCensys; Dista Products; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Pharmacia Corporation; Wyeth-Ayerst Laboratories	19, 20, 99
Donna A. Wirshing, M.D.	Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Organon Inc.; Sanofi Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; PPO Pharmco	13
Thomas N. Wise, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb	20
Katherine L. Wisner, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Solvay Pharmaceuticals, Inc.	62, 83, 101
Scott W. Woods, M.D.	Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories	86
Janet Wozniak, M.D.	Eli Lilly and Company; Alza Pharmaceuticals; Pharmacia Corporation	11, 90
Jesse H. Wright, M.D.	Mindstreet	14, 97
Lawson R. Wulsin, M.D.	Forest Laboratories, Inc.; GlaxoSmithKline	22, 98
Joel Yager, M.D.	Eli Lilly and Company	7, 19, 31, 58, 73
William R. Yates, M.D.	Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Wyeth-Ayerst Laboratories; U.S. Pharmaceuticals, Pfizer Inc.	61

Presenter	Manufacturer(s)	Program Page #
Rachel Yehuda, Ph.D.	U.S. Pharmaceuticals, Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Abbott Laboratories	25, 32, 43, 64, 105
Kimberly A. Yonkers, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; GlaxoSmithKline	62, 67
Douglas L. York, M.P.H.	Westchester Medical Center-Behavioral Health Center	19
Stuart C. Yudofsky, M.D.	Bristol-Myers Squibb; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Diamond Healthcare Corporation	13, 39, 44, 47
John M. Zajecka, M.D.	Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Organon Inc.; Otsuka Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; U.S. Pharmaceuticals, Pfizer Inc.; Pharmacia Corporation; Sanofi Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories	63
Mary C. Zaranini, Ed.D.	Abbott Laboratories; Eli Lilly and Company	23, 60
Carlos A. Zarate, Jr., M.D.	GlaxoSmithKline; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; AstraZeneca Pharmaceuticals	64
Kathryn J. Zerbe, M.D.	Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories	32, 70, 94
Douglas M. Ziedonis, M.D.	Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; U.S. Pharmaceuticals, Pfizer Inc.; Bristol-Myers Squibb; GlaxoSmithKline	5, 54, 87, 102
Sidney Zisook, M.D.	U.S. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc. Eli Lilly and Company; Wyeth-Ayerst Laboratories	59
Frans G. Zitman, M.D.	GlaxoSmithKline; Organon Inc.	61
Neil A. Zolkind, M.D.	Westchester Medical Center-Behavioral Health Center	19

Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following member is participating in an Industry-Supported Symposium and will not receive any compensation:

Presenter	Program Page #
Paul S. Appelbaum, M.D.	Janssen Pharmaceutica and Research Foundation 9

The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:

Alexander Bardey, M.D.	43	Alberto G. Lopez, M.D.	79	Lawrence C. Sack, M.D.	44
Anders Bonde-Jensen, Ph.D.	36	Alexandra MacLean, M.D.	88	Homero R. Sanchez, M.D.	73
H. Westley Clark, M.D.	7	Nestor F. Marchant, M.D.	33	Michael Stark, M.D.	102
Michael A. Cole, M.D.	14	Sheila Marcus, M.D.	29, 43, 71	Glenn T. Stebbins, Ph.D.	86
Gerald A. Cooney	35	Alonso Montoya-Pulido, M.D.	101	James B. Stone, M.D.	73
Ariel K. Dalfen, M.D.	18	Georg Northoff, M.D.	88	Denise A.C. White, M.D.	88
Andrea Eberle, M.D.	89	Jason T. Olin, Ph.D.	106	Jennifer Woehr, Psy.D.	101
Bruce Ebert, Ph.D.	107	Raymond L. Ownby, M.D.	7	Alexander S. Young, M.D.	61
Brian A. Fallon, M.D.	83	Stefano Pallanti, M.D.	103	Higinio Zuniga, M.D.	73
Henry T. Harbin, M.D.	17	Francois J. Primeau.	29		
Ronald L. Kamm, M.D.	35	Ronald O. Reider, M.D.	79		
Reverend James LeBar	107	Everett Rogers, Ph.D.	85		

This page intentionally left blank

SATURDAY, MAY 5, 2001

154TH ANNUAL MEETING

8:00 a.m. Sessions



COURSES 1-4

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon

Room 336, Level 3, Convention Center

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION

Director: Nashaat N. Boutros, M.D.

Faculty: David L. Clark, Ph.D., Edward C. Lauterbach, M.D.

COURSE 2 8:00 a.m.-12 noon

Rooms 338/339, Level 3, Convention Center

DRUG TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.

Faculty: John M. Davis, M.D., Stephen R. Marder, M.D., Rajiv P. Sharma, M.D., Rajiv Tandon, M.D.

COURSE 3 8:00 a.m.-12 noon

Room 341, Level 3, Convention Center

AN INTRODUCTION TO USING THE WORLD WIDE WEB

Psychiatric Society of Informatics

Director: Milton Huang, M.D.

Faculty: Norman E. Alessi, M.D., Daniel A. Deutschman, M.D., Naakesh A. Dewan, M.D., Charles J. Rainey, M.D., John Luo, M.D.

COURSE 4 8:00 a.m.-12 noon

Room 342, Level 3, Convention Center

NEUROLEPTIC-INDUCED MOVEMENT DISORDERS: ASSESSMENT AND TREATMENT

Director: Leonardo Cortese, M.D.

Faculty: Richard Williams, M.D., Michael Caligiuri, Ph.D., Timothy Lambert, M.D.

9:00 a.m. Sessions



COURSES 5-10

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 5 9:00 a.m.-4:00 p.m.

Room 252, Level 2, Convention Center

DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS AND TREATMENT

Director: James F. Masterson, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.

Room 253, Level 2, Convention Center

THE PRACTICAL MANAGEMENT OF PERSONALITY DISORDER

Director: John Livesley, M.D.

COURSE 7 9:00 a.m.-4:00 p.m.

Room 335, Level 3, Convention Center

SUBJECTIVITY: CRUCIAL KEY TO THERAPY AND THE UNIQUENESS OF THE HUMAN MIND

Director: Vincenzo R. Sanguineti, M.D.

Faculty: Donatella Marazziti, M.D.

COURSE 8 9:00 a.m.-4:00 p.m.

Room 340, Level 3, Convention Center

PERSONALITY AND POLITICAL BEHAVIOR

APA Commission on International Psychiatry and International Society for Political Psychology

Director: Jerrold M. Post, M.D.

COURSE 9 9:00 a.m.-4:00 p.m.

Rooms 350/351, Level 3, Convention Center

COGNITIVE-BEHAVIOR THERAPY: AN OVERVIEW

Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

SATURDAY

COURSE 10 9:00 a.m.-4:00 p.m.

Room 352, Level 3, Convention Center

BASIC HYPNOSIS: PRINCIPLES AND APPLICATIONS

Director: Jose R. Maldonado, M.D.

Faculty: David Spiegel, M.D.

1:00 p.m. Sessions



COURSES 11-14

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 11

1:00 p.m.-5:00 p.m.

Room 254, Level 2, Convention Center

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 12

1:00 p.m.-5:00 p.m.

Room 341, Level 3, Convention Center

THE ONLY COMPUTER COURSE YOU WILL EVER NEED

Director: Robert S. Kennedy, M.A.

Faculty: Carlyle H. Chan, M.D.

COURSE 13

1:00 p.m.-5:00 p.m.

Room 342, Level 3, Convention Center

IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE

Director: Lois E. Krahn, M.D.

Faculty: Jarrett W. Richardson, M.D., Mark R. Hansen, M.D., Steven I. Altchuler, M.D.

COURSE 14

1:00 p.m.-5:00 p.m.

Room 356, Level 3, Convention Center

SHORT-TERM DYNAMIC PSYCHOTHERAPY: THEORIES AND TECHNIQUES

Co-Directors: Manuel Trujillo, M.D., Waguhi W. Ishak, M.D.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-7

INDUSTRY-SUPPORTED SYMPOSIUM 1

7:00 p.m.-10:00 p.m.

Grand Ballroom A/B, Street Level, Hilton

SLEEP: A WINDOW ON MIND AND BRAIN

Supported by Wyeth-Ayerst Laboratories

Chp.: Milton K. Erman, M.D.

A The Pathogenesis of Narcolepsy and Hypersomnia
Emmanuel Mignot, M.D.

B Influences of Light on Sleep and Mood
Barbara L. Parry, M.D.

C Violent Behaviors Arising from the Sleep Period
Mark W. Mahowald, M.D.

D Sleep Apnea: Why Treat It?
Meir H. Kryger, M.D.

E New Options in the Treatment of Insomnia
Milton K. Erman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2

7:00 p.m.-10:00 p.m.

Grand Ballroom C/D, Street Level, Hilton

ADVANCES IN THE TREATMENT OF DEPRESSION IN WOMEN: BEYOND CLINICAL LORE

Supported by Eli Lilly and Company

Chp.: Teri B. Pearlstein, M.D.

Co-Chp.: Lee S. Cohen, M.D.

A Gender-Based Differences in the Treatment of Depressed Women
Susan G. Kornstein, M.D.

B Treatment Strategies of PMS and PMDD
Teri B. Pearlstein, M.D.

C Challenges and Controversies in the Treatment of Childbearing Women
Lee S. Cohen, M.D.

D Critical Issues in Mood and Cognition for Menopausal Women
Hadine Joffe, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3

7:00 p.m.-10:00 p.m.

Napoleon Ballroom, Third Floor, Hilton

SUICIDE RISK AND BIPOLAR DISORDER: NEUROBIOLOGY AND TREATMENT

Supported by the American Foundation for Suicide Prevention and Solvay Pharmaceuticals, Inc.

Chp.: J. John Mann, M.D.

A Clinical Factors Affecting Suicide Risk in Bipolar Disorder
Kay R. Jamison, Ph.D.

B Neurobiology of Suicide and Bipolar Disorder
J. John Mann, M.D.

- C Efficacy of Mood Stabilizers in Suicide Prevention**
Ross J. Baldessarini, M.D., Leonardo Tondo, M.D., John Hennen, Ph.D.

- D Clinical Management of the Suicidal Bipolar Patient**
Frederick K. Goodwin, M.D.

- E Evaluation of Suicide Risk in Bipolar Disorder in Children**
David Shaffer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4

7:00 p.m.-10:00 p.m.

Acadia Ballroom, Third Floor, Marriott

TO SWITCH OR AUGMENT? CONTEMPORARY APPROACHES TO RESISTANT DEPRESSION

Supported by Pharmacia Corporation

Chp.: Andrew A. Nierenberg, M.D.

- A Neurological Mechanisms of Treatment Resistance: The Role of Stress**
Juan F. Lopez, M.D.

- B The Neural Basis of Antidepressant Response and Nonresponse**
Wayne C. Drevets, M.D.

- C When to Augment Antidepressants**
Andrew A. Nierenberg, M.D.

- D The Use of Switching in Depression Treatment**
Charles DeBattista, M.D.

- E The Role of Nonpharmacological Intervention for Treatment-Resistant Depression**
Lauren B. Marangell, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5

7:00 p.m.-10:00 p.m.

Carondelet Ballroom, Third Floor, Marriott

THE NEW BIOLOGY OF DEPRESSION AND ANTIDEPRESSANT TREATMENT

Supported by Forest Laboratories, Inc.

Chp.: Jerrold F. Rosenbaum, M.D.

- A The Depressed Brain Imaged**
Helen S. Mayberg, M.D.

- B The Neurobiology of Mood Disorders**
Dennis S. Charney, M.D.

- C What Do Antidepressants Do? Understanding Antidepressant Molecules, Neurotransmitters, and Receptors**
Pierre Blier, M.D.

- D Healing the Depressed Brain: Signal Transduction and Neural Plasticity**

Eric J. Nestler, M.D., Ronald S. Duman, Ph.D.

Discussant: Steven E. Hyman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6

7:00 p.m.-10:00 p.m.

Mardi Gras Ballroom, Third Floor, Marriott

GLUCOSE CONTROL AND DIABETES MELLITUS DURING ANTIPSYCHOTIC TREATMENT

Supported by Janssen Pharmaceutica

Chp.: John W. Newcomer, M.D.

- A Diagnosis, Classification, and Pathogenesis of Hyperglycemia**
Harold E. Lebovitz, M.D.

- B Cardiovascular Risk Increases with Glucose Levels Regardless of Diabetes Status**
Hertzel C. Gerstein, M.D.

- C Antipsychotic-Related Change in Glucose Regulation**
John W. Newcomer, M.D.

- D Atypical Antipsychotic Agents: Diabetes and Bergman's Minimal Model Analysis**
David C. Henderson, M.D.

- E Inhibition of Glucose Transport by Antipsychotic Drugs**
Donard S. Dwyer, Ph.D., Timothy D. Ardizzone, B.S., Harold B. Pinkofsky, M.D., Arthur M. Freeman III, M.D., Ronald J. Bradley

Discussant: Herbert Y. Meltzer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7

7:00 p.m.-10:00 p.m.

Grand Ballroom A-C, Fifth Floor, Sheraton

PTSD: CLINICAL CHARACTERISTICS AND TREATMENT OPTIONS

Supported by Pfizer Inc.

Chp.: Kathleen T. Brady, M.D.

- A PTSD: Diagnostic Issues and Comorbidity**
Kathleen T. Brady, M.D.

- B Sympathetic Nervous System Dysregulation in PTSD**
Steven M. Southwick, M.D.

- C Advances in the Pharmacotherapy of PTSD**
Charles R. Marmar, M.D., Thomas C. Neylan, M.D., Frank B. Schoenfeld, M.D.

- D Psychotherapy of PTSD**
Barbara O. Rothbaum, Ph.D.

American Psychiatric Association

**Audiotapes
Recorded Live!**

***High Quality Continues for
the 2001 Annual Meeting ...***



Live recordings will be available
for most of the following:

- Lectures • Advances in Research
- Presidential Symposium • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth in the Convention Center, Lobby Level.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ♦ (800) 369-5718
Fax: (661) 295-8474
Webside: www.mobiltape.com

SUNDAY, MAY 6, 2001

154TH ANNUAL MEETING

8:00 a.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 8-14

INDUSTRY-SUPPORTED SYMPOSIUM 8

8:00 a.m.-11:00 a.m.

Grand Ballroom A/B, Street Level, Hilton

SYMPTOMATIC AND FUNCTIONAL RECOVERY: ATTAINABLE GOALS IN TREATING DEPRESSION?

Supported by Wyeth-Ayerst Laboratories

Chp.: A. John Rush, M.D.

A What Is Remission; Why Is It Important; and When Does It Occur?

Lauren B. Marangell, M.D.

B Are All Antidepressant Medications Equivalent in Attaining Remission?

Michael E. Thase, M.D.

C Does Combining Medications or Medication Sequences Lead to Remissions?

Jack M. Gorman, M.D.

D What Is the Role of Psychotherapy in Attaining Remission?

A. John Rush, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9

8:00 a.m.-11:00 a.m.

Grand Ballroom C/D, Street Level, Hilton

CRITICAL DECISIONS IN THE LIFETIME TREATMENT OF SCHIZOPHRENIA

Supported by Eli Lilly and Company

Chp.: Diana O. Perkins, M.D.

Co-Chp.: Jeffrey A. Lieberman, M.D.

A First Episode: Establishing Neuroprotection

Diana O. Perkins, M.D.

B Consequences and the Cost of Relapse

Gerald A. Maguire, M.D.

C Neuroplasticity and the Development of Treatment Resistance in Patients with Schizophrenia: Strategies for Prevention

Jeffrey A. Lieberman, M.D.

D Critical Decisions in the Treatment of Adolescent and Pediatric Psychosis

Linmarie Sikich, M.D.

E Cognition Across the Lifetime

Richard S.E. Keefe, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10

8:00 a.m.-11:00 a.m.

Napoleon Ballroom, Third Floor, Hilton

TO WORK AND TO LOVE: FOCUS ON QUALITY OF LIFE IN MOOD AND ANXIETY DISORDERS

Supported by SmithKline Beecham Pharmaceuticals

Chp.: Mark H. Rapaport, M.D.

Co-Chp.: Mark H. Pollack, M.D.

A Measures of Quality of Life

Jean Endicott, Ph.D.

B Improving Quality of Life for Patients with Bipolar Disorders

Holly A. Swartz, M.D.

C Quality of Life in the Anxiety Disorders

Mark H. Pollack, M.D.

D The Impact of Depression and Its Treatment

Mark H. Rapaport, M.D., Cathryn M. Clary, M.D., Lewis L. Judd, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11

8:00 a.m.-11:00 a.m.

Acadia Ballroom, Third Floor, Marriott

MEETING THE CHALLENGE OF SCHIZOPHRENIA AND CO-OCCURRING ADDICTIONS

Supported by Novartis Pharmaceuticals Corporation

Chp.: Alan I. Green, M.D.

Co-Chp.: William M. Glazer, M.D.

A Schizophrenia and Co-Occurring Disorders: The Scope of the Problem and Impact on Outcomes

Lisa B. Dixon, M.D.

B The Neurobiology of Addiction and Schizophrenia in Relation to the Action of Antipsychotic Drugs

Herbert Y. Meltzer, M.D.

C Pharmacotherapy of Comorbid Substance Use Disorders

Alan I. Green, M.D.

D Integrating Pharmacotherapy and Dual Recovery Therapy

Douglas M. Ziedonis, M.D.

E Best Systems and Practices for Dual Diagnosis

Robert E. Drake, M.D., Kim T. Mueser, Ph.D.

Discussant: William M. Glazer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12

8:00 a.m.-11:00 a.m.

Carondelet Ballroom, Third Floor, Marriott

MEN OVER 50: AN ENDANGERED SPECIES

Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A Testosterone Decline in Aging Men: Does Andropause Exist?

Stuart N. Seidman, M.D.

B Sexual Functioning Past 50

Raymond C. Rosen, Ph.D.

C Vascular Disease and Depression

K. Ranga R. Krishnan, M.D.

D Depression and Dementia in Older Men

Gary W. Small, M.D.

E Suicide in Men Over 50: An Epidemic

Steven P. Roose, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13

8:00 a.m.-11:00 a.m.

Mardi Gras Ballroom, Third Floor, Marriott

ISSUES IN THE LONG-TERM TREATMENT OF DEPRESSION

Supported by Glaxo Wellcome Inc.

Chp.: Anita L.H. Clayton, M.D.

Co-Chp.: Maurizio Fava, M.D.

A Weight Changes During Long-Term Antidepressant Treatment

Maurizio Fava, M.D.

B Antidepressant-Induced Sexual Dysfunction

Anita L.H. Clayton, M.D.

C The Role of Psychotherapy in the Long-Term Treatment of Depression

Gabor I. Keitner, M.D.

D Identification of Depressive Relapse

P. Murali Doraiswamy, M.D.

E Management of Depressive Breakthrough During Long-Term Treatment

Jonathan E. Alpert, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14

8:00 a.m.-11:00 a.m.

Grand Ballroom A-C, Fifth Floor, Sheraton

ALCOHOLISM AND BIPOLAR DISORDER: TREATMENT OPTIONS CIRCA 2001

Supported by Pfizer Inc.

Chp.: Mark A. Frye, M.D.

A New Pharmacotherapies for Alcohol Dependence

Barbara J. Mason, Ph.D.

B Suicidality, Impulsivity, and Alcoholism

Joseph F. Goldberg, M.D.

C Antiepileptic Drugs in Alcohol Withdrawal and Relapse

Hugh Myrick, M.D.

D Bipolar Disorder and Comorbid Alcoholism: Course of Illness and Treatment Implication

Mark A. Frye, M.D.

E Antiepileptic Drugs and Lithium in the Treatment of Bipolar Illness and Alcohol Use Disorders

Patricia Suppes, M.D.



COURSES 15-20

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 15

8:00 a.m.-12 noon

Room 252, Level 2, Convention Center

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 16

8:00 a.m.-12 noon

Room 254, Level 2, Convention Center

CURRENT CODING AND DOCUMENTATION REQUIREMENTS

Director: Chester W. Schmidt, Jr., M.D.

COURSE 17

8:00 a.m.-12 noon

Room 337, Level 3, Convention Center

BALINT GROUP: UNDERSTANDING THE DOCTOR AND PATIENT

Director: Geoffrey M. Margo, M.D.

Faculty: Katherine Margo, M.D., Laurel C. Milberg, Ph.D., C. Paul Scott, M.D.

COURSE 18

8:00 a.m.-12 noon

Rooms 338/339, Level 3, Convention Center

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

COURSE 19 8:00 a.m.-12 noon

Room 341, Level 3, Convention Center

MAKING A HOME ON THE WORLD WIDE WEB*Psychiatric Society of Informatics***Director:** Milton Huang, M.D.**Faculty:** Norman E. Alessi, M.D., Daniel A. Deutschman, M.D., Robert C. Hsiung, M.D., Charles J. Rainey, M.D., Raymond L. Ownby, M.D.**COURSE 20** 8:00 a.m.-12 noon

Room 352, Level 3, Convention Center

ADD IN CHILDREN AND ADOLESCENTS**Director:** Thomas E. Brown, Ph.D.**Faculty:** Margaret D. Weiss, M.D.**SEE COURSE 24 BELOW. SPECIAL 8:00 A.M. START TIME.****9:00 a.m. Sessions****COURSES 21-26**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 21 9:00 a.m.-4:00 p.m.

Room 253, Level 2, Convention Center

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS**Director:** David C. Jimerson, M.D.**Faculty:** W. Stewart Agras, M.D., Katherine A. Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.**COURSE 22** 9:00 a.m.-4:00 p.m.

Room 336, Level 3, Convention Center

MONEY MATTERS: USING THEORY IN CLINICAL PRACTICE**Director:** Cecilia M. Mikalac, M.D.**COURSE 23** 9:00 a.m.-4:00 p.m.

Room 342, Level 3, Convention Center

ADVANCED INTERVIEWING TECHNIQUES**Director:** Shawn C. Shea, M.D.**COURSE 24** 8:00 a.m.-4:30 p.m.

Rooms 343-345, Level 3, Convention Center

OFFICE-BASED TREATMENT OF OPIATE DEPENDENT PATIENTS*APA Council on Addiction Psychiatry and American Academy of Addiction Psychiatry***Director:** Thomas R. Kosten, M.D.**Faculty:** Eric C. Strain, M.D., Laura F. McNicholas, M.D., Herbert D. Kleber, M.D., David Fiellin, M.D., Joseph G. Liberto, M.D., H. Westley Clark, M.D.**NOTE SPECIAL TIME OF THIS COURSE****COURSE 25** 9:00 a.m.-4:00 p.m.

Rooms 348/349, Level 3, Convention Center

PASS THE BOARDS! THE PART II ORAL EXAM**Director:** James C.Y. Chou, M.D.**Faculty:** Gregory C. Bunt, M.D.**COURSE 26** 9:00 a.m.-4:00 p.m.

Rooms 350/351, Level 3, Convention Center

MEDICAL ETHICS 101**Director:** Edmund G. Howe, M.D.**12:30 p.m. Session****BUSINESS MEETING**

(Voting Members Only*)

12:30 p.m.-1:30 p.m.

LaNouvelle Ballroom B/C, Level 2, Convention Center

CALL TO ORDERDaniel B. Borenstein, M.D., *President***MEMORIAL TO DECEASED MEMBERS****ANNOUNCEMENT OF ELECTION RESULTS**Fred G. Hilkert, M.D., *Chairperson, Committee of Tellers***REPORTS TO THE MEMBERSHIP***Secretary:* Michelle Riba, M.D.*Treasurer:* Carol A. Bernstein, M.D.*Speaker, Assembly:* R. Michael Pearce, M.D.*Speaker-Elect, Assembly:* Nada L. Stotland, M.D.*Chairperson, By-Laws Committee:*

Jo-Ellyn M. Ryall, M.D.

Chairperson, Elections Committee:

Mary Jane Massie, M.D.

Chairperson, Membership Committee:

Bernard A. Katz, M.D.

Medical Director: Steven M. Mirin, M.D.*Chairpersons of the 11 Councils***ANNUAL FORUM****ADJOURNMENT**

*Members-in-Training, General Members, Fellows, Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions



COURSES 27-34

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 27 1:00 p.m.-5:00 p.m.
Room 252, Level 2, Convention Center

EVIDENCE-BASED TREATMENT OF SAD: FOCUS ON LIGHT THERAPY

Co-Directors: Raymond W. Lam, M.D., Anthony J. Levitt, M.D.

COURSE 28 1:00 p.m.-5:00 p.m.
Room 254, Level 2, Convention Center

DUAL DIAGNOSIS: BASIC PRINCIPLES OF SUCCESSFUL INTERVENTION

Director: Kenneth Minkoff, M.D.

COURSE 29 1:00 p.m.-5:00 p.m.
Room 335, Level 3, Convention Center

DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH

Director: Milton Kramer, M.D.

COURSE 30 1:00 p.m.-5:00 p.m.
Rooms 338/339, Level 3, Convention Center

PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM

Co-Directors: Shaila Misri, M.D., Kristin S. Sivertz, M.D.
Faculty: Diana Carter, M.B., Maria R. Corral, M.D., Deirdre M. Ryan, M.B.

COURSE 31 1:00 p.m.-5:00 p.m.
Room 340, Level 3, Convention Center

SHAME AND SOCIAL ANXIETY DISORDER

Director: Paul B. Bohn, M.D.

COURSE 32 1:00 p.m.-5:00 p.m.
Room 341, Level 3, Convention Center

USING OPEN INFRASTRUCTURE FOR OUTCOME: A CUSTOMIZABLE WEB-BASED CLINICAL AND RESEARCH RECORD SYSTEM

Director: Andrew P. Ho, M.D.
Faculty: David Haponiski, M.S.W., Carol Giannini, R.N., Christy Finazzo, M.S.W.

COURSE 33 1:00 p.m.-5:00 p.m.
Room 347, Level 3, Convention Center

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

COURSE 34 1:00 p.m.-5:00 p.m.
Room 352, Level 3, Convention Center

VIDEO REVIEW OF NEUROPSYCHIATRIC CONDITIONS

Director: Thomas E. Hansen, M.D.
Faculty: Edward C. Lauterbach, M.D., Dietrich P. Blumer, M.D., Andrew J. Francis, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 15-20

INDUSTRY-SUPPORTED SYMPOSIUM 15
1:30 p.m.-4:30 p.m.
Grand Ballroom A/B, Street Level, Hilton

TREATING PSYCHOTIC DISORDERS: WHAT IS THE STATE OF THE ART?

Supported by Bristol-Myers Squibb Company

Chp.: Jeffrey A. Lieberman, M.D.

A Issues in Managing Psychosis in Geriatric Patients
Dilip V. Jeste, M.D., Jonathan P. Lacro, Pharm.D., Michael Caligiuri, Ph.D., Sidney Zisook, M.D.

B Treatment of Depression with Psychosis
Robert N. Golden, M.D.

C Emerging Treatments in Acute Mania and Bipolar Disorders
Terence A. Ketter, M.D., Po W. Wang, M.D.

D Treating the Spectrum of Symptoms in Schizophrenia
Jeffrey A. Lieberman, M.D.

E Treatment of Pediatric Psychosis
Judith H.L. Rapoport, M.D.

Discussant: James W. Jefferson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16
1:30 p.m.-4:30 p.m.
Grand Ballroom C/D, Street Level, Hilton

PROVIDING COMPLETE TREATMENT FOR PATIENTS WITH BIPOLAR DISORDER

Supported by the National Depressive and Manic-Depressive Association and Eli Lilly and Company

Chp.: Paul E. Keck, Jr., M.D.

A Manic and Mixed Episodes: The Challenge of Improving Functional Outcome

Paul E. Keck, Jr., M.D.

B New Horizons in the Treatment of Bipolar Disorder

K.N. Roy Chengappa, M.D.

C Women and Bipolar Disorder

Lori L. Altshuler, M.D., Mark A. Frye, M.D., Victoria Hendrick, M.D.

D Maintenance Treatments for Patients with Bipolar Disorder

Joseph F. Goldberg, M.D.

E The Face of Bipolar Illness: Results of a National Depressive and Manic-Depressive Association Survey

Lydia J. Lewis

INDUSTRY-SUPPORTED SYMPOSIUM 17

1:30 p.m.-4:30 p.m.

Acadia Ballroom, Third Floor, Marriott

MAOIS REVISITED

Supported by Somerset Pharmaceuticals, Inc.

Chp.: Jay D. Amsterdam, M.D.

A An Update on MAO and Behavior

Lynn Wecker, Ph.D.

B Cellular Antidepressant Mechanism of MAO Inhibitors

Pierre Blier, M.D.

C Clinical Use of MAO Inhibitors

Jay D. Amsterdam, M.D.

D Next Generation of MAO Inhibitors

Andrew A. Nierenberg, M.D.

E Transdermal Selegiline in Depression

J. Alexander Bodkin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18

1:30 p.m.-4:30 p.m.

Carondelet Ballroom, Third Floor, Marriott

ADVANCES IN THE TREATMENT OF GERIATRIC DEPRESSION

Supported by Organon Inc.

Chp.: J. Craig Nelson, M.D.

Co-Chp.: Greer M. Murphy, M.D.

A Diagnosis and Treatment of Depression in the Older Patient

J. Craig Nelson, M.D.

B Benefits of Different Classes of Antidepressants for Geriatric Depression

Alan F. Schatzberg, M.D.

C DNA Microarray Technology and the Treatment of Depression

Greer M. Murphy, M.D.

D Pharmacology of Antidepressants Pertinent to Older Patients

Bruce G. Pollock, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19

1:30 p.m.-4:30 p.m.

Mardi Gras Ballroom, Third Floor, Marriott

CHEMICAL RESTRAINTS: CLINICAL, RESEARCH, AND ETHICAL IMPLICATIONS

Supported by Janssen Pharmaceutica

Chp.: Douglas H. Hughes, M.D.

A Preventing Psychological Trauma Following Forced Medication

Terence M. Keane, Ph.D.

B Atypical Antipsychotics in the Emergency Setting

Glenn W. Currier, M.D.

C Depot Antipsychotics: An Alternative to Forced Medications

Sally A. Berry, M.D.

D Historical Legal Trends and Civil Liberties in Forced Medications

Renee L. Binder, M.D.

E Dealing with the New Legal Framework for Chemical Restraints

Paul S. Appelbaum, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 20

1:30 p.m.-4:30 p.m.

Grand Ballroom A-C, Fifth Floor, Sheraton

ATYPICAL ANTIPSYCHOTIC DRUGS: HOW DO THEY WORK?

Supported by AstraZeneca Pharmaceuticals

Chp.: Shitij Kapur, M.D.

Co-Chp.: Daniel R. Weinberger, M.D.

A What Really Is "Atypical" About Atypical Antipsychotics: Lessons from PET Imaging Studies

Shitij Kapur, M.D., Robert B. Zipursky, M.D., Gary J. Remington, M.D., Philip Seeman, Ph.D.

B Understanding the Action of Antipsychotic Drugs at the Level of Gene Expression

Barbara K. Lipska, Ph.D.

C Intrinsic Circuitry in Cortex: Receptors, Drug Action, and Cognition

Patricia S. Goldman-Rakic, Ph.D.

D Behavioral and Neurochemical Predictors of Antipsychotic Drug Action

Charles B. Nemeroff, M.D.

E Therapeutic Insights from the Clinical Search for Genes

Daniel R. Weinberger, M.D.

2:30 p.m. Session**LECTURE 1**

2:30 p.m.-4:00 p.m.

Rooms 353-355, Level 3, Convention Center

**AAPL/APA'S MANFRED S. GUTTMACHER
AWARD LECTURE****Paul E. Mullen, M.B., Michelle Pathé, M.D.
and Rosemary Purcell****Stalkers and Their Victims****Chp.:** Brian Crowley, M.D.**Co-Chp.:** Elissa P. Benedek, M.D.

Stalking includes brief, albeit distressing incidents of harassment as well as patterns of pursuit that continue for months or years. Both the victims of stalking and their pursuers may experience disturbances of mental and social health, and psychiatrists may find themselves called on to assist victims and to manage perpetrators. Paul E. Mullen, M.B., Michelle Pathé, M.D., and Ms. Rosemary Purcell, authors of the recent book *Stalkers and Their Victims*, discuss the psychological and social impact of stalking, present a typology of stalkers based on what initiates and what sustains stalking behavior, and offer clinicians suggestions for treating victims and perpetrators of stalking. Dr. Mullen is Professor of Forensic Psychiatry at Monash University Medical School and Clinical Director of the Victorian Institute of Forensic Mental Health in Melbourne, Australia. He is the author of more than 100 scholarly publications and has contributed chapters to the standard British textbooks on forensic psychiatry. He is the co-author of the books *Jealousy: Theory, Research, and Clinical Strategies* and *Child Sexual Abuse: An Evidence-Based Perspective*. Dr. Pathé is a consultant forensic psychiatrist and Assistant Clinical Director at the Victorian Institute of Forensic Mental Health. She is an Honorary Senior Lecturer at Monash University and a Fellow in the Department of Criminology at the University of Melbourne. Ms. Purcell is a registered psychologist currently completing a doctoral program in the Department of Psychological Medicine at Monash University. She is employed as a project officer at the Victorian Institute of Forensic Mental Health, where she is coordinating a pilot therapeutic support group for victims of stalking, and works as a sessional psychologist for the Institute's Community Forensic Mental Health Service, where she provides clinical services for stalkers and victims of stalking.

THIS SESSION WILL BE AUDIOTAPED.**5:00 p.m. Session****OFFICIAL OPENING SESSION**

5:00 p.m.-6:30 p.m.

Hall G, Lobby Level, Convention Center

CALL TO ORDER

Daniel B. Borenstein, M.D.

*President***INTRODUCTION OF STAGE GUESTS****INTRODUCTION OF CHAIRPERSONS OF
THE SCIENTIFIC PROGRAM COMMITTEE
AND THE TASK FORCE ON LOCAL
ARRANGEMENTS**

Philip R. Muskin, M.D.

Chairperson, Annual Meeting Scientific Program Committee

Edward F. Foulks, M.D.

*Co-Chairperson, Task Force on Local Arrangements***INTRODUCTION OF VISITING
DIGNITARIES****PRESIDENTIAL ADDRESS**

Daniel B. Borenstein, M.D.

To be introduced by Leo Rangell, M.D.

RESPONSE OF THE PRESIDENT-ELECT

Richard K. Harding, M.D.

To be introduced by Steven M. Mirin, M.D.

ADJOURNMENT**7:00 p.m. Sessions****INDUSTRY-SUPPORTED SYMPOSIA 21-26****INDUSTRY-SUPPORTED SYMPOSIUM 21**

7:00 p.m.-10:00 p.m.

Grand Ballroom A/B, Street Level, Hilton

CRITICAL QUESTIONS IN ANXIETY DISORDERS*Supported by Wyeth-Ayerst Laboratories***Chp.:** David V. Sheehan, M.D.**A Cost Burden of Anxiety Disorders**

Ronald C. Kessler, Ph.D.

**B Antidepressants and Anxiolytics: Do They All Work in
Social Phobia?**

Jonathan R.T. Davidson, M.D.

C Should GAD Be Treated Long Term?

David V. Sheehan, M.D.

D Treatment of Comorbid Anxiety and Bipolar Disorders
Susan L. McElroy, M.D.

E Barriers to the Effective Treatment of Anxiety Disorders
Mark Olfson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22

7:00 p.m.-10:00 p.m.

Grand Ballroom C/D, Street Level, Hilton

MANAGEMENT OF ANXIETY: AN INTERNATIONAL PERSPECTIVE

Supported by Solvay Pharmaceuticals, Inc.

Chp.: Murray B. Stein, M.D.

Co-Chp.: Eric Hollander, M.D.

A The Functional Impact of Anxiety Disorders: Focus on Social Phobia
Murray B. Stein, M.D.

B Integrating Neuroscience and Psychotherapy: The Study of Human Emotions
Donatella Marazziti, M.D.

C Childhood Anxiety Disorders: NIMH Initiatives
Benedetto Vitiello, M.D.

D Refractory OCD: An International Perspective
Eric Hollander, M.D., Stefano Pallanti, M.D., Sherie L. Novotny, M.D., Daphne Simeon, M.D., Sallie Jo Hadley, M.D., Carol Bienstock, B.A.

E Anxiety and Suicide
Jan A. Fawcett, M.D.

Discussant: Michael R. Liebowitz, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23

7:00 p.m.-10:00 p.m.

Acadia Ballroom, Third Floor, Marriott

TREATMENT-RESISTANT DEPRESSION ACROSS THE LIFE SPAN

Supported by Pharmacia Corporation

Chp.: Maurizio Fava, M.D.

A The Phenomenology and Course of Treatment-Resistant Depression
Patrick J. McGrath, M.D., Jonathan W. Stewart, M.D.

B Pharmacological Treatment Options
Maurizio Fava, M.D.

C Management of Depression in the Medically Ill: Practical Approaches to Treatment
Prakash S. Masand, M.D.

D Juvenile Bipolar Disorder: An Overlooked Condition
Janet Wozniak, M.D.

E Treatment Advances in Geriatric Depression
George S. Alexopoulos, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 24

7:00 p.m.-10:00 p.m.

Carondelet Ballroom, Third Floor, Marriott

NEUROBIOLOGY, DEPRESSION, AND THE SPECIFICITY OF TREATMENT RESPONSE

Supported by Organon Inc.

Chp.: Alexander H. Glassman, M.D.

Co-Chp.: Pedro L. Delgado, M.D.

A 5HT and Norepinephrine in Depression
Pedro L. Delgado, M.D., Francisco A. Moreno, M.D.

B The Role of Dopamine in Depression and Antidepressant Treatment
Alexander H. Glassman, M.D.

C Brain Structure and Function in Major Depression
Harold A. Sackeim, Ph.D.

D The Biology of Depressive Subtypes and Treatment Response
Steven P. Roose, M.D.

Discussant: Alan F. Schatzberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25

7:00 p.m.-10:00 p.m.

Mardi Gras Ballroom, Third Floor, Marriott

PSYCHOSIS IN ALZHEIMER'S DISEASE: NEW KNOWLEDGE, NEW TREATMENT STRATEGIES

Supported by Janssen Pharmaceutica

Chp.: Ira R. Katz, M.D.

A Psychosis of Dementia
Lon S. Schneider, M.D.

B Efficacy of Antipsychotic Agents
Ira R. Katz, M.D.

C Effects of Other Psychotherapeutic Medications
Constantine G. Lyketsos, M.D.

D Practical Strategies for the Treatment of Psychoses Due to Dementia
Jacobo E. Mintzer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 26

7:00 p.m.-10:00 p.m.

Grand Ballroom A-C, Fifth Floor, Sheraton

MOVING TOWARDS A MORE COMPREHENSIVE MANAGEMENT OF PATIENTS WITH SCHIZOPHRENIA

Supported by Pfizer Inc.

Chp.: Daniel E. Casey, M.D.

Co-Chp.: Nina R. Schooler, Ph.D.

(Continued on next page)

A Acute Psychotic Agitation: Exploring New Options

Alan J. Mendelowitz, M.D.

B Beyond the Acute Phase: Issues in Stabilization

Peter J. Weiden, M.D.

C Psychosocial Treatment for Schizophrenia: Strategies for the New Era

Nina R. Schooler, Ph.D.

D Raising the Bar from Symptom Reduction to Disability Reduction

Michael F. Green, Ph.D.

E Improving the Overall Health of Patients with Schizophrenia

Daniel E. Casey, M.D.

MEDIA SESSIONS 1-2

MEDIA SESSION 1

7:00 p.m.-10:00 p.m.

Napoleon Ballroom, Third Floor, Hilton

FOUR STORIES OF MOTHER/DAUGHTER RESILIENCE

Chp.: Francis G. Lu, M.D.

1 The Joy Luck Club

(138 minutes)

Distributor: Buena Vista Video

Department CS

Burbank, CA 91521

The Joy Luck Club depicts four stories of the transmission of resilience from Chinese mothers to their American-born daughters. The film shows not only the mothers' courage in facing their collective traumas of war, arranged marriages, infidelity, infanticide, and abandonment of babies, but also scenes of great epiphany when previously estranged mothers and daughters achieve an "I-Thou" level of intimacy which transforms the lives of the four daughters. While rooted in the particular life circumstances and customs of the Chinese, the film explores universal themes of resilience in the face of trauma and the eventual reconciliation of mothers and daughters through hope and love.

MEDIA SESSION 2

7:00 p.m.-10:00 p.m.

Versailles Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

American Psychoanalytic Association

Co-Chps.: Bruce H. Sklarew, M.D., Harvey R. Greenberg, M.D.

2 The Conformist

(115 minutes)

Distributor: Swank Motion Pictures, Inc.

350 Vanderbilt Motor Parkway

Hauppauge, NY 11787

The Conformist is a film directed by Bernardo Bertolucci. The film is set in the 1930s and stars Jean-Louis Trintignant and Stefanie Sandrelli. Trintignant portrays Marcello Clerici, an ambitious professor in 1938 Italy. As Mussolini comes into power, Clerici lets it be known that he is a fascist, and a blind friend has gotten him an assignment with the secret police. Clerici soon marries Giulia, portrayed by actress Stefania Sandrelli, and receives his assignment during his honeymoon in Paris to assassinate the head of an antifascist resistance group. While in Paris, Clerici is assailed by doubts. He faces many challenges in his endeavor, and his desperate attempt to find acceptance in society leads him to commit an act of murder. *The Conformist* is a fine blend of drama and suspense that boasts several strong performances.

MONDAY, MAY 7, 2001

154TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 27-32

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 1

7:00 a.m.-8:30 a.m.

La Nouvelle Ballroom, Level 2, Convention Center

OPTIMIZING TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC DEPRESSION

Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

A Pharmacotherapy and Psychotherapy: New Data on the Long-Term Treatment of Chronic Depression

Martin B. Keller, M.D.

B Achieving Remission in the Treatment of Chronic Depression

A. John Rush, M.D.

Discussant: Robert M.A. Hirschfeld, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom A/B, Street Level, Hilton

WOMEN'S MENTAL HEALTH: ANTIDEPRESSANT THERAPY DURING THE CHILDBEARING YEARS

Supported by Forest Laboratories, Inc.

Chp.: Lori L. Altshuler, M.D.

A The Epidemiology of Depression Throughout the Female Life Cycle

Vivien K. Burt, M.D.

B Diagnosis and Treatment of PMDD

Elias Eriksson, Ph.D.

C The Implications of Antidepressant Therapy During Pregnancy

Lori L. Altshuler, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom C/D, Street Level, Hilton

COMPARING ATYPICAL ANTIPSYCHOTIC THERAPIES: MAKING SENSE OF THE DATA

Supported by AstraZeneca Pharmaceuticals

Chp.: Rajiv Tandon, M.D.

A Examining the Efficacy of Atypical Antipsychotics: Is There a Difference?

Alan J. Mendelowitz, M.D.

B EPS and the Essence of Atypicality: Are All Atypical Antipsychotics the Same?

Rajiv Tandon, M.D.

C Relative Tolerability of Novel Antipsychotics: Impact on Weight Gain and Sexual Function

Donna A. Wirshing, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 1

7:00 a.m.-8:30 a.m.

Acadia Ballroom, Third Floor, Marriott

MOOD AND ANXIETY DISORDERS IN UNDERSTUDIED POPULATIONS

Supported by SmithKline Beecham Pharmaceuticals

Chp.: Karen D. Wagner, M.D.

A Major Depression in Children and Adolescents

Karen D. Wagner, M.D.

B OCD and Social Anxiety Disorder in Children and Adolescents

John T. Walkup, M.D.

C Use of Antidepressants in Pregnant and Breastfeeding Women

Zachary S. Stowe, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 1

7:00 a.m.-8:30 a.m.

Carondelet Ballroom, Third Floor, Marriott

WEIGHING THE OPTIONS FOR MANAGING BIPOLAR DEPRESSION

Supported by Glaxo Wellcome Inc.

Chp.: Gary S. Sachs, M.D.

A Initial Treatment Options for Bipolar Depression

Russell T. Joffe, M.D.

B Alternatives for Patients Refractory to an Initial Course of Treatment

Claudia Baldessano, M.D.

INDUSTRY-SUPPORTED BREAKFAST

SYMPOSIUM 32, PART 1

7:00 a.m.-8:30 a.m.

Mardi Gras Ballroom, Third Floor, Marriott

**THE IMPULSIVE AGGRESSIVE SPECTRUM:
CHALLENGING POPULATIONS**

Supported by Abbott Laboratories

Chp.: Eric Hollander, M.D.

A The Impulsive Affective Spectrum

Alan C. Swann, M.D.

B Very Bad Behaviors

Eric Hollander, M.D.

C Substance Abuse, Sensitization, and Impulsivity

Stephen M. Strakowski, M.D.

RESIDENTS' SESSION

7:00 a.m.-8:30 a.m.

Kabby's Restaurant Riverside, Hilton

MEET THE EXPERTS: SUNNY SIDE-UP

Chp.: Daniel B. Borenstein, M.D.

Co-Chp.: Richard K. Harding, M.D.

Nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include psychotherapy, cultural competency, public and community psychiatry, academic psychiatry, psychiatric aspects of HIV/AIDS, child and adolescent psychiatry, board preparation, neuropsychiatry, women's mental health, forensic psychiatry, leadership development, and technology and psychiatry, among others.

8:00 a.m. Sessions



COURSES 35-43

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 35

8:00 a.m.-12 noon

La Galerie 2, Second Floor, Marriott

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

COURSE 36

8:00 a.m.-12 noon

La Galerie 3, Second Floor, Marriott

ECT PRACTICE UPDATE

Director: Charles H. Kellner, M.D.

Faculty: Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

COURSE 37

8:00 a.m.-12 noon

La Galerie 6, Second Floor, Marriott

COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS

Director: Jesse H. Wright, M.D.

Faculty: Michael E. Thase, M.D., Monica A. Basco, Ph.D.

COURSE 38

8:00 a.m.-12 noon

Bacchus Room, Fourth Floor, Marriott

FAMILIES AND MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH

Director: John S. Rolland, M.D.

COURSE 39

8:00 a.m.-12 noon

Balcony N, Fourth Floor, Marriott

ASSESSMENT AND TREATMENT OF TRAUMATIC GRIEF

Director: Edward K. Rynearson, M.D.

Faculty: Jennifer L. Favell, Ph.D.

COURSE 40

8:00 a.m.-12 noon

Iberville Room, Fourth Floor, Marriott

OUTPATIENT GROUP THERAPY FOR THE SERIOUSLY MENTALLY ILL

American Group Psychotherapy Association

Director: Walter N. Stone, M.D.

COURSE 41

8:00 a.m.-12 noon

Rhythms Ballroom I, Second Floor, Sheraton

MEDICAL AND PSYCHIATRIC IMPLICATIONS OF CYTOCHROME P450: AN UPDATE

Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.

Faculty: Michael A. Cole, M.D., Jessica R. Oesterheld, M.D.

COURSE 42

8:00 a.m.-12 noon

Edgewood Rooms A/B, Fourth Floor, Sheraton

USING HUMANITIES TO UNDERSTAND MOOD DISORDERS

Co-Directors: Steven D. Targum, M.D., Emilie Passow, Ph.D.

Faculty: Jerome S. Gans, M.D.

COURSE 43

8:00 a.m.-12 noon

Ellendale Room, Fourth Floor, Sheraton

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.

Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

9:00 a.m. Sessions**CLINICAL CASE CONFERENCE 1**

9:00 a.m.-10:30 a.m.

Room 263, Level 2, Convention Center

**A NEUROSCIENCE PERSPECTIVE ON
TRANSFERENCE IN PSYCHOTHERAPY****Moderator:** Glen O. Gabbard, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA
MEMBERSHIP CARD REQUIRED FOR
ADMITTANCE.**

**CONTINUOUS CLINICAL CASE
CONFERENCE: PART 1**

9:00 a.m.-12 noon

Room 262, Level 2, Convention Center

**COGNITIVE-BEHAVIORAL THERAPY: A CASE OF
COMORBID MAJOR DEPRESSION, PERSONALITY
DISORDER, AND EPISODIC ALCOHOL ABUSE****Presenter:** Anton C. Trinidad, M.D.**Discussant:** Stephen P. McDermott, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA
MEMBERSHIP CARD REQUIRED FOR
ADMITTANCE.**

**COURSES 44-50**

Course descriptions are available in the *CME
Course Brochure* included in your registration
packet. Admission by ticket only.

COURSE 44

9:00 a.m.-4:00 p.m.

Balcony J, Fourth Floor, Marriott

**THE MULTIPLE PERSPECTIVES OF COUPLES
THERAPY: SKILLS AND TECHNIQUES****Co-Directors:** Lois S. Slovik, M.D., James L. Griffith, M.D.**COURSE 45**

9:00 a.m.-4:00 p.m.

Balcony M, Fourth Floor, Marriott

**PERSONNEL MANAGEMENT FOR
CLINICIANS/MANAGERS****Director:** Stephen M. Soltys, M.D.**Faculty:** Mark Binkley, J.D., William Noyes, M.P.A., Joseph J. Parks, M.D., Brenda Ratliff, M.D., Thomas W. Hester, M.D.**COURSE 46**

9:00 a.m.-4:00 p.m.

Rhythms Ballroom II, Second Floor, Sheraton

**DELIRIUM AND OTHER ACUTE CONFUSIONAL
STATES: DIAGNOSIS AND MANAGEMENT****Director:** Jose R. Maldonado, M.D.**COURSE 47**

9:00 a.m.-4:00 p.m.

Rhythms Ballroom III, Second Floor, Sheraton

**DEMENTIA: ADVANCED DIAGNOSIS AND
TREATMENT****Director:** William E. Reichman, M.D.**Faculty:** Constantine G. Lyketsos, M.D., David L. Sultzer, M.D.,
Jacobo E. Mintzer, M.D., Peter M. Aupperle, M.D., Pierre N.
Tariot, M.D.**COURSE 48**

9:00 a.m.-4:00 p.m.

Bayside Room B, Fourth Floor, Sheraton

**TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC
ASSESSMENT****Director:** Robert P. Granacher, M.D.**COURSE 49**

9:00 a.m.-4:00 p.m.

Grand Ballroom D, Fifth Floor, Sheraton

ADVANCES IN NEUROPSYCHIATRY**Director:** C. Edward Coffey, M.D.**Faculty:** Michael R. Trimble, M.D., Mark S. George, M.D.**COURSE 50**

9:00 a.m.-4:00 p.m.

Salon 828, Eighth Floor, Sheraton

ISSUES IN TRANSPERSONAL PSYCHIATRY**Co-Directors:** Bruce W. Scotton, M.D., Allan B. Chinen, M.D.**Faculty:** John R. Battista, M.D., William W. Foote, M.D.,
John F. Hiatt, M.D., Francis G. Lu, M.D., Bruce S. Victor, M.D.**DISCUSSION GROUPS 1-2**

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-
come, first-served basis.

1 **Nada L. Stotland, M.D.**, on Treating Women Patients:
What Clinicians Need to Know
Chequers Suite, Second Floor, Hilton

2 **Maurice D. Steinberg, M.D.**, on Psychiatric Aspects of
End-of-Life Care
Norwich Suite, Third Floor, Hilton

LECTURES 2-3

LECTURE 2

9:00 a.m.-10:30 a.m.

Hall G, Lobby Level, Convention Center

APA'S MARMOR AWARD LECTURE

Eric R. Kandel, M.D.

Genes, Synapses, and Long-Term Memory

Co-Chps.: Steven M. Mirin, M.D., John F. Greden, M.D.

Advances in cognitive psychology and molecular biology have allowed scientists to combine the disciplines to study the neurobiology of mental processes such as memory. Eric R. Kandel, M.D., reviews recent studies in *Aplysia*, *Drosophila*, and mice showing that the synthesis of new proteins required for long-term memory is reflected in gene activation leading to the growth of new synaptic connections. Dr. Kandel is University Professor at Columbia University College of Physicians and Surgeons in New York City and a Senior Investigator at the Howard Hughes Medical Institute. His research has been concerned with the molecular mechanisms of memory storage in *Aplysia* and mice, and recent work has focused on the genetic switch for converting short-term to long-term memory and on how long-term memory can be synapse specific. In 2000, he was awarded the Nobel Prize for Physiology or Medicine in recognition of his work on synaptic function in memory. A member of the United States National Academy of Sciences and national science academies of Germany and France, Dr. Kandel has also received the Albert Lasker Award, the Wolf Prize of Israel, and the National Medal of Science. A graduate of New York University School of Medicine, Dr. Kandel trained in neurobiology at the National Institutes of Health and in psychiatry at Harvard Medical School.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3

9:00 a.m.-10:30 a.m.

Rooms 338/339, Level 3, Convention Center

APA'S OSKAR PFISTER AWARD LECTURE

Irvin D. Yalom, M.D.

Existential Psychotherapy and Religious Consolation: Convergence and Divergence

Chp.: Irving S. Wiesner, M.D.

Co-Chp.: Reverend Clark S. Aist, Ph.D.

Both religious consolation and existential therapy seek to minister to anxiety emanating from concerns rooted in the human condition, including death, meaning-

lessness, freedom, and isolation. Irvin D. Yalom, M.D., discusses these concerns and explores differences and similarities between an existential psychotherapeutic and a religious consolatory approach to amelioration of anxiety. Dr. Yalom is Emeritus Professor of Psychiatry at Stanford University School of Medicine, and the author of several best-selling books, both clinical works and novels, centered on the therapist-patient relationship. His first book, *The Theory and Practice of Group Psychotherapy*, currently in its fourth edition, has been widely used as a text for training therapists. His novel, *When Nietzsche Wept*, was awarded the Commonwealth Club Gold Medal Award for Best Novel of 1992. His other books include *Every Day Gets a Little Closer*, *Love's Executioner and Other Tales of Psychotherapy*, *Lying on the Couch*, and *Morning and the Meaning of Life*. Dr. Yalom has been awarded the APA's Foundations' Fund Prize for Research in Psychiatry and the Edward Strecker Award from the Institute of Pennsylvania Hospital for his contributions to psychiatric patient care. A graduate of Boston University School of Medicine, Dr. Yalom completed his residency in psychiatry at the Henry Phipps Clinic of Johns Hopkins Hospital in Baltimore.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR
CLINICAL CONSULTATIONS 1-3

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 Leah J. Dickstein, M.D., on Unique Gender Issues in All of Psychiatric Assessment and Treatment
Room 337, Level 3, Convention Center
- 2 Mary Jane Massie, M.D., on the Psychiatric Aspects of Breast Cancer
Room 340, Level 3, Convention Center
- 3 Roger G. Kathol, M.D., on Psychiatric Problems in Medical/Surgical Patients
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 3-4

MEDIA SESSION 3

9:00 a.m.-11:00 a.m.

Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Cheryl A. Kennedy, M.D.

3 Boys Don't Cry (114 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

Boys Don't Cry is a compelling and absorbing film for general audiences and the kind of movie that can reach and touch anyone. It's the story of a girl named Teena Brandon who decided to become a boy named Brandon Teena. Moving to a small town, she, now he, falls in with a crowd of redneck pool players and their girls. Brandon begins dating and falls in love with Lana, a girl about her age. They live in a violent world of drinking and drugging macho bullies, who at first accepted Brandon and then eventually discover his secret that leads to murder. This film, directed by Kimberly Pierce, is a sad and beautiful story of two star-crossed lovers.

MEDIA SESSION 4 9:00 a.m.-11:00 a.m.
Versailles Ballroom, Third Floor, Hilton

WHEN MENTAL ILLNESS HITS HOME

Chp.: Ian E. Alger, M.D.

4 Out of My Mind (27 minutes)

Distributor: Filmmakers Library
for V4 & V5: Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

Out of My Mind is an intimate portrait of twenty-three year old John Cadigan, the filmmaker's brother who became seriously mentally ill while he was an art student at college. Soon after his first psychotic break, John asked his sister, the filmmaker and his primary caretaker, to document his story. Filmed over three years, the sibling narrates the story of John's painful deterioration despite various therapies. Rarely has the family experience of the early stages of schizophrenia been articulated so clearly. Day to day John struggles with a steady stream of paranoid and violent thoughts. He continues to battle his illness, which has now been diagnosed as schizoaffective disorder. Obtaining an accurate diagnosis, medical benefits, and housing were part of the arduous process of searching for help. Despite multiple hospitalizations he tries to lead as normal a life as possible, relying on the love and support of his family.

5 A Journey Back: Coping with a Parent's Suicide (24 minutes)

When a parent commits suicide, he or she leaves behind a wake of pain and guilt for children and spouse. It may take years for the survivors to resolve their feelings. Louise Gallup, the filmmaker, was nine years old when her father shot himself. She and her brothers and sisters grew into productive human beings, upstanding members of the community, but never spoke of the personal tragedy that engulfed their family. *A Journey Back* is a moving account of her coming to terms, 15 years later, with her father's suicide.

6 Means of Grace (57 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Means of Grace is a haunting and evocative documentary written by J. Clements. It takes an inside look at one woman writer's struggle with mental illness. Clements' mother, Ann, was hospitalized for paranoid schizophrenia in the 1950s. She was one of more than a million American women who were committed to mental hospitals during that period and often treated with massive doses of tranquilizers or electric shock treatments. Told through Ann's journals, diaries and fiction, interwoven with medical records, home movies, archival footage, and dramatizations, the film raises provocative questions about social control, the nuclear family, women's roles, definitions of madness, and our treatment of the mentally ill.

NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1

9:00 a.m.-10:30 a.m.
Exhibition Center, Second Floor, Hilton

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

ROUNDTABLE DISCUSSION

9:00 a.m.-10:30 a.m.
Room 356, Level 3, Convention Center

THE FUTURE OF BEHAVIORAL HEALTHCARE

Moderators: Robert Michels, M.D., Robert K. Schreter, M.D.
Participants: Henry T. Harbin, M.D., Steven S. Sharfstein, M.D., Miles F. Shore, M.D., Howard H. Goldman, M.D., Richard Frank, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 1-10

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.
Rooms 265/266, Level 2, Convention Center

PHYSICIAN DISABILITY: TREATMENT, INSURANCE, AND CONFLICTS

APA Committee on Physician Health, Illness, and Impairment

Co-Chps: Michael H. Gendel, M.D., Linda Logsdon, M.D.
Participants: Richard F. Limoges, M.D., Michael F. Myers, M.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room 270, Level 2, Convention Center

CONTINUING THE DIALOGUE ON RACISM AND PSYCHOPATHOLOGY

APA Committee of Black Psychiatrists

Chp.: Michelle O. Clark, M.D.
Participants: George L. Mallory, M.D., Carl C. Bell, M.D.

MONDAY

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room 271, Level 2, Convention Center

MEDICARE AND MEDICAID: PROBLEMS AND PROGRESS

APA Medicare Advisory Committee

Chp.: Edward Gordon, M.D.

Participants: Irvin L. Muszynski, Seth P. Stein, J.D., Lloyd I. Sederer, M.D.

COMPONENT WORKSHOP 4 9:00 a.m.-10:30 a.m.
Room 272, Level 2, Convention Center

THE GREAT BEYOND: MAKING CAREER DECISIONS AT THE END OF RESIDENCY TRAINING

APA Committee of Early Career Psychiatrists

Co-Chps: Ronald C. Albucher, M.D., Keith W. Young, M.D.

Participant: Samson J. Cho, M.D.

COMPONENT WORKSHOP 5 9:00 a.m.-10:30 a.m.
Rooms 333/334, Level 3, Convention Center

THE INTERPRETATION OF DREAMS: FANTASY AND REALITY IN RESIDENCY TRAINING

APA/GlaxoWellcome Fellows

Chp.: Michael A. Scarf, M.D.

Participants: Thomas G. Cobb, M.D., Rebecca A. Kornbluh, M.D., Mark S. Groves, M.D., Ariel K. Dalfen, M.D., Laura B. Dunn, M.D., Lyle B. Forehand, Jr., M.D., Joseph M. Smurda, M.D., Bernard J. Biermann, M.D.

COMPONENT WORKSHOP 6 9:00 a.m.-10:30 a.m.
Room 352, Level 3, Convention Center

PSYCHIATRISTS IN THE SCHOOLS: REDUCING THE IMPACT OF TRAUMA

APA Committee on Psychiatry and Mental Health in the Schools

Chp.: Lois T. Flaherty, M.D.

Participants: Veronica L. Williams, M.D., Edward M. Stephens, M.D., Amy M. Ursano, M.D.

COMPONENT WORKSHOP 7 9:00 a.m.-10:30 a.m.
Room 357, Level 3, Convention Center

PSYCHIATRIC VIEWS ON TALKING ABOUT HOMOSEXUALITY TO KIDS

APA Committee on Gay, Lesbian, and Bisexual Issues

Chp.: Jack Drescher, M.D.

Participants: Diana C. Miller, M.D., Daniel W. Hicks, M.D., Kenneth B. Ashley, M.D., Howard C. Rubin, M.D., Serena Y. Volpp, M.D.

COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

MAKE THE MEDIA WORK FOR YOU: TELEVISION INTERVIEW TIPS AND TECHNIQUES

APA Joint Commission on Public Affairs

Co-Chps: Michael Blumenfield, M.D., Mary H. Davis, M.D.

Participants: William E. Callahan, Jr., M.D., John Blamphin

COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m.
Jasperwood Room, Third Floor, Hilton

TO RETIRE OR NOT TO RETIRE, THAT IS THE QUESTION

APA Committee on Senior Psychiatrists and APA Lifers

Chp.: Irvin M. Cohen, M.D.

Participants: Abram M. Hostetter, M.D., Hugo Van Dooren, M.D., Philip M. Margolis, M.D.

COMPONENT WORKSHOP 10 9:00 a.m.-10:30 a.m.
Belle Chasse Room, Third Floor, Hilton

STUDENTS AND SCHOOLS AT RISK: WHERE IS THE VIOLENCE?

APA Alliance

Chp.: Gail S. Fuller, R.N.

Participants: Betty Ann J. Muller, M.D., Joseph M. Bertrand, A.T.T.

ISSUES 1-22

ISSUE WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room 264, Level 2, Convention Center

PSYCHIATRIC ILLNESS AND THE WORKPLACE

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m.
Rooms 267-268, Level 2, Convention Center

SCHUMANN, MANIC-DEPRESSIVE ILLNESS, AND THE CREATIVE PROCESS

Chp.: Richard Kogan, M.D.

Participant: Kay R. Jamison, Ph.D.

ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room 269, Level 2, Convention Center

WORKING-THROUGH IN PSYCHOTHERAPY

Chp.: Steven H. Lipsius, M.D.

ISSUE WORKSHOP 4 — CANCELLED

ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m.
Rooms 335/336, Level 3, Convention Center

HOSPITAL-BASED PROGRAM FOR LESBIAN, GAY, BISEXUAL, AND TRANSGENDER PATIENTS

Chp.: Douglas L. York, M.P.H.
Participants: Neil A. Zolkind, M.D., Maralee Walsh, Ph.D., Donna Festa, C.S.W.

ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m.
Room 342, Level 3, Convention Center

E-SUPPORTING CLINICAL PRACTICE: GUIDELINES AND THE PSYCHIATRIC RESEARCH NETWORK

Chp.: Joel Yager, M.D.
Participants: Kenneth Z. Altshuler, M.D., Madhukar H. Trivedi, M.D., G. Richard Smith, Jr., M.D.

ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.
Rooms 346/347, Level 3, Convention Center

ABPN UPDATE: REQUIREMENTS FOR ABPN EXAMINATION

Chp.: Thomas A.M. Kramer, M.D.
Participants: Glenn C. Davis, M.D., Michael H. Ebert, M.D., Larry R. Faulkner, M.D., Burton V. Reifler, M.D., Pedro Ruiz, M.D., James H. Scully, Jr., M.D., Elizabeth B. Weller, M.D., Daniel K. Winstead, M.D.

ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m.
Rooms 348/349, Level 3, Convention Center

TOWARDS A RATIONAL, INTEGRATED TREATMENT APPROACH TO MENTALLY RETARDED AND DEVELOPMENTALLY DISABLED PATIENTS

Co-Chps: Harvey Stabinsky, M.D., Susan Stabinsky, M.D.
Participants: Michael M. Scimeca, M.D., Sheldon Travin, M.D., David W. Preven, M.D.

ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m.
Rooms 350/351, Level 3, Convention Center

SLEEP PROBLEMS IN DUAL-DIAGNOSIS PATIENTS: PHYSIOLOGY AND MANAGEMENT

Chp.: R. Jeffrey Goldsmith, M.D.

ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

NONSEXUAL BOUNDARY VIOLATIONS

Chp.: Malkah T. Notman, M.D.
Participants: Linda M. Jorgenson, J.D., Carl P. Malmquist, M.D., Carol C. Nadelson, M.D.

ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m.
Grand Salon Section 4, Street Level, Hilton

NEUROANATOMY AND NEUROPHYSICS OF THE UNCONSCIOUS

Chp.: Vincenzo R. Sanguineti, M.D.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

CLOZAPINE AUGMENTATION IN REFRACTORY SCHIZOPHRENIA

Chp.: Jean-Pierre Lindenmayer, M.D.
Participants: John W. Rosenberger, M.D., Joseph I. Friedman, M.D., Richard H. McCarthy, M.D., Zafar Sharif, M.D.

ISSUE WORKSHOP 13 9:00 a.m.-10:30 a.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

MAKING TELEPSYCHIATRY WORK FOR YOUR SYSTEM

Psychiatric Society of Informatics

Chp.: William M. Tucker, M.D.
Participants: Alan Q. Radke, M.D., Harry Karlinsky, M.D., Gerald Segal, M.S.

ISSUE WORKSHOP 14 9:00 a.m.-10:30 a.m.
Grand Salon Sections 15 & 18, Street Level, Hilton

FROM PLAY THERAPY TO PILLS AND BACK AGAIN: CHILD TREATMENT IN THE DECADE OF THE MIND

Chp.: Peter D. Ganime, M.D.
Participants: Joanne Dunnigan, M.S.W., Grace Hickey, Psy.D., Phillip Repasky, M.A., Diane Beebe, M.S.

ISSUE WORKSHOP 15 9:00 a.m.-10:30 a.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

A UNIVERSITY DEPRESSION-MANAGEMENT PROGRAM

Chp.: Stuart J. Eisendrath, M.D.
Participants: Ellen Haller, M.D., Jonathan E. Lichtmacher, M.D., David H. Taylor, M.D., Anne M. Fleming, M.D., L. Alison McInnes, M.D., Yoon K. Jung, B.S., Margaret Fritch, M.S., Sharon Hall, Ph.D.

ISSUE WORKSHOP 16 9:00 a.m.-10:30 a.m.
Grand Salon Sections 21 & 24, Street Level, Hilton

DISASTER PSYCHIATRY: LAPA FLIGHT 3142

Chp.: Daniel L. Mosca, M.D.
Participants: Marcelo R. Muro, M.D., Liliana Sanchez, Psy.D.

MONDAY

ISSUE WORKSHOP 17 9:00 a.m.-10:30 a.m.
Prince of Wales Suite, Second Floor, Hilton

TWO DOGMAS OF PSYCHOANALYSIS

Chp.: Avak A. Howsepian, M.D.

ISSUE WORKSHOP 18 9:00 a.m.-10:30 a.m.
Melrose Room, Third Floor, Hilton

THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.

Participants: Jane Tillman, Ph.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 19 9:00 a.m.-10:30 a.m.
Rosedown Room, Third Floor, Hilton

HOW TO DEVELOP A LECTURE

Chp.: Marianne T. Guschwan, M.D.

Participant: Susan Tapert, Ph.D.

ISSUE WORKSHOP 20 9:00 a.m.-10:30 a.m.
Magnolia Room, Third Floor, Hilton

RECENT ADVANCES IN FEMALE SEXUAL MEDICINE

Chp.: Barbara D. Bartlik, M.D.

Participants: Laura Berman, Ph.D., Marina Rozenberg

ISSUE WORKSHOP 21 9:00 a.m.-10:30 a.m.
Oak Alley Room, Third Floor, Hilton

THE ART OF HEALING: USE OF ART THERAPY AND GROUP PSYCHOTHERAPY FOR TREATMENT OF TRAUMATIZED IMMIGRANT POPULATIONS

Co-Chps: Abbas Azadian, M.D., Mary E. Sanderson, R.A.T.

Participant: Rosemary Meier, M.D.

ISSUE WORKSHOP 22 9:00 a.m.-10:30 a.m.
Elmwood Room, Third Floor, Hilton

TEACHING BEHAVIORAL SCIENCES TO FAMILY DOCTORS

Chp.: Jonathan S. Davine, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH

10:30 a.m.-12:30 p.m.

Rooms 343-345, Level 3, Convention Center

FROM THEORY TO THERAPY: DRUG DISCOVERY, TESTING, AND CLINICAL USE

APA Scientific Program Committee and APA Council on Research

Chp.: Herbert Pardes, M.D.

Co-Chp.: Daniel K. Winstead, M.D.

Participants: Perry Molinoff, M.D., on **Drug Discovery in the Year 2000 and Beyond**

Philip Morgan, Ph.D., on **Lead Optimization and the Role of In Vitro and In Vivo in Testing**

Cathryn M. Clary, M.D., on **New Molecules, New Markets: Update on Clinical Drug Development**

Stephen M. Stahl, M.D., on **From Clinical Trials to Clinical Practice: Can You Get There From Here?**

THIS SESSION WILL BE AUDIOTAPED.

11:00 a.m. Sessions

DISCUSSION GROUPS 3-5

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

3 **Edward F. Foulks, M.D.**, on **Psychiatrists in Mental Health Advocacy Groups**

Chequers Suite, Second Floor, Hilton

4 **Clarice J. Kestenbaum, M.D.**, on **Risk Factors for Adolescent Psychotic Disorders**

Trafalgar Suite, Third Floor, Hilton

5 **Sara C. Charles, M.D.**, on **the Professional Ethic and Current Psychiatric Practice**

Norwich Suite, Third Floor, Hilton

LECTURES 4-5

LECTURE 4

11:00 a.m.-12:30 p.m.

Rooms 252-254, Level 2, Convention Center

Paul R. McHugh, M.D.

Beyond DSM IV: From Appearances to Essences

Co-Chps.: Thomas N. Wise, M.D., Geetha Jayaram, M.D., Constantine Lyketsos, M.D.

Psychiatry faces three major problems in taking its place as a medical discipline: the mind/brain problem, factionalism in the discipline, and a classification system based on appearances. Paul R. McHugh, M.D., discusses how coherence in psychiatric practice, teaching, and research can be advanced by a structure of reasoning that links clinical presentations to distinct groups of disorders with particular issues of evaluation, research, and treatment. Dr. McHugh is Henry Phipps Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and Johns Hopkins Hospital and Professor of Mental Hygiene at the Johns Hopkins University School of Hygiene and Public Health. In 1992 he assumed leadership of the Blades

Center for Clinical Practice and Research in Alcohol/Drug Dependence of the Johns Hopkins Medical Institutions. A member of the Institute of Medicine of the National Academy of Sciences, Dr. McHugh has received the William C. Menninger Award from the American College of Physicians for his contributions to the science of mental health. Dr. McHugh received his medical education at Harvard Medical School, completed a neurology and neuropathology residency at the Massachusetts General Hospital, and trained in psychiatry at the Institute of Psychiatry, University of London, and in the Division of Neuropsychiatry at Walter Reed Army Institute of Research.

Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 5

11:00 a.m.-12:30 p.m.

Rooms 353-355, Level 3, Convention Center

APA/NIMH VESTERMARK PSYCHIATRY EDUCATOR AWARD LECTURE

Jerald Kay, M.D.

**Why Play on Only Three Strings, When You Can
Play on the Whole Violin? The Importance of
Psychotherapy Education**

Chp.: Michelle Riba, M.D.

Co-Chp.: Katharine A. Phillips, M.D.

Psychotherapy instruction in residency training programs has been increasingly limited, and managed care organizations have pressed many psychiatrists to adopt a split-treatment model in which psychotherapy is provided by a nonphysician mental health professional. However, recent research has supported the critical importance of psychotherapy conducted by psychiatrists. Jerald Kay, M.D., reviews aspects of the neurobiology of psychotherapy and discusses ways to strengthen psychiatrists' education in psychotherapy. Dr. Kay is Professor and Chairman of the Department of Psychiatry at Wright State University School of Medicine in Dayton, Ohio. A Fellow of the American Psychiatric Association, Dr. Kay is a member of the APA Editorial Advisory Committee, Distinguished Service Award Committee, and Commission on the Practice of Psychotherapy by Psychiatrists. He is the Founding Editor of the *Journal of Psychotherapy Practice and Research* and the editor of five books, including the *Handbook of Psychiatry Residency Training*. He has been named an Exemplary Psychiatrist by the National Alliance for the Mentally Ill and Psychiatric Educator of the Year by the Association for Academic Psychiatry. A graduate of the University of Maryland School of Medicine in Baltimore, Dr. Kay completed his general and child and adolescent psychiatry residencies at the University of Cincinnati. He is a graduate and faculty member of the Cincinnati Psychoanalytic Institute.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 4-6

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 4 **Ruth E. Levine, M.D.**, on Using Cinema to Enhance the Teaching of Psychiatry and Behavioral Sciences (ADMSEP Council on Education Master Teacher)
Room 337, Level 3, Convention Center
- 5 **Steven P. Roose, M.D.**, on Medication and Psychodynamic Therapies: Can Treatments in Conflict Be Integrated?
Room 340, Level 3, Convention Center
- 6 **Donna E. Stewart, M.D.**, on Use of Psychotropic Drugs in Pregnancy and Lactation
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSION 5

11:00 a.m.-12:30 p.m.

Versailles Ballroom, Third Floor, Hilton

INNOCENCE FOR SALE

Chp.: John K. Burton, M.D.

- 7 **Stolen Lives**
(46 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

It has been estimated that over 300,000 children work in the sex trade in North America. Every year, in the United States and Canada, several billion dollars are generated by the sexual exploitation of children under the age of 18. *Stolen Lives* takes a hard look at this world through the eyes of the teenaged boys and girls who are being exploited in the fast-growing business of child prostitution. While many die before they can leave the industry, there are some survivors. Their stories, diverse, poignant, courageous, and compelling, expose the painful reality of this modern form of slavery, while interviews with pimps and johns make clear the realities of economics and power which fuel this growing crisis.

MEDICAL UPDATE 1

11:00 a.m.-12:30 p.m.

Grand Salon Sections 3 & 6, Street Level, Hilton

CAN STEM CELLS FROM BONE MARROW SERVE AS A FOUNTAIN OF YOUTH FOR THE BRAIN?

Chp.: Leslie H. Gise, M.D.

Presenter: Darwin J. Prockop, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-12

SCIENTIFIC AND CLINICAL REPORT SESSION 1

11:00 a.m.-12:30 p.m.

Room 264, Level 2, Convention Center

ISSUES IN SEXUAL DYSFUNCTION

Chp.: Stuart N. Seidman, M.D.

Co-Chp.: Richard Balon, M.D.

11:00 a.m.

2 Correlation Between Patient Self-Assessment of Erectile Function and the International Index of Erectile Function (IIEF-5)

Joseph Cappelleri, Ph.D., Richard L. Siegel, M.D.,
Raymond C. Rosen, Ph.D.

11:30 a.m.

3 Sildenafil Citrate Effectively Treats Erectile Dysfunction in Men Who Have Been Successfully Treated for Depression

Jean L. Tignol, M.D., Otto Benkert, M.D.

12 noon

4 Psychotropic-Induced Sexual Dysfunction Among Outpatients

Kenneth P. Rosenberg, M.D., Kathryn Bleiberg, Ph.D.,
James H. Kocsis, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2

11:00 a.m.-12:30 p.m.

Rooms 265/266, Level 2, Convention Center

PRESIDENTIAL THEME: "MIND MEETS BRAIN"

Chp.: David A. Casey, M.D.

Co-Chp.: Mercedes M. Rodriguez, M.D.

11:00 a.m.

5 Self, Object, and Neurobiology

Richard M. Brockman, M.D.

11:30 a.m.

6 Conceptual Integration of Mind and Brain in Philosophy and Psychiatry

David H. Brendel, M.D.

12 noon

7 Dreaming Contributes to Adaptation in the Depressed: A Review

Milton Kramer, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 3

11:00 a.m.-12:30 p.m.

Room 270, Level 2, Convention Center

DEPRESSION IN THE MEDICALLY ILL

Chp.: Aretta J. Rathmell, M.D.

Co-Chp.: Julie K. Schulman, M.D.

11:00 a.m.

8 A Systematic Review of Depression as a Risk Factor for Coronary Disease

Lawson R. Wulsin, M.D., Bonita Singal, M.D., Charles
Hattermer, M.D.

11:30 a.m.

9 Training Primary Care Physicians in the Diagnosis and Treatment of Depression

Robert Kohn, M.D., Itzhak Levav, M.D., Norman Sartorius, M.D.,
Ivan Mantoya, M.D., Claudio Miranda, M.D., Benjamin
Vicente, M.D.

12 noon

10 Screening for Depression in Head and Neck Cancer Patients

Mark R. Katz, M.D., Neil Kopek, B.S.C., John Waldron, M.D.,
Gerald M. Devins, Ph.D., George Tomlinson, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4

11:00 a.m.-12:30 p.m.

Room 271, Level 2, Convention Center

SECLUSION, RESTRAINT, AND EMERGENCY ISSUES

Chp.: Susan Stabinsky, M.D.

Co-Chp.: Roy V. Varner, M.D.

11:00 a.m.

11 Reducing Restraint and Seclusion: One Hospital's Experience

Paul Plasky, M.D.

11:30 a.m.

12 Reducing Restraint Use in a Public Psychiatric Hospital

Robert E. McCue, M.D., Leonel Urcuyo, M.D., Yehezkel
Lilu, Ph.D., Teresa Tobias, R.N., Michael Chambers, M.P.A.

12 noon

13 Factors Influencing the Psychiatric Emergency Room

Davin A. Agustines, B.A., Christopher K. Chung, M.D.,
Jambur V. Ananth, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5

11:00 a.m.-12:30 p.m.

Rooms 335/336, Level 3, Convention Center

SPECIAL ISSUES IN FAMILY AND CHILD PSYCHIATRY

Chp.: Cynthia W. Santos, M.D.

Co-Chp.: Julie Holman, M.D.

11:00 a.m.

14 Some Long-Term Consequences of Orphanage Care

John J. Sigal, Ph.D., Michel Rossignol, Ph.D., John C. Perry, M.D.,
Marie-Claude Ouimet, M.A.

11:30 a.m.

15 Familial Background and Literary Creativity

Albert Rothenberg, M.D.

12 noon

16 Self-Comforting Strategies Used by Adolescent Males and Females

Paul C. Horton, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6

11:00 a.m.-12:30 p.m.

Rooms 346/347, Level 3, Convention Center

ANXIETY DISORDERS

Chp.: Irma J. Bland, M.D.

Co-Chp.: Anand Pandya, M.D.

11:00 a.m.

17 PTSD Versus Panic Disorder: Differences in HPA

Axis/Noradrenergic Functioning
Randall D. Marshall, M.D., Carlos Blanco-Jerez, M.D.,
Michael R. Liebowitz, M.D., David Printz, M.D., Donald F.
Klein, M.D., Jeremy D. Coplan, M.D.

11:30 a.m.

18 Beyond One-Year Imipramine Maintenance in Panic Disorder with Agoraphobia

Matig R. Mavissakalian, M.D., James M. Perel, Ph.D.

12 noon

19 Social Phobia Treatment Survey

Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D.,
Peter Farvolden, Ph.D., Jonathan Oakman, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7

11:00 a.m.-12:30 p.m.

Rooms 348/349, Level 3, Convention Center

PERSONALITY DISORDERS

Chp.: Roslyn Seligman, M.D.

Co-Chp.: Mara S. Goldstein, M.D.

11:00 a.m.

20 Psychiatric Treatment of Borderline Patients Followed for Four Years

Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.,
John Hennen, Ph.D.

11:30 a.m.

21 Predictors of Outcome in a 27-Year Follow-Up of BPD

Joel F. Paris, M.D., Hallie Zweig-Frank, Ph.D.

12 noon

22 Confirmatory Factor Analysis of DSM-IV Schizotypal Personality Disorder Criteria

Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., Leslie C.
Morey, Ph.D., Donna S. Bender, Ph.D., Thomas H.
McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 8

11:00 a.m.-12:30 p.m.

Room 357, Level 3, Convention Center

ALCOHOL AND DRUG-RELATED DISORDERS

Chp.: Joel M. Silberberg, M.D.

Co-Chp.: Earl L. Loschen, M.D.

11:00 a.m.

23 Longitudinal Predictors of Adolescent Alcohol Disorder Onset

Martha A. Rueter, Ph.D., K. A. S. Wickrama, Ph.D.

11:30 a.m.

24 Delirium Tremens: Diagnosis, Misdiagnosis, and Terminology

Milton Rosenbaum, M.D., Teresita A. McCarty, M.D.

12 noon

25 Cigarette Smoking and Risk for Anxiety Disorders

Jeffrey G. Johnson, Ph.D., Patricia R. Cohen, Ph.D.,
Donald F. Klein, M.D., Daniel S. Pine, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 9

11:00 a.m.-12:30 p.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

COMORBIDITY IN MOOD DISORDERS

Chp.: Paul J. Goodnick, M.D.

Co-Chp.: Patrick T. O'Neill, M.D.

11:00 a.m.

26 Does Medical Comorbidity Impact the Severity of Depression and Its Treatment?

Dan V. Iosifescu, M.D., Megan M. Smith, B.A., Stella Bitran, B.A.,
Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D.,
John J. Worthington III, M.D., Maurizio Fava, M.D.

(Continued on next page)

11:30 a.m.

27 Treatment-Resistant Depression and Axis I

Comorbidity

Timothy J. Petersen, Ph.D., Johanna A. Gordon, B.A., Alexis Kant, Maurizio Fava, M.D., Jerrold F. Rosenbaum, M.D., Andrew A. Nierenberg, M.D.

12 noon

28 The Complex Comorbidity Between Bipolar Illness and OCD: Clinical Implications and Treatment Outcome

Giulio Perugi, M.D., Cristina Toni, M.D., Hagop S. Akiskal, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 10

11:00 a.m.-12:30 p.m.

Rosedown Room, Third Floor, Hilton

PSYCHOPHARMACOLOGY TOXICITIES

Chp.: Arthur L. Lazarus, M.D.

Co-Chp.: Roberto A. Dominguez, M.D.

11:00 a.m.

29 Myotoxicity and Neurotoxicity During Clozapine Treatment

Ilya Reznik, M.D., Roberto Mester, M.D., Lior Volchek, M.D., Moshe Kotler, M.D., Ida Sarova-Pinchas, M.D., Baruch Spivak, M.D., Abraham Weizman, M.D.

11:30 a.m.

30 Olanzapine and NMS: Case Report and Literature Review

Cristinel M. Coconcea, M.D., Nicoleta Coconcea, M.D.

12 noon

31 A Case of Ketamine Psychosis

Seema Kochhar, M.D., Edward A. Volkman, M.D., David Wald, D.O.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11

11:00 a.m.-12:30 p.m.

Magnolia Room, Third Floor, Hilton

ADDICTION PSYCHIATRY

Chp.: Richard T. Suchinsky, M.D.

Co-Chp.: Lydia O. Fazzio, M.D.

11:00 a.m.

32 Polymorphisms in the 5HT Transporter Gene and Cocaine Dependence

Ashwin A. Patkar, M.D., Wade H. Berrettini, M.D., Edward Gotthel, M.D., Robert C. Sterling, Ph.D., Kevin P. Hill, B.A., Stephen P. Weinstein, Ph.D.

11:30 a.m.

33 Addictions Psychiatry and Treatment Outcomes in a Therapeutic Community

Gregory C. Bunt, M.D., A. Jonathan Porteus, Ph.D.,

12 noon

34 Spirituality in the Detoxification Phase of Substance Abuse Treatment

Camilo A. Martin, M.D., Charlie A. Gass, D.M., Alice T. Allen, M.S.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12

11:00 a.m.-12:30 p.m.

Belle Chasse Room, Third Floor, Hilton

PREDICTORS IN SCHIZOPHRENIA

Chp.: Harvey Stabinsky, M.D.

Co-Chp.: Ronald C. Albucher, M.D.

11:00 a.m.

35 What Predicts Functioning Across 10 Years of Schizophrenic Illness?

Ellen S. Herbener, Ph.D., Martin Harrow, Ph.D.

11:30 a.m.

36 Perinatal Brain Damages and Slower Development Interact as Risks for Psychosis

Peter B. Jones, Ph.D., Tim J. Croudace, Ph.D., Kristiina Moilanen, M.D., Marjo-Riitta Jarvelin, M.D., Jari Jokelainen, B.S.C., Paula Rantakallio, M.D., Matti K. Isohanni, M.D.

12 noon

37 Social Sequels of Mental Disorders in the 1966 North Finland Birth Cohort

Matti K. Isohanni, M.D., Irene Isohanni, M.Ed., Peter B. Jones, Ph.D., Tim J. Croudace, Ph.D., Marjo-Riitta Jarvelin, M.D., Jari Jokelainen, B.S.C., Kaisa Riala, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 11-16

COMPONENT WORKSHOP 11 11:00 a.m.-12:30 p.m.

Rooms 267-268, Level 2, Convention Center

MUSIC IN THE LIVES OF PSYCHIATRISTS

APA San Diego Psychiatric Society

Chp.: Edward A. Siegel, M.D.

Participants: John P. Feighner, M.D., Dominick Addario, M.D., Stephen R. Shuchter, M.D.

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.

Room 269, Level 2, Convention Center

A MODEL INFANT PSYCHIATRY PROGRAM FOR ABUSE AND NEGLECT CASES

APA Committee on Pre-School Children

Co-Chps: Michael S. Scheeringa, M.D., Charles H. Zeanah, M.D.

Participants: Julie A. Larrieu, Ph.D., Anna T. Smyke, Ph.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.

Rooms 338/339, Level 3, Convention Center

THE INTERFACE BETWEEN RELIGION AND EXISTENTIAL PSYCHOTHERAPY

APA Committee on Religion, Spirituality, and Psychiatry

Chp.: George T. Harding IV, M.D.

Participants: Irvin D. Yalom, M.D., T. Byram Karasu, M.D., William N. Grosch, M.D., Reverend Clark S. Aist, Ph.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.

Grand Salon Section 4, Street Level, Hilton

RBRVS CODING AND DOCUMENTATION UPDATE

APA Committee on RBRVS, Codes, and Reimbursements

Chp.: Chester W. Schmidt, Jr., M.D.

Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D., Melodie Morgan-Minott, M.D., Joseph M. Schwartz, M.D., Steven S. Sharfstein, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

XTC AND K, ETC.: THE NEW ABC'S OF ADOLESCENT SUBSTANCE USE

APA Committee on Treatment Services for Addicted Patients

Co-Chps: Bernard J. Biermann, M.D., Sheila B. Blume, M.D.

Participants: Teresa Frausto, M.D., Ramon Solhkhah, M.D., Deborah Deas, M.D., Pamela Swedlow, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

MISSION IMPOSSIBLE: TREATING THE UNDIAGNOSABLE CHILD

APA Committee on Children with Mental or Developmental Disorders

Chp.: Carl B. Feinstein, M.D.

Participants: Roxanne Dryden-Edwards, M.D., Gabrielle Carlson, M.D., Robert L. Hendren, D.O., Donald J. Mordecai, M.D.

ISSUES 23-31

ISSUE WORKSHOP 23 11:00 a.m.-12:30 p.m.

Room 272, Level 2, Convention Center

ALCOHOLISM PHARMACOTHERAPY: A CASE-BASED REVIEW FOR CLINICIANS

Chp.: Lance P. Longo, M.D.

Participants: Michael J. Bohn, M.D., Robert M. Swift, M.D.

ISSUE WORKSHOP 24 11:00 a.m.-12:30 p.m.

Room 273, Level 2, Convention Center

BALANCING CAREER AND FAMILY

Chp.: Margery S. Sved, M.D.

Participants: Emily A. McCort, M.D., Karl M. Jacobs, M.D.

ISSUE WORKSHOP 25 11:00 a.m.-12:30 p.m.

Rooms 333/334, Level 3, Convention Center

NARCISSISM BELOW SEA LEVEL: A DUTCH VIEW OF FUTURE GAY DEVELOPMENTS

Co-Chps: Nicolaas F.J. Hettinga, M.D., Rudolf A.M. Feijen, M.D.

Participants: Wilco Tuinebreijer, Bastiaan L. Oele, M.D., Wilhelm G.W. Vanderplaats, M.D.

ISSUE WORKSHOP 26 11:00 a.m.-12:30 p.m.

Room 342, Level 3, Convention Center

COMPUTER ODYSSEY 2001: UPDATES FOR NEW COMPUTER PURCHASERS

Co-Chps: Lawrence K. Richards, M.D., Alan W. Newman, M.D.

ISSUE WORKSHOP 27 11:00 a.m.-12:30 p.m.

Rooms 350/351, Level 3, Convention Center

UNDERSTANDING THE DYNAMICS OF ABUSIVE RELATIONSHIPS

Chp.: Gary J. Maier, M.D.

ISSUE WORKSHOP 28 11:00 a.m.-12:30 p.m.

Prince of Wales Suite, Second Floor, Hilton

MENTAL HEALTH EDUCATION FOR THE PRIMARY CARE PHYSICIAN

Co-Chps: Linda Gask, M.D., Amelia E. Musacchio de Zan, M.D.

Participants: Pedro Ruiz, M.D., Rodolfo D. Fahrner, M.D., David A. Baron, D.O.

ISSUE WORKSHOP 29 11:00 a.m.-12:30 p.m.

Melrose Room, Third Floor, Hilton

INTERGENERATIONAL ASPECTS OF TRAUMA AND AGGRESSIVE BEHAVIOR

Chp.: Andrei Novac, M.D.

Participants: Rita R. Newman, M.D., Rachel Yehuda, Ph.D.

ISSUE WORKSHOP 30 11:00 a.m.-12:30 p.m.

Oak Alley Room, Third Floor, Hilton

FUNDING OPPORTUNITIES FROM THE NATIONAL INSTITUTES OF HEALTH

National Institutes of Health

Chp.: Lucinda Miner, Ph.D.

Participants: Ernestine Vanderveen, Ph.D., Walter Goldschmidt, Ph.D.

ISSUE WORKSHOP 31 11:00 a.m.-12:30 p.m.

Elmwood Room, Third Floor, Hilton

CURRENT AND FUTURE TRENDS IN PSYCHIATRY AND EMPLOYMENT LAW

Chp.: Michael M. Welner, M.D.

Participants: Joseph P. Merlino, M.D., Ron Honberg, J.D., Lewis A. Opler, M.D., William F. Foote, Ph.D.

12 noon Sessions

FORUMS 1-3

FORUM 1 12 noon-1:30 p.m.
Room 263, Level 2, Convention Center

ALONG THE DEATH TRAIL: INSIDE THE MIND OF AN EXECUTION TEAM

Chp.: Ira D. Glick, M.D.
Co-Chp.: Howard J. Osofsky, M.D.
Participants: Michael J. Osofsky, Robert Michels, M.D., Robert S. Pynoos, M.D.

FORUM 2 12 noon-1:30 p.m.
Room 352, Level 3, Convention Center

WHY HARRY? WHY NOW? UNDERSTANDING THE HARRY POTTER PHENOMENON

Chp.: Leah J. Dickstein, M.D.
Participants: Professor JoAnne M. Isbey, Elissa P. Benedek, M.D., Daniel P. Dickstein, M.D.

FORUM 3 12 noon-1:30 p.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

DAYCARE: IMPACT ON KIDS

Chp.: Nada L. Stotland, M.D.
Participants: Carol C. Nadelson, M.D., Tanya R. Anderson, M.D., David S. Rue, M.D., Silvia W. Olarte, M.D.

MEDIA SESSION 6
12 noon-2:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

JAZZ AT LUNCH

Chp.: Bruce B. Raeburn, Ph.D.
Co-Chp.: Herbert W. Peterson, M.D.

8 A Century of Satchmo

A Century of Satchmo is an audio-visual lecture on the life, musical career, and significance of New Orleans trumpeter, Louis Armstrong. There will be a viewing of video clips from films, excerpts from oral history interviews, and sample audio recordings to illustrate aspects of his musical style and life story. The lecture will examine such topics as the special contextual features of the New Orleans music scene in the early 20th century; the factors contributing to the development of Armstrong's instrumental and vocal styles; his relationships with Joe Oliver, Lil Hardin, Sidney Bechet, Bessie Smith, and other musicians; and his emergence as one of the dominant musical personalities of the 20th century.

Discussant: Edward K. Ryneearson, M.D.

12:30 p.m. Session

MEDIA SESSION 7
12:30 p.m.-2:00 p.m.
Versailles Ballroom, Third Floor, Hilton

PAIN AND THE MIND: ART AND THE SOUL

Chp.: Sandra C. Walker, M.D.

9 The Art of Being Human (28 minutes)

Distributor Bullfrog Films
for V9 & V10: P.O. Box 149
Oley, PA 19547

The Art of Being Human is an inspirational portrait of the artist, Frederick Franck, author of "The Zen of Seeing." Born on the border of Holland and Belgium, where both World Wars began, Franck has seen first hand the horrors of modern warfare. Living now in upstate New York, his life's work, through painting, sculpture, and books, has been to help people see the humanity in others, so that they will not be able to tolerate or be involved in violence towards others. It's a message with particular significance in the wake of Bosnia, Rwanda, and Oklahoma City.

10 Faces of the Hand (41 minutes)

There is nothing more intriguing than what is hidden behind the obvious. The human hand is a miracle, which we completely take for granted. The work of our hands, in their eloquence, silence, restlessness, creativity, and violence have made human history and continue to shape the present and future. *Faces of the Hand* takes you on a visual journey through different cultures and a range of human experiences and shows the many faces of our hands; working, communicating, creating art and music, expressing our sensuality, used as weapons for defense or aggression; and as instruments for healing and worship. This film is both poetry and anthropology, science and art, sacred and profane. It is an odyssey from cave art thirty millennia ago to robot hands controlled by computers.

1:00 p.m. Sessions



COURSES 51-56
Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 51 1:00 p.m.-5:00 p.m.
La Galerie 2, Second Floor, Marriott

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

COURSE 52 1:00 p.m.-5:00 p.m.

Balcony K, Fourth Floor, Marriott

**INTEGRATIVE PSYCHOTHERAPY SUPERVISION:
BASIC TOOLS**

Director: Paul Rodenhauser, M.D.

Faculty: Ramona Dvorak, M.D., Albert F. Painter, Psy.D.,
John R. Rudisill, Ph.D.

COURSE 53 1:00 p.m.-5:00 p.m.

Waterbury Ballroom, Second Floor, Sheraton

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.

Faculty: Margaret D. Weiss, M.D.

COURSE 54 1:00 p.m.-5:00 p.m.

Pontchartrain Ballroom A, Third Floor, Sheraton

ANTICONVULSANTS IN BIPOLAR DISORDER

Co-Directors: Joseph R. Calabrese, M.D., Terence A. Ketter, M.D.

Faculty: Mark A. Frye, M.D.

COURSE 55 1:00 p.m.-5:00 p.m.

Pontchartrain Ballroom D, Third Floor, Sheraton

PERSONALITY DISORDERS IN THE WORKPLACE

Director: James H. Reich, M.D.

Faculty: David P. Bernstein, Ph.D., Elsa F. Ronningstam, Ph.D.,
Per Vaglum, M.D.

COURSE 56 1:00 p.m.-5:00 p.m.

Bayside Room C, Fourth Floor, Sheraton

**SEXUAL HARASSMENT: PSYCHOLOGICAL AND
LEGAL ASPECTS**

Director: Gail E. Robinson, M.D.

Faculty: Renee L. Binder, M.D., Sharyn A. Lenhart, M.D.,
Michael F. Myers, M.D.

**NEW RESEARCH YOUNG INVESTIGATORS'
ORAL/SLIDE SESSIONS 2-4**

1:00 p.m.-2:30 p.m.

**2 BIOLOGICAL PSYCHIATRY AND
NEUROSCIENCE OF DEPRESSION**

Grand Salon Section 4, Street Level, Hilton

3 FRONTIERS OF PSYCHIATRY

Marlborough Suite A/B, Second Floor, Hilton

**4 BIOLOGICAL PSYCHIATRY AND NEURO-
SCIENCE OF SCHIZOPHRENIA, PEDIATRIC
DEPRESSION, AND PREGNANCY**
Melrose Room, Third Floor, Hilton

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

2:00 p.m. Sessions

LECTURES 6-7

LECTURE 6

2:00 p.m.-3:30 p.m.

Rooms 252-254, Level 2, Convention Center

Ellen Leibenluft, M.D.

**Bipolar Disorder: Using Affective Neuroscience to
Bridge the Gap Between Children and Adults**

Chp.: Carolyn B. Robinowitz, M.D.

Co-Chp.: Brian B. Doyle, M.D.

The increasing frequency with which the diagnosis of Bipolar Disorder is being assigned to young children has sparked considerable controversy. Is the diagnosis being applied too liberally, or has the prevalence of Bipolar Disorder increased? The existence of a significant cohort of children with severe behavioral and emotional dysregulation is unquestioned; the challenge is to identify which children have, or will develop, Bipolar Disorder. Ellen Leibenluft, M.D., discusses recent developments in affective neuroscience that are relevant to understanding the manifestations of Bipolar Disorder across the developmental spectrum. Dr. Leibenluft is Chief of the Unit on Affective Disorders in the Pediatrics and Developmental Neuropsychiatry Branch of the Mood and Anxiety Disorders Program at the National Institute of Mental Health in Bethesda, Maryland. She is also Clinical Associate Professor of Psychiatry at Georgetown University School of Medicine in Washington, D.C. Nationally recognized for her research on Bipolar Disorder, Dr. Leibenluft has also published and spoken widely on issues concerning women in academic psychiatry. She is a member of the Council on Research and the Research Training Committee of the American Psychiatric Association and has served as President of the Association for Academic Psychiatry. Dr. Leibenluft received her medical degree from Stanford University and completed her residency in psychiatry at Georgetown University School of Medicine.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 7

2:00 p.m.-3:30 p.m.
Rooms 338/339, Level 3, Convention Center

Professor Latanya Sweeney

Chp.: Elizabeth Galton, M.D.
Co-Chp.: Victoria Barnes, M.D.

Professor Sweeney is an expert in privacy issues.
Abstract was not available at time of printing this publication.

Distributor: Video Press
University of Maryland
School of Medicine
100 North Greene Street, Suite 300
Baltimore, MD 21201

King Gimp follows the life of Dan Keplinger for 13 years as he moves from a special elementary school to the mainstream. Through his battle with cerebral palsy, he is confined to a wheelchair and unable to communicate easily with words; however, Dan's emotional life explodes on to canvas when he discovers art. This documentary, which is exhilarating in its way, tells the story leading up to how Daniel Keplinger, the flailing man in the wheelchair, tries to force the world to see only the man.

MEDIA SESSIONS 8-9

MEDIA SESSION 8 2:00 p.m.-5:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Alan A. Stone, M.D.

11 *Girl, Interrupted: The Film and the Book*
(150 minutes)

Distributor: Columbia Pictures
Sony Entertainment
10202 W. Washington Boulevard
Culver City, CA 90232

The memoir, *Girl, Interrupted*, was published in 1993, 26 years after Susanna Kaysen's 1967 hospitalization for treatment of her BPD. It described an era of long-term inpatient treatment in psychiatry that no longer exists. Nonetheless, the book won critical acclaim and became a national bestseller. A film version starring Winona Ryder and Angelina Jolie was released in 1999. It is a flawed and banal version of Kaysen's memoir, but is typical of cinematic portrayals of mental disorders and those who try to treat them.

Discussant: Lawrence Hartman, M.D.

MEDIA SESSION 9 2:00 p.m.-5:00 p.m.
Versailles Ballroom, Third Floor, Hilton

IN SPITE OF ADVERSITY: HEALING BY CHALLENGE

Chp.: William G. Reiner, M.D.

12 *King Gimp*
(47 minutes)

13 *Soop on Wheels*
(52 minutes)

Distributor Filmmakers Library
for V13 & Attn: Linda Gottesman
V14: 124 East 40th Street
New York, NY 10016

Everett Soop, a Blackfoot, lives on the Blood Indian Reserve in southern Alberta. Muscular dystrophy has confined him to a wheelchair for several years, but it has not subdued his spirit. He is an outspoken journalist and political cartoonist, a crusader for Native rights, and a man of acerbic wit who has educated himself in anthropology, arts, and philosophy. In *Soop on Wheels*, the filmmaker captures the essence of a man with impressive intellectual and spiritual resources, who has had to face the challenges of being both indigenous and disabled. These problems have been compounded by the loneliness of being set apart from his own people, who fear his illness and are often put off by his controversial stands. Everett's survival tools have been his sense of humor, his artistic gifts, and the spiritual values taught to him by his grandparents.

14 *The Remarkable Story of John/Joan*
(30 minutes)

Eight-month old baby John was the victim of an accident during circumcision, which left him with almost no penis. The next year, when he was almost two, the family brought him to Dr. John Money at Johns Hopkins University Medical School, who advised them to have his testicles surgically removed. The theory was that John could be brought up as a girl; that nurture rather than nature created sexual identity, a theory that had gained some acceptance in the sixties. Following the doctor's advice, the family renamed him Joan, dressed him in frilly dresses and treated him like a little girl. However, beneath the curls and dresses, John/Joan was miserable in his female persona. His twin brother recalls that he was never "feminine." When John was an adolescent, he learned the truth about his birth. Now in his thirties, he had undergone reconstructive surgery that has enabled him to live his life as a man and have a normal sex life.

Discussant: Richard E. D'Alli, M.D.

PRESIDENTIAL SYMPOSIUM

2:00 p.m.-5:00 p.m.

Room 356, Level 3, Convention Center

THE ROYAL ROAD REVISITED: DREAMS IN THE 21ST CENTURY

Chp.: Daniel B. Borenstein, M.D.

Presenters: Harold P. Blum, M.D., Morton F. Reiser, M.D., Eve Caligor, M.D., Mark L. Solms, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

REVIEW OF PSYCHIATRY: SECTION 1

2:00 p.m.-5:30 p.m.

Rooms 343-345, Level 3, Convention Center

TREATMENT OF RECURRENT DEPRESSION: A CALL TO ARMS

Chp.: John F. Greden, M.D.

- 1 **Recurrent Depression and Mania: Their Overwhelming Burden**
John F. Greden, M.D.
- 2 **Recurrent Depression in Women Through the Lifespan**
Sheila Marcus, M.D., Heather A. Flynn, Ph.D.
- 3 **Chronic and Recurrent Depression: Pharmacotherapy and Psychotherapy Combinations**
Robert J. Boland, M.D.
- 4 **Prevention of Recurrences in Bipolar Patients: The Best of the Old and the New**
Charles L. Bowden, M.D.
- 5 **Clinical Prevention of Recurrent Depression: The Need for Paradigm Shifts**
John F. Greden, M.D.

SYMPOSIA 1-29**SYMPOSIUM 1**

2:00 p.m.-5:00 p.m.

Room 262, Level 2, Convention Center

RESIDENTS AND THE PHARMACEUTICAL INDUSTRY: HOW TO MAINTAIN ETHICAL INTEGRITY

Chp.: Ashley D. Wazana, M.D.

Co-Chp.: Annette Granich, M.D.

- A **Deontological and Ethical Considerations in Resident-Industry Interactions**
Francois J. Primeau, M.D.

- B **Residents and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?**
Ashley D. Wazana, M.D.

- C **Induction, Seduction, and Deduction: Teaching the Resident About Physician-Industry Interactions**
Nadeem Bhanji, M.D.

- D **The Pharmaceutical Industry Relations Committee at McGill**
Annette Granich, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2

2:00 p.m.-5:00 p.m.

Room 263, Level 2, Convention Center

RISK FACTORS FOR SCHIZOPHRENIA AND PREVENTION

Chp.: Nigel M. Bark, M.D.

Co-Chp.: Dolores Malaspina, M.D.

- A **Early Associates of Schizophrenia in the 1966 North Finland Birth Cohort**
Juha M. Veijola, M.D., Peter B. Jones, Ph.D., Juha Moring, M.D., Taru H. Makikyro, M.D., Paula Rantakallio, M.D., Matti K. Isohanni, M.D.
- B **Prenatal Infection and Adult Schizophrenia**
Alan S. Brown, M.D.
- C **Risk Factors for the Brain Deviations Associated with Schizophrenia**
Robin M. Murray, M.B., Colm McDonald, Tonmoy Sharma, M.D., Chiara Nosari
- D **Traumatic Brain Injury and Risk for Schizophrenia**
Dolores Malaspina, M.D., Cheryl M. Corcoran, M.D., Stephen V. Faraone, Ph.D., Ming T. Tsuang, M.D., C. Robert Cloninger, M.D., John I. Nurnberger, Jr., M.D., Mary Blehar, Ph.D.
- E **Neurodevelopmental Genes and Risk of Schizophrenia**
Hiroshi Kunugi, M.D., Akihisa Akahane, M.D., Kumiko Fujii, M.D., Hiroshi Tanaka, M.D., Mineko Hattori, Ph.D., Tadafumi Kato, M.D., Shinichiro Nanko, M.D.
- F **Predicting Schizophrenia and Depression: Would You Help or Harm?**
Peter B. Jones, Ph.D., Tim J. Croudace, Ph.D., Jim J. Vanos

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3

2:00 p.m.-5:00 p.m.

Room 264, Level 2, Convention Center

NEW APPROACHES TO IMPROVE LONG-TERM TREATMENT ADHERENCE IN SCHIZOPHRENIA

Chp.: Steven J. Siegel, M.D.

(Continued on next page)

A Treatment Adherence in Schizophrenia

John M. Kane, M.D.

B Psychosocial and Pharmacological Strategies for Improving Treatment Adherence in Schizophrenia

Stephen R. Marder, M.D., Donna A. Wirshing, M.D., William C. Wirshing, M.D.

C "I Am Not Sick, I Don't Need Help!": Helping Patients Accept Treatment

Xavier Amador, Ph.D.

D Caduceus on the Scales of Justice: Legal Interventions to Provide Treatment

Jonathan A. Stanley, J.D.

E A Role for Surgically Implantable Long-Term Neuroleptic Delivery System

Steven J. Siegel, M.D., Karen Winey, Ph.D., Raquel E. Gur, M.D., Robert H. Lenox, M.D., Neel Ghandi, Debbie Ikeda, B.A., Wendy Zhang, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.

Rooms 265/266, Level 2, Convention Center

PTSD: A BIOPSYCHOSOCIAL APPROACH

Chp.: Joel F. Paris, M.D.

A The Stressor Criterion in DSM-IV

Naomi Breslau, Ph.D.

B Individual Difference in Post-Traumatic Response

Marilyn L. Bowman, Ph.D.

C Has PTSD Become a Post-Traumatic Neurosis?

Allan Young, Ph.D.

D Culture, Trauma, and PTSD

Laurence J. Kirmayer, M.D., G. Eric Jarvis, M.D.

E Personality Factors in Susceptibility to PTSD

Joel F. Paris, M.D.

Discussant: Jack M. Gorman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.

Rooms 267-268, Level 2, Convention Center

PERIMENOPAUSE, MOOD, AND COGNITION: THE ROLE OF REPRODUCTIVE HORMONES

Chp.: Claudio N. Soares, M.D.

Co-Chp.: Hadine Joffe, M.D.

A The Modulation of Neurotransmitters by Gonadal Steroids: An Update

David R. Rubinow, M.D.

B The Relationship Between Depression and the Transition to Menopause: Results from a Cohort Study

Lee S. Cohen, M.D., Claudio N. Soares, M.D., Michael W. Otto, Ph.D., Bernard L. Harlow, Ph.D.

C The Role of Estrogen as an Antidepressant Strategy for Perimenopausal Depression

Claudio N. Soares, M.D., Osvaldo P. Almeida, M.D., Lee S. Cohen, M.D.

D The Impact of Estrogen Therapy on Cognition in Perimenopausal and Postmenopausal Women

Hadine Joffe, M.D.

Discussant: Peter J. Schmidt, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 6 2:00 p.m.-5:00 p.m.

Room 269, Level 2, Convention Center

A DEPARTMENT OF PSYCHIATRY'S EXTENSIONS INTO THE COMMUNITY

Chp.: Martin J. Drell, M.D.

A Older Adults: Work and Psychological Well-Being

Patricia Morse, Ph.D., Charles Foti, J.D., Howard J. Osofsky, M.D., Roger Scott, B.A., Barbara Jennings, M.S.W.

B Psychiatry and Welfare to Work

Charles Foti, J.D., Edward V. Morse, Ph.D., Diane Glazer, M.S.W., Howard J. Osofsky, M.D.

C The Violence Intervention: A Community-Based Program for Children and Families

Joy D. Osofsky, Ph.D., Nancy Freeman, L.C.S.W., Michael Rovaris, M.S.W., Amy Dickson, Psy.D.

D Mental Health Evaluations in Police Recruitment and Retention

Howard J. Osofsky, M.D., Penelope Dralle, Ph.D., Wayne Greenleaf, Ph.D., Ben Lousteau, M.B.A.

E A Juvenile, Court-Related After School and Weekend Therapeutic Program

Ernestine S. Gray, J.D., Charles Foti, J.D., Howard J. Osofsky, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 7 2:00 p.m.-5:00 p.m.

Room 270, Level 2, Convention Center

ARAB PERSPECTIVE ON CHILD AND ADOLESCENT PSYCHIATRY

Arab American Psychiatric Association

Chp.: Abdel F. Amin, M.D.

A The Validity of Psychiatric Diagnosis: Application in Children

Ahmed S. Aboraya, M.D., Abdel F. Amin, M.D.

B The Arab Family Structures in Arab Civilizations: A Historical Review

Nasser F. Loza, M.B.

C The Current Status of Child Psychiatry: An Egyptian Perspective

Ahmed M.F. Okasha, M.D.

D Mental Health in Children and Adolescents in Morocco

Driss Moussaoui, M.D., K.H. Chihabeddine

E Disciplinary Practices and Child Maltreatment Among Egyptian Families in an Urban Area in Ismailia

Mohamed H. El-Defrawi, M.D., Fatma Hassan, M.D.,
Amany Refaat, M.D., Hesham El-Sayed

Discussant: David V. Sheehan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8

2:00 p.m.-5:00 p.m.

Room 271, Level 2, Convention Center

EATING DISORDERS: NEW FEATURES AND NEW TREATMENTS

Chp.: Joel Yager, M.D.

Co-Chp.: David B. Herzog, M.D.

A Cognitive Functioning in Anorexia Nervosa

David B. Herzog, M.D., Bonnie J. Sherman, M.A., Kamryn T. Eddy, B.A., Mark A. Blais, Psy.D., Cathelene E. Connor, B.A., Thilo Deckersbach, Ph.D., Scott L. Rauch, M.D., Cary R. Savage, Ph.D.

B Eating Behavior While Driving a Car

James E. Mitchell, M.D., John B. Glass, M.D.

C Cognitive-Behavior Therapy Relapse Predictors for Bulimia Nervosa

Katherine A. Halmi, M.D., W. Stewart Agras, M.D., James E. Mitchell, M.D., Scott J. Crow, M.D., G. Terrence Wilson, Ph.D.

D New Treatment Strategies for Anorexia Nervosa

Walter H. Kaye, M.D., Maria Lavia, M.D., Guido Frank, M.D., Amanda Molina, B.S.

E Adjunctive Treatment of Anorexia Nervosa by E-Mail

Joel Yager, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9

2:00 p.m.-5:00 p.m.

Room 272, Level 2, Convention Center

PSYCHODYNAMIC PSYCHOTHERAPY: CONTEMPORARY ISSUES

APA Commission on Psychotherapy by Psychiatrists and American College of Psychoanalysts

Chp.: Jerald Kay, M.D.

A Psychotherapy in the Spectrum of Antisocial Personality: Possibilities and Limitations

Michael H. Stone, M.D.

B Dynamic Psychotherapy of Women with Cancer of the Reproductive Organs

Jennifer I. Downey, M.D.

C The Psychotherapy of Psychotic Patients

Gerald J. Sarwer-Foner, M.D.

D Computers: Clinical Effects of Today's Blank Screen

Marcia K. Goin, M.D.

Discussant: Richard C. Friedman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 10

2:00 p.m.-5:00 p.m.

Room 273, Level 2, Convention Center

TREATING THE PSYCHIATRICALY ILL HIV PATIENT

Chp.: Marshall Forstein, M.D.

A Treatment Approaches to HIV-Related Neurocognitive Disorders

Francisco Fernandez, M.D.

B Mood Disorders: Depression

Stephen J. Ferrando, M.D.

C Complications of Drug-Drug Interactions

Milton L. Wainberg, M.D.

D Psychotic Disorders

Francine Cournos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11

2:00 p.m.-5:00 p.m.

Rooms 333/334, Level 3, Convention Center

NEW FINDINGS ON PSYCHIATRIC PRACTICE: ACCESS AND PATTERNS OF CARE

Chp.: John S. McIntyre, M.D.

Co-Chp.: Joyce C. West, M.P.P.

A Measuring Quality of Care

John M. Oldham, M.D.

B Integrated Versus Split Treatment: Pharmacotherapy and Psychotherapy for Mood Disorders

Farifteh F. Duffy, Ph.D., Joyce C. West, M.P.P., Deborah A. Zarin, M.D., William E. Narrow, M.D., Diane M. Herbeck, M.A., Anna P. Suarez, M.P.H.

C Axis I and Axis II Comorbidity in Psychiatric Practice

William E. Narrow, M.D., Diana J. Fitek, B.A., Diane M. Herbeck, M.A., Steven C. Marcus, Ph.D.

(Continued on next page)

- D Characteristics of Patients with Substance Use Disorders Affected by Financial Constraints**
Diane M. Herbeck, M.A., Steven C. Marcus, Ph.D., Clifton R. Tennison, Jr., M.D., Laura J. Fochtmann, M.D.

Discussant: Joyce C. West, M.P.P.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 12 2:00 p.m.-5:00 p.m.

Rooms 335/336, Level 3, Convention Center

PTSD IN WOMEN: INTEGRATING MIND AND BRAIN IN TREATMENT

Chp.: Leah J. Dickstein, M.D.

Co-Chp.: Marian I. Butterfield, M.D.

- A Immune Neuroanatomic Neuroendocrine Gender Differences in PTSD**
Rachel Yehuda, Ph.D.
- B The Psychodynamics of Trauma in Women**
Kathryn J. Zerbe, M.D.
- C Domestic Violence, PTSD, and Women of Color**
Tana A. Grady-Weliky, M.D.
- D Treatment of PTSD in Women: Lessons from Women Veterans**
Marian I. Butterfield, M.D., Paula G. Panzer, M.D., Catherine Forneris, Ph.D.
- E Pharmacotherapeutic Treatment for Women with PTSD**
Kathleen T. Brady, M.D.

Discussant: Carol C. Nadelson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.

Room 342, Level 3, Convention Center

PSYCHIATRY, THE INTERVIEW, AND MEDICAL OUTCOMES

Chp.: Joseph S. Weiner, M.D.

Co-Chp.: Steven A. Cole, M.D.

- A New Concepts and Data on the Relationship of the Interview to Outcomes**
Geoffrey H. Gordon, M.D.
- B Adherence and Behavior Change Skills for the Practicing Psychiatrist**
Michael G. Goldstein, M.D.
- C Teaching Skeptical Medical Housestaff Communication Skills with Patients**
M. Philip Lubner, M.D.

- D Depression Education for Primary Care: The MacArthur Foundation Initiative**
Steven A. Cole, M.D., Mary Raju, N.P.

E Learning and Teaching Listening Skills

Joseph S. Weiner, M.D.

Discussant: Don R. Lipsett, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.

Rooms 346/347, Level 3, Convention Center

TRAUMA AND THE LIFE CYCLE: MULTIDISCIPLINARY PERSPECTIVES

Chp.: Randall D. Marshall, M.D.

- A Contemporary Psychodynamic Perspectives on Trauma and Development**
Arieh Y. Shalev, M.D.
- B Integrating Medication and Psychosocial Therapeutic Models in PTSD**
Randall D. Marshall, M.D.
- C Variable Foraging Demand Rearing in Primates: Biobehavioral Sequelae**
Jeremy D. Coplan, M.D., Eric L. P. Smith, Ph.D., Bruce A. Scharf, Shirn Baptiste, Altamash I. Oureshi, M.D., Jack M. Gorman, M.D., Leonard A. Rosenbaum, Ph.D.
- D Ethnocultural Factors in PTSD**
Roberto Lewis-Fernandez, M.D., Bruce Dohrenwend, M.D., J. Blake Turner, Ph.D., Randall D. Marshall, M.D.

E The Cognitive-Affective Science of Trauma and Development

Dan J. Stein, M.D.

Discussant: Charles R. Marmar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.

Rooms 348/349, Level 3, Convention Center

ADDICTIONS: GAMBLING AND SUBSTANCE ABUSE: CUTTING-EDGE TREATMENT

Chp.: Herbert D. Kleber, M.D.

Co-Chp.: David M. McDowell, M.D.

- A Treatment of Cocaine Dependence**
Marian W. Fischman, Ph.D.
- B Treatment of Heroin Dependence**
Herbert D. Kleber, M.D.

C Marijuana Dependence and Club Drug Use: Future Concerns and Possible Strategies for a Generation at Risk
David M. McDowell, M.D.

D Gambling Addictions
Robert W. Johnson, M.D.

E Treatment of Comorbid Conditions
Frances R. Levin, M.D.

Discussant: Edward V. Nunes, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Room 352, Level 3, Convention Center

CHILDHOOD SEXUAL ABUSE: PERPETRATORS AND VICTIMS

Chp.: Igor I. Galynker, M.D.
Co-Chp.: J. Douglas Bremner, M.D.

A Personality Profiles and Childhood Sexual Histories of Male Perpetrators
Lisa J. Cohen, Ph.D., Igor I. Galynker, M.D., Erik Klein, B.A., Aleksey Ten, M.D., Carrie Weaver, M.A., Enid Gertemian-King, B.A., Kenneth Cullen, M.S.W.

B Cerebral Glucose Metabolism and Deviant Sexual Arousal in Male Pedophiles
Igor I. Galynker, M.D., Lisa J. Cohen, Ph.D., Kostantine Nikiforov, M.D., Sara Acker, B.A., Thomas Moesse, Richard N. Rosenthal, M.D., Kenneth Cullen, M.S.W.

C Psychophysiological Reactivity to Stressful Scripts in BPD and PTSD
Christian G. Schmahl, M.D., Bernet M. Elzinga, M.S.C., Thomas H. McGlashan, M.D., J. Douglas Bremner, M.D.

D Role of Hippocampus and Medical Prefrontal Cortex in Abuse-Related PTSD
J. Douglas Bremner, M.D., Meena Narayan, M.D., Eric Vermetten, M.D., Steven M. Southwick, M.D., Thomas H. McGlashan, M.D., L. Viola Vaccarino, M.D., Lawrence H. Staib

Discussant: Clinton D. Kilts, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
Room 357, Level 3, Convention Center

PSYCHOTHERAPY IN THE AMERICAS
Inter-American Council of Psychiatric Organizations

Chp.: Roberto E. Chaskel, M.D.
Co-Chp.: Nestor F. Marchant, M.D.

A Psychotherapy in the General Hospital Setting: A Cultural Experience in Liaison Psychiatry
Rodolfo D. Fahrer, M.D., Amelia E. Musacchio de Zan, M.D.

B Folkloric Roots of Psychiatry and Development of Psychotherapy
Carlos Leon-Andrade, M.D., Ricardo Heinlein, Miguel R. Jorge, M.D.

C Psychotherapy Among Indigenous Caribbean Patients: Folk Traditions and Future
Sharon C. Harvey, M.D.

D Psychotherapy in a Violent Society
Ruben J. Hernandez-Serrano, M.D., Antonio Pacheco, M.D., Roberto E. Chaskel, M.D.

E Phenomenological and Descriptive Legacies in Latin-American Psychiatry
Renato D. Alarcon, M.D.

Discussants: Carlos Berganza, Pedro Ruiz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Grand Salon Sections 3 & 6, Street Level, Hilton

MIND AND BRAIN: THE CONCEPTS OF PSYCHIATRY
Association for the Advancement of Philosophy and Psychiatry

Chp.: S. Nassir Ghaemi, M.D.

A The Methodological View of Neuroscience and Psychoanalysis
Marshal F. Folstein, M.D.

B Overt and Covert Theories of Mind in Psychiatric Education
John Z. Sadler, M.D.

C Mind and Brain Do Not Have to Be Integrated if We Don't Segregate Them in the First Place
Michael A. Schwartz, M.D.

D Mind/Brain Theories in Clinical Psychiatry
S. Nassir Ghaemi, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19 2:00 p.m.-5:00 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

HOW CAN PSYCHIATRISTS IMPACT THE PROBLEM OF SUICIDE AT THE COMMUNITY LEVEL?
APA Alliance

Chp.: Gail S. Fuller, R.N.

A How to Prevent Youth Suicide: Challenges for Psychiatrists
Cynthia R. Pfeffer, M.D.

B Awareness of Suicide Risk in the Community
Jan A. Fawcett, M.D.

C Youth Suicide: Understanding and Prevention
Paul J. Fink, M.D.

Discussant: Paul J. Fink, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20 2:00 p.m.-5:00 p.m.

Grand Salon Sections 9 & 12, Street Level, Hilton

**THINKING ABOUT MIND AND BRAIN:
PSYCHOANALYSTS AND NEUROSCIENTISTS
CONVERSE: PART I**

American Academy of Psychoanalysis and American Psychoanalytic Association

Chp.: Edward Nersessian, M.D.

Co-Chp.: Ann-Louise S. Silver, M.D.

A Is There a Place for an Unconscious in Biological Psychiatry?

Howard Shevrin, Ph.D.

B Affective Neuroscience and Socioemotional Systems of the Brain: Implications for Understanding Psychiatric Disorders

Jaak Panksepp, Ph.D.

C Toward A Neurobiology of the Unconscious

Richard M. Brockman, M.D.

D Psychoanalytic and Neurobiologic Perspectives on Alexithymia

Graeme J. Taylor, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.

Grand Salon Sections 13 & 16, Street Level, Hilton

**ACHIEVING COMPREHENSIVE CARE FOR THE
SUICIDAL INDIVIDUAL**

Chp.: Ian C. Dawe, M.D.

A A Needs-Based Approach to the Care of Suicidal Individuals

Ian C. Dawe, M.D.

B Journey of Care of the Suicidal Patient: St. Michael's-Style Crisis Perspective

Michele K. Cook, R.N.

C Inpatient Management of the Suicidal Patient

Kenneth E. Balderson, M.D.

D Comprehensive Care for the Suicidal Individual: Outpatient Group Intervention

Yvonne Bergmans, M.S.W., Ian C. Dawe, M.D.

E Comprehensive Care for the Suicidal Patient: Research Perspectives

Anne E. Rhodes, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

FRONTIERS OF DEPRESSION IN CHILDREN AND ADOLESCENTS

Chp.: Mohammad Shafii, M.D.

A Neurobiology of Depression and Suicidal Behavior

J. John Mann, M.D.

B Depressed Mothers Identified in Primary Care

Myrna M. Weissman, Ph.D., Adriana Feder, M.D., Daniel J. Pilowsky, M.D., Mark Olfson, M.D., Milton Fuentes, Psy.D.

C Trends in Current Clinical Research on Child and Adolescent Major Depression

Maria Kovacs, Ph.D., Joel T. Sherrill, Ph.D.

D Pharmacology of Child and Adolescent Depression

Neal D. Ryan, M.D.

E Treatment Guidelines and Algorithms in Depressed Children and Adolescents

Graham J. Emslie, M.D.

F Cognitive-Behavioral Treatment and Prevention of Adolescent Depression

Greg Clarke, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.

Grand Salon Sections 21 & 24, Street Level, Hilton

**RESULTS FROM THE TEXAS MEDICATION
ALGORITHM PROJECT (TMAP)**

Chp.: A. John Rush, M.D.

Co-Chp.: Steven P. Shon, M.D.

A The Texas Medication Algorithm Project (TMAP): Rationale and Study Design

A. John Rush, M.D.

B Issues and Tensions in Specifying and Developing Medication Algorithms

M. Lynn Crismon, Pharm.D.

C Results from the Texas Medication Algorithm Project (TMAP) Schizophrenia Treatment Module

Alexander L. Miller, M.D.

D Results from the Texas Medication Algorithm Project (TMAP) Bipolar Disorder Treatment Module

Patricia Suppes, M.D.

E Results from the Texas Medication Algorithm Project (TMAP) Major Depressive Disorder Treatment Module

Madhukar H. Trivedi, M.D.

Discussant: Kenneth Z. Altshuler, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.

Rosedown Room, Third Floor, Hilton

FIELD TESTING DIMENSIONAL MODELS FOR DSM-V AXIS II

Chp.: Robert L. Spitzer, M.D.

Co-Chp.: Michael B. First, M.D.

A Dimensional Representation of DSM-IV Personality Disorders

Andrew E. Skodol II, M.D., John M. Oldham, M.D., Donna S. Bender, Ph.D., Mary C. Zanarini, Ed.D., Ingrid R. Dyck, M.P.H., Charles A. Sanislow, Ph.D., Regina T. Dolan, Ph.D.

B A Stepwise Psychobiological Classification

C. Robert Cloninger, M.D.

C A Two-Component Adaptational Model for Classifying Personality Disorders

John Livesley, M.D., Kerry L. Jang, Ph.D.

D Clinical Application of the Five Factors of Personality

Thomas A. Widiger, Ph.D.

E A Prototype-Matching Approach to Diagnosis of Personality Disorders

Drew Westen, Ph.D., Jonathon Shedler, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.

Magnolia Room, Third Floor, Hilton

ADHD: A LIFE CYCLE PERSPECTIVE

Chp.: Thomas J. Spencer, M.D.

A ADHD Across the Life Cycle: Symptomatology and Validity

Thomas J. Spencer, M.D.

B Neuropsychology Deficits and Symptomatology of ADHD

Rosemary Tanneck, Ph.D.

C ADHD and Alcohol or Drug Abuse

Timothy E. Wilens, M.D.

D A Novel Nonstimulant Therapy for ADHD: New Data from Controlled Trials

David Michelson, M.D., Joachim Wernicke, M.D., Thomas J. Spencer, M.D., John H. Heiligenstein, M.D., Douglas Faries, Ph.D.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.

Jasperwood Room, Third Floor, Hilton

EXERCISE, ATHLETIC PARTICIPATION, AND MENTAL HEALTH: WHEN IT WORKS AND WHEN IT DOESN'T

International Society for Sport Psychiatry

Chp.: Ronald L. Kamm, M.D.

A Exercise and Its Positive Impact on Mental Health

Robert W. Burton, M.D., Ronald L. Kamm, M.D.

B When the Athlete Has an Emotional Disorder: Special Psychopharmacological Considerations

Antonia L. Baum, M.D.

C The Role of the Family in an Athlete's Emotional Life

Ian R. Tofler, M.D.

Discussants: Derrick Adkins, Gerald A. Cooney, Julie Krone
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.

Oak Alley Room, Third Floor, Hilton

WOMEN'S MENTAL HEALTH: A CURRENT PERSPECTIVE

Chp.: Susan G. Kornstein, M.D.

Co-Chp.: Mary Blehar, Ph.D.

A Psychiatric Aspects of Hormonal Contraception

Julia K. Warnock, M.D.

B Depression in Women

Susan G. Kornstein, M.D.

C Female Sexual Dysfunction

Anita L.H. Clayton, M.D.

D Women with Cancer: Psychosocial Issues in Breast, Gynecologic, and Lung Cancer

Elisabeth J. S. Kunkel, M.D., Emmie Chen, M.S.

E Career and Workplace Issues for Women

Diane K. Shrier, M.D.

Discussant: Mary Blehar, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.

Elmwood Room, Third Floor, Hilton

CULTURAL IDENTITY AND QUALITY OF LIFE

The World Psychiatric Association

Chp.: Juan E. Mezzich, M.D.

Co-Chp.: Harold I. Eist, M.D.

A Asian-American Culture, Spirituality, and Quality of Life

Nalini V. Juthani, M.D.

B Identification at a Different Place and Time

Ezra E.H. Griffith, M.D.

(Continued on next page)

C Latino Biculturalism and Quality of Life

Juan E. Mezzich, M.D., Maria A. Ruiperez, Ph.D.

D European Cultures, Identity, and Quality of Life

Heinz Katschnig, M.D.

E Australian Cultures and Quality of Life

Helen E. Herrman, M.D., Hilary L. Schofield, Ph.D., Barbara Murphy, Ph.D.

Discussants: Marianne C. Kastrup, M.D., John L. Cox, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29

2:00 p.m.-5:00 p.m.

Belle Chasse Room, Third Floor, Hilton

**GROUP THERAPY FOR BREAST CANCER:
INTERNATIONAL RANDOMIZED TRIALS**

Chp.: David Spiegel, M.D.

**A Australian RCTs of Group Therapy for Breast Cancer:
Outcome Data**

David W. Kissane, M.D., Sydney Bloch, M.D., David M. Clarke, Ph.D., Graeme C. Smith, M.D., Dean P. McKenzie, B.A., Anthony Love, Ph.D., Jillian Ikin, B.A.

**B Group Therapy for Metastatic Breast Cancer: A
Randomized Trial**

David Spiegel, M.D., Catherine Classen, Ph.D., Lisa Butler, Ph.D., Janine Giese-Davis, Ph.D., Robert Carlson, M.D., Cheryl Koopman, Ph.D.

**C Supportive-Expressive Group Therapy for Women with
Breast Cancer: A Danish Experience**

Anders Bonde-Jensen, Ph.D., Marianne Lau, Ph.D., Carsten Rose, M.D.

**D Support Group for Women at Genetic Risk for Breast
and Ovarian Cancer**

Kathryn M. Kash, Ph.D., Mary-Kay Dabney, M.S., Jimmie C. Holland, M.D.

**E Psychosocial Distress and Group Intervention Among
Breast Cancer Patients**

Luigi Grassi, M.D., Katia Magnani, Ph.D., Marino Gatti, M.D., Diletta Aguiari, Ph.D., Silvana Sabato, Ph.D., Alessandra Marsillo, M.D.

**F Group Therapy for Primary Breast Cancer: A
Randomized, Multicenter Trial**

Catherine Classen, Ph.D., David Spiegel, M.D., Cheryl Koopman, Ph.D., Gail Stonisch-Riggs, M.S.W., Joan Westendord, R.N., Gary Morrow, Ph.D.

Discussant: Jimmie C. Holland, M.D.

THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

**NEW RESEARCH YOUNG INVESTIGATORS'
POSTER SESSION 5**

3:00 p.m.-5:00 p.m.

Exhibition Center, Second Floor, Hilton

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

7:30 p.m. Session

CONVOCATION OF FELLOWS

7:30 p.m.

Hall G, Lobby Level, Convention Center

All Fellows, members, and registered guests are invited.

Presiding: Daniel B. Borenstein, M.D., *President*

Grand Marshals: Max Sugar, M.D., Gene L. Usdin, M.D.

Marshals: Irma J. Bland, M.D., Dudley M. Stewart, Jr., M.D.

INTRODUCTION OF LIFE FELLOWS

Richard K. Harding, M.D., *President-Elect*

INDUCTION OF FELLOWS

Richard K. Harding, M.D.

**INTRODUCTION OF FIFTY-YEAR LIFE
FELLOWS, LIFE MEMBERS, INTER-
NATIONAL FELLOWS, AND
DISTINGUISHED FELLOW**

Daniel B. Borenstein, M.D.

**PRESENTATION OF SPECIAL
PRESIDENTIAL COMMENDATIONS**

Daniel B. Borenstein, M.D.

**PRESENTATION OF DISTINGUISHED
SERVICE AWARDS**

Daniel B. Borenstein, M.D.

**INTRODUCTION OF THE MEMBERSHIP
COMMITTEE CHAIRPERSON AND AWARD
BOARD CHAIRPERSONS**

Daniel B. Borenstein, M.D.

PRESENTATION OF AWARDS

Daniel B. Borenstein, M.D.

APA Award for Research in Psychiatry
APA/Lilly Resident Research Awards
Human Rights Award

Blanche F. Ittleson Award for Research
in Child Psychiatry
Kempf Fund Awards for Research Development in
Psychobiological Psychiatry
Agnes Purcell McGavin Awards
Robert T. Morse Writers Awards
Isaac Ray Award
Robert L. Robinson Award
Jack Weinberg Memorial Award for
Geriatric Psychiatry

**WILLIAM C. MENNINGER MEMORIAL
CONVOCAION LECTURE**

Harrison H. Schmitt, Ph.D.

LECTURE 8

7:30 p.m.-9:00 p.m.

Hall G, Lobby Level, Convention Center

**WILLIAM C. MENNINGER MEMORIAL
LECTURE**

Harrison H. Schmitt, Ph.D.

A Trip to the Moon and Beyond

Harrison H. Schmitt, Ph.D., a native of Silver City, NM, has the diverse experience of a geologist, pilot, astronaut, administrator, businessman, writer, and U. S. Senator. He received his B.S. in Science at Caltech, studied as a Fulbright Scholar at Oslo, and attended graduate school at Harvard. He received his Ph.D. in geology in 1964 based on geological field studies in Norway. As a civilian, he received Air Force jet pilot wings in 1965 and Navy helicopter wings in 1967. Selected for the Scientist-Astronaut program in 1965, he organized the lunar science training for the Apollo Astronauts, represented the crews during the development of hardware and procedures for lunar surface exploration, and oversaw the final preparation of the Apollo Lunar Module Descent Stage. He was designated Mission Scientist in support of the Apollo 11 mission. After training as back-up Lunar Module Pilot for Apollo 15, Dr. Schmitt served in that same capacity on Apollo 17 - the last Apollo mission to the moon. On December 11, 1972, he landed in the Valley of Taurus-Littrow as the only scientist and the last of 12 men to step on the Moon. In 1975, after two years managing NASA's Energy Program Office, Dr. Schmitt fulfilled a long-standing personal commitment by entering politics in 1976. He served in the U.S. Senate from 1977 through 1982, representing his home state of New Mexico. Senator Schmitt was a member of the Senate Commerce, Banking, Appropriations, Intelligence, and Ethics Committees. In his last two years in the Senate, he held the position of Chairman of the Subcommittee on Science, Technology, and Space and of the Appropriations Subcommittee on Labor, Health

and Human Services, and Education. He later served on the President's Foreign Intelligence Advisory Board, the President's Commission on Ethics Law Reform, as Co-Chairman of the International Observer Group for the 1992 Romanian elections, as Vice Chairman of the U.S. delegation to the 1992 World Administrative Radio Conference in Spain, and as chairman of the Technical Advisory Board for the U.S. Army Research Laboratory. Harrison Schmitt consults, speaks, and writes on policy issues of the future, space, and the American Southwest. He presently is Chair Emeritus of The Annapolis Center (risk assessment evaluation) and holds an appointment as Adjunct Professor in the Department of Engineering, University of Wisconsin-Madison, teaching "Resources from Space." His corporate board memberships include Orbital Sciences Corporation, PhDx Systems, Inc., Magplane Technology, Inc., and he is a Member of the Corporation of the Draper, Laboratory. He is a founder and the Chairman of Interlune-Intermars Initiative, Inc., advancing the private sector's acquisition of lunar resources and He-three fusion power and broad clinical use of medical isotopes produced by fusion-related processes. Dr. Schmitt's honors include 1973 Arthur S. Fleming Award, 1973 Distinguished Graduate of Caltech, 1973 Caltech Sherman Fairchild Scholar, NASA Distinguished Service Award, Fellow of the AIAA, Honorary Member of the Norwegian Geographical Society and Geological Association of Canada, 1989 Lovelace Award (space biomedicine), 1989 G.K. Gilbert Award (planetology), and Honorary Fellow of the Geological Society of America, American Institute of Mining, and Geological Society of London. Dr. Schmitt has received several honorary degrees from U.S. and Canadian Universities.

THIS SESSION WILL BE AUDIOTAPED.

CALL FOR PAPERS

PRESIDENT'S THEME: The 21st Century Psychiatrist

*Richard K. Harding, M.D.
President*

*Philip R. Muskin, M.D., Chairperson
Scientific Program Committee*

THE SUBMISSION SCHEDULE

Format	Deadline
Industry-Supported Symposium	June 4, 2001
Course	September 4, 2001
Media	September 4, 2001*
Reports	September 4, 2001
Symposium	September 4, 2001
Workshops	Issue: September 4, 2001 Component: September 17, 2001
New Research	January 4, 2002

Incomplete and/or Incorrect Forms Will Not Be Considered.

*A single copy of the media item *must be included* with submission material.

For complete submission forms, contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.



If you want to volunteer to chair a session, please send a letter to the attention of Dr. Muskin at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

TUESDAY, MAY 8, 2001

154TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 27-32

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 2

7:00 a.m.-8:30 a.m.

La Nouvelle Ballroom, Level 2, Convention Center

OPTIMIZING TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC DEPRESSION

Supported by Bristol-Myers Squibb Company

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

A Maximizing Patient Satisfaction During the Long-Term Treatment of Depression

Susan G. Kornstein, M.D.

B Pharmacoeconomic and Psychosocial Outcomes in the Management of Chronic Depression

Robert M.A. Hirschfeld, M.D.

Discussant: Robert M.A. Hirschfeld, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom A/B, Street Level, Hilton

WOMEN'S MENTAL HEALTH: ANTIDEPRESSANT THERAPY DURING THE CHILDBEARING YEARS

Supported by Forest Laboratories, Inc.

Chp.: Lori L. Altshuler, M.D.

A The Treatment of Postpartum Depression: Risks and Benefits to Mother and Child

Victoria Hendrick, M.D.

B Treatment Guidelines for Breastfeeding

Zachary S. Stowe, M.D., Amy L. Hostetter, B.A.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom C/D, Street Level, Hilton

COMPARING ATYPICAL ANTIPSYCHOTIC THERAPIES: MAKING SENSE OF THE DATA

Supported by AstraZeneca Pharmaceuticals

Chp.: Rajiv Tandon, M.D.

A Beyond Efficacy and Symptom Control: Effectiveness as the Best Measure of Antipsychotic Drug Therapy

Henry A. Nasrallah, M.D.

B Optimizing Optimistically: Getting the Most Out of the Atypical Antipsychotics

Peter J. Weiden, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 2

7:00 a.m.-8:30 a.m.

Acadia Ballroom, Third Floor, Marriott

MOOD AND ANXIETY DISORDERS IN UNDERSTUDIED POPULATIONS

Supported by SmithKline Beecham Pharmaceuticals

Chp.: Karen D. Wagner, M.D.

A The Cancer Patient with Depression

Dominique L. Musselman, M.D.

B Psychiatric Implications of Menopause

Dwight L. Evans, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, PART 2

7:00 a.m.-8:30 a.m.

Carondelet Ballroom, Third Floor, Marriott

WEIGHING THE OPTIONS FOR MANAGING BIPOLAR DEPRESSION

Supported by Glaxo Wellcome Inc.

Chp.: Gary S. Sachs, M.D.

A Interpersonal and Social Rhythm Therapy Prevents Depressive Symptomatology for Bipolar I Disorder

Ellen Frank, Ph.D.

B Bipolar Depression: Continuation-Phase Options

Gary S. Sachs, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, PART 2

7:00 a.m.-8:30 a.m.

Mardi Gras Ballroom, Third Floor, Marriott

THE IMPULSIVE AGGRESSIVE SPECTRUM: CHALLENGING POPULATIONS

Supported by Abbott Laboratories

Chp.: Eric Hollander, M.D.

A Anticonvulsants as Adjunctive Treatment in Psychosis

Daniel E. Casey, M.D.

B Aggression, Violence, and Psychopathology: From Adolescence to Adulthood

Hans Steiner, M.D.

8:00 a.m. Sessions**COURSES 57-64**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 57 8:00 a.m.-12 noon
La Galerie 2, Second Floor, Marriott

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 58 8:00 a.m.-12 noon
La Galerie 4, Second Floor, Marriott

ECT IN NEUROLOGICAL DISORDERS

American Neuropsychiatric Association

Co-Directors: Georgios Petrides, M.D., Charles H. Kellner, M.D.
Faculty: C. Edward Coffey, M.D., Max Fink, M.D., Keith Rasmussen, M.D., Raymond A. Faber, M.D.

COURSE 59 8:00 a.m.-12 noon
La Galerie 5, Second Floor, Marriott

FUNDAMENTAL KNOWLEDGE NEEDED FOR CLINICAL WORK WITH INFANTS AND TODDLERS

Harris Center for Infant Mental Health

Co-Directors: Martin J. Drell, M.D., Howard J. Osofsky, M.D.
Faculty: Joy D. Osofsky, Ph.D., Jean M. Thomas, M.D., Harry H. Wright, M.D., Charles H. Zeanah, M.D.

COURSE 60 8:00 a.m.-12 noon
Bacchus Room, Fourth Floor, Marriott

INTRODUCTION TO CORRECTIONAL PSYCHIATRY

Co-Directors: James E. Dillon, M.D., Lee H. Rome, M.D.
Faculty: Richard S. Jackson, M.D., Sanjeev Venkataraman, M.D.

COURSE 61 8:00 a.m.-12 noon
Balcony M, Fourth Floor, Marriott

TRAINING IN THE USE OF THE POSITIVE AND NEGATIVE SYNDROME SCALE

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 62 8:00 a.m.-12 noon
Balcony N, Fourth Floor, Marriott

DEALING WITH RESISTANCE IN ADDICTION PATIENTS

Director: David Mee-Lee, M.D.

COURSE 63 8:00 a.m.-12 noon
Waterbury Ballroom, Second Floor, Sheraton

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.
Faculty: Margaret D. Weiss, M.D.

COURSE 64 8:00 a.m.-12 noon
Bayside Room C, Fourth Floor, Sheraton

DOING RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

9:00 a.m. Sessions**CLINICAL CASE CONFERENCE 2**

9:00 a.m.-10:30 a.m.

Room 263, Level 2, Convention Center

A VITAL ROLE FOR PSYCHOTHERAPY IN NEUROPSYCHIATRY: BODY IMAGE ANXIETY IN HUNTINGTON'S DISEASE

Presenter: Stuart W. Taylor, M.D.
Discussant: Gary J. Tucker, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE: PART 2

9:00 a.m.-12 noon

Room 262, Level 2, Convention Center

COGNITIVE-BEHAVIORAL THERAPY: A CASE OF COMORBID MAJOR DEPRESSION, PERSONALITY DISORDER, AND EPISODIC ALCOHOL ABUSE

Presenter: Anton C. Trinidad, M.D.
Discussant: Stephen P. McDermott, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

**COURSES 65-70**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 65 9:00 a.m.-4:00 p.m.

La Galerie 6, Second Floor, Marriott

ADVANCED HYPNOSIS: APPLICATIONS IN PSYCHIATRY

Director: Jose R. Maldonado, M.D.

Faculty: David Spiegel, M.D.

COURSE 66 9:00 a.m.-4:00 p.m.

Balcony K, Fourth Floor, Marriott

TRANSPERSONAL PSYCHIATRY: CLINICAL APPLICATIONS

Co-Directors: John F. Hiatt, M.D., William W. Foote, M.D.

COURSE 67 9:00 a.m.-4:00 p.m.

Pontchartrain Ballroom A, Third Floor, Sheraton

A PRACTICAL APPROACH TO HERBS AND NUTRIENTS IN PSYCHIATRY

Director: Richard P. Brown, M.D.

Faculty: Patricia L. Gerbarg, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.

Pontchartrain Ballroom D, Third Floor, Sheraton

WORKING WITH EMOTION IN PSYCHOTHERAPY

Director: Richard D. Lane, M.D.

Faculty: Leslie S. Greenberg, Ph.D.

COURSE 69 9:00 a.m.-4:00 p.m.

Bayside Room B, Fourth Floor, Sheraton

INTERPERSONAL PSYCHOTHERAPY

Co-Directors: Scott P. Stuart, M.D., Michael W. O'Hara, Ph.D.

Faculty: Michael D. Robertson, M.D.

COURSE 70 9:00 a.m.-4:00 p.m.

Grand Ballroom E, Fifth Floor, Sheraton

OUTCOMES: USE OF RATING SCALES

Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.

Faculty: Sudeep Kundu, Ph.D., C. Raymond Bingham, Ph.D.

DISCUSSION GROUPS 6-9

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

6 Deborah Spitz, M.D., on Why Hospitalize?
Chequers Suite, Second Floor, Hilton

7 Catherine A. Crone, M.D., on Consultation-Liaison
Psychiatry: Career and Subspecialization Opportunities at the
Medicine-Psychiatry Interface (*For Residents Only*)
Trafalgar Suite, Third Floor, Hilton

8 L. Lee Tynes, M.D., on Screening and Treating Depression
in Primary Care: Let's Be Realistic!
Norwich Suite, Third Floor, Hilton

9 James H. Scully, Jr., M.D., on Academic-Public Psychiatry:
Thriving and/or Surviving
Durham Suite, Third Floor, Hilton

LECTURES 9-10**LECTURE 9**

9:00 a.m.-10:30 a.m.

Rooms 252-254, Level 2, Convention Center

Robert Sapolsky, Ph.D.

Gene Therapy and Its Potential Applications to Psychiatry

Chp.: Joel J. Wallack, M.D.

Co-Chp.: David H. Taylor, M.D.

Gene therapy involves the transfer into diseased tissue of protective transgenes or of antisense sequences meant to block expression of native genes that results in pathology. Such interventions in the central nervous system are particularly challenging. Robert Sapolsky, Ph.D., reviews the techniques underlying gene therapy in the nervous system, discusses the use of gene therapy to protect neurons from neurological diseases, and explores the potential applicability of gene therapy to psychiatric disorders. Dr. Sapolsky is Professor of Biological Sciences at Stanford University and Professor of Neurology and Neurological Sciences at Stanford University School of Medicine. A Fellow of the American Association for the Advancement of Science, he has received the John D. and Catherine T. MacArthur Foundation Fellowship, the A.B. Bennett Award from the Society of Biological Psychiatry, the C. Richter Award from the International Society of Psychoneuroendocrinology, and the Young Investigator Award from the Society for Neuroscience. He is

(Continued on next page)

the author of the books *Stress, the Aging Brain, and the Mechanisms of Neuron Death* and *Why Zebras Don't Get Ulcers: An Updated Guide to Stress, Stress-Related Disease, and Coping*, as well as more than 250 scientific papers and book chapters. Dr. Sapolsky received his doctoral degree in neuroendocrinology from Rockefeller University in New York City.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 10

9:00 a.m.-10:30 a.m.

Rooms 338/339, Level 3, Convention Center

APA'S SOLOMON CARTER FULLER AWARD LECTURE

Ezra E.H. Griffith, M.D.

Authentic Representation, Belonging, and the
Narrative of Self-Identification

Chp.: Patrice A. Harris, M.D.

Co-Chp.: Michelle O. Clark, M.D.

The minority professional's task of self-identification occurs in the context of pragmatic influences, including the social insistence that minority professionals must be aware that they represent a minority community and that such representation must be authentic. Ezra E. H. Griffith, M.D., uses narrative discourse to explore the process of minority individuals' self-identification and the context of enmeshed colonialism, racialism, and religion that impacts that process. Dr. Griffith is Professor and Deputy Chairman for Clinical Affairs in the Department of Psychiatry at Yale University School of Medicine and Professor of African-American Studies at Yale University. His most recent book, *Race and Excellence: My Dialogue with Chester Pierce*, was published in 1998. He was named Editor of the *Journal of the American Academy of Psychiatry and the Law* in 1999. Dr. Griffith has served on several components of the APA, including the Committee on Black Psychiatrists, the Council on Psychiatry and Law, the Council on International Affairs, and the Ethics Committee. Dr. Griffith has served as President of the American Board of Forensic Psychiatry, Black Psychiatrists of America, the American Academy of Psychiatry and the Law, and the American Orthopsychiatric Association. He received his medical degree at the University of Strasbourg in Strasbourg, France, and completed his residency in psychiatry at Albert Einstein College of Medicine in the Bronx, New York.

MASTER EDUCATOR CLINICAL CONSULTATIONS 7-8

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 7 Eric R. Marcus, M.D., on Adult Patients with Comorbid Mood and Personality Disorders
Room 340, Level 3, Convention Center

- 8 Donald C. Fidler, M.D., on the Journey: Exploring Learning with Our Students (*AAP Council on Education Master Teacher*)

Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 10-11

MEDIA SESSION 10

9:00 a.m.-11:00 p.m.

Napoleon Ballroom, Third Floor, Hilton

HATE, RACISM, AND YOUTH

Chp.: Jonathan M. Metzl, M.D.

15 Invisible Revolution

(55 minutes)

Distributor: Filmmakers Library

Attn: Linda Gottesman

124 East 40th Street

New York, NY 10016

This disturbing documentary profiles a chilling subculture among American youth. For over a decade, the clash between racist and antiracist youth has been virtually invisible, but now, younger members are taking control of the white supremacy movement. Rising against them are a group of antiracist skinheads, punk rockers, and mainstream kids who call themselves the Antiracist Action (ARA). These groups are often indistinguishable as they battle each other. This hard-hitting film, with its strong language and extreme expressions of racism, will awaken audiences to a frightening adolescent phenomenon.

MEDIA SESSION 11

9:00 a.m.-11:00 a.m.

Versailles Ballroom, Third Floor, Hilton

POISONING THE BRAIN, ALTERING THE MIND

Chp.: Cheryl A. Kennedy, M.D.

16 Methamphetamine: From the Streets of San Diego

(27 minutes)

Distributor: University of California Extension Center

for Media and Independent Learning

2000 Center Street, 4th Floor

Berkeley, CA 94704

Lurking behind San Diego's sunny image of swaying palm trees and beautiful beaches is a drug subculture that is so pervasive that it affects the lives of most Americans. This subculture knows no social boundaries. School-age children, affluent women, and the working class have all been seduced by the intoxicating effects of methamphetamines, only to lose control of their lives.

This chilling investigative documentary explores the reasons why San Diego became the center of methamphetamine production and distribution in America. The film traces the history of the drug, examines its effects on the user, and demonstrates how it has been a factor in some of the nation's most bizarre and violent crimes and contributed to the flooding of courts, jails, and hospital emergency rooms with meth-related cases.

17 Drinking Apart: Families Under the Influence
(71 minutes)

Distributor: Films for Humanities & Science
P.O. Box 2053
Princeton, NJ 08543

Millions of Americans wrestle with a drug or alcohol problem during their lives, usually without the aid of counseling, but at Ackerman Institute for the Family, teams of counselors help many to regain their freedom. This program tracks the progress of a husband and wife, a mother and teenage daughter, and a young couple over a three-year period as they fight their way to recovery. Candidly filmed at Ackerman, at Addicts Rehabilitation Center in New York City, and even in the subjects' homes, the documentary provides valuable insights into both the devastating effects of drug and alcohol dependence on different types of relationships and the methods being used to assist in breaking addictions.

Discussant: Kenneth P. Rosenberg, M.D.

RESEARCH ADVANCES IN MEDICINE

9:00 a.m.-11:00 a.m.

Rooms 265/266, Level 2, Convention Center

BRAIN SCIENCE: FROM IMAGING TO IMPLANTS

Chp.: Michelle L. Kramer, M.D.
Co-Chp.: Kathleen G. Lapp, M.D.

Participants: Carol A. Tamminga, M.D., on *New Direction in In Vivo Brain Imaging*
Larry A. Carver, M.D., on *Schizophrenia and the Thalamus: A New Paradigm*
Christine E. Marx, M.D., on *Neurosteroids in Psychiatry*
Bryan Payne, M.D., on *The Expanding Role of CNS Electrical Stimulation*

REVIEW OF PSYCHIATRY: SECTION 2

9:00 a.m.-12 noon

Rooms 343-345, Level 3, Convention Center

PTSD IN CHILDREN AND ADOLESCENTS

Chp.: Spencer Eth, M.D.

6 Evaluation and Assessment of PTSD in Children and Adolescents
Wilfred G. van Gorp, Ph.D.

7 Forensic Aspects of PTSD in Children and Adolescents
James E. Rosenberg, M.D.

8 PTSD in Children and Adolescents in the Juvenile Justice System

William Arroyo, M.D.

9 Biological Treatment of PTSD in Children and Adolescents

Soraya Seedat, M.D.

10 The Relationship Between Childhood Traumatic Experiences and PTSD in Adults

Rachel Yehuda, Ph.D.

TELECOMMUNICATIONS SESSION 1

9:00 a.m.-12 noon

Rooms 260/261, Level 2, Convention Center

DIGITAL PROSPECTS: TELEPSYCHIATRY AND MULTIMEDIA APPLICATIONS

Chp.: Norman E. Alessi, M.D.

9:15 a.m.

1 Evaluation of a Web-Based Intervention for Depression in Pregnant Women

Sheila Marcus, M.D., Heather A. Flynn, Ph.D., Kristen L. Barry, Ph.D.

10:00 a.m.

2 Use of a CD-ROM Multimedia Interactive System to Teach Interviewing Skills

Alfredo Calcedo-Barba, M.D., Juan J. Lopez-Ibor, Jr., M.D., Maria I. Lopez-Ibor, M.D.

11:00 a.m.

3 Prison Telepsychiatry: Realities and Prospects

Zebulon C. Taintor, M.D., Susan Ducate, M.D., Robert D. Miller, M.D., William M. Tucker, M.D., Alexander Bardey, M.D.

WORKSHOPS

COMPONENTS 17-27

COMPONENT WORKSHOP 17 9:00 a.m.-10:30 a.m.

Room 264, Level 2, Convention Center

DEFINING BOUNDARIES IN MEDICAL EDUCATION: ETHICS APPLIED BY ROLE PLAYING
APA Rhode Island Psychiatric Society's Committee on Women

Co-Chps.: Alison M. Heru, M.D., Christine E. Rayner, M.D.
Participants: Patricia R. Recupero, M.D., Marilyn Price, M.D.

COMPONENT WORKSHOP 18 9:00 a.m.-10:30 a.m.

Rooms 267-268, Level 2, Convention Center

PREDICTION OF DANGEROUSNESS IN PATIENTS
APA Task Force on Psychiatric Aspects of Violence

Co-Chps.: Paul J. Fink, M.D., Bradley R. Johnson, M.D.
Participants: Renee L. Binder, M.D., Judith Becker, Ph.D.

COMPONENT WORKSHOP 19 9:00 a.m.-10:30 a.m.

Room 270, Level 2, Convention Center

THE INDIVIDUAL VERSUS THE STATE: PATIENTS' PRIVACY AND ABUSES OF PSYCHIATRY*APA Committee on Misuse and Abuse of Psychiatry and Psychiatrists***Chp.:** Renato D. Alarcon, M.D.**Participants:** Abraham L. Halpern, M.D., John H. Halpern, M.D., Jose E. De La Gandara, M.D.**COMPONENT WORKSHOP 20** 9:00 a.m.-10:30 a.m.

Room 271, Level 2, Convention Center

LEGAL, ETHICAL, AND PRACTICE IMPLICATIONS OF DOT-COM PSYCHIATRY*APA Council on Psychiatry and Law and APA Committee on Information Technology***Chp.:** Jeffrey L. Metzner, M.D.**Participants:** Ronnie S. Stangler, M.D., Nicholas Terry, J.D.**COMPONENT WORKSHOP 21** 9:00 a.m.-10:30 a.m.

Room 273, Level 2, Convention Center

THE COLOR OF DEATH: SUICIDE AND ITS MYTHS IN SPECIAL POPULATIONS*APA/Center for Mental Health Services Minority Fellows and APA/AstraZeneca Minority Fellows***Co-Chps.:** N. Kalaya Okereke, M.D., F. Ada Ifesinachukwu, M.D.**Participants:** Serena Y. Volpp, M.D., Veronica L. Williams, M.D., Angelica J. Long-Harrell, M.D., Andres J. Pumariega, M.D., Debbie R. Carter, M.D.**COMPONENT WORKSHOP 22** 9:00 a.m.-10:30 a.m.

Rooms 346/347, Level 3, Convention Center

THE COST OF PTSD: A CRISIS WE CAN PREVENT*APA Consortium on Treatment Issues***Co-Chps.:** Robert F. Dobyns, M.D., Sandra L. Bloom, M.D.**Participants:** Richard J. Kessler, D.O., Lawrence C. Sack, M.D.**COMPONENT WORKSHOP 23** 9:00 a.m.-10:30 a.m.

Rooms 348/349, Level 3, Convention Center

FEAR, FANTASY, AND THE REALITY OF PSYCHIATRIC PRACTICE IN THE NEW MILLENNIUM FOR IMGs*APA Committee of International Medical Graduates***Chp.:** Gopalakrishna K. Upadhyay, M.D.**Participants:** Chowallur D. Chacko, M.D., Fructuoso R. Irigoyen-Rascon, M.D., Moitri N. Datta, M.D.**COMPONENT WORKSHOP 24** 9:00 a.m.-10:30 a.m.

Rooms 350/351, Level 3, Convention Center

STALKING: THE PSYCHIATRIC TRAINEE AT RISK*APA Committee of Residents and Fellows***Co-Chps.:** Geoffrey M. Gabriel, M.D., Kira D. Stein, M.D.**Participants:** Alexa L. Bagnell, M.D., Jessica G. Roberts, M.D., Surender P. Punia, M.D., Jason M. Andrus, M.D., Samson J. Cho, M.D., Alexandra C. Obiora-Oputa, M.D.**COMPONENT WORKSHOP 25** 9:00 a.m.-10:30 a.m.

Grand Salon Section 4, Street Level, Hilton

NOVEL CAREER DEVELOPMENTS IN ADDICTION PSYCHIATRY*APA Council on Addiction Psychiatry***Co-Chps.:** Lydia O. Fazzio, M.D., Marianne T. Guschwan, M.D.**Participants:** Shelly F. Greenfield, M.D., Sheldon I. Miller, M.D., Jonathan I. Ritvo, M.D.**COMPONENT WORKSHOP 26** 9:00 a.m.-10:30 a.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART I*APA Committee of Early Career Psychiatrists***Co-Chps.:** William E. Callahan, Jr., M.D., Keith W. Young, M.D.**Participants:** Jacqueline Melonas, J.D., Martin G. Tracy, J.D.**COMPONENT WORKSHOP 27** 9:00 a.m.-10:30 a.m.

Prince of Wales Suite, Second Floor, Hilton

STUDIES ON INTEGRATION OF MENTAL HEALTH AND PRIMARY CARE IN THE VETERANS ADMINISTRATION*APA Consortium on Organized Service Systems***Co-Chps.:** Laurent S. Lehmann, M.D., Frederick G. Guggenheim, M.D.**Participants:** Benjamin G. Druss, M.D., Bradford L. Felker, M.D., Lisa B. Dixon, M.D.**ISSUES 32-50****ISSUE WORKSHOP 32** 9:00 a.m.-10:30 a.m.

Room 269, Level 2, Convention Center

DOES THE MIND MEET THE BRAIN IN RESIDENCY? AND WHAT ABOUT THE BODY?**Chp.:** Avram H. Mack, M.D.**Participants:** Stuart C. Yudofsky, M.D., William E. Greenberg, M.D., James J. Strain, M.D., Tana A. Grady-Weliky, M.D.**ISSUE WORKSHOP 33** 9:00 a.m.-10:30 a.m.

Rooms 333/334, Level 3, Convention Center

REINVENTING DEINSTITUTIONALIZATION IN THE 21ST CENTURY**Chp.:** Richard H. McCarthy, M.D.**Participants:** Rami Kaminsky, M.D., Steven M. Silverstein, Ph.D., Andrew Bloch, M.S.W.**ISSUE WORKSHOP 34** 9:00 a.m.-10:30 a.m.

Rooms 335/336, Level 3, Convention Center

NEUROPSYCHOTHERAPY**Co-Chps.:** David M. Roane, M.D., Elizabeth S. Ochoa, Ph.D.

ISSUE WORKSHOP 35 9:00 a.m.-10:30 a.m.

Room 342, Level 3, Convention Center

WOMEN'S LEADERSHIP AND CAREER DEVELOPMENT**Chp.:** Linda F. Pessar, M.D.**Participants:** Carol A. Bernstein, M.D., Carol C. Nadelson, M.D., Carolyn B. Robinowitz, M.D.**ISSUE WORKSHOP 36** 9:00 a.m.-10:30 a.m.

Room 352, Level 3, Convention Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS**Chp.:** Judith S. Beck, Ph.D.**ISSUE WORKSHOP 37** 9:00 a.m.-10:30 a.m.

Room 357, Level 3, Convention Center

BALANCING POWER IN THE PSYCHIATRIST-PATIENT ALLIANCE FOR THERAPEUTIC SUCCESS**Co-Chps.:** Steve S. Abdool, M.A., Diane K. Whitney, M.D.**Participant:** Wilson M. Lit, M.D.**ISSUE WORKSHOP 38** 9:00 a.m.-10:30 a.m.

Grand Salon Sections 3 & 6, Street Level, Hilton

ETHNICITY AND PSYCHOPHARMACOLOGY: RECENT RESEARCH ADVANCES**Co-Chps.:** Pedro Ruiz, M.D., Keh-Ming Lin, M.D.**Participants:** William B. Lawson, M.D., Edmond H.T. Pi, M.D., Ricardo P. Mendoza, M.D.**ISSUE WORKSHOP 39** 9:00 a.m.-10:30 a.m.

Grand Salon Sections 9 & 12, Street Level, Hilton

CHILDREN OF PSYCHIATRISTS**Co-Chps.:** Leah J. Dickstein, M.D., Michelle Riba, M.D.**Participants:** David Benedek, M.D., Luisa Isbell, Daniel Weintraub, M.D., Katherine H. Johnson**ISSUE WORKSHOP 40** 9:00 a.m.-10:30 a.m.

Grand Salon Sections 13 & 16, Street Level, Hilton

WOMEN AND SUICIDE: HORMONES AND GENES**Co-Chps.:** Jose de Leon, M.D., Kay R. Jamison, Ph.D.**Participant:** Enrique Baca-Garcia, M.D.**ISSUE WORKSHOP 41** 9:00 a.m.-10:30 a.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

GRAPHOTECHNOLOGY: HOW TO SAVE TIME AND REVEAL CLUES IN HANDWRITING ANALYSIS**Co-Chps.:** Sheila M. Kurtz, M.S., Barnard L. Collier, B.A.**ISSUE WORKSHOP 42** 9:00 a.m.-10:30 a.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

THE USE OF THE MOCK TRIAL IN PSYCHIATRIC STAFF EDUCATION**Chp.:** Stewart Levine, M.D.**Participants:** Harold I. Schwartz, M.D., Henry Pinsker, M.D., Raphael A. Morris, M.D., Jose A. Genua, M.D.**ISSUE WORKSHOP 43** 9:00 a.m.-10:30 a.m.

Grand Salon Sections 21 & 24, Street Level, Hilton

ECSTASY AND THE RAVE SCENE: A CANADIAN PERSPECTIVE**Co-Chps.:** Clare Roscoe, M.D., Antonia Seli, M.D.**ISSUE WORKSHOP 44** 9:00 a.m.-10:30 a.m.

Melrose Room, Third Floor, Hilton

INTEGRATED TREATMENT PROGRAMS FOR PREGNANT, MOTHERING WOMEN AND THEIR CHILDREN**Co-Chps.:** Linda L.M. Worley, M.D., Barbara A. Schindler, M.D.**ISSUE WORKSHOP 45** 9:00 a.m.-10:30 a.m.

Rosedown Room, Third Floor, Hilton

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BPD**Co-Chps.:** Eric M. Plakun, M.D., Edward R. Shapiro, M.D.**ISSUE WORKSHOP 46** 9:00 a.m.-10:30 a.m.

Magnolia Room, Third Floor, Hilton

HEALING OF SPIRIT AND BODY THROUGH DANCE AFTER TRAUMA**Chp.:** Russell J. Gardner, Jr., M.D.**Participants:** Doug Rosenberg, M.F.A., Chiao-Ping Li, M.A.**ISSUE WORKSHOP 47** 9:00 a.m.-10:30 a.m.

Jasperwood Room, Third Floor, Hilton

CLINICAL PATHS ACROSS CULTURAL AND RACIAL BARRIERS: HOW TO DO IT**Co-Chps.:** Carl C. Bell, M.D., Nada L. Stotland, M.D.**Participant:** Francis G. Lu, M.D.**ISSUE WORKSHOP 48** 9:00 a.m.-10:30 a.m.

Oak Alley Room, Third Floor, Hilton

BEYOND THE LECTURE HALL: INTEGRATING EDUCATIONAL CONCEPTS**Chp.:** Janet E. Osterman, M.D.

ISSUE WORKSHOP 49 9:00 a.m.-10:30 a.m.

Elmwood Room, Third Floor, Hilton

**THE EMPEROR'S NEW CLOTHES:
POLYPHARMACY AND KIDS**

Chp.: Jacquelyn M. Zavodnick, M.D.

ISSUE WORKSHOP 50 9:00 a.m.-10:30 a.m.

Belle Chasse Room, Third Floor, Hilton

**PSYCHIATRIC ADVERSE EVENTS DURING
REBATRON TREATMENT OF HEPATITIS-C**

Chp.: R. Jeffrey Goldsmith, M.D.

Participant: Debra Patton, R.N.

11:00 a.m. Sessions

DISCUSSION GROUPS 10-13

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 10 **Richard Kogan, M.D.**, on Treating Sexual Dysfunction in the 21st Century
Chequers Suite, Second Floor, Hilton
- 11 **Billy E. Jones, M.D.**, on the Psychiatrist as an Administrator/Manager
Trafalgar Suite, Third Floor, Hilton
- 12 **Elizabeth H. Rand, M.D.**, on Psychiatry in Primary Care: What Do We Want to Accomplish?
Norwich Suite, Third Floor, Hilton
- 13 **Susan J. Stagno, M.D.**, on Ethical Issues in Psychiatric Practice
Durham Suite, Third Floor, Hilton

LECTURES 11-12**LECTURE 11**

11:00 a.m.-12:30 p.m.

Rooms 252-254, Level 2, Convention Center

APA'S SIMON BOLIVAR AWARD LECTURE**F. Moises Gaviria, M.D.****International Cooperation in Mental Health in the Americas: An Agenda for the New Millennium**

Chp.: Oscar E. Perez, M.D.

Co-Chp.: Jose E. De La Gandara, M.D.

For Latin America and other regions with a large number of poor and marginalized people, mental health concerns include not only providing treatment for mental disorders but also ensuring that basic needs for adequate nutrition and clean living conditions are met so that human beings can develop to their potential. Increased immigration from Latin America to the United States and the growth of the U.S. Hispanic population have helped to make such international concerns into domestic issues. F. Moises Gaviria, M.D., discusses how U.S. institutions, including professional associations such as the APA, can foster increased regional leadership and cooperation to address these issues. Dr. Gaviria is Professor and Director of the Neuropsychiatric Division in the Department of Psychiatry at the University of Illinois at Chicago College of Medicine. The current Secretary of the International Neuropsychiatric Association and Past President of the American Society of Hispanic Psychiatrists, Dr. Gaviria has been active in mental health advocacy in the U.S. and Latin America. A native of Lima, Peru, Dr. Gaviria graduated from Universidad Nacional Mayor de San Marcos in Lima, completed his psychiatry residency at the University of Connecticut in Hartford, and completed a fellowship in social psychiatry at the University of Illinois.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 12

11:00 a.m.-12:30 p.m.

Rooms 338/339, Level 3, Convention Center

Edythe London, Ph.D.**Imaging Brain Dysfunction in Substance Abuse**

Chp.: Patricia I. Ordorica, M.D.

Co-Chp.: Raul F. Nodal, M.D.

Noninvasive imaging of the brain offers new opportunities to advance knowledge about the nature of addiction in humans. Edythe D. London, Ph.D., describes recent work with PET and MRI, supplemented with cognitive measures, that supports the importance of the frontal lobe for an understanding of the feeling states that perpetuate drug taking despite negative consequences. Dr. London is Visiting Professor of Psychiatry and Behavioral Sciences at the University of California, Los Angeles, Neuropsychiatric Institute, on leave from her position as Director of the Brain Imaging Center of the National Institute on Drug Abuse in Baltimore. Dr. London's primary research contributions are in the development of new approaches and probes for noninvasive imaging of brain function and biochemistry, particularly the application of brain imaging methods to the study of substance abuse. She is the author of more than 200 research articles and book chapters, the editor of the book *Imaging Drug Action in the Brain*, and a member of the editorial advisory board of several journals, including *Neuropsychopharmacology* and the *American Journal of Drug and Alcohol Abuse*. Dr. London is a member of the

Board of Directors of the College on Problems of Drug Dependence. She received her doctorate in pharmacology at the University of Maryland.
Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 9-11

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 9 **Stuart C. Yudofsky, M.D.**, on Treatment of Patients with Psychiatric Symptoms Complicated with Neurologic Illness
Room 337, Level 3, Convention Center
- 10 **Francine Cournos, M.D.**, on Psychotherapy and Therapist Self-Disclosure
Room 340, Level 3, Convention Center
- 11 **Steven A. Cole, M.D.**, on Optimizing Your Relationship with Primary Care Physicians: Ways to Maximize Your Referral Network and Satisfaction
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 12-13

MEDIA SESSION 12 11:00 a.m.-2:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

LIFE IN "THE GOLDEN YEARS"

Chp.: Ian E. Alger, M.D.

- 18 **The Personals: Improvisations on Romance in the Golden Years**
(35 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

This outstanding video offers an extraordinary look at the emotional lives of elderly Americans. On stage, a drama group of seniors perform their roles with energy and laughter. Off stage, their lives are often lived alone and in silence. *The Personals* follows a group of senior citizens as they rehearse and present an original play at a community theater on Manhattan's Lower East Side. Drawn from the comedy and drama of their own lives, the play is structured around their quest for dates through the personal ads.

- 19 **Bringing the Circle Together**
(56 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

There was a time when old people were known to have the greatest wisdom and were thus revered as teachers for the next generation. *Bringing the Circle Together* suggests that the time has come to return to this tradition. Coming from all walks of life and professions, four elderly men share their wisdom with us. They express their views on old age and its challenges, death, money, work, and the qualities they have come to find most essential in life.

- 20 **A One and a Two**
(27 minutes)

Distributor: Filmmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

This film is a portrait of Angelo, a widower after 37 years of marriage, as he begins to build a new life. During the process of "starting over," he discovers afternoon ballroom dancing; a new passion that is becoming a senior phenomenon. Set against his adventures on the dance floor in search of female companionship, are his down-to-earth descriptions of the adjustments he has had to make. He had depended on his wife for so much in life, preparing his meals, balancing his checkbook, selecting his clothes, etc., and now he must deal with issues of loneliness, retirement, finances, courtship, and fathering all by himself. This is an encouraging film about the potential of people to grow and enjoy life in their later years.

- 21 **As Time Goes By**
(23 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

The simple act of touching another human being, of expressing and receiving affection, companionship and love, is something that we all crave. Yet many of us share a common misconception that our needs for intimacy and romance fade as we grow older. How many of us are comfortable thinking of our parents or grandparents as sexual beings? This new video reminds us that sexuality remains a part of our lives until the very end. The seniors profiled in this documentary openly share their experiences with love, romance, and growing old. This film actively challenges our cultural assumptions that along with age come a disinterest in sex and an inability to share intimacy. *As Time Goes By* shows us a community of vital, social people who want what most of us want, love and affection.

MEDIA SESSION 13 11:00 a.m.-12:30 p.m.
Versailles Ballroom, Third Floor, Hilton

THE CHALLENGES OF CULTURAL DIVERSITY

Chp.: Sandra C. Walker, M.D.

- 22 **The Mirror Lied**
(27 minutes)

(Continued on next page)

Distributor: Filmmakers Library
for V22 & V23 Attn: Linda Gottesman
 124 East 40th Street
 New York, NY 10016

How does a young African-American woman deal with the ideals of feminine beauty imposed by white society? This film shows the struggle of the filmmaker's 15-year-old sister, Jantre, to accept her appearance. Though she spends an hour each day trying to tame her unruly hair, she never feels attractive. She envies the white girls with "hair that blows in the wind." When she asks for a wig for her birthday, her mother accuses her of not accepting her blackness. Jantre's mother grew up in the segregated South and says it took many years to accept herself. One daughter questions whether her mother has really reached self-acceptance, since she herself wears "woven hair." In a bold move to challenge her classmates' standards, Jantre goes to school with her hair in its natural fullness. She finds it a liberating experience.

23 Struggle for Identity
 (21 minutes)

Because of all the upheavals worldwide and the social problems in our country, many idealistic people are tempted to rescue children through foster care and adoption. However, people who provide care for children of a different race may not be prepared for the kinds of problems that can arise. This powerful new video brings into focus the issue of race, culture, and identity in adoptive or foster families.

MEDICAL UPDATE 2
 11:00 a.m.-12:30 p.m.
 Grand Salon Sections 3 & 6, Street Level, Hilton

BREAST CANCER PREVENTION: AN EXAMPLE OF TRANSLATIONAL RESEARCH

Chp.: Cheryl F. McCartney, M.D.
Presenter: Roy S. Weiner, M.D.
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

1 Paula J. Clayton, M.D., on Mood Disorders
 Cambridge Suite, Second Floor, Hilton

SCIENTIFIC AND CLINICAL REPORT SESSIONS 13-22

SCIENTIFIC AND CLINICAL REPORT SESSION 13
 11:00 a.m.-12:30 p.m.
 Room 264, Level 2, Convention Center

ISSUES IN CROSS-CULTURAL PSYCHIATRY

Chp.: Giovanni Caracci, M.D.
Co-Chp.: Megan T. Marumoto, M.D.

11:00 a.m.
38 Body Dissatisfaction and BMI Across Ethnic Groups
 Alayne Yates, M.D., Jeanne Edman, Ph.D., Mara Aruguete, Ph.D.

11:30 a.m.
39 Creativity as a Resource for Moving from Trauma Toward Connection
 Carol L. Kessler, M.D.

12 noon
40 Hypersexuality in Hasidic-Jewish Inpatients
 Nancy J. Needell, M.D., John C. Markowitz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
 11:00 a.m.-12:30 p.m.
 Room 270, Level 2, Convention Center

CHILD AND ADOLESCENT DIAGNOSTIC ISSUES

Chp.: Jacqueline C. McGregor, M.D.
Co-Chp.: Teresa Frausto, M.D.

11:00 a.m.
41 Diagnostic Efficiency of BPD Criteria in Hospitalized Adolescents
 Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., William S. Edell, Ph.D., Thomas H. McGlashan, M.D.

11:30a.m.
42 Overlap Between Child Depressive Inventory and Projectives in Uncovering a Child's Depression
 Sidney Fein, M.D., Delrita Abercrombie, Ph.D., Chaneve Jeanniton, B.S.

12 noon
43 Comorbidity in Conduct Disorder: Gender and Age Differences
 Atilla Turgay, M.D., Ozlem Erman, M.D., Bedriye Onch, Rubaba Ansari, M.A., Verka Urdarevic, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
 11:00 a.m.-12:30 p.m.
 Room 271, Level 2, Convention Center

TREATMENT ISSUES WITH SSRIS

Chp.: Vinod Kumar, M.D.
Co-Chp.: Joel J. Wallack, M.D.

11:00 a.m.
44 Sildenafil Citrate in SSRI Antidepressant Treatment Emergent Sexual Dysfunction
 H. George Numberg, M.D., Alan J. Gelenberg, M.D., Maurizio Fava, M.D., Paula L. Hensley, M.D., John Lauriello, M.D., Wilma M. Harrison, M.D., Richard L. Siegel, M.D.

11:30 a.m.
45 Do the SSRIs Make You "Better than Well"?
 David J. Hellerstein, M.D.

12 noon

46 Cholesterol Levels Decrease with Fluoxetine Treatment of MDD

Shamsah B. Sonawalla, M.D., Lindsay M. Dececco, B.A.,
Johanna A. Gordon, B.A., Joyce R. Tedlow, M.D., David
Mischoulon, M.D., Jerrold F. Rosenbaum, M.D., Maurizio
Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16

11:00 a.m.-12:30 p.m.

Room 272, Level 2, Convention Center

HISTORY OF GERIATRIC PSYCHIATRY

Chp.: Lesley M. Blake, M.D.

Co-Chp.: Art C. Walaszek, M.D.

11:00 a.m.

47 Antipsychotics in Geriatric Psychiatric Patients

John W. Goethe, M.D., Bonnie L. Szarek, R.N.

11:30 a.m.

48 Cerebral Hemodynamics and Depression in the Elderly

Henning Tiemeier, M.D., Stef L.M. Bakker, M.D., Peter J.
Koudstaal, Ph.D., Albert Hofman, Ph.D., Monique M.B.
Breteler, Ph.D.

12 noon

49 Integrating End-of-Life Care with Disease Management Programs

Arthur L. Lazarus, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17

11:00 a.m.-12:30 p.m.

Rooms 335/336, Level 3, Convention Center

HIV-RELATED ISSUES

Chp.: David W. Brook, M.D.

Co-Chp.: William S. Gilmer, M.D.

11:00 a.m.

50 College Students' Perceptions of Self and Others' Risk for HIV

Randolph J. Canterbury, M.D., Elizabeth L. McGarvey, Ed.D.

11:30 a.m.

51 Seriously Mentally Ill Persons Who Are HIV Positive

Greer Sullivan, M.D., Weiwei Feng, Ph.D., Xiaotong Han, M.S.,
David E. Kanouse, Ph.D., Paul Koegel, Ph.D.

12 noon

52 HIV, Health Care, and Mental Health Outcomes of Childhood Disruption

Charles T. Robinson III, M.D., Lisa B. Dixon, M.D., Mindy J.
Fullilove, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18

11:00 a.m.-12:30 p.m.

Rooms 346/347, Level 3, Convention Center

TREATMENT OF SCHIZOPHRENIA

Chp.: Henry A. Nasrallah, M.D.

Co-Chp.: Joel L. Steinberg, M.D.

11:00 a.m.

53 Placebo-Controlled Trial of Omega-3 Fatty Acid in Schizophrenia

Wayne S. Fenton, M.D., Faith Dickerson, Ph.D., John J.
Boronow, M.D., Joseph R. Hibbeln, M.D., Michael B.
Knable, D.O.

11:30 a.m.

54 Atypical Antipsychotics and Hostility in Schizophrenia: A Double-Blind Study

Leslie L. Citrome, M.D., Jan Volavka, M.D., Pal Czobor, Ph.D.,
Brian B. Sheitman, M.D., Jean-Pierre Lindenmayer, M.D.,
Joseph P. McEvoy, M.D., Jeffrey A. Lieberman, M.D.

12 noon

55 Factors Associated with Medication Adherence in Persons with Schizophrenia

Ann L. Hackman, M.D., Lisa B. Dixon, M.D., Letitia T.
Postrado, Ph.D., Janine C. Delahanty, M.A., Julie A.
Kreyenbuhl, Ph.D., Alicia Lucksted, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 19

11:00 a.m.-12:30 p.m.

Room 357, Level 3, Convention Center

BIOLOGICAL ISSUES IN PSYCHIATRY

Chp.: James Knowles, M.D.

Co-Chp.: Uriel Halbreich, M.D.

11:00 a.m.

56 Schizophrenia and Bipolar Disorder: Specific and Common Susceptibility Loci

Michel Maziade, M.D., Marc-Andre Roy, M.D., Luc
Bissonnette, Ph.D., Jean-Pierre Fournier, M.D., Denis
Cliche, M.D., Noel Montgrain, M.D., Chantal Merette

11:30 a.m.

57 Comorbid Panic Disorder as a Marker of Genetic Heterogeneity in Bipolar Disorder

Alessandro Rotondo, M.D., Liliana Dell'osso, M.D., Siham
Bouanani, M.D., Chiara Gonnelli, M.D., David Goldman, M.D.,
Lorella Pardini, M.D., Chiara Mazzanti, Ph.D., Giovanni B.
Cassano, M.D.

12 noon

58 Antibodies to Prothrombin and Thrombin in First Psychotic Episode of Schizophrenia

Pinkhas Sirota, M.D., Irena Bogdanov, M.D., Amos D.
Korczyn, Joab Chapman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20

11:00 a.m.-12:30 p.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

BIPOLAR DISORDERS

Chp.: Robert C. Marks, M.D.

Co-Chp.: Maria L. Tiamson, M.D.

11:00 a.m.

59 Perceptions and Impact of Bipolar Disorder: How Far Have We Really Come?

Lydia J. Lewis

11:30 a.m.

60 Unipolar Compared with Bipolar Depression: Similar Depressive Subtypes

Andrew A. Nierenberg, M.D., Jordan W. Smoller, M.D., Candace N. White, M.Ed., Constance Guille, B.A., Stella Bitran, B.A., Nicole B. Neault, B.A., Gary S. Sachs, M.D., Maurizio Fava, M.D., Jerrold F. Rosenbaum, M.D.

12 noon

61 Cognitive Function in Euthymic Bipolar Patients, Schizophrenics, and Controls

Alessandro Rossi, M.D., Luca Arduini, M.D., Paolo Stratta, M.D., Enrico Daneluzzo, M.D., Osvaldo Rinaldi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21

11:00 a.m.-12:30 p.m.

Rosedown Room, Third Floor, Hilton

PSYCHIATRIC EDUCATION

Chp.: James H. Scully, Jr., M.D.

Co-Chp.: Kathy M. Vincent, M.D.

11:00 a.m.

62 Using the "Moral Accounting" Metaphor to Teach Psychodynamic Formulations

Rodney J.S. Deaton, M.D.

11:30 a.m.

63 A Comparison of Evaluations of Male and Female Psychiatry Supervisors

Janet M. de Groot, M.D., Aileen S. Brunet, M.D., Allan S. Kaplan, M.D.

12 noon

64 Training in Depression and Suicide: A National Survey of Primary Care

Donna M. Sudak, M.D., Howard S. Sudak, M.D., Alec Roy, M.D., Alan Lipschitz, M.D., Herbert Hendin, M.D., John T. Maltsberger, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22

11:00 a.m.-12:30 p.m.

Magnolia Room, Third Floor, Hilton

DANGEROUS OFFENDERS

Chp.: David A. Lowenthal, M.D.

Co-Chp.: James L. Knoll IV, M.D.

11:00 a.m.

65 Can Psychologists Help Psychiatrists in Assessing Sex Offenders?

Linda S. Grossman, Ph.D., Orest E. Wasyliv, Ph.D., Andrea F. Benn, Ph.D., Kevin L. Gyoerkoe, Ph.D.

11:30 a.m.

66 Heterogeneity of Psychopathology Among Juvenile Sexual Offenders

Relana C. Pinkerton, Ph.D., Elizabeth L. McGarvey, Ed.D., Dennis Waite, Ph.D., Bruce J. Cohen, M.D., Robert Diamond, Ph.D.

12 noon

67 Dangerous Offender Statutes: The Canadian Perspective

Louis Morissette, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENT'S 28-32

COMPONENT WORKSHOP 28 11:00 a.m.-12:30 p.m.

Room 273, Level 2, Convention Center

PUTTING YOUR BEST FOOT FORWARD: THE ART OF SELF-PRESENTATION

APA Committee on Women

Chp.: Smita H. Patel, M.D.

Participants: Donna E. Stewart, M.D., Leslie H. Gise, M.D., Marian I. Butterfield, M.D., Sara K. Gardiner, M.D.

COMPONENT WORKSHOP 29 11:00 a.m.-12:30 p.m.

Room 342, Level 3, Convention Center

CAREER DEVELOPMENT IN ACADEMIC PSYCHIATRY FOR ASIAN PSYCHIATRISTS

APA Committee of Asian-American Psychiatrists

Co-Chps.: Nang Du, M.D., Jacquelyn B. Chang, M.D.

Participants: Ming T. Tsuang, M.D., Francis G. Lu, M.D., Nalini V. Juthani, M.D., Edmond H.T. Pi, M.D.

COMPONENT WORKSHOP 30 11:00 a.m.-12:30 p.m.

Rooms 350/351, Level 3, Convention Center

GENETICS, ETHNICITY, AND ALZHEIMER'S DISEASE

APA Council on Aging and APA Committee on Ethnic Minority Elderly

Chp.: Josepha A. Cheong, M.D.

Participants: Jacobo E. Mintzer, M.D., Helen H. Kyomen, M.D., Kenneth M. Sakauye, M.D., Warachal E. Faison, M.D., Frank W. Brown, M.D.

COMPONENT WORKSHOP 31 11:00 a.m.-12:30 p.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART II*APA Committee of Early Career Psychiatrists***Co-Chps.:** William E. Callahan, Jr., M.D., Keith W. Young, M.D.**Participants:** Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.**COMPONENT WORKSHOP 32** 11:00 a.m.-12:30 p.m.

Belle Chasse Room, Third Floor, Hilton

LEGAL ISSUES IN PSYCHIATRIC PRIVATE PRACTICE*APA Committee on Private Practice***Chp.:** Thomas K. Ciesla, M.D.**Participant:** Daniel H. Willick, J.D.**ISSUES 51-59****ISSUE WORKSHOP 51** 11:00 a.m.-12:30 p.m.

Rooms 267-268, Level 2, Convention Center

HOW THE THEORY OF EVOLUTION IS FUNDAMENTAL TO OUR BIOPSYCHOSOCIAL MODEL**Chp.:** John R. Evaldson, M.D.**ISSUE WORKSHOP 52** 11:00 a.m.-12:30 p.m.

Room 269, Level 2, Convention Center

COGNITIVE-BEHAVIORAL TREATMENT: PROLONGED EXPOSURE FOR TREATMENT OF TRAUMA VICTIMS**Co-Chps.:** Abbas Azadian, M.D., Ari E. Zaretsky, M.D.**ISSUE WORKSHOP 53** 11:00 a.m.-12:30 p.m.

Rooms 333/334, Level 3, Convention Center

THE CONSUMER PERSPECTIVE IN PSYCHIATRIC EDUCATION**Co-Chps.:** Fernando Rodriguez-Villa, M.D., Anne Whitman, Ph.D.**Participants:** Kenneth S. Duckworth, M.D., Moe Armstrong, M.B.A.**ISSUE WORKSHOP 54** 11:00 a.m.-12:30 p.m.

Grand Salon Section 4, Street Level, Hilton

FOLKTALES AND MOVIES: USING THE MEDIA TO LEARN ABOUT CULTURE**Co-Chps.:** Sandra Sexson, M.D., Arden D. Dingle, M.D.**ISSUE WORKSHOP 55** 11:00 a.m.-12:30 p.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

POEMS ON PSYCHIATRY**Chp.:** Charles R. Joy, M.D.**ISSUE WORKSHOP 56** 11:00 a.m.-12:30 p.m.

Prince of Wales Suite, Second Floor, Hilton

COMMUNITY PSYCHIATRY: HOW TO AVOID BEING A PSYCHOTECH SLAVE CHAINED TO THE PILL BOX**Chp.:** Charles W. Huffine, Jr., M.D.**ISSUE WORKSHOP 57** 11:00 a.m.-12:30 p.m.

Marlborough Suite A/B, Second Floor, Hilton

EARLY CAREER PSYCHIATRIST: ROLE OF MENTORSHIP**Co-Chps.:** Gabriela Cora-Locatelli, M.D., Edward F. Foulks, M.D.**Participants:** Linda B. Andrews, M.D., Vinay Kapoor, M.D., Anu A. Matorin, M.D.**ISSUE WORKSHOP 58** 11:00 a.m.-12:30 p.m.

Melrose Room, Third Floor, Hilton

CLINICAL AND FORENSIC ASPECTS OF SEXUAL HARASSMENT IN SCHOOLS**Chp.:** Malkah T. Notman, M.D.**Participants:** Elissa P. Benedek, M.D., Linda M. Jorgenson, J.D., Carl P. Malmquist, M.D.**ISSUE WORKSHOP 59** 11:00 a.m.-12:30 p.m.

Elmwood Room, Third Floor, Hilton

STUDENTS DISCUSSING WHY THEY HAVE CHOSEN A PSYCHIATRIC CAREER IN 2000**Co-Chps.:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.**Participants:** Asher B. Simon, Joyce Adams**12 noon Sessions****FORUMS 4-8****FORUM 4** 12 noon-1:30 p.m.

Room 263, Level 2, Convention Center

SUBSTANCE ABUSE IN THE SEVERELY MENTALLY ILL**Chp.:** Rodrigo A. Munoz, M.D.**Participants:** Pedro Ruiz, M.D., Ivan D. Montoya, M.D., Ismael Roldan, Maria Clara de Cleves, Marian I. Butterfield, M.D., Guido Belsasso, M.D.**FORUM 5** 12 noon-1:30 p.m.

Room 352, Level 3, Convention Center

HERE'S LOOKING AT YOU! SELF-REFLECTION IN PSYCHOTHERAPY*APA Commission on Psychotherapy by Psychiatrists***Chp.:** Jerald Kay, M.D.**Participants:** Bernard D. Beitman, M.D., Glen O. Gabbard, M.D., James L. Griffith, M.D., Joan A. Lange, M.D.

FORUM 6 12 noon-1:30 p.m.

Room 356, Level 3, Convention Center

PRESIDENTIAL FORUM: CONFIDENTIALITY AND MEDICAL RECORD PRIVACY IN THE 21ST CENTURY**Chp.:** Daniel B. Borenstein, M.D.**Participants:** Professor Latanya Sweeney, Margo P. Goldman, M.D., Richard K. Harding, M.D., Marcia K. Goin, M.D., Paul W. Mosher, M.D.**FORUM 7** 12 noon-1:30 p.m.

Grand Salon Sections 9 & 12, Street Level, Hilton

TRAUMA, PTSD, AND PERSONALITY DISORDERS: UNDERSTANDING THE CONNECTIONS**Chp.:** Randall D. Marshall, M.D.**Participants:** Bessel A. Van Der Kolk, M.D., Kenneth R. Silk, M.D., Marylene Cloitre, Ph.D.**FORUM 8** 12 noon-1:30 p.m.

Grand Salon Sections 13 & 16, Street Level, Hilton

DIAGNOSTIC AND STATISTICAL MANUAL (DSM) RESEARCH PLANNING PROCESS**Chp.:** David J. Kupfer, M.D.**Co-Chp.:** Darrel A. Regier, M.D.,**Participants:** Anthony F. Lehman, M.D., Michael B. First, M.D., Daniel S. Pine, M.D., Dennis S. Charney, M.D., Bruce J. Rounsaville, M.D., Renato D. Alarcon, M.D.**NEW RESEARCH POSTER SESSION 6**

12 noon-2:00 p.m.

Exhibition Center, Second Floor, Hilton

SCHIZOPHRENIA, BRAIN IMAGING, NEUROPSYCHIATRY, SOCIAL AND COMMUNITY PSYCHIATRY, CREATIVITY, AND MANAGED CAREFor further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.**12:30 p.m. Session****MEDIA SESSION 14**

12:30 p.m.-2:00 p.m.

Versailles Ballroom, Third Floor, Hilton

A JOURNEY TO SELF**Chp.:** Sandra C. Walker, M.D.**24 Fat Chance**
(72 minutes)**Distributor:** Bullfrog Films

P.O. Box 149

Oley, PA 19547

Fat Chance is the funny and sensitive story of Rick Zakowich who started on a diet to lose half his body weight and found all of himself along the way. Rick's journey is to a new identity, but in the process of discovery, he finds himself moving towards a destination he could not have anticipated. Values, assumptions, and perspectives are turned inside out where fat may be the issue but difference is the ultimate truth.

1:00 p.m. Sessions**COURSES 71-78**Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.**COURSE 71**

1:00 p.m.-5:00 p.m.

La Galerie 3, Second Floor, Marriott

COGNITIVE THERAPY: THE BASICS**Director:** Dean Schuyler, M.D.**COURSE 72**

1:00 p.m.-5:00 p.m.

La Galerie 4, Second Floor, Marriott

PSYCHIATRISTS AS TEACHERS OF BOUNDARIES TO PHYSICIANS**Director:** Samia Barakat, M.D.**Faculty:** Mark S. Etkin, M.D., Mark A. Prober, M.D.**COURSE 73**

1:00 p.m.-5:00 p.m.

Bacchus Room, Fourth Floor, Marriott

ACHIEVING EFFECTIVE DUAL DIAGNOSIS TREATMENT**Director:** John W. Tsuang, M.D.**Faculty:** Andrew P. Ho, M.D.**COURSE 74**

1:00 p.m.-5:00 p.m.

Balcony M, Fourth Floor, Marriott

DSM-IV CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY**Director:** Russell F. Lim, M.D.**Faculty:** Candace M. Fleming, Ph.D., J. Charles Ndelela, M.D., Francis G. Lu, M.D., Roberto Lewis-Fernandez, M.D., Michael W. Smith, M.D.

COURSE 75 1:00 p.m.-5:00 p.m.
Rhythms Ballroom II, Second Floor, Sheraton

THE ADVANCED PRACTICE OF PSYCHOTHERAPY

Director: T. Byram Karasu, M.D.

COURSE 76 1:00 p.m.-5:00 p.m.
Pontchartrain Ballroom B, Third Floor, Sheraton

THE EVALUATION AND MANAGEMENT OF PAIN

Director: Steven A. King, M.D.

COURSE 77 1:00 p.m.-5:00 p.m.
Edgewood Rooms A/B, Fourth Floor, Sheraton

USE OF THE HUMANITIES IN PSYCHIATRIC EDUCATION

Co-Directors: Paul R. Miller, M.D., Jasmine Mackic-Magyar, M.D.
Faculty: Robert Dasher, M.D.

COURSE 78 1:00 p.m.-5:00 p.m.
Gallier Rooms A/B, Fourth Floor, Sheraton

INDIVIDUAL AND COMMUNITY INTERVENTIONS IN DISASTER

Director: Carol S. North, M.D.
Faculty: Betty Pfefferbaum, M.D., Phebe M. Tucker, M.D.

2:00 p.m. Sessions

LECTURES 13-14

LECTURE 13

2:00 p.m.-3:30 p.m.
Rooms 252-254, Level 2, Convention Center

Donna E. Stewart, M.D.

What Do Women Really Want?

Chp.: Mary Jane Massie, M.D.
Co-Chp.: Yvonne B. Ferguson, M.D.

In the latter years of the 20th century, psychiatrists' perspectives on women as both patients and health care providers developed in the context of increased efforts by women to establish ownership of their bodies, health, minds, and roles in society. Donna E. Stewart, M.D., discusses some of the ways organized psychiatry has dealt with changes in women's roles. Dr. Stewart holds the Lillian Love Chair in Women's Health at the University Health Network hospitals and the University of Toronto, where she is Professor in the

Departments of Psychiatry, Obstetrics/Gynecology, Medicine, Anesthesia, Family and Community Medicine, and Surgery in the Faculty of Medicine. She chairs the Section on Women's Mental Health of the World Psychiatric Association and the Committee on Women of the American Psychiatric Association, and is a member of the Women's Health Council of the Ministry of Health of Canada. The author of more than 100 articles in peer-reviewed journals, Dr. Stewart is the editor of a textbook on the psychological aspects of women's health care and a book on menopause. She has served as a consultant to Health Canada and the U.S. Department of Health and Human Services.
Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 14

2:00 p.m.-3:30 p.m.
Rooms 338/339, Level 3, Convention Center

Mark L. Solms, Ph.D.

An Example of Neuropsychanalytic Research: The Right Hemisphere Syndrome

Chp.: Randall D. Marshall, M.D.
Co-Chp.: Sheila Judge, M.D.

Dysfunction of the right cerebral hemisphere is associated with a group of striking neuropsychiatric symptoms: denial of illness, unawareness of the left side of space (including one's own body), and other abnormalities of spatial cognition and perception. Prevailing theories of right hemisphere function are based on neurobehavioral analyses of these symptoms. However, psychoanalytic findings concerning neurological patients' subjective experience of these symptoms reveal unexpected complications incompatible with the existing theories. Mark Solms, Ph.D., describes a new theory of right hemisphere functioning that reconciles the neurobehavioral and psychoanalytic data. A neuro-psychologist and a psychoanalyst, Dr. Solms is Director of the Arnold Pfeffer Center for Neuro-Psychoanalysis of the New York Psychoanalytic Institute. His research has centered on examining the neurological origins of Freud's psychoanalytic concepts and developing methods to make psychoanalytic theories accessible to neuro-scientific findings. His books include *The Neuropsychology of Dreams* and *Clinical Studies in Neuro-Psychoanalysis*. He is the editor and translator of the forthcoming four-volume series, *The Complete Neuroscientific Works of Sigmund Freud* and the co-editor of *Neuro-Psychoanalysis*, the interdisciplinary journal for psychoanalysis and neurosciences. Dr. Solms received his doctoral degree in neuropsychology from the University of the Witwatersrand in South Africa and his training in psychoanalysis from the Institute of Psychoanalysis in London.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MEDIA SESSIONS 15-16

MEDIA SESSION 15 2:00 p.m.-5:00 p.m.

Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Harvey R. Greenberg, M.D.

25 Mr. Death
(91 minutes)**Distributor:** Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

Mr. Death tells the story of Fred A. Leuchter, Jr., an engineer who decided to become the "Florence Nightingale of death row." His mission was to design and repair gas chambers, electric chairs, and lethal injection systems. But Leuchter became infamous for his work with anti-Holocaust writer Ernst Zundel, who commissioned Leuchter to conduct a forensic investigation into the use of poison gas in World War II Nazi concentration camps. Leuchter's controversial findings eventually hypothesized that the Holocaust never happened. He fully expected his involvement with Zundel to be the crowning achievement of his career; instead, it ruined him.

MEDIA SESSION 16 2:00 p.m.-5:00 p.m.

Versailles Ballroom, Third Floor, Hilton

TRANSPLANTED COMMUNITY: THE BEAT GOES ON

Chp.: Richard E. D'Alli, M.D.

26 The Italian Gardens of South Brooklyn
(26 minutes)**Distributor:** University of California Extension Center
for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704

The *Italian Gardens of South Brooklyn* is an infectiously enjoyable and inventive documentary that illustrates how a mixture of "old-world values and new-world horse sense" invigorates the traditional Italian-American community of South Brooklyn. It infuses it with a strong respect for family, friends, and neighborhood.

27 Delta Jews
(57 minutes)**Distributor:** Filmmakers Library
For V27 & Attn: Linda Gottesman
V28 124 East 40th Street
New York, NY 10016

Through the eyes of those who remain, *Delta Jews*, traces the history of the community and its relationship to its white Christian and black neighbors. We meet families who as merchants and farmers have taken on many characteristic speech patterns and social attitudes of their neighbors. Yet the families

maintained their traditions, even if it took importing rabbis and traveling miles for services or seders. These families developed an active social network to reinforce their identity and keep the younger generation "in the fold." This is a unique film, not only for Jewish and Southern studies, but also for anthropology and sociology courses dealing with cultural identity and assimilation.

28 A Wok in Progress
(56 minutes)

The third film of Paul Kwan's odyssey interweaves a love of food with cultural and psychic survival. In *A Wok in Progress*, Paul triumphs over the demons with his sense of whimsy, lyricism, and of course, his enjoyment of food and family. This film is a joyous romp through memory, a touch of personal philosophy, and a distillation of sensory perceptions surrounding food and its preparation. Identity and a sense of well being are recreated in the kitchen. The film is a celebration of the powers of recovery.

REVIEW OF PSYCHIATRY: SECTION 3

2:00 p.m.-5:30 p.m.

Rooms 343-345, Level 3, Convention Center

INTEGRATED TREATMENT: AN OVERVIEW

Chp.: Jerald Kay, M.D.

11 CANCELLED**12 Integrated Treatment Planning for BPD**
John M. Oldham, M.D.**13 Integrated Treatment of Substance Abuse Disorders**
Douglas M. Ziedonis, M.D.**14 A Cognitive Therapy Approach to Medication Compliance**
Judith S. Beck, Ph.D.**15 The Challenges of Split Treatment**
Michelle Riba, M.D.**SYMPOSIA 30-63****SYMPOSIUM 30** 2:00 p.m.-5:00 p.m.
Room 262, Level 2, Convention Center**PROFESSIONAL BOUNDARIES AND TRAINING IN PSYCHIATRY: A COMPREHENSIVE VIEW**Chp.: Gregg E. Gorton, M.D.
Co-Chp.: Linda M. Jorgenson, J.D.**A Critical Issues in Education About Boundaries for Physicians and Others**

Gregg E. Gorton, M.D., Steven E. Samuel, Ph.D.

B Adapting and Expanding Boundaries: Training in and Outside Psychiatry
Gail E. Robinson, M.D.

C Boundaries in a Broader Context: A Swiss Psychiatric Perspective
Werner Tschan, M.D.

D Preventive and Remedial Boundaries Training: Effective Tools and Methods
Gary R. Schoener, Psy.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.
Room 263, Level 2, Convention Center

THE ROLE OF ANTIDEPRESSANTS IN THE TREATMENT OF BIPOLAR DISORDER: PRO AND CON

Chp.: S. Nassir Ghaemi, M.D.
Co-Chp.: Frederick K. Goodwin, M.D.

A Antidepressant-Induced Mania: Overview of Current Controversies
Joseph F. Goldberg, M.D.

B Efficacy and Safety of Antidepressants in Bipolar II Disorder
Jay D. Amsterdam, M.D.

C Long-Term Risks with the Use of Antidepressants in Bipolar Disorder
S. Nassir Ghaemi, M.D.

D Diagnosis and Treatment of the Bipolar Spectrum: A Clinician's Perspective
Jacob J. Katzow, M.D.

Discussant: Frederick K. Goodwin, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32 2:00 p.m.-5:00 p.m.
Room 264, Level 2, Convention Center

PHYSIOLOGY AND BEHAVIOR: THE CONNECTION IN EATING DISORDERS

Chp.: Katherine A. Halmi, M.D.

A Personality Features and Monoamine Function in Eating Disorders
Francesca Brambilla, M.D.

B Cognitive Dysfunction in Eating Disorders: Relationships with Neuroendocrine Indices
Silvana Galderisi, M.D., Armida Mucci, M.D., Palmiero Monteleone, M.D., Annunziata Buongiovanni, M.D., Mario Maj, M.D.

C Role of Leptin in Eating Disorders
Palmiero Monteleone, M.D., Antonio Fuschino, M.D., Martiadis Vassilis, M.D., Mario Maj, M.D.

D Fluvoxamine in Relapse Prevention of Bulimia Nervosa
Manfred M. Fichter, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.
Rooms 265/266, Level 2, Convention Center

EVIDENCE-BASED MANAGEMENT OF SSRI ANTIDEPRESSANT-ASSOCIATED SEXUAL DYSFUNCTION

Chp.: H. George Nurnberg, M.D.
Co-Chp.: Julia K. Warnock, M.D.

A Sildenafil for Management of Antidepressant-Associated Sexual Dysfunction
H. George Nurnberg, M.D., Paula L. Hensley, M.D.

B Avoidance of SSRI-Induced Sexual Dysfunction
Harry A. Croft, M.D.

C The Prevalence, Assessment, and Course of Antidepressant-Associated Sexual Dysfunction
Paula L. Hensley, M.D., H. George Nurnberg, M.D.

D Psychotropic Antidotes for Antidepressant-Related Sexual Dysfunction
Lawrence A. Labbate, M.D.

E Assessing Sexual Dysfunction in Women: Impact of Sex Hormones
Julia K. Warnock, M.D.

Discussant: Alan J. Gelenberg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34 2:00 p.m.-5:00 p.m.
Rooms 267-268, Level 2, Convention Center

CLINICAL ISSUES IN BIPOLAR DISORDER: THE STANLEY FOUNDATION BIPOLAR NETWORK

Chp.: Robert M. Post, M.D.
Co-Chp.: Mark A. Frye, M.D.

A The Treatment of Bipolar Depression
Robert M. Post, M.D., Lori L. Altshuler, M.D., Patricia Suppes, M.D., Kirk D. Denicoff, M.D., Ralph Kupka, M.D., Willem A. Nolen, M.D.

B Early Trauma and Bipolar Disorder
Gabriele S. Leverich, M.S.W., Patricia Suppes, M.D., Kirk D. Denicoff, M.D., Willem A. Nolen, M.D., Ralph Kupka, M.D., Karen A. Autio, B.A.

(Continued on next page)

- C Gender Difference in Bipolar Disorder: Alcohol Abuse Comorbidity**
Mark A. Frye, M.D., Lori L. Altshuler, M.D., Kirk D. Denicoff, M.D., Paul E. Keck, Jr., M.D., Susan L. McElroy, M.D., Patricia Suppes, M.D.

- D Correlates and Management of Overweight in Bipolar Disorder**
Susan L. McElroy, M.D.

- E New Antiepileptics in the Treatment of Bipolar Disorder**
Paul E. Keck, Jr., M.D.

Discussant: Hagop S. Akiskal, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.
Room 269, Level 2, Convention Center

SUBSTANCE USE AND PSYCHOSIS: TACKLING THE CHICKEN-AND-EGG PROBLEM

Chp.: Michael B. First, M.D.

- A Using the Psychiatric Research Interview for Substance and Mental Disorders to Diagnose Psychotic Disorders in Substance Abusers**
Deborah S. Hasin, Ph.D., Sharon Samet, M.S.W., Jakob Meydan, M.S.

- B Autonomous Drug-Induced Psychosis: State of the Evidence**
Nashaat N. Boutros, M.D., Malcolm B. Bowers, Jr., M.D.

- C Illness Course of Substance-Induced and Primary Psychotic Disorders**
Carol L.M. Caton, Ph.D., Deborah S. Hasin, Ph.D., Michael B. First, M.D., Ellen M. Stevenson, M.D., James L. Curtis, M.D., Gary L. Lefer, M.D., Patrick Shrout, Ph.D.

- D Differential Diagnosis of Psychosis in Drug Abusers**
Richard N. Rosenthal, M.D.

- E The Impact of Substance Abuse: Dependence on Diagnosing Patients with Psychosis**
Mark J. Sedler, M.D., Joseph Schwartz, Evelyn Bromet, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room 270, Level 2, Convention Center

BLACK RAGE, WHITE SUPREMACISTS, PSYCHIATRY, AND CRIMINAL LAW

Chp.: Michael M. Welner, M.D.

- A Black Rage: Myths and Realities**
Michael M. Welner, M.D.

- B White Supremacists: Psychiatry Beneath the Hate**
James F. Hooper, IV, M.D.

- C Ethnic Rage: Guidelines for Forensic Psychiatric Assessment**
Michael M. Welner, M.D.

- D Cross-Cultural Aspects of Ethnic Rage**
Andres J. Pumariega, M.D.

Discussant: Carl C. Bell, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Room 271, Level 2, Convention Center

THE BIOPSYCHOSOCIAL MODEL: SOCIAL PERSPECTIVES

American Association for Social Psychiatry

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Lawrence Hartmann, M.D.

- A Theoretical Perspectives**
Gerald J. Sarwer-Foner, M.D.

- B Integrational Perspectives**
Tanya M. Luhmann, Ph.D.

- C Psychotherapy Perspectives**
Edward F. Foulks, M.D.

- D Biological Perspectives**
Charles B. Nemeroff, M.D.

- E Social Perspectives**
Joel S. Feiner, M.D.

Discussants: Steven S. Sharfstein, M.D., Kenneth S. Thompson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Room 272, Level 2, Convention Center

THE USE OF CHOLINESTERASE INHIBITORS IN CLINICAL PRACTICE

Chp.: Constantine G. Lyketsos, M.D.

- A Evidence-Based Medicine as Applied to Treatment Decisions in Alzheimer's Disease**
Lon S. Schneider, M.D.

- B Efficacy and Risks of Marketed Cholinesterase Inhibitors**
Pierre Tarriot, M.D.

- C Long-Term Treatment: Is There Evidence for Safety and Efficacy?**
Lon S. Schneider, M.D.

**D Assessing Efficacy in Day-to-Day Practice:
Opportunities and Barriers**
William E. Reichman, M.D.

E Using the Cholinesterase Inhibitors in Clinical Practice
Constantine G. Lyketsos, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 39 2:00 p.m.-5:00 p.m.
Room 273, Level 2, Convention Center

**PERSONALITY AND PSYCHOPATHOLOGY: A
BEHAVIOR-GENETIC PERSPECTIVE**

Chp.: John Livesley, M.D.
Co-Chp.: Kerry L. Jang, Ph.D.

**A Behavioral-Genetic Perspectives on the Comorbidity of
Behavior**
Kerry L. Jang, Ph.D.

**B Causal Connections Between Impulsive Personality
Traits and Externalizing Disorders**
Robert F. Krueger, Ph.D., Brian M. Hicks, B.S., William G.
Iacono, Ph.D., Christopher Patrick, Ph.D., Matt McGue, Ph.D.,
Scott R. Carlson, B.A.

**C Born Fearful: Heritability of Avoidant and Social
Anxiety Related Traits**
Murray B. Stein, M.D.

**D Etiological Relationships Among Personality Disorders
and Axis I Disorders**
John Livesley, M.D.

Discussant: Thomas A. Widiger, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40 2:00 p.m.-5:00 p.m.
Rooms 333/334, Level 3, Convention Center

**THE USE OF FORCE IN PSYCHIATRY: WHEN IS IT
HELPFUL AND WHEN IS IT NOT: PART I**
American Association of Community Psychiatrists

Chp.: David A. Pollack, M.D.

A Seclusion and Restraint Update
Nicholas Meyers, J.D.

B Use of Force with Older Adults
Cornelia K. Beck, Ph.D.

**C Use-of-Force Issues for Persons in Police Custody and
Corrections Settings**
Randolph T. Dupont, Ph.D., Fred C. Osher, M.D.

D The Use of Force: Consumer Perspective
Frank D. Burgman

E The Use of Force: Staff Perspective
Richard O'Dea, R.N.

Discussant: Paul S. Appelbaum, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 41 2:00 p.m.-5:00 p.m.
Rooms 335/336, Level 3, Convention Center

**BIPOLAR DISORDER: CURRENT GUIDELINES,
PRACTICES, AND EFFECTIVENESS RESEARCH**

Chp.: Gary S. Sachs, M.D.
Co-Chp.: Michael E. Thase, M.D.

**A Current Treatment Guideline Recommendations for
Bipolar Disorder**
Robert M.A. Hirschfeld, M.D.

**B Systematic Treatment Enhancement Program for
Bipolar Disorder (STEP-BD) Study Design and Sample
Characteristics**
Gary S. Sachs, M.D., Michael E. Thase, M.D., Steve
Wisniewski, Leslie F. Leahy, Ph.D., Jennifer Conley, M.A.

**C The Texas Implementation of Medication Algorithms
for Bipolar Disorder**
Patricia Suppes, M.D.

D Treatment of Bipolar Disorder in Routine Practice
Joyce C. West, M.P.P., David A. Kahn, M.D., Deborah A.
Zarin, M.D., Steven C. Marcus, Ph.D., Victoria E. Cosgrove, B.A.,
Mark H. Townsend, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 42 2:00 p.m.-5:00 p.m.
Room 342, Level 3, Convention Center

TEACHING ETHICS TO PSYCHIATRIC RESIDENTS
APA Ethics Committee

Chp.: Donald G. Langsley, M.D.
Co-Chp.: Richard D. Milone, M.D.

**A Teaching About Boundary Violations in a Psychiatry
Ethics Course**
Peter B. Gruenberg, M.D.

B Practical Ethics in Treatment of Children
William Arroyo, M.D.

C Teaching About the Ethics of Confidentiality
David S. Wahl, M.D.

D Ethical Aspects of Gifts from Patients
Edward Hanin, M.D.

E Forensic Issues in the Practice of Ethical Psychiatry
Wade C. Myers, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43 2:00 p.m.-5:00 p.m.

Rooms 346/347, Level 3, Convention Center

MUSIC THERAPY: INTEGRATED ART AND SCIENCE IN HEALTH CARE**Chp.:** John S. McIntyre, M.D.**Co-Chp.:** Bryan C. Hunter, Ph.D.

- A The Mozart Phenomenon: Myth and Reality**
Bryan C. Hunter, Ph.D.
- B Music Therapy in Neurologic Rehabilitation: A Scientific Model of Rhythmicity in Brain Function**
Michael H. Thaut, Ph.D.
- C Music Therapy Outcome Research in Patients with Alzheimer's Disease**
Alicia A. Clair, Ph.D.
- D Music Therapy in Psychosocial Care and Pain Management**
Deforia L. Lane, Ph.D.
- E The Effect of Drumming on Immune System Modulation**
Barry B. Bittman, M.D.

Discussant: Richard Kogan, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 44** 2:00 p.m.-5:00 p.m.

Rooms 348/349, Level 3, Convention Center

CULTURAL INFLUENCES ON THE PSYCHIATRIC TREATMENT OF WOMEN**Chp.:** Nina E. Cerfolio, M.D.**Co-Chp.:** Morisa Schiff-Mayer, M.D.

- A Mental Health Treatment of Chinese Women: Issues and Opportunities**
Henry Chung, M.D.
- B Cultural Issues in the Psychiatric Treatment of Orthodox Jewish Women**
Michelle E. Friedman, M.D.
- C Cultural Influences in Psychiatric Treatment of Indian Women**
Nalini V. Juthani, M.D.
- D Treating Latino Women Patients: Clinical Challenges**
Silvia W. Olarte, M.D.
- E Emerging Issues in Psychiatric Treatment for African-American Women**
Altha J. Stewart, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 45** 2:00 p.m.-5:00 p.m.

Rooms 350/351, Level 3, Convention Center

FEEDING, EATING, AND EATING DISORDERS: THE DEVELOPMENT OF DISORDERED EATING**Chp.:** Evelyn Attia, M.D.**Co-Chp.:** Laurel Mayer, M.D.

- A Early Influences on Disordered Eating**
W. Stewart Agras, M.D.
- B The Association of Television Exposure with Disordered Eating Among Ethnic Fijian Adolescent Girls**
Anne E. Becker, M.D., Rebecca Burwell, M.P.H., Stephen E. Gilman, S.M., David B. Herzog, M.D., Paul Hamburg, M.D.
- C Cultural Change as a Risk Factor for Eating Disorder: The Case of Eastern Europe**
Katarzyna Bisaga, M.D.
- D Gender Differences in 5HT Function: A Risk Factor for Anorexia Nervosa?**
Evelyn Attia, M.D., Katherine G. Meehan
- E Body-Fat Distribution Before and After Weight Gain in Anorexia Nervosa**
Laurel Mayer, M.D., B. Timothy Walsh, M.D., Richard Pierson, Jr., M.D., Claire Barrett, B.A., Erin Killory

Discussant: Joel Yager, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 46** 2:00 p.m.-5:00 p.m.

Room 352, Level 3, Convention Center

NATIONAL BIOETHICS ADVISORY COMMISSION (NBAC) REVISITED: IMPLEMENTATION OF INDEPENDENT CAPACITY ASSESSMENT**Chp.:** Catherine A. Roca, M.D.**Co-Chp.:** David R. Rubinow, M.D.

- A National Bioethics Advisory Commission (NBAC) Recommendation for Independent Capacity Assessment: Overview and Implications for Research**
Catherine A. Roca, M.D., Donald L. Rosenstein, M.D., David R. Rubinow, M.D.
- B Methods to Assess Decision-Making Capacity**
Paul S. Appelbaum, M.D.
- C Validating Informed Consent: Process and Verification**
William T. Carpenter, Jr., M.D., Robert R. Conley, M.D.
- D Greater than Minimal Risk Research with Vulnerable Subjects: A View from the National Institute of Mental Health Intramural Research Program**
Donald L. Rosenstein, M.D.

Discussant: E. Greg Koski, M.D.**THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.

Room 356, Level 3, Convention Center

TREATMENT PATHWAYS (ALGORITHMS) IN MANAGING DEPRESSION

Chp.: A. John Rush, M.D.

Co-Chp.: Michael Bauer, M.D.

A Theory and Models of Treatment Algorithms

Michael Linden, M.D.

B Algorithm-Guided Treatment Versus Treatment as Usual: Randomized Trial in Inpatients with Depression

Michael Bauer, M.D., Mazda Adli, M.D., Ursula Kiessler, M.A., Peter Neu, M.D., Michael Smolka, M.D., Michael Linden, M.D.

C Texas Medication Algorithm Project (TMAP): Results for Major Depressive Disorder

Madhukar H. Trivedi, M.D.

D Issues in Implementing Algorithms: Texas Medication Algorithm Project (TMAP) and Star D Experiences

A. John Rush, M.D.

Discussant: Lydia J. Lewis

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.

Room 357, Level 3, Convention Center

THE TRAUMA OF BEREAVEMENT: A NEW PARADIGM

Chp.: Edward K. Rynearson, M.D.

A Measurement and Diagnosis of Traumatic Grief

Holly G. Prigerson, Ph.D., Selby C. Jacobs, M.D., Paul K. Maciejewski, Ph.D., Stanislav Kasl, Ph.D., Gabriel K. Silverman, B.A.

B Traumatic Grief Therapy

M. Katherine Shear, M.D.

C Bereavement After Violent Dying: Description and Conceptual Frame

Edward K. Rynearson, M.D.

D Clinical Screening Battery, Treatment Implications, and Short-Term Group Intervention Outcomes

Jennifer L. Favell, Ph.D.

E Pharmacologic Treatment of Bereavement Complications

Sidney Zisook, M.D.

Discussants Selby C. Jacobs, M.D., Jennifer L. Favell, Ph.D.

SYMPOSIUM 49 2:00 p.m.-5:00 p.m.

Grand Salon Sections 3 & 6, Street Level, Hilton

PSYCHOTHERAPY VIEWED FROM A BASIC SCIENCE SOCIAL BRAIN PERSPECTIVE*The World Psychiatric Association*

Chp.: Russell Gardner, M.D.

Co-Chp.: Frank G. Koerselman, M.D.

A Sociophysiological Exegesis of Michels' "Thinking While Listening"

Russell Gardner, M.D.

B Psychiatry and Biological Psychotherapy

Frank G. Koerselman, M.D.

C Memes, Mutual Suggestion, and Psychotherapy

John O. Beahrs, M.D.

Discussants: Daniel Wilson, M.D., Robert Michels, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART III*APA Committee of Early Career Psychiatrists and APA Assembly Committee of Early Career Psychiatrists*

Chp.: William E. Callahan, Jr., M.D.

A Personal Factors Leading to a Successful Private Practice

Ann S. Maloney, M.D.

B Office Location and Design for Efficiency and Success

Barry W. Wall, M.D.

C Streamlining Overhead and Managing Your Business in Private Practice

Keith W. Young, M.D.

D Marketing Your Unique Private Practice

William E. Callahan, Jr., M.D.

Discussants: Ann S. Maloney, M.D., Barry W. Wall, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 51 2:00 p.m.-5:00 p.m.

Grand Salon Sections 9 & 12, Street Level, Hilton

THINKING ABOUT MIND AND BRAIN: PSYCHOANALYSTS AND NEUROSCIENTISTS CONVERSE: PART II*American Academy of Psychoanalysis and American Psychoanalytic Association*

Chp.: Ann-Louise S. Silver, M.D.

(Continued on next page)

A Affect Theory: Neurobiological Findings and Psychological Structures

Otto F. Kernberg, M.D.

B A Biological Analysis of Transference

Mark G. Barad, M.D.

C Primitive Dreams and Neuropsychological Markers of Borderline or Psychotic States

Michael H. Stone, M.D.

D Early Empirical Psychoanalytic Research and Modern Neuroscience

Samuel Slipp, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 52

2:00 p.m.-5:00 p.m.

Grand Salon Sections 13 & 16, Street Level, Hilton

PSYCHOTHERAPEUTIC ASPECTS OF HIV

Chp.: Francine Cournos, M.D.

A Epidemiology: Shifting Populations, Shifting Cultural Concerns

Warren M. Liang, M.D.

B What Role Do Psychiatrists Have in Providing Baseline and Continuing HIV Counseling and Testing?

Robert S. Stasko, M.D.

C Psychotherapy with People Living with HIV

Marshall Forstein, M.D.

D Therapeutic Interventions with the High-Risk Patient

Kenneth B. Ashley, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53

2:00 p.m.-5:00 p.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

A MOST COMMON CHALLENGE: THE DUAL-DIAGNOSED PATIENT

Chp.: Roger Peele, M.D.

A Treatment of Patients with Bipolar Disorders and Alcoholism

Richard J. Frances, M.D., Avram H. Mack, M.D.

B Treatment of Comorbid Bipolar Disorder and Cocaine Addiction

David A. Gorelick, M.D.

C Treatment of Patients with Bipolar Disorders and Heroin Abuse

Herbert D. Kleber, M.D.

D Group Psychotherapy for Bipolar Patients with Substance Abuse

Mark J. Albanese, M.D., Edward J. Khantzian, M.D.

E Individual Psychotherapy with the Dual-Diagnosed Patient

George E. Woody, M.D.

Discussant: Patricia I. Ordorica, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54

2:00 p.m.-5:00 p.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

PSYCHOPHARMACOLOGY OF BPD

Chp.: Mary C. Zanarini, Ed.D.

Co-Chp.: Kenneth R. Silk, M.D.

A Olanzapine Treatment of Female Borderline Patients

Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.

B Divalproex Sodium Treatment of Women with BPD

Frances R. Frankenburg, M.D., Mary C. Zanarini, Ed.D.

C SSRIs in BPD: Unresolved Issues

Paul S. Links, M.D., Ian C. Dawe, M.D., Rahel Eynan-Harvey, M.A.

D Medication Choice in BPD

Kenneth R. Silk, M.D., Lawrence Thompson, Ph.D., Joann Heap, C.S.W., Naomi Lohr, Ph.D.

E Impulsivity: The Primary Target Symptom in BPD

Joel F. Paris, M.D.

Discussant: Bruce M. Pfohl, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55

2:00 p.m.-5:00 p.m.

Grand Salon Sections 21 & 24, Street Level, Hilton

PSYCHOANALYSIS AND PSYCHOTHERAPY LONG-TERM OUTCOME

Chp.: John C. Perry, M.D.

A Therapist Interventions in Completed Psychoanalyses: The Penn Psychoanalytic Treatment Collection

Elisabeth Banon, M.D., John C. Perry, M.D., Lester Luborsky, M.D., Carmella Roy, M.D.

B Changes in Defensive Functioning in Completed Psychoanalyses: The Penn Collection

Carmella Roy, M.D., John C. Perry, M.D., Elisabeth Banon, M.D., Lester Luborsky, M.D.

C A Follow-Along Study of Change in Long-Term Psychotherapy

Michael P. Bond, M.D., John C. Perry, M.D., Joan Oppenheimer, B.A., Natali Sanlian, M.P.S.

D The Austen Riggs Follow-Along Study: Five-Year Outcome

John C. Perry, M.D., Barbara Zheutlin, M.S., Eric M. Plakun, M.D., Stephen Beck, M.P.S., J. Christopher Fowler, Ph.D., Stephanie Speanberg, M.S.W.

E The Impact of Psychotherapy on the Brain

Glen O. Gabbard, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 56

2:00 p.m.-5:00 p.m.

Marlborough Suite A/B, Second Floor, Hilton

CLOSING THE EFFICACY/EFFECTIVENESS GAP IN PSYCHOPHARMACOLOGY

Chp.: Henry A. Nasrallah, M.D.

Co-Chp.: Greer Sullivan, M.D.

A The Gap Between Research Versus Clinical Outcomes of Pharmacotherapy

Henry A. Nasrallah, M.D.

B Policies Regarding Novel Antipsychotic Prescribing

Greer Sullivan, M.D., Dana M. Perry, B.A., Wen D. Grimes, M.A., Helen Weatherbee, J.D.

C Strategies for Implementing Schizophrenia Guidelines

Richard R. Owen, Jr., M.D., Teresa J. Hudson, Pharm.D.

D The Quality of Medication Treatment for Schizophrenia

Alexander S. Young, M.D., Greer Sullivan, M.D.

E Administrative Barriers to Closing the Efficacy and Effectiveness Gap

Kathryn J. Kotrla, M.D.

Discussant: Grayson S. Norquist, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57

2:00 p.m.-5:00 p.m.

Melrose Room, Third Floor, Hilton

VOYEURISM IN THE NEW MILLENNIUM: A PRIME-TIME OBSESSION?

Chp.: Norman E. Alessi, M.D.

A From Scopophilia to Survivor: Psychiatric Approaches to Voyeurism

Jonathan M. Metzl, M.D.

B Voyeurism and Cinema

Lee H. Rome, M.D.

C Voyeurism and the Internet

Robert A. Kowatch, M.D.

D Adolescents, Voyeurism, and the Internet

Norman E. Alessi, M.D.

SYMPOSIUM 58

2:00 p.m.-5:00 p.m.

Rosedown Room, Third Floor, Hilton

BEYOND MIND AND BRAIN: CONSIDERING THE PATIENT'S WORLD VIEW

Chp.: Allan M. Josephson, M.D.

A The Weltanschauung of Sigmund Freud: Clinical Implications

Armand M. Nicholi, Jr., M.D.

B Clinical Psychiatry and Spirituality: Another Level of Integration

Allan M. Josephson, M.D.

C Suffering and the Patient's World View

John R. Peteet, M.D.

D World Views and Hope in Psychiatry

Leigh C. Bishop, M.D.

E A Clinician Looks at Patients and Their World Views

Irving S. Wiesner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59

2:00 p.m.-5:00 p.m.

Magnolia Room, Third Floor, Hilton

BODY IMAGE DISORDERS IN MEN

Chp.: Katharine A. Phillips, M.D.

Co-Chp.: David Castle, M.D.

A The Prevalence of Body Image Disorders Among the Male Population

David Castle, M.D.

B Body Image in Males

Arnold Anderson

C BDD: An Underrecognized Body Image Disorder in Men

Katharine A. Phillips, M.D.

D Body Image and Muscle Dysmorphia in Men

Roberto Olivardia, M.A.

E Illicit Anabolic Steroid Use: Risk Factors and Psychosexual Effects

William R. Yates, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60

2:00 p.m.-5:00 p.m.

Jasperwood Room, Third Floor, Hilton

REDUCTION OF CHRONIC BENZODIAZEPINE USE: A MYTH AND REALITY

Chp.: Frans G. Zitman, M.D.

(Continued on next page)

- A Benzoredux Study: A Two-Phase Approach to Reduce Chronic Benzodiazepine Use**
Richard C. Oude Voshaar, M.D., W. D. J. Gorgels, M.D., Audrey J. Mol, M.S.C., Anton J.L.M. Van Balkom, M.D., Rien M. Breteler, Ph.D., Frans G. Zitman, M.D.
- B How to Stop Chronic Benzodiazepine Use in Depressed Patients**
Jaap E. Couvee, M.S.C., Frans G. Zitman, M.D.
- C Memory Impairment in Patients who Attempted Suicide by Benzodiazepine Overdose**
Bas Verwey, M.D., Paul Eling, Ph.D., Henu Wientjes, Ph.D., Frans G. Zitman, M.D.
- D Benzodiazepine Craving**
Audrey J. Mol, M.S.C., Richard C. Oude Voshaar, M.D., W. D. J. Gorgels, M.D., Rien M. Breteler, Ph.D., Anton J.L.M. Van Balkom, M.D., Eloy H. Van de Lisdonk, Ph.D., Frans G. Zitman, M.D.
- E Assessing Benzodiazepine Dependence: Development of the Benzodiazepine Dependence Self-Report Questionnaire**
Cornelis C. Kan, M.D., Frans G. Zitman, M.D., Rien M. Breteler, Ph.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.

Oak Alley Room, Third Floor, Hilton

REFORM, RESIDENT TRAINING, CONTEMPORARY PRACTICE, AND THE PUBLIC'S HEALTH

Chp.: Leighton Y. Huey, M.D.
Co-Chp.: Michael Hoge, Ph.D.

- A Aligning Resident Training and Workforce Proficiency: Is Reform Necessary?**
Leighton Y. Huey, M.D.
- B Changing Academic Psychiatry for Clinical Care**
Joseph A. Flaherty, M.D.
- C The Dartmouth Experience: Reform in Psychiatry Residency, Five Years Out**
Ronald L. Green, M.D., Bradford Watts, M.D.
- D Strategies for Catalyzing Change in Residency Training Programs**
Michael Hoge, Ph.D.

Discussant: Mary Jane England, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.

Elmwood Room, Third Floor, Hilton

PSYCHOTROPIC USE DURING PREGNANCY AND LACTATION: MORE DATA AND EVOLVING DEBATE

Chp.: Lee S. Cohen, M.D.

- A Psychotropic Use During Pregnancy and Lactation: Weighing the Risks**
Lee S. Cohen, M.D.
- B Psychotropic Medication Use During the Peripartum Period**
Kimberly A. Yonkers, M.D.
- C Controversial Issues in the Treatment of Pregnant and Breastfeeding Women**
Katherine L. Wisner, M.D.
- D Monitoring the Nursing Infant: Measures and Interpretations**
Zachary S. Stowe, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.

Belle Chasse Room, Third Floor, Hilton

THE PSYCHIATRIC CONSEQUENCES OF STRESS

Chp.: William B. Lawson, M.D.

- A PTSD in a Developmental Matrix: Evaluation and Treatment**
Robert S. Pynoos, M.D.
- B Inner-City Violence and PTSD**
William B. Lawson, M.D.
- C Collective Trauma and African-American Health Disparities**
Mindy J. Fullilove, M.D.
- D Psychobiology of PTSD**
Dennis S. Charney, M.D.
- E Pharmacotherapy for PTSD**
Matthew J. Friedman, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

TELECOMMUNICATIONS SESSION 2

2:00 p.m.-5:00 p.m.

Rooms 260/261, Level 2, Convention Center

DIGITAL SYSTEMS: INFORMATION SYSTEMS IN THE OFFICE

Chp.: Milton Huang, M.D.

- 4 Electronic Medical Record: Psychiatric Survival Tool for the Decade**
Daniel A. Deutschman, M.D., Arnold M. Rosen, M.D.
- 5 The CAPER System: Patient Assessment and Treatment Planning Software**
Peter F. Fore, M.D., Richard Weaver, Ph.D.

- 6 **Booting Up Your Practice: Computerized Record Keeping in Psychiatry**
Theron C. Bowers, Jr., M.D.
- 7 **Interfaced Information Systems: Networked Office**
Carmen Sugai, M.D., Edward Sugai, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7

3:00 p.m.-5:00 p.m.

Exhibition Center, Second Floor, Hilton

MOOD, DISSOCIATIVE, EATING, PREMENSTRUAL DYSPHORIC, AND SLEEP DISORDERS; DIAGNOSTIC AND RESEARCH ISSUES; GENETICS; AND SUICIDE

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 33-39

INDUSTRY-SUPPORTED SYMPOSIUM 33

7:00 p.m.-10:00 p.m.

Hall G, Lobby Level, Convention Center

RECOGNITION AND TREATMENT OF ALZHEIMER'S DISEASE: PRACTICAL LESSONS FROM NEW RESEARCH

Supported by Eisai Inc., Pfizer Inc.

Chp.: Gary W. Small, M.D.

Co-Chp.: Jeffrey L. Cummings, M.D.

- A **Alzheimer's Disease: Integrating Mind and Brain**
Jeffrey L. Cummings, M.D.
- B **An Update on Brain Imaging and Genetic Risk in Alzheimer's Disease Assessment**
Gary W. Small, M.D.
- C **Pathogenesis and Treatment Strategies in Alzheimer's Disease**
Rachelle S. Doody, M.D.
- D **The Interface of Depression and Dementia**
Davangere P. Devanand, M.D.
- E **Long-Term Benefits of Early Pharmacologic Treatment**
Pierre N. Tariot, M.D.
- F **Rediscovering Nonpharmacologic Approaches to Behavior and Function**
Kevin F. Gray, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 34

7:00 p.m.-10:00 p.m.

La Nouvelle Ballroom, Level 2, Convention Center

EVERYDAY CHALLENGES IN MANAGING PATIENTS ON PSYCHOTROPIC MEDICATIONS

Supported by Bristol-Myers Squibb Company

Chp.: Charles B. Nemeroff, M.D.

- A **Approaches to Optimizing Therapies Across Psychiatric Diagnoses: Remission Is the Goal**
Charles B. Nemeroff, M.D.
- B **Optimizing Patient Outcomes Across Psychiatric Diagnoses: Focus on Safety and Tolerability**
John M. Zajecka, M.D.
- C **Special Challenges When Using Psychotropic Medications in Children and Adolescents**
Karen D. Wagner, M.D.
- D **Special Challenges When Using Psychotropic Medications in the Geriatric Population**
K. Ranga R. Krishnan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35

7:00 p.m.-10:00 p.m.

Grand Ballroom A/B, Street Level, Hilton

OFF-LABEL ON THE TABLE: USING NEW PHARMACOLOGICAL AGENTS

Supported by Novartis Pharmaceuticals Corporation

Chp.: William M. Glazer, M.D.

Co-Chp.: Jerrold F. Rosenbaum, M.D.

- A **Symptoms, Syndrome, or Spectrum: How Do We Select Medications? A Clinical Case Vignette**
William M. Glazer, M.D., Jerrold F. Rosenbaum, M.D.
- B **Atypical Antipsychotics in the Treatment of Aggressive Behaviors**
Paul E. Keck, Jr., M.D.
- C **The Role of Antidepressant Medications for Aggressive Behaviors**
Jonathan E. Alpert, M.D., Maurizio Fava, M.D.
- D **The Role of Mood Stabilizers for Aggressive Behavior**
Alan C. Swann, M.D.
- E **Synthesis: Spectrum Versus Signal**
Jerrold F. Rosenbaum, M.D., William M. Glazer, M.D.

Discussant: Hayne D. McMeekin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36

7:00 p.m.-10:00 p.m.

Grand Ballroom C/D, Street Level, Hilton

MEN, WOMEN, AND SCHIZOPHRENIA: DOES ANATOMY DETERMINE DESTINY?

Supported by AstraZeneca Pharmaceuticals

Chp.: Henry A. Nasrallah, M.D.

Co-Chp.: Diana O. Perkins, M.D.

(Continued on next page)

A Normal Sexual Brain Dimorphisms: Impact on Schizophrenia in Men and Women

Jill M. Goldstein, Ph.D.

B Outcome and Treatment Response in Schizophrenia: Influences of Gender

Peter F. Buckley, M.D.

C Male-Female Difference in Schizophrenia: A Biopsychosocial Perspective

Mary V. Seeman, M.D.

D Neuroendocrine Side Effects of Antipsychotic Treatment on Men and Women

Diana O. Perkins, M.D.

E Gender Differences in Late-Life Schizophrenia and Its Treatment

Dilip V. Jeste, M.D., Laurie L. Lindamer, Ph.D., Jonathan P. Lacro, Pharm.D., Enid Rockwell, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 37

7:00 p.m.-10:00 p.m.

Acadia Ballroom, Third Floor, Marriott

IMAGES OF ANXIETY: A NEW LOOK AT GAD AND PTSD

Supported by SmithKline Beecham Pharmaceuticals

Chp.: Jack M. Gorman, M.D.

A Update on Neuroimaging

Jack M. Gorman, M.D.

B The Anxious Brain: GAD and PTSD

Jeremy D. Coplan, M.D.

C The Comorbidity Factor in GAD and PTSD

James C. Ballenger, M.D.

D An Update on PTSD

Rachel Yehuda, Ph.D.

E Current Concepts in the Diagnosis and Treatment of GAD

David V. Sheehan, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38

7:00 p.m.-10:00 p.m.

Carondelet Ballroom, Third Floor, Marriott

RESPONDING TO THE CHALLENGE OF TREATING BIPOLAR DISORDER

Supported by Glaxo Wellcome Inc.

Chp.: Joseph R. Calabrese, M.D.

A Novel Aspects of Lithium Therapy in Bipolar Disorder

Guy M. Goodwin, M.D.

B Molecular Mechanisms Underlying Mood Stabilization in Bipolar Disorder

Husseini K. Manji, M.D.

C Exploring Novel Treatment Strategies for Bipolar Disorder

Patricia Suppes, M.D.

D Combination Treatment with Atypical Antipsychotic Agents in Bipolar Disorder

Carlos A. Zarate, Jr., M.D., Sarah R. Cavanagh, B.A.

INDUSTRY-SUPPORTED SYMPOSIUM 39

7:00 p.m.-10:00 p.m.

Mardi Gras Ballroom, Third Floor, Marriott

CURRENT AND FUTURE MANAGEMENT OF INSOMNIA AND PSYCHIATRIC ILLNESSES

Supported by Sanofi-Synthelabo, Inc.

Chp.: Michael E. Thase, M.D.

A The Correlation Between Insomnia and Psychiatric Illnesses

Ruth M. Benca, M.D.

B The Neurobiology of Sleep in Health and Psychiatric Illness

Daniel J. Buysse, M.D.

C Safety and Tolerability Issues in the Treatment of Insomnia

David J. Greenblatt, M.D.

D Comparative Management of Insomnia: Worldwide Perspectives

Goran Hajak, M.D.

Discussant: Michael E. Thase, M.D.

MEDIA SESSIONS 17-18

MEDIA SESSION 17

7:00 p.m.-10:00 p.m.

Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Harvey R. Greenberg, M.D.

29 The Matrix
(136 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

The Matrix is a sci-fi thriller directed by Larry and Andy Wachowski starring Keanu Reeves and Laurence Fishburne. Reeves believes he is living a normal life in the 90s, but discovers he and the rest of humanity are living a delusion fed to them by

their computer captors in the future. Reeves breaks free and joins an underground group of computer hackers, led by Fishburne, to lead their enslaved society in a revolution against their machine masters.

MEDIA SESSION 18 7:00 p.m.-10:00 p.m.
Versailles Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Sandra C. Walker, M.D.

30 Sankofa
(125 minutes)

Distributor: Mypheduh Films, Inc.
P.O. Box 10035
Washington, DC 20018-0035

Sankofa is an Akan word that means "one must return to the past in order to move forward." In *Sankofa* the video, Mona, a contemporary model, is possessed by spirits lingering in the Cape Coast Castle in Ghana. She travels to the past where as a house servant called Shola, she is constantly abused by the slave master. Nunu, an African-born field hand, and Shango, Shola's West Indian lover, continuously rebel against the slave system. For Nunu this means direct conflict with her son, a mulatto benefiting from the system as a head slave. Inspired by Nunu and Shango's determination to defy the system, Shola finally takes her fate into her own hands.



Photo courtesy of Linda S. Reneke NOMCVB

**American Psychiatric Association
53rd Institute on Psychiatric Services**

**Wednesday, October 10 – Sunday, October 14, 2001
Orlando, FL**

“Multidisciplinary Roles in the 21st Century”

• Symposia • Workshops • CME Courses •
• Computer and Video Sessions • Debates •
• Full-Day Sessions • Poster Sessions • Forums •
• Discussion Groups • Innovative Programs
• Industry-Supported Symposia • Medical Updates •
• Leadership and Career Development Seminars •
• Distinguished Lecturers • Clinical Consultations •

INSTITUTE OBJECTIVES: At the conclusion of the 2001 Institute on Psychiatric Services, participants will:

- 1) Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- 2) Better understand how the current health care system affects patient care;
- 3) Gain new knowledge and skills useful in public psychiatric settings; and
- 4) Better understand the usefulness of Multidisciplinary Roles in the 21st Century.

Did you know that...

- ★ *The 2000 Institute received the highest attendee-rated evaluations?*
- ★ *APA members receive a 40% discount on their cost for registration?*
- ★ *All scientific sessions will be held in the Renaissance Orlando Resort Hotel?*
- ★ *Industry-Supported Breakfast, Lunch and Dinner Symposia are presented each day?*
- ★ *You can earn up to 48 hours of category 1 credit for attending the Institute?*
- ★ *There are prize drawings, beverages and receptions held daily in the exhibit hall?*


For further information, please write to:

Annual Meetings Department
American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20015

Telephone: 1 (888) 357-7924 (Toll Free)

Fax: (202) 682-6345

E-Mail: apa@psych.org



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

WEDNESDAY, MAY 9, 2001

154TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 40-43

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 1

7:00 a.m.-8:30 a.m.

Hall G, Lobby Level, Convention Center

CLINICAL CHALLENGES IN ANXIETY

Supported by Pfizer Inc.

Chp.: Mark H. Pollack, M.D.

Co-Chp.: James W. Jefferson, M.D.

A Anxiety Disorders: Moving from Better to Well

Mark H. Pollack, M.D.

B Innovative Pharmacological Approaches to Treatment- Resistant Anxiety Disorders

James W. Jefferson, M.D.

C Novel Anxiolytics in Development and Abroad

Stuart A. Montgomery, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 1

7:00 a.m.-8:30 a.m.

La Nouvelle Ballroom, Level 2, Convention Center

A NEW ERA FOR MANAGING PSYCHOSIS: REBUILDING LIVES FOR PATIENTS AND FAMILIES

Supported by Janssen Pharmaceutica

Chp.: Ira D. Glick, M.D.

Co-Chp.: Stephen R. Marder, M.D.

A Integrating Pharmacological and Psychosocial Treatments: Improving Social and Vocational Outcomes

Stephen R. Marder, M.D.

B The Treatment of Juvenile-Onset Psychosis

Patrick D. McGorry, Ph.D.

C The Older Patient and Family

Soo Borson, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom A/B, Street Level, Hilton

TREATMENT OF DEPRESSION IN WOMEN: FROM ACUTE REMISSION TO SUSTAINED RECOVERY

Supported by Wyeth-Ayerst Laboratories

Chp.: Lee S. Cohen, M.D.

Co-Chp.: Adele C. Viguera, M.D.

A Sex-Based Differences in Mood and Anxiety Disorders

Adele C. Viguera, M.D.

B Postpartum Depression: From Acute Treatment Response to Functional Recovery

Lee S. Cohen, M.D.

C PMDD: How It Affects Women's Lives

Kimberly A. Yonkers, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom C/D, Street Level, Hilton

DEPRESSION: GENDER, AGE, AND SPECIAL POPULATIONS

Supported by Eli Lilly and Company

Chp.: David L. Dunner, M.D.

A Mood Disorders in the Child and Adolescent

Graham J. Emslie, M.D.

B Ethnic and Gender Issues in the Treatment of Depression

David L. Dunner, M.D.

C The Elderly Patient: A Delicate Balance

Alan P. Siegel, M.D.

8:00 a.m. Sessions



COURSES 79-87

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 79

8:00 a.m.-12 noon

La Galerie 2, Second Floor, Marriott

INNOVATIVE THERAPEUTICS IN CONSULTATION-LIAISON PSYCHIATRY

Co-Directors: Francisco Fernandez, M.D., Edwin H. Cassem, M.D.

Faculty: James L. Griffith, M.D.

COURSE 80 8:00 a.m.-12 noon

La Galerie 4, Second Floor, Marriott

PSYCHIATRIC ASPECTS OF EPILEPSY**Co-Directors:** David J. Goode, M.D., Christine Dean, M.D.**COURSE 81** 8:00 a.m.-12 noon

La Galerie 5, Second Floor, Marriott

THE FORENSIC ASSESSMENT OF COMPETENCY TO MAKE A DECISION (IN SPANISH)**Director:** Alfredo Calcedo-Barba, M.D.**Faculty:** Julio E. Arboleda-Florez, M.D.**COURSE 82** 8:00 a.m.-12 noon

Balcony L, Fourth Floor, Marriott

BEHAVIORAL NEUROANATOMY: AN INTRODUCTION**Director:** Nashaat N. Boutros, M.D.**Faculty:** David L. Clark, Ph.D., Edward C. Lauterbach, M.D.**COURSE 83** 8:00 a.m.-12 noon

Balcony M, Fourth Floor, Marriott

DIALECTICAL BEHAVIOR THERAPY AND PARTIAL HOSPITAL IN THE DIFFICULT-TO-TREAT PATIENT**Director:** Elizabeth B. Simpson, M.D.**Faculty:** Karen J. Rosen, M.D., Ellen Costello, Ph.D., Marydale Stevens, R.N.**COURSE 84** 8:00 a.m.-12 noon

Balcony N, Fourth Floor, Marriott

TREATMENT ISSUES FOR WOMEN IN MINORITY GROUPS**Director:** Susan R. Downs, M.D.**Faculty:** Ellen Haller, M.D., Michelle O. Clark, M.D., Silvia W. Olarte, M.D., Elisabeth C. Small, M.D.**COURSE 85** 8:00 a.m.-12 noon

Bayside Room B, Fourth Floor, Sheraton

INSANITY DEFENSE EVALUATIONS**Director:** Phillip J. Resnick, M.D.**COURSE 86** 8:00 a.m.-12 noon

Bayside Room C, Fourth Floor, Sheraton

THE PSYCHOSOCIAL MANAGEMENT OF BIPOLAR DISORDER**Co-Directors:** Michael D. Robertson, M.D., Lee K. Wolfson, M.Ed.**COURSE 87** 8:00 a.m.-12 noon

Grand Ballroom E, Fifth Floor, Sheraton

PARTIAL HOSPITALIZATION FOR PATIENTS WITH BPD**Director:** Lawrence L. Kennedy, M.D.**9:00 a.m. Sessions****CLINICAL CASE CONFERENCES 3-4****CLINICAL CASE CONFERENCE 3**

9:00 a.m.-10:30 a.m.

Room 263, Level 2, Convention Center

VOCAL CORD DYSKINESIA: A DYNAMIC INTERCHANGE BETWEEN MEDICINE AND PSYCHIATRY**Moderator:** Geoffrey M. Gabriel, M.D.**Discussant:** Harold J. Wain, Ph.D.**CLINICAL CASE CONFERENCE 4**

9:00 a.m.-10:30 a.m.

Room 262, Level 2, Convention Center

ASSESSMENT OF PROGNOSTIC FACTORS IN THE ALCOHOLIC PATIENT**Presenter:** Kathy L. Coffman, M.D.**Discussant:** Thomas P. Beresford, M.D.**THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.****COURSES 88-90**Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.**COURSE 88** 9:00 a.m.-4:00 p.m.

La Galerie 1, Second Floor, Marriott

ASSESSMENT AND TREATMENT OF PATIENTS WITH MENTAL RETARDATION**Director:** Ruth M. Ryan, M.D.

COURSE 89 9:00 a.m.-4:00 p.m.

La Galerie 6, Second Floor, Marriott

PSYCHOTHERAPY OF BORDERLINE PERSONALITY**Co-Directors:** Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.
Faculty: John F. Clarkin, Ph.D.**COURSE 90** 9:00 a.m.-4:00 p.m.

Bacchus Room, Fourth Floor, Marriott

THE ASSESSMENT AND TREATMENT OF CHILD MOLESTERS**Director:** John M.W. Bradford, M.B.
Faculty: Gene G. Abel, M.D., Graham G. Glancy, M.B.**DISCUSSION GROUPS 14-17**

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 14 Ellen Leibenluft, M.D.**, on Bipolar Disorder in Children and Adults: Clinical and Research Issues
Chequers Suite, Second Floor, Hilton
- 15 Vivien K. Burt, M.D.**, on Career Opportunities in Women's Mental Health (*For Residents Only*)
Trafalgar Suite, Third Floor, Hilton
- 16 Carl C. Bell, M.D.**, on Administrative Psychiatry: Leaderless Leadership
Norwich Suite, Third Floor, Hilton
- 17 James L. Levenson, M.D.**, on Psychiatric Drugs in the Medically Ill
Durham Suite, Third Floor, Hilton

LECTURES 15-17**LECTURE 15**

9:00 a.m.-10:30 a.m.

Rooms 252-254, Level 2, Convention Center

Gerald M. Edelman, M.D.

How Matter Becomes Imagination: From Brain Dynamics to Consciousness**Chp.:** Regina Pally, M.D.**Co-Chp.:** Michael A. Gates, M.D.

Most approaches to understanding consciousness emphasize the contributions of specific brain areas or

groups of neurons. Gerald M. Edelman, M.D., presents a contrasting model in which processes of neural integration account for key properties of conscious experience. The approach draws on a theory of neuronal group selection known as Neural Darwinism and leads to the dynamic core hypothesis, which is built on cortical mechanisms involving reentrant signaling. Dr. Edelman is Director of the Neurosciences Institute in San Diego, California, President of the Institute's parent organization, the Neurosciences Research Foundation, and Professor and Chairman of the Department of Neurobiology at the Scripps Research Institute in La Jolla, California. Dr. Edelman was awarded the 1972 Nobel Prize for Physiology or Medicine for his early studies on the structure and diversity of antibodies. His more recent work in theoretical neuroscience is the subject of his books *Neural Darwinism*, *The Remembered Present*, *Bright Air*, *Brilliant Fire*, and *A Universe of Consciousness: How Matter Becomes Imagination*, coauthored with Giulio Tononi. In addition, Dr. Edelman is the author of more than 450 research publications. Dr. Edelman received his medical degree from the University of Pennsylvania and his doctoral degree in biochemistry and immunology from Rockefeller University in New York City.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 16

9:00 a.m.-10:30 a.m.

Rooms 338/339, Level 3, Convention Center

APA'S ADMINISTRATIVE PSYCHIATRY AWARD LECTURE

Steven M. Mirin, M.D.

Surviving Organizational Change**Co-Chps.:** William H. Reid, M.D., Dave M. Davis, M.D., Gordon H. Clark, Jr., M.D.

The last decade has been one of enormous change for both health care organizations and professional associations. Advances in technology and telecommunications, coupled with the need to respond to a rapidly changing health care environment, have challenged these organizations to review their strategic priorities and reconfigure their budgets to address current and future threats to their survival. Steven M. Mirin, M.D., Medical Director of the American Psychiatric Association in Washington, D.C., discusses the challenges faced by these organizations and the staff and volunteer leaders who work within them and describes survival strategies for coping with rapid organizational change. Dr. Mirin was President and Psychiatrist-in-Chief of McLean Hospital in Belmont, Massachusetts, and currently is Professor of Psychiatry at Harvard Medical School in

(Continued on next page)

Boston. A Fellow of the APA, Dr. Mirin has served on numerous APA task forces and committees, including the work group that developed the *Practice Guideline for the Treatment of Patients with Substance Use Disorders*, which he chaired. He is the author of approximately 130 professional papers and the author or editor of seven books. He received his medical degree from the State University of New York Upstate Medical Center in Syracuse and completed his psychiatry residency at Boston University Medical Center.
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 17

9:00 a.m.-10:30 a.m.

Rooms 353-355, Level 3, Convention Center

APA'S ADOLF MEYER AWARD LECTURE

Steven E. Hyman, M.D.

Psychiatric Diagnosis:
 Are We Prepared for a New Millennium?

Chp.: Darrel A. Regier, M.D.
 Co-Chp.: Alan Langlieb, M.D.

Psychiatric diagnostic systems developed during the 20th century, including the *APA Diagnostic and Statistical Manuals*, were based largely on clusters of clinical symptoms and signs, in the absence of definitive biological markers and adequate family data for mental illness. The strength of such efforts lay in their reliability rather than their validity. Steven E. Hyman, M.D., Director of the National Institute of Mental Health, examines the nature of mental illness and the ways in which modern genomics, genetics, and neuroscience may ultimately yield diagnoses that are not only reliable, but also valid. In addition to his duties as NIMH director, Dr. Hyman directs an active research program in molecular neurobiology at the National Institutes of Health. He is the author of numerous scientific articles and the author or editor of several widely used clinical texts. He serves on several review and advisory boards, including those of the Riken Brain Sciences Institute in Japan, the Max Planck Institute in Germany, and the Howard Hughes Medical Institute in the United States. Dr. Hyman received his medical degree from Harvard Medical School and completed a residency in psychiatry at McLean Hospital in Belmont, Massachusetts, a clinical fellowship in neurology at Massachusetts General Hospital in Boston, and a postdoctoral fellowship in molecular biology at Harvard University.
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 12-14

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

12 Kathryn J. Zerbe, M.D., on Psychotherapy for Women
 Room 337, Level 3, Convention Center

13 Paul R. McHugh, M.D., on Treatments Based on the Perspectives of Psychiatry
 Room 340, Level 3, Convention Center

14 Troy L. Thompson II, M.D., on Depression, Antidepressants, and Sexual Dysfunction: Differential Diagnosis, Avoiding, Treating
 Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 19-20

MEDIA SESSION 19

9:00 a.m.-11:00 a.m.

Napoleon Ballroom, Third Floor, Hilton

PAIN IN CHILDHOOD: BODY AND MIND

Chp.: Richard E. D'Alli, M.D.

31 No Fears... No Tears: Thirteen Years Later
 (46 minutes)

Distributor: Fanlight Productions
 4196 Washington Street, Suite 2
 Boston, MA 02131

Thirteen years ago the award-winning video documented how eight children suffering from cancer go through painful medical treatments with the therapeutic support of clinical psychologist, Dr. Leora Kuttner. Now in *No Fear... No Tears: Thirteen Years Later*, Dr. Kuttner reconnects to determine the long-term benefits of learning as a child how to deal with pain and fear. These young adults vividly recollect their painful childhood experiences, dramatically showing how children can actively help themselves through taxing medical treatments and enhance their appreciation of life.

32 In Grandma's Hands
 (25 minutes)

Distributor: University of California Extension Center
 for Media and Independent Learning
 2000 Center Street, 4th Floor
 Berkeley, CA 94704

America's drug epidemic grabs headlines when addiction spirals into violence; but behind every story of addiction there is another story that is rarely investigated, a story of shattered families and the people who pick up the broken pieces. In America today some four million children are being raised by their grandparents. This intimate and gently probing documentary studies three diverse urban families in which grandparents are raising their grandchildren as a result of their own children's drug addiction. In candid, reflective interviews, the grandparents comment on the challenges of raising young children at a time in their lives when they expected to be enjoying a quiet retirement.

MEDIA SESSION 20 9:00 a.m.-11:00 a.m.
Versailles Ballroom, Third Floor, Hilton

WHEN THE BRAIN HICCUPS

Chp.: John T. Walkup, M.D.

33 Twitch and Shout
(59 minutes)

Distributor: New Day Films
22-D Hollywood Avenue
Ho Ho Kus, NJ 07423

Twitch and Shout provides an intimate journey into the startling world of Tourette's Syndrome (TS) told through the eyes of a photojournalist with TS. This film is an emotionally absorbing, sometimes unsettling, and ultimately uplifting film about people who must contend with a society that often sees them as crazy or bad and a body and mind that won't do what it's told.

REVIEW OF PSYCHIATRY: SECTION 4
9:00 a.m.-12 noon
Rooms 343-345, Level 3, Convention Center

BRAIN IMAGING IN THE NEW MILLENNIUM

Chp.: John M. Morihisa, M.D.

16 Neuroimaging Studies in Children: Implications for Research on Affect
Daniel S. Pine, M.D.

17 Imaging Human Cognition and Cognitive Disability in Mental Disorders
Cameron S. Carter, M.D.

18 Structural and Functional Imaging in Late-Life Depression
Harold A. Sackeim, Ph.D.

19 Future Applications for fMRI in Psychiatry
Joseph H. Callicott III, M.D.

20 Neuroimaging Abnormalities in Primary Mood Disorder
Wayne C. Drevets, M.D.

TELECOMMUNICATIONS SESSION 3

9:00 a.m.-12 noon

Rooms 260/261, Level 2, Convention Center

DIGITAL EFFECTS: TECHNOLOGY IN THE CLINICAL PRACTICE

Chp.: Ronnie S. Stangler, M.D.

9:15 a.m.

8 The Impact of Electronic Psychiatric Records on Patients and the Doctor-Patient Relationship
Heather A. Flynn, Ph.D., Sheila Marcus, M.D., Norman E. Alessi, M.D.

9:30 a.m.

9 Digital Phenomenology of Depression
Norman E. Alessi, M.D., Milton Huang, M.D.

9:50 a.m.

10 Using Virtual Reality to Treat Acrophobia
Milton Huang, M.D.

10:10 a.m.

11 Internet Algorithms for the Pharmacotherapy of Depression: Java Version
David N. Osser, M.D., Robert D. Patterson, M.D.

WORKSHOPS

COMPONENTS 33-38

COMPONENT WORKSHOP 33 9:00 a.m.-10:30 a.m.
Room 264, Level 2, Convention Center

DEVELOPING A STATEWIDE PSYCHIATRIC DISASTER PLAN

APA Committee on Psychiatric Dimensions of Disasters

Chp.: Sheila G. Jowsey, M.D.

Participants: Alan Q. Radke, M.D., Mark D. Williams, M.D., David R. Johnson, M.D., Steve M. Kubas, M.D., Jennifer S. Lahmann, M.D., Joseph C. Napoli, M.D.

COMPONENT WORKSHOP 34 9:00 a.m.-10:30 a.m.
Rooms 333/334, Level 3, Convention Center

TRANSGENDER ISSUES: FEMALE TO MALE

APA Northern California Psychiatric Society's Committee on Lesbian, Gay, Bisexual, and Transgender Issues

Chp.: Dan H. Karasic, M.D.

Participants: Robin A. Dea, M.D., Patrick Califia-Rice, M.A., Jamison Green, M.F.A.

COMPONENT WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room 342, Level 3, Convention Center

USING PRACTICE GUIDELINES IN RESIDENCY TRAINING

APA Steering Committee on Practice Guidelines

Chp.: John S. McIntyre, M.D.

Participants: David A. Garfield, M.D., Sheila H. Gray, M.D., Amarendra Das, M.D., Margaret T. Lin, M.D.

COMPONENT WORKSHOP 36 9:00 a.m.-10:30 a.m.
Rooms 346/347, Level 3, Convention Center

PSYCHIATRY IN THE NEUROSCIENCE CURRICULUM: PROMISE AND PERIL

APA Committee on Medical Student Education

Chp.: Carl B. Greiner, M.D.

Participants: H. Jonathan Polan, M.D., Linda F. Pessar, M.D., Kristin J. O'Dell, M.D., Michael J. Vergare, M.D.

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 352, Level 3, Convention Center

MIND, BRAIN, AND ENVIRONMENT: HOW CAN CLINICIANS ADDRESS SOCIAL ILLS?

APA Committee on Poverty, Homelessness, and Psychiatric Disorders

Chp.: Hunter L. McQuiston, M.D.

Participants: Carl I. Cohen, M.D., Carles Muntaner, M.D., Leslie A. Horton, M.D.

COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room 357, Level 3, Convention Center

CAREER CHANGE FOR PSYCHIATRISTS AND PATIENTS YOUNG AND OLD

APA Committee on Psychiatry in the Workplace

Chp.: Harry Prosen, M.D.

Participants: Leonard T. Sperry, M.D., Marcia Scott, M.D., Stephen H. Heidel, M.D.

ISSUES 60-86

ISSUE WORKSHOP 60 9:00 a.m.-10:30 a.m.
Rooms 265/266, Level 2, Convention Center

SPIRITUAL/RELIGIOUS ASSESSMENT IN CLINICAL WORK

Chp.: Francis G. Lu, M.D.

Participant: David B. Larson, M.D.

ISSUE WORKSHOP 61 9:00 a.m.-10:30 a.m.
Rooms 267-268, Level 2, Convention Center

HOMEOPATHIC MEDICINE AND PSYCHIATRY

Chp.: Edward B. Gogek, M.D.

ISSUE WORKSHOP 62 9:00 a.m.-10:30 a.m.
Room 269, Level 2, Convention Center

TREATING PHYSICIANS: CUTTING-EDGE ISSUES

Chp.: Michael F. Myers, M.D.

Participants: Gerald Schneiderman, M.D., Nada L. Stotland, M.D., Leah J. Dickstein, M.D., John D. Wynn, M.D.

ISSUE WORKSHOP 63 9:00 a.m.-10:30 a.m.
Room 270, Level 2, Convention Center

PSYCHODYNAMICS IN TREATMENT-REFRACTORY DEPRESSION

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 64 9:00 a.m.-10:30 a.m.
Room 271, Level 2, Convention Center

NATURE AND NURTURE: DEVELOPING COMPREHENSIVE SERVICES FOR YOUNG CHILDREN

Chp.: Peter D. Ganime, M.D.

Participants: Joanne Dunnigan, M.S.W., Grace Hickey, Psy.D., Phillip Repasky, M.A., Diane Beebe, M.S.

ISSUE WORKSHOP 65 9:00 a.m.-10:30 a.m.
Room 272, Level 2, Convention Center

CRISIS-STABILIZATION UNITS: ALTERNATIVE TO HOSPITAL OR DE FACTO HOSPITAL?

Chp.: Neil D. Price, M.D.

Participants: Patrick S. Maidman, M.D., David A. Moltz, M.D.

ISSUE WORKSHOP 66 9:00 a.m.-10:30 a.m.
Room 273, Level 2, Convention Center

TREATING HAREDI (VERY ORTHODOX) JEWS IN THE UNITED STATES AND ISRAEL

The Mesorah Society for Traditional Judaism and Psychiatry

Chp.: Abba E. Borowich, M.D.

Participant: David Greenberg, M.D.

ISSUE WORKSHOP 67 9:00 a.m.-10:30 a.m.
Rooms 335/336, Level 3, Convention Center

A REVIEW OF PATIENT ASSAULTS ON STAFF

Co-Chps.: Brandon Z. Erdos, M.D., Douglas H. Hughes, M.D.
Participant: Janet E. Osterman, M.D.

ISSUE WORKSHOP 68 9:00 a.m.-10:30 a.m.

Rooms 348/349, Level 3, Convention Center

SPIRITUAL STRUGGLES: THE NEW PRIORITY IN TREATMENT

Co-Chps.: Stephen M. Soltys, M.D., Larry R. Wagner, Ph.D.

ISSUE WORKSHOP 69 9:00 a.m.-10:30 a.m.

Rooms 350/351, Level 3, Convention Center

WHAT EVER HAPPENED TO PSYCHOTHERAPY?

Chp.: Edmundo J. Ruiz, M.D.

Participants: Homero R. Sanchez, M.D., James B. Stone, M.D., Higinio Zuniga, M.D.

ISSUE WORKSHOP 70 9:00 a.m.-10:30 a.m.

Room 356, Level 3, Convention Center

WORKING WITH SMALL BUSINESSES

Co-Chps.: R. Mark Webb, M.D., Melissa M. Hankins, M.D.

ISSUE WORKSHOP 71 9:00 a.m.-10:30 a.m.

Grand Salon Sections 3 & 6, Street Level, Hilton

EDUCATING PATIENTS AND FAMILIES ABOUT ECT

Chp.: Harold A. Sacheim, Ph.D.

Participant: Shoshana Peyser, Ph.D.

ISSUE WORKSHOP 72 9:00 a.m.-10:30 a.m.

Grand Salon Section 4, Street Level, Hilton

DO I NEED AN MBA TO TRANSFORM MY CAREER?

Chp.: Arthur L. Lazarus, M.D.

ISSUE WORKSHOP 73 9:00 a.m.-10:30 a.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

DISTANCE-LEARNING OPTIONS

Co-Chps.: Howard J. Osofsky, M.D., Paul M. Balson, M.D.

Participant: Andrew P. Twyman, M.S.W.

ISSUE WORKSHOP 74 9:00 a.m.-10:30 a.m.

Grand Salon Sections 9 & 12, Street Level, Hilton

MARIJUANA AND PSYCHIATRY: DILEMMAS FOR THE CLINICIAN

Chp.: David H. Friar, M.D.

Participants: David A. Wolkoff, M.D., Ernest P. Alaimalo, M.D.

ISSUE WORKSHOP 75 9:00 a.m.-10:30 a.m.

Grand Salon Sections 13 & 16, Street Level, Hilton

HOW TO DETECT DECEPTION

Chp.: Alan R. Hirsch, M.D.

Participants: Charles J. Wolf, M.D., Rodgers M. Wilson, M.D., Carl M. Wahlstrom, Jr., M.D., David E. Hartman, Ph.D.

ISSUE WORKSHOP 76 9:00 a.m.-10:30 a.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

MID-CAREER PSYCHIATRY: STAYING FRESH AND CREATIVE

Chp.: Joel Yager, M.D.

Participants: Jerald Kay, M.D., Carol C. Nadelson, M.D., Carolyn B. Robinowitz, M.D., Zebulon C. Taintor, M.D.

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

CURRENT AND FUTURE TRENDS IN PSYCHIATRY AND CRIMINAL LAW

Chp.: Michael M. Welner, M.D.

Participants: Robert D. Miller, M.D., Abraham L. Halpern, M.D., Ann Burgess, D.N., Robert L. Sadoff, M.D.

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.

Grand Salon Sections 21 & 24, Street Level, Hilton

USING HAMLET TO LEARN ABOUT TEACHING, INTERVIEWING, AND THERAPEUTIC INTERACTION

Chp.: Dinko Podrug, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.

Prince of Wales Suite, Second Floor, Hilton

INTERNATIONAL PROBLEMS WITH PERSONALITY DISORDERS IN THE WORKPLACE

Co-Chps.: James H. Reich, M.D., Giovanni de Girolamo, M.D.

Participants: Julien D. Guelfi, M.D., Lisa Ekselius, M.D.

ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m.

Melrose Room, Third Floor, Hilton

FOR BETTER OR FOR WORSE: SPOUSES OF PATIENTS WITH DEMENTIA

Chp.: Sheila M. Loboprabhu, M.D.

Participants: James W. Lomax II, M.D., Victor Molinari, Ph.D., Kimberly A. Arlinghaus, M.D., Kristin A. Kassaw, M.D.

ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m.

Rosedown Room, Third Floor, Hilton

DOES JOHNNY NEED METHYLPHENIDATE?

Chp.: Antonio J. Gracia, M.D.

Participants: Betsy Nix, L.M.S.W., Brenda McCorvey, R.N., Clint Stone, M.S.U.

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.
Magnolia Room, Third Floor, Hilton

TREATING PTSD COMPLICATED BY MEDICAL PROBLEMS: MIND AND BRAIN MEET BODY

Co-Chps.: Gordon D. Strauss, M.D., Michelle A. Fiorella, D.O.

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.
Jasperwood Room, Third Floor, Hilton

TRAINING IMG RESIDENTS: CHALLENGES AND OPPORTUNITIES

Co-Chps.: Nalini V. Juthani, M.D., Richard Balon, M.D.
Participants: Vinay Kapoor, M.D., Anu A. Matorin, M.D., Pedro Ruiz, M.D., Tarek A. Okasha, M.D.

ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.
Oak Alley Room, Third Floor, Hilton

NEUROIMAGING: INTEGRATING BIOETHICS WITH CLINICAL AND BASIC SCIENCES

Chp.: Igor Elman, M.D.
Participants: Hans C. Breiter, M.D., David R. Gastfriend, M.D., Katherine Karlsogdt, B.A., Jasmin S. Roman, B.A.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.
Elmwood Room, Third Floor, Hilton

IMPLEMENTING MULTIDISCIPLINARY DIAGNOSIS AND MANAGEMENT OF PSEUDOSEIZURES

Co-Chps.: Martin A. Goldstein, M.D., Cynthia L. Harden, M.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.
Belle Chasse Room, Third Floor, Hilton

BEYOND REDUCTIONISM: CLINICAL IMPLICATIONS

Chp.: Ian E. Alger, M.D.
Participants: Clarice J. Kestenbaum, M.D., Lewis A. Opler, M.D., Eric R. Marcus, M.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 18-21

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

18 Richard J. Frances, M.D., on Treating Addicted Patients with Psychiatric Comorbidity
Chequers Suite, Second Floor, Hilton

19 Ann R. Turkel, M.D., on Medicine, Marriage, and Motherhood
Trafalgar Suite, Third Floor, Hilton

20 Joel J. Wallack, M.D., on Psychiatry at the Medical Interface: Opportunities in the New Millennium
Norwich Suite, Third Floor, Hilton

21 Randall D. Marshall, M.D., on Integrating Pharmacotherapy and Psychotherapy in PTSD
Durham Suite, Third Floor, Hilton

LECTURES 18-19

LECTURE 18

11:00 a.m.-12:30 p.m.

Rooms 252-254, Level 2, Convention Center

Giulio Tononi, M.D.

Consciousness Integrated and Differentiated

Chp.: Regina Pally, M.D.
Co-Chp.: Michael A. Gales, M.D.

A useful way of identifying the neural basis of consciousness is to consider the kinds of neural processes that could account for its most fundamental properties, including both its unity and its complexity. Giulio Tononi, M.D., discusses a novel theory, the dynamic core hypothesis, which proposes that consciousness is a consequence of dynamic interactions of a continually changing functional cluster of nerve cells in the thalamus and cerebral cortex. Dr. Tononi is a Senior Fellow in Theoretical and Experimental Neurobiology at the Neurosciences Institute in San Diego, California, and Associate Professor at the Scripps Research Institute in La Jolla, California. In his recent research, he has used imaging techniques to study the mechanisms by which the brain gives rise to conscious experience and has examined the functions of sleep using electrophysiological and molecular biology methods. Dr. Tononi is the author of more than 120 scientific publications, a co-editor of *Selectionism and the Brain*, and the author, with Gerald M. Edelman, of *A Universe of Consciousness: How Matter Becomes Imagination*. Dr. Tononi received his medical degree at the University of Pisa, Italy, and received his doctoral degree in neuroscience as a fellow of the Scuola Superiore S. Anna in Pisa.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 19

11:00 a.m.-12:30 p.m.

Rooms 338/339, Level 3, Convention Center

Doug Wright

Quills: The Marquis on the Marquee

Chp.: David M. McDowell, M.D.

The renowned libertine and author of the Marquis de Sade has had many incarnations in the popular arts. Doug Wright, author of the play *Quills*, which is set during de Sade's confinement in an asylum, traces the experience of representing the notorious French philosopher, from the birth of the play at the New York Theater Workshop to its recent motion picture adaptation, for which Mr. Wright wrote the screenplay. He discusses key moments in de Sade's life, explores questions of poetic license in literary adaptation, and highlights research he undertook to recreate an early nineteenth-century asylum on stage and on film. Mr. Wright won an Obie Award for outstanding achievement in playwriting and the Kesselring Award for Best New American Play from the National Arts Club for *Quills*. In addition, his numerous awards include the William L. Bradley Fellowship at Yale University, the Charles MacArthur Fellowship at the Eugene O'Neill Theater Centre, and the Alfred Hodder Fellowship at Princeton University. His work has been published in *The Best Short Plays* series and in *The Paris Review*. He has also authored screenplays for Dreamworks, Warner Brothers, Universal Studios, and Artisan Entertainment. Mr. Wright holds a master's degree in playwriting from New York University.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL
CONSULTATIONS 15-17

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

15 Ronald O. Rieder, M.D., on Teaching Psychopathology to Medical Students (*AADPRT Council on Education Master Teacher*)
Room 337, Level 3, Convention Center

16 Susan Lieff, M.D., on the Agitated Geriatric Patient
Room 340, Level 3, Convention Center

17 Francis G. Lu, M.D., on Cultural Issues in Clinical Case Formulation
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 21-22

MEDIA SESSION 21

11:00 a.m.-2:00 p.m.

Napoleon Ballroom, Third Floor, Hilton

AGING BRAINS, FADING MINDS

Chp.: Peter V. Rabins, M.D.

34 Grace
(57 minutes)

Distributor: Video Press
University of Maryland School of Medicine
100 North Greene Street, Suite 300
Baltimore, MD 21201

This video follows the life of Grace Kirkland, who suffers from a progressive dementia disorder and the inspirational caregiving efforts of her husband for a period of seven years. At the onset, Grace is seen to be having difficulty with short-term memory. Nonetheless, her enthusiasm for life shines through her troubled moments. Four years later, Grace is no longer able to speak and paces through her home. Finally, Grace is no longer able to walk or eat without assistance. This program is a tribute to the spirit of Grace and the care provided by her husband.

35 Choices and Challenge: Caring for Aggressive Adults
(22 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

Choice and Challenge is a training program developed during a yearlong project sponsored by the American Psychiatric Nurses Association. This videotape provides a view of "real people" in "real life" settings and includes care challenges faced by hospital and nursing home personnel. Aggressive behavior is perhaps the most troubling, and at the same time, least understood of all behavioral problems. The program provides practical solutions to a variety of real-life problems experienced by older adults and their care providers.

36 Something Should Be Done About Grandma Ruthie
(54 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Something Should Be Done About Grandma Ruthie is a moving and unsettling portrait of the filmmakers' family as they struggle to deal with her 85-year-old grandmother's deteriorating mental condition due to Alzheimer's Disease. Though still physically healthy, Ruth Hammer no longer can be relied on to bathe and feed herself, or even to remember where and with whom she is. Her children live out of town, and a series of compassionate caregivers find themselves unable to deal with her growing disorientation. Yet Ruthie refuses to leave her long-time home, and the family must confront the necessity of medicating her against her will and eventually forcing her to move to a long-term care facility.

MEDIA SESSION 22 11:00 a.m.-12:30 p.m.

Versailles Ballroom, Third Floor, Hilton

BETWEEN SANITY AND INSANITY: A FRAGILE BOUNDARY

Chp.: Jacquelyn B. Chang, M.D.

37 Through Madness

(30 minutes)

Distributor: Filmmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

This penetrating documentary demystified psychotic illnesses such as schizophrenia and manic depression, and humanizes those who suffer from them. It is essential viewing for mental health professionals and students who need to understand mental illness, as well as for general audiences. *Through Madness* documents the lives of three people who describe their bout with psychosis: Eileen, a once promising actress, who now lives in a halfway house and has a severe form of schizophrenia; Lionel, a former NFL football star who had been diagnosed with paranoid schizophrenia; and Joe, a troubled adolescent with delusions and hallucinations who had been diagnosed with manic depression.

38 Between the Lines

(21 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Between the Lines is a visually lyrical experimental documentary about women who cut themselves. The film explores the gray areas in women's relationships to their bodies in the context of deliberately self-inflicted injury. The women in this film negotiate the fine line between self-destructive behavior and self-preserving coping mechanisms.

MEDICAL UPDATE 3

11:00 a.m.-12:30 p.m.

Grand Salon Sections 3 & 6, Street Level, Hilton

WILL MEDICALIZING OBESITY TREATMENT IMPROVE OUTCOMES?

Chp.: Lisa A. Kotler, M.D.

Presenter: Donna H. Ryan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

2 David Shaffer, M.D., on Youth Suicide Research
Cambridge Suite, Second Floor, Hilton

SCIENTIFIC AND CLINICAL REPORT SESSIONS 23-32

SCIENTIFIC AND CLINICAL REPORT SESSION 23

11:00 a.m.-12:30 p.m.

Room 264, Level 2, Convention Center

DEPRESSION ACROSS CULTURES

Chp.: Renato D. Alarcon, M.D.

Co-Chp.: Jambur V. Ananth, M.D.

11:00 a.m.

68 Depression in Chinese Primary Care Patients

L.K. George Hsu, M.D., Yu M. Wan, M.A., William Tsang, M.A.,
William Rand, M.D., Elaine Choi, M.D.

11:30 a.m.

69 Illness Beliefs of Depressed Chinese Americans in Primary Care

Albert Yeung, M.D., Robert L. Gresham, Jr., B.A., David Mischoulon, M.D., Raymond Chan, B.S., Shamsah B. Sonawalla, M.D., Maurizio Fava, M.D., Andrew A. Nierenberg, M.D.

12 noon

70 Depression in College Students in Bombay

Rajesh M. Parikh, M.D., Nabonita Chakravorthy, M.D.,
Shamsah B. Sonawalla, M.D., Gayatri Mehra, M.A., Sarah Dracass, M.A., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 24

11:00 a.m.-12:30 p.m.

Room 270, Level 2, Convention Center

PSYCHOTHERAPY ISSUES

Chp.: Paul J. Goodnick, M.D.

Co-Chp.: Roslyn Seligman, M.D.

11:00 a.m.

71 A 45-Year Experience with OCD Patients Who Fear Harming Someone or Fear Harm or Humiliation to Themselves

Albert H. Schrut, M.D.

11:30 a.m.

- 72 **Solving the Riddle of Working Through in Psychotherapy**
Steven H. Lipsius, M.D.

12 noon

- 73 **Telepsychiatry for Suicidal Outpatients: Lower Morbidity, Mortality, and Cost**
Ann M. Oberkirch, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25

11:00 a.m.-12:30 p.m.

Rooms 335/336, Level 3, Convention Center

RISK FACTORS IN SUICIDE

- Chp.: David W. Preven, M.D.
Co-Chp.: Peter J. Drescher, M.D.

11:00 a.m.

- 74 **Suicide Mortality in the Ukraine in 1999**
Ludmila Kryzhanovskaya, Ph.D., Elizabeth L. McGarvey, Ed.D.,
Randolph J. Canterbury, M.D.

11:30 a.m.

- 75 **Decreasing Suicide Mortality in Hungary: What Are the Main Causes?**
Zoltan Rihmer, M.D.

12 noon

- 76 **Suicide Risk Factors Among Treated Patients with BPD**
Thomas M. Kelly, Ph.D., Paul H. Soloff, M.D., J. John Mann, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26

11:00 a.m.-12:30 p.m.

Rooms 346/347, Level 3, Convention Center

ETHICS AND JUSTICE

- Chp.: Howard W. Telson, M.D.
Co-Chp.: Donald G. Langsley, M.D.

11:00 a.m.

- 77 **Willingness and Competence of Depressed Inpatients to Consent to Research**
Bruce J. Cohen, M.D., Ludmila Kryzhanovskaya, Ph.D.,
Elizabeth L. McGarvey, Ed.D., Relana C. Pinkerton, Ph.D.

11:30 a.m.

- 78 **Arthur Kronfeld: Professional and Personal Tragedy of a Great Psychiatrist**
Elena B. Bezzubova, M.D.

12 noon

- 79 **False Confessions: The Bane of Criminal Justice**
Hanus J. Grosz, M.D., Alan D. Schmetzer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27

11:00 a.m.-12:30 p.m.

Rooms 348/349, Level 3, Convention Center

ISSUES IN VIOLENCE AND TRAUMA

- Chp.: Jose M. Canive, M.D.
Co-Chp.: Rahn K. Bailey, M.D.

11:00 a.m.

- 80 **Violence and Clinical Symptoms in Different Diagnoses**
Menahem Krakowski, M.D.

11:30 a.m.

- 81 **Post-Traumatic Spectrum Disorders: A Radical Revision of PTSD**
K. Elan Jung, M.D.

12 noon

- 82 **Open Study of Nefazodone in Depression with Anger Attacks**
David Mischoulon, M.D., Kathryn A. Bottonari, B.A., Darin D. Dougherty, M.D., Alan Fischman, M.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28

11:00 a.m.-12:30 p.m.

Room 357, Level 3, Convention Center

PSYCHOPHARMACOLOGY AND CHILD AND ADOLESCENT PSYCHIATRY

- Chp.: Laurence L. Greenhill, M.D.
Co-Chp.: Manoj R. Shah, M.D.

11:00 a.m.

- 83 **Adderall and Methylphenidate in ADHD**
Stephen V. Faraone, Ph.D., Steven R. Pliszka, M.D., Rene L. Olvera, M.D., Joseph Biederman, M.D.

11:30 a.m.

- 84 **Comparison of Duration of Effect of OROS MPH with MPH TID in ADHD Children**
Sharon Wigal, Ph.D., James M. Swanson, Ph.D., Mark Lerner, M.D.

12 noon

- 85 **Once-Daily-Dosed SLI381 for Pediatric ADHD**
Joseph Biederman, M.D., Frank Lopez, M.D., Samuel Boellner, M.D., Mark C. Chandler, M.D., L. Eugene Arnold, M.D., Ward T. Smith, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29

11:00 a.m.-12:30 p.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

DEPRESSION

- Chp.: Charles S. Price, M.D.
Co-Chp.: David A. Gutman, M.D.

11:00 a.m.

- 86 **The Response of Psychotic-Like Symptoms to Fluoxetine in Nonpsychotic MDD**
Christina M. Dording, M.D., Andrea H. Sickinger, B.A., Karen E. Kelly, B.A., Lindsay M. Dececco, B.A., John D. Matthews, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

11:30 a.m.

- 87 **Predictors of Stable Personality Disorders in Remitted Depressed Outpatients**
Amy Farabaugh, M.A., Nicole B. Neault, B.A., Andrea H. Sickinger, B.A., Joel A. Pava, Ph.D., Albert Yeung, M.D., Jonathan E. Alpert, M.D., Maurizio Fava, M.D.

(Continued on next page)

12 noon

88 Personality Disorders in Psychotic Major Depression

John D. Matthews, M.D., Kathryn A. Bottonari, B.A.,
Robert L. Gresham, Jr., B.A., Christina M. Dording, M.D.,
Mark A. Blais, Psy.D., Jonathan E. Alpert, M.D., Maurizio
Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30

11:00 a.m.-12:30 p.m.

Rosedown Room, Third Floor, Hilton

INTERNATIONAL PERSPECTIVES ON PSYCHIATRY

Chp.: Javier I. Escobar, M.D.

Co-Chp.: Maria A. Oquendo, M.D.

11:00 a.m.

89 Lifetime and 12-Month Prevalence of Mental Illness in Chile

Benjamin Vicente, M.D., Robert Kohn, M.D., Pedro
Rioseco, M.D.

11:30 a.m.

90 Race and Psychiatry in Post-Apartheid South Africa

Christopher P. Szabo, M.D., Robert Kohn, M.D., Alan L.
Gordon, M.D., Clifford W. Allwood, M.D.

12 noon

91 The World Psychiatric Association: An International Survey of Urban Mental Health

Giovanni Caracci, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31

11:00 a.m.-12:30 p.m.

Magnolia Room, Third Floor, Hilton

SOCIAL AND COMMUNITY PSYCHIATRY

Chp.: Michael A. Silver, M.D.

Co-Chp.: Hunter L. McQuiston, M.D.

11:00 a.m.

92 Mental Health and Stress in Highly Educated Employees

Cheryl Koopman, Ph.D., Robert A. Matano, Ph.D., Stanley
Wanat, Ph.D., Darrah Westrup, Ph.D., Shelly Whitsell, B.A.

11:30 a.m.

93 The Next Step Group: Multimodal Strategies in Group Therapy for Serious Illness

Victor McGregor, Ph.D.

12 noon

94 Psychiatric Issues in Space: Implications from the Space Shuttle/MIR Program

Nick A. Kanas, M.D., Vyacheslav Salnitskiy, Ph.D., Ellen M.
Grund, M.S., Daniel S. Weiss, Ph.D., Vadim Gushin, M.D.,
Olga Kozerenko, M.D., Aleksander Sled, M.S., Charles R.
Marmar, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 32

11:00 a.m.-12:30 p.m.

Jasperwood Room, Third Floor, Hilton

ISSUES IN THE TREATMENT OF MOOD DISORDERS

Chp.: Thomas K. Ciesla, M.D.

Co-Chp.: Eva M. Szigethy, M.D.

11:00 a.m.

95 Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania

Mauricio F. Tohen, M.D., Robert W. Baker, M.D., Denai R.
Milton, M.S., Richard C. Risser, M.S., Julie A. Gilmore, Ph.D.,
Amy R. Davis, R.Ph., Angela L. Richey, R.Ph.

11:30 a.m.

96 Risk of Postpartum Depression in Women with Pregravid Major Depression Disorder

Ruta M. Nonacs, M.D., Lee S. Cohen, M.D., Suzanne M.
Bouffard, B.A., Lauren Wise, M.S.C., Bernard L. Harlow, Ph.D.

12 noon

97 The Rising Prevalence of Antidepressant Treatment for U.S. Youth

Julie M. Zito, Ph.D., Susan Dosreis, Ph.D., Karen Soeken, Ph.D.,
Daniel J. Safer, M.D., Myde Boles, Ph.D., James Gardner, S.M.,
Frances Lynch, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 39-45

COMPONENT WORKSHOP 39 11:00 a.m.-12:30 p.m.

Rooms 333/334, Level 3, Convention Center

CAREER CHOICES IN PSYCHIATRY

APA Assembly Committee of Area Member-in-Training Representatives

Co-Chps.: Mary Ann Schaepper, M.D., Cathryn A. Galanter, M.D.

Participants: Barry W. Wall, M.D., Patrice A. Harris, M.D.,
Blaine S. Greenwald, M.D., Petros Levounis, M.D.

COMPONENT WORKSHOP 40 11:00 a.m.-12:30 p.m.

Rooms 350/351, Level 3, Convention Center

NEW REGULATORY REQUIREMENTS FOR SECLUSION AND RESTRAINTS

APA Committee on Standards and Survey Procedures

Chp.: Charles E. Riordan, M.D.

Participants: Robert A. Wise, M.D., D. Jean Miller, Nicholas
Meyers, J.D.

COMPONENT WORKSHOP 41 11:00 a.m.-12:30 p.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

HOW TO ENHANCE MOTIVATION IN PATIENTS WITH SUBSTANCE ABUSE PROBLEMS*APA Committee on Training and Education in Addiction Psychiatry and American Academy of Addiction Psychiatry***Co-Chps.:** Jonathan I. Ritvo, M.D., Richard S. Schottenfeld, M.D.**Participants:** William M. Greenberg, M.D., Joyce A. Tinsley, M.D., David R. McDuff, M.D.**COMPONENT WORKSHOP 42** 11:00 a.m.-12:30 p.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

A COLLABORATIVE EFFORT TO DEFINE AND MEASURE PSYCHIATRIC COMPETENCIES*APA Council on Medical Education and Career Development***Chp.:** Nyapati R. Rao, M.D.**Participants:** Sherwyn M. Woods, M.D., Sheldon I. Miller, M.D., James H. Scully, Jr., M.D., Ronald O. Reider, M.D., Marijo B. Tamburrino, M.D.**COMPONENT WORKSHOP 43** 11:00 a.m.-12:30 p.m.

Melrose Room, Third Floor, Hilton

HISPANICS AND ALTERNATIVE MEDICINE*APA Committee of Hispanic Psychiatrists***Chp.:** Oscar E. Perez, M.D.**Participants:** Alberto G. Lopez, M.D., Ricardo P. Mendoza, M.D., Roberto Lewis-Fernandez, M.D., Pedro Ruiz, M.D.**COMPONENT WORKSHOP 44** 11:00 a.m.-12:30 p.m.

Oak Alley Room, Third Floor, Hilton

SUCCESSFUL MODELS OF PSYCHIATRIC CARE IN THE NURSING HOME*APA Committee on Long-Term Care and Treatment for the Elderly and APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly***Chp.:** Deborah A. Banazak, D.O.**Participants:** Judith H. W. Crossett, M.D., Colleen J. Northcutt, M.D., Sharon S. Levine, M.D., Jacobo E. Mintzer, M.D.**COMPONENT WORKSHOP 45** 11:00 a.m.-12:30 p.m.

Elmwood Room, Third Floor, Hilton

THE ADMINISTRATIVE PSYCHIATRY CREDENTIAL*APA Committee on Psychiatric Administration and Management***Co-Chps.:** William H. Reid, M.D., W. Walter Menninger, M.D.**Participants:** Paul Rodenhauser, M.D., Dave M. Davis, M.D., Stuart B. Silver, M.D.**ISSUES 87-96****ISSUE WORKSHOP 87** 11:00 a.m.-12:30 p.m.

Rooms 265/266, Level 2, Convention Center

PSYCHIATRIC ILLNESS IN PSYCHIATRISTS: OVERCOMING STIGMA*National Alliance for the Mentally Ill***Co-Chps.:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.**Participants:** Carol S. North, M.D., Marian Fireman, M.D., Elizabeth A. Baxter, M.D., Suzanne E. Vogel-Scibilia, M.D., James P. Scibilia, M.D., Laurie M. Flynn**ISSUE WORKSHOP 88** 11:00 a.m.-12:30 p.m.

Rooms 267-268, Level 2, Convention Center

THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM**Chp.:** Steven E. Pflanz, M.D.**ISSUE WORKSHOP 89** 11:00 a.m.-12:30 p.m.

Room 269, Level 2, Convention Center

MAKING THE MEDIA WORK FOR YOU**Chp.:** Nada L. Stotland, M.D.**Participant:** Gabriela Cora-Locatelli, M.D.**ISSUE WORKSHOP 90** 11:00 a.m.-12:30 p.m.

Room 271, Level 2, Convention Center

COMPARATIVE EFFICACY OF ANTIDEPRESSANTS AND PSYCHOTHERAPY FOR DEPRESSION**Chp.:** Sidney L. Werkman, M.D.**Participants:** Frederick M. Quitkin, M.D., Alan A. Stone, M.D., Myrna M. Weissman, Ph.D.**ISSUE WORKSHOP 91** 11:00 a.m.-12:30 p.m.

Room 273, Level 2, Convention Center

PRIVATE PRACTICE AND THE WORLD PSYCHIATRIC ASSOCIATION**Chp.:** Michael C. Hughes, M.D.**Participants:** Theodore Hovaguimian, M.D., Norman Sartorius, M.D.**ISSUE WORKSHOP 92** 11:00 a.m.-12:30 p.m.

Room 342, Level 3, Convention Center

UPDATE ON THE PRACTICE GUIDELINE ON BPD**Chp.:** John M. Oldham, M.D.**Participants:** John S. McIntyre, M.D., Katharine A. Phillips, M.D., David Spiegel, M.D., Paul H. Soloff, M.D.

ISSUE WORKSHOP 93 11:00 a.m.-12:30 p.m.
Grand Salon Section 4, Street Level, Hilton

**FOUNDATION OF THE WORLD FEDERATION OF
PSYCHIATRIC TRAINEES**

Co-Chps.: Victor J.A. Buwalda, M.D., Michelle Riba, M.D.

ISSUE WORKSHOP 94 11:00 a.m.-12:30 p.m.
Prince of Wales Suite, Second Floor, Hilton

**EIGHT-DAY TREATMENT OF PANIC WITH
MODERATE TO SEVERE AGORAPHOBIA**

Chp.: David A. Spiegel, M.D.

ISSUE WORKSHOP 95 11:00 a.m.-12:30 p.m.
Marlborough Suite A/B, Second Floor, Hilton

**MIND MEETS BRAIN IN FAMILY THERAPY:
BRIDGES FOR HEALING**

Chp.: Roy O. Resnikoff, M.D.

ISSUE WORKSHOP 96 11:00 a.m.-12:30 p.m.
Belle Chasse Room, Third Floor, Hilton

**CONFIDENTIALITY AND SEXUAL HISTORY ISSUES
IN SEXUAL HARASSMENT CASES**

Chp.: Rita R. Newman, M.D.

Participants: Liza H. Gold, M.D., Annette J. Hollander, M.D.,
Louise F. Fitzgerald, Ph.D., Naomi J. Weinshenker, M.D.

12 noon Sessions

FORUM 9
12 noon-1:30 p.m.
Grand Salon Sections 13 & 16, Street Level, Hilton

**THE PHARMACEUTICAL INDUSTRY AND THE APA:
CONTROVERSIES AND APPROACHES**
APA Committee on Commercial Support

Chp.: Stephen M. Goldfinger, M.D.

Participants: Ian E. Alger, M.D., Harvey Bluestone, M.D.,
Jacqueline M. Feldman, M.D., Charles R. Goldman, M.D.,
Philip R. Muskin, M.D., James W. Thompson, M.D., David S.
Wahl, M.D.

NEW RESEARCH POSTER SESSION 8
12 noon-2:00 p.m.
Exhibition Center, Second Floor, Hilton

**PSYCHOPHARMACOLOGY, COMBINED PHARMACO-
THERAPY AND PSYCHOTHERAPY, OTHER SOMATIC
THERAPIES, AIDS AND HIV-RELATED DISORDERS,
AND PSYCHIATRIC EDUCATION**

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

12:30 p.m. Session

MEDIA SESSION 23
12:30 p.m.-2:00 p.m.
Versailles Ballroom, Third Floor, Hilton

LOSS AND GRIEF: THREE PERSPECTIVES

Chp.: Jacquelyn B. Chang, M.D.

39 Fighting Grandpa
(21 minutes)

Distributor Filmmakers Library
For V39 &: Attn: Linda Gottesman
V40 124 East 40th Street
New York, NY 10016

Korean-American filmmaker Grek Pak creates a touching meditation on the human heart. He tells the story of his immigrant grandmother's 70-year struggle with her husband. Forced to give up her dreams of becoming a nurse, left with four children for ten years alone in Korea while her husband studied in America, and finally brought to Hawaii to endure new hardships created in part by her husband's parsimonious ways, Grandma had every right to be bitter. But, as the filmmaker discovers, questions of love have no simple answers. When Grandpa dies, Grandma's stoicism gives way to a piercing grief, which surprises and confounds her family. Clearly, the love that bound together their immigrant forebears, shaped by a history of hardship, could only be dimly understood by the young of today.

40 Men Like My Father, Families Like My Own
(27 minutes)

This is a sensitive portrait of men who had each lost a dearly loved wife at an early age, through illness or sudden act of fate. We learn how they fare bringing up their children, housekeeping, dealing with their emotions, and sometimes finding new love. The filmmaker's mother had died when he was young, and his father had never been able to speak of their loss. It was this silence that ultimately propelled him to make the film and explore the effect of loss on young families. During the course of filming, father and son grew closer and the filmmaker is given his parents' precious wedding album. This is an impressive film on male psychology as well as grief studies.

41 What Do I Tell My Children?
(30 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

What Do I Tell My Children? is a classic film internationally recognized as the most outstanding video available for families and professionals who are dealing with children and grief issues. In this surprising video, children and parents share their stories and feelings about the loss of a loved one, while leading professionals in the field offer advice about coping and grief.

1:00 p.m. Sessions



COURSES 91-94

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 91 1:00 p.m.-5:00 p.m.
La Galerie 2, Second Floor, Marriott

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.

COURSE 92 1:00 p.m.-5:00 p.m.
La Galerie 3, Second Floor, Marriott

SUICIDAL PATIENTS IN THE MANAGED CARE ERA: ASSESSMENT AND RISK MANAGEMENT

Co-Directors: Mohammad Saced, M.D., Thomas F. Brozovich, D.O.

COURSE 93 1:00 p.m.-5:00 p.m.
La Galerie 5, Second Floor, Marriott

UNDERSTANDING AND TREATING BIPOLAR DISORDER TODAY: AN UPDATE OF GOODWIN AND JAMISON'S MANIC-DEPRESSIVE ILLNESS

Co-Directors: Frederick K. Goodwin, M.D., Kay R. Jamison, Ph.D.

COURSE 94 1:00 p.m.-5:00 p.m.
Bonaparte Room, Fourth Floor, Marriott

CONTEMPORARY MALPRACTICE LIABILITY

Co-Directors: Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.
Faculty: Richard G. Hersh, M.D., Jacqueline Melonas, J.D.

2:00 p.m. Sessions

LECTURES 20-21

LECTURE 20

2:00 p.m.-3:30 p.m.
Rooms 252-254, Level 2, Convention Center

Leo Rangell, M.D.

The Science of Psychotherapy: Legacy of Psychoanalysis

Chp.: Marian L. Butterfield, M.D.

The influence of psychoanalysis on psychiatry in the 20th century was as profound as any scientific development affecting the theoretical armamentarium of the healing professions. Recent neuroscientific findings can be integrated with psychoanalytic perspectives to further a rational and comprehensive application of basic research across the spectrum of disciplines embracing behavior and mental functioning. Leo Rangell, M.D., examines the scientific base of psychoanalytic psychotherapy, the main enduring legacy of the science of psychoanalysis, and discusses its wide applicability throughout the healing professions. Dr. Rangell is Clinical Professor of Psychiatry at the University of California, Los Angeles, and Clinical Professor of Psychiatry (Psychoanalysis) at the University of California, San Francisco. A Past-President of the International Psychoanalytic Association and the American Psychoanalytic Association, Dr. Rangell has been a Fellow at the Center for Advanced Study in the Behavioral Sciences in Stanford, California. He is the author of more than 400 scientific articles in the fields of psychoanalysis, psychiatry, and neurology. A graduate of the Pritzker School of Medicine of the University of Chicago, Dr. Rangell completed psychiatry residencies at Grasslands Hospital in Valhalla, New York, and at the New York State Psychiatric Institute and received his psychoanalytic training at the Los Angeles Psychoanalytic Institute.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 21

2:00 p.m.-3:30 p.m.
Rooms 338/339, Level 3, Convention Center

Donald S. Kornfeld, M.D.

Psychiatry for the Medically Ill: What Is It?
What Was It? What Has It Done?

Chp.: Philip R. Muskin, M.D.

"Psychiatry for the medically ill" is the proposed new designation for what has been known as consultation-liaison psychiatry. Donald S. Kornfeld, M.D., discusses why there is a need to change the name of this subspecialization at this time, examines the contributions of this subspecialization to the practice of medicine and the practice of psychiatry, and explores what the future may hold for psychiatrists with added qualifications in this area. Dr. Kornfeld is Professor of Clinical Psychiatry, Associate Dean of the Faculty of Medicine, Chairman of the Institutional Review Board, and Director of Continuing Medical Education at Columbia University College of Physicians and Surgeons in New York City. He is also Director of the Consultation-Liaison/Behavioral Medicine Service at Columbia Presbyterian Medical Center. A Past President of the American Psychosomatic Society, he is

(Continued on next page)

a Fellow of the APA, the New York Academy of Medicine, and the American College of Psychiatrists. Dr. Kornfeld received his medical degree from Yale University School of Medicine, completed his psychiatry residency at the New York State Psychiatric Institute, and received his psychoanalytic training at Columbia University Psychoanalytic Institute. Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MEDIA SESSIONS 24-25

MEDIA SESSION 24 2:00 p.m.-5:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

YOUTH AND VIOLENCE

Chp.: Jacquelyn B. Chang, M.D.

42 Generations of Violence
(55 minutes)

Distributor: Filmmakers Library
For V42 &: Attn: Linda Gottesman
V43 124 East 40th Street
New York, NY 10016

This documentary is a compelling portrait of the legacy of family violence that is passed on from one generation to another. It shows that children who experience abuse grow up to become abusive parents. It also shows that there are solutions for breaking this chain of destructiveness. We meet both the victims and the perpetrators of violent behavior, and hear their personal experiences. One young boy tells how his mother's live-in boyfriend sexually abused him, and a mother reveals how she severely mistreated her son as a youth.

43 Colors Straight Up
(60 minutes)

In the ghetto of South Central, Los Angeles, where Latino and African-American kids struggle against a myriad of destructive influences, there is an option for a better life. Troubled teens discover their talents and self-dignity through "Colors United," a performing arts group created for inner-city youth. This uplifting and emotional documentary offers powerful insights into the thoughts and feelings of these "at risk" children.

MEDIA SESSION 25 2:00 p.m.-5:00 p.m.
Versailles Ballroom, Third Floor, Hilton

WHEN DEVELOPMENT GOES AWRY

Chp.: Lesly T. Mega, M.D.

44 Come Back Jack
(55 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

Persistent ear infections, misguided medical treatments, and other mysterious physiological factors sent Jack's mind spinning. His brilliant blue eyes grew glassy. He became a captive in his own world. By the time Jack reached the age of two, his intellectual and emotional development had come to a screeching halt. Terrified by the prospect of losing their youngest son, Jack's parents began searching for answers. Initially, the medical "experts" labeled their handsome little boy as moderately to severely autistic. *Come Back Jack* chronicles the ups and downs of the Parish's therapeutic journey, which led them to the Language and Cognitive Development Center in Lynnfield, Massachusetts. There, with the guidance of a team of special educators, Jack Parish began to emerge from his internal chaos, embracing life and the people who love him.

45 Autism: A World Apart
(29 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

Autism's cause is unknown. There is no cure, and it strikes each victim differently. In *Autism: A World Apart*, three families show us what the textbooks cannot and what it's like to live with autism. The video will show how to love and raise children who may be withdrawn, violent, and unable to connect with their families.

46 A Dyslexic Family Diary
(53 minutes)

Distributor: Filmmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

This film chronicles a mother's 18-year struggle with the politics of teaching reading in order to get an education for her bright, dyslexic son. Dorothy Tod, the filmmaker/mother's approach with the school is challenged by the very different perspective of her husband, a lawyer and former school board member. In a surprising twist, Dorothy discovers that she too has dyslexia, although it had not been diagnosed during her own school days. Dorothy's son, Ben, was on the verge of suicide by the end of the sixth grade. This documentary explores the gift as well as the difficulties that come with dyslexia; how it plays out in education systems, legal and health systems, work, family, marriage, and daily life.

REVIEW OF PSYCHIATRY: SECTION 5
2:00 p.m.-5:30 p.m.
Rooms 343-345, Level 3, Convention Center

**PSYCHIATRY UPDATE: SOMATOFORM AND
FACTITIOUS DISORDERS**

Chp.: Katharine A. Phillips, M.D.

21 BDD

Katharine A. Phillips, M.D.

22 A Critical Analysis of Factitious Disorder

Marc D. Feldman, M.D.

23 Somatization Disorder

Vicenzo Holder-Perkins, M.D.

24 Conversion Disorder

Jose R. Maldonado, M.D.

25 Hypochondriasis

Brian A. Fallon, M.D.

SYMPOSIA 64-89

SYMPOSIUM 64

2:00 p.m.-5:00 p.m.

Room 262, Level 2, Convention Center

**FINDINGS FROM MULTISITE COLLABORATIVE
LONGITUDINAL STUDY OF PERSONALITY**

Chp.: Carlos M. Grilo, Ph.D.

**A Confirmatory Factor Analysis of the DSM-IV BPD
Criteria**

Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., Leslie C. Morey, Ph.D., John G. Gunderson, M.D., Andrew E. Skodol II, M.D., Mary C. Zanarini, Ed.D., Thomas H. McGlashan, M.D.

**B A Schedule for Nonadaptive and Adaptive Personality:
Dimensional Representation of Four Personality
Disorders**

Leslie C. Morey, Ph.D., Megan B. Warner, M.A., Charles A. Sanislow, Ph.D., Donna S. Bender, Ph.D.

**C 12-Month Remission of Major Depressive Disorder:
Influence of Personality Disorders**

Carlos M. Grilo, Ph.D., Robert L. Stout, Ph.D., Ingrid R. Dyck, M.P.H., Andrew E. Skodol II, M.D., Charles A. Sanislow, Ph.D., Thomas H. McGlashan, M.D.

**D Graphical Methods for Dynamic Relationships Between
Axis I and Axis II Disorders**

Robert L. Stout, Ph.D., Jenifer Allsworth, M.A., Jason Machan, M.A., Ingrid R. Dyck, M.P.H., Martin B. Keller, M.D.

E Early Remissions in Borderline Patients

John G. Gunderson, M.D., Donna S. Bender, Ph.D., Charles A. Sanislow, Ph.D., Regina T. Dolan, Ph.D., Leslie C. Morey, Ph.D., Elizabeth H. Schaefer, Ed.M.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 65

2:00 p.m.-5:00 p.m.

Room 264, Level 2, Convention Center

UPDATE ON DEFICIT SCHIZOPHRENIA

Chp.: Silvana Galderisi, M.D.

Co-Chp.: Brian Kirkpatrick, M.D.

A The Italian Multicenter Study of Deficit Schizophrenia

Silvana Galderisi, M.D., Giovanni B. Cassano, M.D., Maria Del Zompo, M.D., Giordano Invernizzi, M.D., Alessandro Rossi, M.D., Antonio Vita, M.D., Mario Maj, M.D.

B The Treatment of Negative Symptoms

Donald C. Goff, M.D.

**C Family Studies of Eye Tracking and the Heterogeneity
of Schizophrenia**

Dolores Malaspina, M.D.

D Course of Illness in Deficit Schizophrenia

Cenk Tek, M.D., Robert W. Buchanan, M.D., Brian Kirkpatrick, M.D.

**E A Separate Disease Within the Syndrome of
Schizophrenia**

Brian Kirkpatrick, M.D., Robert W. Buchanan, M.D., David Ross, M.D., William T. Carpenter, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66

2:00 p.m.-5:00 p.m.

Rooms 265/266, Level 2, Convention Center

WOMEN'S RESILIENCY TO ADVERSITY

Chp.: Susanne I. Steinberg, M.D.

**A A Prospective Study of Depression in Pregnant Women:
Risk Factors Related to Postpartum Relapse**

Shaila Misri, M.D., Xanthoula Kostaras, B.S.C.

B Stalking: An Overview of the Problem

Gail E. Robinson, M.D., Karen M. Abrams, M.D.

**C Attachment, Abuse, and Psychopathology Risk: Human
Papillomavirus**

Susanne I. Steinberg, M.D., Angela Lambrinos, M.S.C., Harriet Richardson, M.S.C., Eduardo L. Franco, Ph.D.

**D Attributions of Cause and Recurrence in Long-Term
Breast Cancer Survivors**

Donna E. Stewart, M.D., A. Cheung, M.D., S. Duff, Felicia Wong, M. McQuestion, T. Cheng, Laura Purdy

E Challenges for Women in Academic Medicine

Katherine L. Wisner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67 2:00 p.m.-5:00 p.m.

Rooms 267-268, Level 2, Convention Center

CLINICAL ISSUES AND ETHICAL CONCERNS REGARDING ATTEMPTS TO CHANGE SEXUAL ORIENTATION: AN UPDATE*Association of Gay and Lesbian Psychiatrists and APA Committee on Gay, Lesbian, and Bisexual Issues*

Chp.: Philip A. Bialer, M.D.

- A Overview of the Research Problems and Ethics of Therapy to Change Sexual Orientation**
Marshall Forstein, M.D.
- B Subjects Who Claim to Have Benefited from Sexual Reorientation Therapy**
Robert L. Spitzer, M.D., Jerome Wakefield, M.D.
- C Clinical and Religious Attempts to Change Homosexual Orientations: An Empirical Study**
Ariel Shidlo, Ph.D., Michael Schroeder, Psy.D.
- D Ethical Issues in Efforts to Ban Reorientation Therapies**
Mark Yarhouse, Psy.D., Warren Throckmorton, Ph.D.
- E Ethical Concerns Raised When Patients Seek to Change Same-Sex Attractions**
Jack Drescher, M.D.

Discussant: Paul S. Appelbaum, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68 2:00 p.m.-5:00 p.m.

Room 269, Level 2, Convention Center

STATE VERSUS TRAIT DISTURBANCES FOUND IN EATING DISORDERS: RECENT FINDINGS

Chp.: Evelyn Attia, M.D.

- A 5HT Function in Women with Anorexia Nervosa**
Evelyn Attia, M.D., Sara Wolk, M.A., Thomas Cooper, M.A., Wahida Karmaly, Lauren Escott
- B Resting Energy Metabolism in Anorexia Nervosa**
Laurel Mayer, M.D., B. Timothy Walsh, M.D., Michael Rosenbaum, M.D., Rudolph Leibel, M.D., Richard Pierson, Jr., M.D., Erin Killory
- C Psychobiological Studies of Women with Bulimia Nervosa**
B. Timothy Walsh, M.D., Robyn J. Sysko, B.A., Ellen Zimmerli, Ph.D., Michael J. Devlin, M.D., Janet Guss, B.A., Harry Kissileff
- D Eating Behavior in Binge Eating Disorder: Implications for Treatment**
Michael J. Devlin, M.D., Claudia Kamenetz

Discussant: Walter H. Kaye, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.

Room 270, Level 2, Convention Center

MODEL RESIDENCY PROGRAMS ON RELIGION AND SPIRITUALITY

Chp.: Francis G. Lu, M.D.

- A Psychiatric Residency Training on Religion/Spirituality: An Overview**
Francis G. Lu, M.D., Christina M. Puchalski, M.D.
- B The Emory Spirituality, Religion, and Culture in Child and Adolescent Psychiatry Curriculum**
Sandra Sexson, M.D., Shamina J. Henkel, M.D.
- C The University of Alabama Curriculum on Religion, Spirituality, and Psychiatry**
Nathan B. Smith, M.D.
- D Expectable and Surprising Consequences of Templeton Award: A Three-Year Follow-Up at Baylor**
James W. Lomax II, M.D., Linda B. Andrews, M.D., Arif M. Shoaib, M.D.

Discussant: David B. Larson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.

Room 271, Level 2, Convention Center

PSYCHOPATHOLOGICAL PATHWAYS FOLLOWING TRAUMATIC LIFE EXPERIENCE

Chp.: Bessel A. Van Der Kolk, M.D.

Co-Chp.: Julian Ford, Ph.D.

- A Multiple Comorbidities or Trauma-Spectrum Disorders in the U.S. National Comorbidity Survey**
Joseph F. Spinazzola, Ph.D., Cassandra Kiesel, Ph.D., Allison Tracy, Ph.D., Bessel A. Van Der Kolk, M.D.
- B Traumatic Stress as an Antecedent to Psychotic Disorder**
Alexander McFarlane, M.D., Gavin Andrews, Lorna Peters, Ph.D.
- C Simple and Complex PTSD Among the Dually Diagnosed**
Walter E. Penk, Ph.D., Jill Rierdan, Ph.D., Marylee Losardo, M.S., Tatjana Mesheda, M.S., Charles Drebing, Ph.D.
- D Trauma, PTSD, and Disorders of Extreme Stress in Women with Severe Mental Illness**
Julian Ford, Ph.D., Debra Fournier, B.A., Katherine Moffitt, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m.-5:00 p.m.

Rooms 335/336, Level 3, Convention Center

THE WORLD PSYCHIATRIC ASSOCIATION GLOBAL PROGRAM TO REDUCE THE STIGMA OF SCHIZOPHRENIA*The World Psychiatric Association***Chp.:** Norman Sartorius, M.D.**Co-Chp.:** Richard Warner, M.B.**A The German Program**

Wolfgang Gaebel, M.D.

B World Psychiatric Association Antistigma Project: The Campaign in Canada

Julio E. Arboleda-Florez, M.D., Heather Stuart, Ph.D.

C The Campaign in Spain

Juan J. Lopez-Ibor, Jr., M.D.

D The Campaign in Egypt: Development, Activities, and Achievements

Mohamed H. El-Defrawi, Ismail Yosef, Magda Fahmy, Wafaa Hagag, Ashraf Tantany, Fatheia Nusseir, Moheb Salem

E The Campaign in India

Srinivasa Murthy, M.D.

Discussants: Bruce Link, Ph.D., Everett Rogers, Ph.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 72** 2:00 p.m.-5:00 p.m.

Room 342, Level 3, Convention Center

EUROPEAN PERSPECTIVES ON THE BIOLOGY OF PERSONALITY DISORDERS*International Society for the Study of Personality Disorders***Chp.:** Kenneth R. Silk, M.D.**Co-Chp.:** Jose L. Carrasco, M.D.**A Childhood Abuse and the HPA Axis in Adult Female Patients**

Thomas Rinne, M.D., Wim Brink-Vanden, Ph.D., Jaap G. Geokoop, Ph.D., Roel Rijkode, Ph.D., E. Ronald Kloet, Ph.D.

B Dimensional Psychobiological Studies in BPD

Jose L. Carrasco, M.D., Marina Diaz-Marsa, M.D.

C Studies on Temperament Markers on Eating Disorders

Marina Diaz-Marsa, M.D., Jose L. Carrasco, M.D.

D Schizotypy: A Genetic, Epidemiological and Developmental Perspective

Marco Battaglia, M.D., Sverre Torgersen, Ph.D., Andrea Fossati, M.D., Cesare Maffei, M.D.

E Serotonergic and Cognitive Impairment in Personality-Disordered Offenders

Mairead Dolan, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 73** 2:00 p.m.-5:00 p.m.

Rooms 346/347, Level 3, Convention Center

AN EIGHT-WEEK RANDOMIZED TRIAL OF FLUVOXAMINE FOR PEDIATRIC ANXIETY DISORDER**Chp.:** Laurence L. Greenhill, M.D.**A Background and Significance of the Research Units of Pediatric Psychopharmacology (RUPP) Pediatric Anxiety Disorder Trial of Fluvoxamine**

Laurence L. Greenhill, M.D.

B Moderators and Mediators of Treatment Effect in the RUPP Pediatric Anxiety Disorder Trial of Fluvoxamine

Benedetto Vitiello, M.D.

C Data from the Intent-to-Treat Data Analysis: RUPP Pediatric Anxiety Disorder Trial of Fluvoxamine

Daniel S. Pine, M.D.

D Use of the Pediatric Anxiety Rating Scale in the RUPP Pediatric Anxiety Disorder Trial of Fluvoxamine

John T. Walkup, M.D., Mark A. Riddle, M.D.

Discussant: Mark A. Riddle, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 74** 2:00 p.m.-5:00 p.m.

Room 352, Level 3, Convention Center

PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE**Chp.:** Edward C. Lauterbach, M.D.**A Psychiatric Aspects of Parkinson's Disease**

Matthew A. Menza, M.D.

B Psychiatric Management in Huntington's Disease

Neal G. Ranen, M.D.

C Psychiatric Management in Wilson's Disease

Edward C. Lauterbach, M.D.

D Psychiatric Management of Stroke

Robert G. Robinson, M.D.

E Psychiatric Management in Multiple Sclerosis

Randolph B. Schiffer, M.D.

F Neuropsychiatric Aspects of AIDS

Francisco Fernandez, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 75** 2:00 p.m.-5:00 p.m.

Room 356, Level 3, Convention Center

CRITICAL ISSUES IN EARLY INTERVENTION OF THE PSYCHOSIS PRODROME**Chp.:** Tandy J. Miller, Ph.D.**Co-Chp.:** Thomas H. McGlashan, M.D.*(Continued on next page)*

A Early Detection by Screening Relatives of Schizophrenic Patients

Scott W. Woods, M.D., Tandy J. Miller, Ph.D., Lawrence Davidson, Ph.D., Keith A. Hawkins, Psy.D., Michael J. Sernyak, M.D.

B Diagnosing and Rating the Psychosis Prodrome

Tandy J. Miller, Ph.D., Thomas H. McGlashan, M.D., Joanna Rosen, Ph.D., Scott W. Woods, M.D.

C Psychosis Prodrome, Conversion, and Neuropsychological Course

Keith A. Hawkins, Psy.D., Kimberly B. Edwards, Michelle Bobulinski, Ph.D., Ralph E. Hoffman, M.D., Thomas H. McGlashan, M.D.

D Medication Prescribed by Community Providers for Patients in Schizophrenic Prodromal States

Adrian Preda, M.D., Tandy J. Miller, Ph.D., Scott W. Woods, M.D., Joanna Rosen, Ph.D., Lubnee Somjee, Ph.D., Thomas H. McGlashan, M.D.

E Short-Term Outcome of Prodromal Patients Treated at Conversion to Psychosis

Joanna Rosen, Ph.D., Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Lubnee Somjee, Ph.D., Scott W. Woods, M.D.

F Ethical Issues in the Pre-Onset Treatment of Schizophrenia

Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Scott W. Woods, M.D., Joanna Rosen, Ph.D., Lawrence Davidson, Ph.D., Adrian Preda, M.D., Philip Markovich, B.S.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76

2:00 p.m.-5:00 p.m.

Room 357, Level 3, Convention Center

MIND/BRAIN, REDUCTION, AND SCHIZOPHRENIA

Chp.: John Z. Sadler, M.D.

Co-Chp.: Gerrit Glas, M.D.

A Understanding Anxiety: Conceptual, Clinical, and Neuroscientific Considerations

Gerrit Glas, M.D.

B Mind and Brain in Schizophrenia: Two Sides of the Same Coin?

Aaron L. Mishara, Ph.D.

C Ontological Reduction and Integration in Psychiatric Genetics Research

John Z. Sadler, M.D.

D The Cognitive Neuropsychiatry of Disorders of Will and Volition

Sean A. Spence, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77

2:00 p.m.-5:00 p.m.

Grand Salon Sections 3 & 6, Street Level, Hilton

CHILDHOOD-ONSET DEPRESSION: A MULTIGENERATIONAL MULTIDISCIPLINARY STUDY

Chp.: James L. Kennedy, M.D.

Co-Chp.: Maria Kovacs, Ph.D.

A Risk Factors for Childhood-Onset Depression: Understanding and Treatment

Maria Kovacs, Ph.D., Joel T. Sherrill, Ph.D.

B Molecular Genetic Studies of Childhood-Onset Depression

James L. Kennedy, M.D., Bernard Devlin, Ph.D., Maria Kovacs, Ph.D., Karen Wigg, B.S.C., Nicole A. King, Cathy L. Barr, Ph.D.

C EEG Asymmetry and Vagal Tone in Childhood-Onset Depression: Probands and Offspring

Nathan A. Fox, Ph.D., Jeffrey Cohn, Ph.D., Anita Keener, Ph.D., Erika Forbes, B.A.

D Parenting Risk Factors Among Offspring of Childhood-Onset Depressed Mothers

Daniel Shaw, Ph.D., Joel T. Sherrill, Ph.D., Michael Schonberg, B.A., Joella Lukon, B.S.

Discussants: Hagop S. Akiskal, M.D., Robert M. Post, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78

2:00 p.m.-5:00 p.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

PSYCHIATRIC DISTURBANCES IN PARKINSON'S DISEASE: RECOGNITION AND MANAGEMENT

Chp.: F. Moises Gaviria, M.D.

Co-Chp.: Melanie Brandabur, M.D.

A Multidisciplinary Management of Psychiatric Manifestations of Parkinson's Disease

Melanie Brandabur, M.D.

B Treatment of Depressive Disorders in Patients with Parkinson's Disease

F. Moises Gaviria, M.D.

C Managing Psychotic Symptoms in Parkinson's Disease

David A. Medina, M.D.

D Functional Neuroimaging and Neurobiological Correlates of Cognitive Impairment in Patients with Parkinson's Disease

Glenn T. Stebbins, Ph.D., Maria C. Carrillo, Ph.D., John D. E. Gabrieli, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.

Grand Salon Sections 9 & 12, Street Level, Hilton

PSYCHOBIOLOGY AND PHARMACOTHERAPY OF BPD

Chp.: John M. Oldham, M.D.

Co-Chp.: Andrew E. Skodol II, M.D.

A Biological Correlates of BPD

Emil F. Coccaro, M.D.

B Psychobiology of Human Personality

C. Robert Cloninger, M.D.

C Longitudinal Patterns of Medication Utilization in BPDJohn M. Oldham, M.D., Andrew E. Skodol II, M.D.,
Donna S. Bender, Ph.D., Regina T. Dolan, Ph.D., John G.
Gunderson, M.D.**D Pharmacotherapy of BPD**

Paul H. Soloff, M.D.

E Clinical Management of Suicidality in BPD

Maria A. Oquendo, M.D., J. John Mann, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 80** 2:00 p.m.-5:00 p.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

SPECIAL TOPICS IN WOMEN'S MENTAL HEALTH

Chp.: Rajesh M. Parikh, M.D.

Co-Chp.: Shamsah B. Sonawalla, M.D.

A Alcoholism and Drug Abuse in Women

Monica L. Zilberman, Ph.D., Hermano Tavares, Ph.D.

B Pathological Gambling in WomenHermano Tavares, Ph.D., Monica L. Zilberman, Ph.D.,
Fabio J. Beites, M.D., Valentim Gentil, M.D.**C The Role of Estrogen in Perimenopausal Depression**

Claudio N. Soares, M.D., Lee S. Cohen, M.D.

D Comorbid Depression and Anxiety Disorders in Couples Presenting for In Vitro FertilizationRajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D.,
Firuza R. Parikh, M.D.

Discussant: David Mischoulon, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 81** 2:00 p.m.-5:00 p.m.

Grand Salon Sections 21 & 24, Street Level, Hilton

THE ROLE OF RELIGION IN THE LIVES OF OUR PATIENTS: CLINICAL APPROACHES

Chp.: Irving S. Wiesner, M.D.

A Religion as a Framework in Understanding and Responding to Mental Illness

Irving S. Wiesner, M.D.

B The Role of Religion in the Lives of Our Patients: A Hindu Approach

Nalini V. Juthani, M.D.

C The Special Needs of the Orthodox Jewish Patient

Abba E. Borowich, M.D.

D Personhood and the Pursuit of Happiness: A Catholic Perspective

Judith A. Hughes, M.D.

E Clinical Challenges with Protestant Patients: Sin, Guilt, and Forgiveness

Mark E. Servis, M.D.

Discussant: Mohammad Shafii, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 82** 2:00 p.m.-5:00 p.m.

Marlborough Suite A/B, Second Floor, Hilton

UPDATE ON TREATMENT OF STIMULANT ABUSE

Chp.: David A. Gorelick, M.D.

A Recovery-Oriented Psychosocial TreatmentsDouglas M. Ziedonis, M.D., Jonathan Krejci, Ph.D., Marc
Steinberg, M.A., Sylvia Atdjian, Carolyn Eick, M.A., David A.
Smelson, Psy.D.**B Psychotherapy and Counseling Approaches for Cocaine Abuse Treatment**

David R. Gastfriend, M.D.

C Pharmacological Treatment of Stimulant Abuse

David A. Gorelick, M.D.

D Psychiatric Comorbidity in Stimulant Abusers

Richard N. Rosenthal, M.D.

E Methamphetamine Abuse: Update 2001

Steven L. Batki, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 83** 2:00 p.m.-5:00 p.m.

Melrose Room, Third Floor, Hilton

POLITICS OF ADMINISTRATIVE RELATIONSHIPS IN PSYCHIATRY

Chp.: Wesley E. Sowers, M.D.

A Defining Administrative Roles: Divide and Cooperate

Clifton R. Tennison, Jr., M.D.

B Developing Relationships and Enhancing Roles in a Managed Care Organization

William G. Wood, M.D.

(Continued on next page)

- C Psychiatrist/Administrator Alliances in Public Psychiatry**
Thomas A. Simpatico, M.D., Christopher G. Fichtner, M.D.
- D Navigating in Rough Water: When It Doesn't Work**
Gordon H. Clark, Jr., M.D.
- E The Value of Medical Leadership: More Than a Dream?**
Kathleen A. Daly, M.D.

Discussants: A. Anthony Arce, M.D., Jacqueline M. Feldman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 84 **2:00 p.m.-5:00 p.m.**
Rosedown Room, Third Floor, Hilton

OUTREACH TO BUSINESS: THE AMERICAN PSYCHIATRIC ASSOCIATION BUSINESS INITIATIVE
APA Committee on APA/Business Relationships

Chp.: Norman A. Clemens, M.D.
Co-Chp.: Jeffrey P. Kahn, M.D.

- A Quality Mental Health Care and the Corporate Bottom Line**
Norman A. Clemens, M.D.
- B Organizations and Their Impact on Productivity and Health**
Leonard T. Sperry, M.D.
- C Helping Business to Understand Psychiatric Skills**
Marcia K. Goin, M.D.
- D Patients' Workplace Lives: Career, Performance, and Development**
Jeffrey P. Kahn, M.D.
- E Special Concerns of Business Conflict Management, Disability, Violence, and Employee Turnover**
Stephen H. Heidel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85 **2:00 p.m.-5:00 p.m.**
Magnolia Room, Third Floor, Hilton

QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA: RESEARCH IN EUROPE AND THE AMERICAS

Chp.: Jacques Fortineau, M.D.
Co-Chp.: John A. Talbott, M.D.

- A Quality of Life: History and Development in the U.S.**
Anthony F. Lehman, M.D.
- B The Definition and Evaluation of Quality of Life**
Pierre Lalonde, M.D.

- C Schizophrenia and Quality of Life Across Europe**
Viviane Kovess, M.D., Jose M. Caldas de Almeida, M.D., Mauro G. Carta, M.D., Jacques M. Dubuis, M.D., Jacques Pellet, M.D., Jean-Luc Roelandt, M.D., Hans Salize, Ph.D.

- D Quality of Life for Patients with Schizophrenia Treated in Day Hospitals**
Francois C. Petitjean, M.D., Corinne Launay, M.D., Franck Salone, Jean-Claude Demant, M.D.

- E Quality of Life in Schizophrenia: A Two-Year Follow-Up Study of 145 Outpatients**
Oliver J. Canceil, M.D., Marcos Sampaio-Meireles, M.D., Marie-Chantal Bourdel, Jean-Pierre Olie, M.D., Marie F. Poirier-Littre, M.D.

- F Quality-Adjusted Life Year (QALY) Measurement in Persons with Schizophrenia**
Jeffrey M. Pyne, M.D., Greer Sullivan, M.D., D. Keith Williams, Ph.D.

Discussants: Alexandra MacLean, M.D., F. Regis Cousin, M.D., Gerald J. Sarwer-Foner, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86 **2:00 p.m.-5:00 p.m.**
Jasperwood Room, Third Floor, Hilton

CATATONIA AND NMS: PAST, PRESENT, AND FUTURE

Chp.: Brendan T. Carroll, M.D.
Co-Chp.: Harold W. Goforth, M.D.

- A Development of the Concept of Catatonia: A Historical Overview**
Stephanie Kruger, M.D., Peter Braunig, M.D.
- B The Nosology of Catatonia**
Gabor S. Ungvari, M.D.
- C Laboratory Findings in Catatonia**
Joseph W. Lee, M.D.

- D Catatonia in the Context of Medical Illness**
Brendan T. Carroll, M.D., Harold W. Goforth, M.D.

- E NMS and Other Drug-Induced Catatonias**
Andrew J. Francis, M.D.

Discussants: Georg Northoff, M.D., Denise A.C. White, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87 **2:00 p.m.-5:00 p.m.**
Oak Alley Room, Third Floor, Hilton

ADVANCE DIRECTIVES IN PSYCHIATRY: TREATMENT RESEARCH AND END OF LIFE

Chp.: Mary E. Foti, M.D.
Co-Chp.: Philip J. Candilis, M.D.

A Psychiatric Advance Directives: An Emerging Form of Psychosocial Intervention?
Patricia Backlar, Ph.D.

B Research Advance Directives in Psychiatry
Donald L. Rosenstein, M.D.

C End-of-Life Care and Mental Illness: A Model for All Disciplines
Philip J. Candilis, M.D., Mary E. Foti, M.D.

D Cognitive Variables in the Informed-Consent Assessment Process
Jacob C. Holzer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m.

Elmwood Room, Third Floor, Hilton

PSYCHOCUTANEOUS MEDICINE

Chp.: Donald J. Kushon, Jr., M.D.

A Introduction: Overview and Classification System for Psychocutaneous Disease
Donald J. Kushon, Jr., M.D.

B Stress and Cutaneous Biology
Francisco Tausk, M.D.

C Pruritus: Psychogenic and Central Factors
Iona Ginsberg, M.D.

D Treatment of Self-Mutilation
Sylvia G. Garnis-Jones, M.D.

E Integration of Psychotherapy and Psychoanalysis Into Dermatology Practice
Caroline S. Koblenzer, M.D.

F Psychopharmacology
Donald J. Kushon, Jr., M.D.

G Nonpharmacologic Management of Psychocutaneous Problems
Richard G. Fried, M.D.

Discussants: Francisco Tausk, M.D., Iona Ginsberg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m.

Belle Chasse Room, Third Floor, Hilton

THE USE OF FORCE IN PSYCHIATRY: WHEN IS IT HELPFUL AND WHEN IS IT NOT? PART II

American Association of Community Psychiatrists

Chp.: David A. Pollack, M.D.

A Seclusion and Restraint in Child and Adolescent Facilities
Wanda Mohr, Ph.D.

B Excessive Use of Force: The Family Perspective
Andrea Eberle, M.D.

C Seclusion, Restraint, and Holding of Children and Adolescents: A Clinical Community Perspective
Charles W. Huffine, Jr., M.D.

D Use of Seclusion, Restraint, and Force in Juvenile Justice Settings
Debbie R. Carter, M.D.

E Managing and Treating Behavioral Dyscontrol in People with Developmental Disabilities
Ruth M. Ryan, M.D.

F Pharmacological Approaches: When Are They Indicated?
Andres J. Pumariega, M.D.

THIS SESSION WILL BE AUDIOTAPED.

TELECOMMUNICATIONS SESSION 4

2:00 p.m.-5:00 p.m.

Rooms 260/261, Level 2, Convention Center

DIGITAL DANGERS: SEX, SUICIDE, AND ADDICTIONS ON THE WEB

Chp.: Jonathan M. Metzl, M.D.

12 Caught in the Web: Sex, Suicide, and Addictions on the Internet

Keith Cheng, M.D., Kyle P. Johnson, M.D., Joshua F. Boverman, M.D., Laura Proud, B.A.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9

3:00 p.m.-5:00 p.m.

Exhibition Center, Second Floor, Hilton

ANXIETY, ALCOHOL AND DRUG, SEX AND GENDER, AND SOMATOFORM DISORDERS; ADDICTION PSYCHIATRY; HEALTH SERVICES RESEARCH; PSYCHOIMMUNOLOGY; STRESS; AND VIOLENCE

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 44-48

INDUSTRY-SUPPORTED SYMPOSIUM 44

7:00 p.m.-10:00 p.m.

Hall G, Lobby Level, Convention Center

PLASTICITY AS EFFICACY? NEUROTROPHIC EFFECTS OF MOOD STABILIZERS

Supported by Abbott Laboratories

(Continued on next page)

Chp.: Pierre N. Tariot, M.D.
Co-Chp.: Husseini K. Manji, M.D.

- A Neurotrophic and Neuroprotective Effects of Mood Stabilizers**
Husseini K. Manji, M.D.
- B Clinical and Neuroimaging Evidence of Illness Progression in Bipolar Disorder**
Terence A. Ketter, M.D.
- C Implications for the Treatment of Alzheimer's Disease**
Pierre N. Tariot, M.D.
- D PTSD, Substance Use Disorders, and Personality Disorders: Commonalties in Mechanisms and Treatment**
Hugh Myrick, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 45

7:00 p.m.-10:00 p.m.

La Nouvelle Ballroom, Level 2, Convention Center

BIPOLAR SPECTRUM DISORDERS: U.S. AND EUROPEAN PERSPECTIVES

Supported by the International Academy for Biomedical and Drug Research

Chp.: Lewis L. Judd, M.D.
Co-Chp.: Giorgio Racagni, Ph.D.

- A Longitudinal Studies of Bipolar Disorders: Is There a Spectrum?**
Lewis L. Judd, M.D.
- B Bipolar Spectrum: Clinical and Familial Validation**
Hagop S. Akiskal, M.D.
- C Molecular Genetic Evidence for the Bipolar Spectrum**
Julien Mendlewicz, M.D.
- D Treatment Advances in Bipolar Spectrum Disorders: Mood Stabilizers**
Susan L. McElroy, M.D.
- E Treatment Advances in Bipolar Spectrum Disorders: Atypical Antipsychotics**
Guy M. Goodwin, M.D.

Discussants: Julien Mendlewicz, M.D., Giorgio Racagni, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 46

7:00 p.m.-10:00 p.m.

Grand Ballroom A/B, Street Level, Hilton

ADVANCES IN ADHD: NAVIGATING COMORBIDITY

Supported by Alza Corporation

Chp.: Timothy E. Wilens, M.D.
Co-Chp.: Joseph Biederman, M.D.

- A Overview of Comorbid Conditions in ADHD**
Joseph Biederman, M.D.
- B Patterns of Comorbidity in ADHD: Artifact or Reality?**
Stephen V. Faraone, Ph.D.
- C Depressive Disorders and ADHD**
Thomas J. Spencer, M.D.
- D Bipolar Disorder and ADHD: An Overlooked Comorbidity**
Janet Wozniak, M.D.
- E ADHD and the Substance Use Disorders**
Timothy E. Wilens, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 47

7:00 p.m.-10:00 p.m.

Grand Ballroom C/D, Street Level, Hilton

EXCESSIVE DAYTIME SLEEPINESS: EVALUATION AND MANAGEMENT IN PSYCHIATRY

Supported by Cephalon Inc.

Chp.: John W. Winkelman, M.D.

- A Neural Substrates of Arousal and Sleep: New Vistas**
Robert W. McCarley, M.D.
- B Evaluation and Measurement of Daytime Sleepiness**
Mary A. Carskadon, Ph.D.
- C Disorders of Excessive Daytime Somnolence: Diagnosis and Management**
Karl Dogramji, M.D.
- D Excessive Daytime Sleepiness in the Psychiatric Patient**
John W. Winkelman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 48

7:00 p.m.-10:00 p.m.

Grand Ballroom A-C, Fifth Floor, Sheraton

AN EVIDENCE-BASED MEDICINE APPROACH TO PEDIATRIC PSYCHIATRY

Supported by Ortho-McNeil Pharmaceutical

Chp.: Robert L. Findling, M.D.

- A Effects of Risperidone on the Behavior of Children with Subaverage IQs and Conduct Disorder or Oppositional Defiant Disorder**
Michael G. Aman, Ph.D., Robert L. Findling, M.D., Albert T. Derivan, M.D., Ursula Merriman, M.S.
- B Long-Term Efficacy in Conduct Disorder: Evidence from Maintenance Trials**
Robert L. Findling, M.D.

- C A Placebo-Controlled Trial of Risperidone in Tourette's Disorder: Preliminary Results**
Lawrence D. Scahill, Ph.D.
- D Comparative Use of Olanzapine and Risperidone in Psychotic Youth**
Linmarie Sikich, M.D., Joseph P. Horrigan, M.D., Jeffrey A. Lieberman, M.D., L. Jarrett Barnhill, Jr., M.D., Brian B. Sheitman, M.D., Helen E. Courvoisie, M.D.

Discussant: Judith H.L. Rapoport, M.D.

MEDIA SESSIONS 26-27

MEDIA SESSION 26 7:00 p.m.-10:00 p.m.
Napoleon Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: David A. Halperin, M.D.

47 The Talented Mr. Ripley
(139 minutes)

Distributor: Facets Multimedia
1517 West Fullerton
Chicago, IL 60614

To be young and carefree amid the blue waters and idyllic landscape of sun-drenched Italy in the late 1950s is the life that Tom Ripley, played by Matt Damon, craved and the life that Dickie Greenleaf, played by Jude Law, led. When Dickie's father, a wealthy ship builder, asks Tom to bring his errant playboy son back home to America, Dickie and his beautiful expatriate girlfriend, Marge Sherwood, played by Gwyneth Paltrow, never suspect the dangerous extremes to which Ripley will go to make their lifestyle his own. After all, it's better to be a fake somebody than a real nobody. Paramount Pictures and Miramax Films present *The Talented Mr. Ripley* directed by Academy Award winner Anthony Minghella.

MEDIA SESSION 27 7:00 p.m.-10:00 p.m.
Versailles Ballroom, Third Floor, Hilton

PSYCHIATRY GOES TO THE MOVIES

Chp.: Richard E. D'Alli, M.D.

48 2001: A Space Odyssey
(148 minutes)

Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787

Ushering in a new era of cinematic special effects, Stanley Kubrick's grand space fantasy unfolds almost like an avant-garde film, telling its largely nonverbal story through balletic, hypnotic imagery. *2001: A Space Odyssey* provides the metaphor of a mysterious monolith that advances human development in various eras. Kubrick's breathtakingly evolutionary leaps of logic and almost abstract visual expression convey his meditations on the godlike potential within the ape-like human species. Emotionally remote, with characters seeming less human than the computer onboard the spacecraft, *2001* brought about a quantum jump in the aspirations of the sci-fi genre.

American Psychiatric Association

**Audiotapes
Recorded Live!**

***High Quality Continues for
the 2001 Annual Meeting ...***



Live recordings will be available
for most of the following:

- Lectures • Advances in Research
- Presidential Symposium • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth in the Convention Center, Lobby Level.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 ♦ (800) 369-5718
Fax: (661) 295-8474
Webside: www.mobiltape.com

THURSDAY, MAY 10, 2001

154TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 40-43

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 2

7:00 a.m.-8:30 a.m.

Hall G, Lobby Level, Convention Center

CLINICAL CHALLENGES IN ANXIETY

Supported by Pfizer Inc.

Chp.: Mark H. Pollack, M.D.

Co-Chp.: James W. Jefferson, M.D.

A Clinical Challenges: Anxiety and Substance Abuse
Kathleen T. Brady, M.D.

B PTSD: Phenomenology and Treatment Approaches
Naomi M. Simon, M.D.

C Integrated Psychosocial Strategies with Pharmacotherapy
Michael W. Otto, Ph.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 2

7:00 a.m.-8:30 a.m.

La Nouvelle Ballroom, Level 2, Convention Center

A NEW ERA FOR MANAGING PSYCHOSIS: REBUILDING LIVES FOR PATIENTS AND FAMILIES

Supported by Janssen Pharmaceutica

Chp.: Ira D. Glick, M.D.

Co-Chp.: Stephen R. Marder, M.D.

A Consumer Organizations Improve Medication Compliance
Ira D. Glick, M.D.

B Enhancing Outcomes with Atypical Antipsychotics: Weight, Akathisia, Affect, and Insight
S. Nassir Ghaemi, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom A/B, Street Level, Hilton

TREATMENT OF DEPRESSION IN WOMEN: FROM ACUTE REMISSION TO SUSTAINED RECOVERY

Supported by Wyeth-Ayerst Laboratories

Chp.: Lee S. Cohen, M.D.

Co-Chp.: Adele C. Viguera, M.D.

A The Neuroendocrinology of Maternal Depression and Stress During Pregnancy
Donald J. Newport, M.D., Zachary S. Stowe, M.D., James R. Strader, Jr., B.S.

B Role of Hormonal Therapies for Depressed Perimenopausal Women
Catherine A. Roca, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 43, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom C/D, Street Level, Hilton

DEPRESSION: GENDER, AGE, AND SPECIAL POPULATIONS

Supported by Eli Lilly and Company

Chp.: David L. Dunner, M.D.

A Depression and the Treatment-Resistant Patient
Richard C. Shelton, M.D.

B The Depressed Patient with Comorbid Illness
Wayne J. Katon, M.D.

8:00 a.m. Sessions



COURSES 95-99

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 95

8:00 a.m.-12 noon

La Galerie 1, Second Floor, Marriott

HOW TO COMBAT THE STIGMA OF MENTAL ILLNESS

The World Psychiatric Association

Director: Richard Warner, M.B.

Faculty: Corinne L. Shefner-Rogers, Ph.D., Barbara Hocking, B.S.C., Otto F. Wahl, Ph.D., Fay Herrick

COURSE 96

8:00 a.m.-12 noon

La Galerie 4, Second Floor, Marriott

INCREASING THE RELIABILITY OF OUTCOME MEASURES IN PSYCHIATRIC CLINICAL TRIALS

Director: Nina Engelhardt, Ph.D.

Faculty: Pierre V. Tran, M.D.

COURSE 97 – CANCELLED

COURSE 98 8:00 a.m.-12 noon
Bacchus Room, Fourth Floor, Marriott

HOW TO BE MORE EFFECTIVE WITH MANAGED CARE "DOC-TO-DOC" REVIEWS

Director: Gabriel Kaplan, M.D.
Faculty: Elizabeth J. Rody, M.D., Matthew M. Keats, M.D., Neal R. Satten, M.D.

COURSE 99 8:00 a.m.-12 noon
Balcony K, Fourth Floor, Marriott

LIMIT SETTING WITH PSYCHIATRIC PATIENTS

Director: Donald A. Misch, M.D.
Faculty: Lydia E. Weisser, D.O., David W. Heilman, M.D.

9:00 a.m. Sessions



COURSES 100-102
Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

COURSE 100 9:00 a.m.-4:00 p.m.
La Galerie 2, Second Floor, Marriott

MODEL COMPLIANCE PLAN FOR SMALL PSYCHIATRIC PRACTICES

Co-Directors: Michael D. Murphy, M.D., Anne M. DeFelippo, J.D.

COURSE 101 9:00 a.m.-4:00 p.m.
Balcony J, Fourth Floor, Marriott

MULTIMODAL TREATMENT OF EATING DISORDERS

Co-Directors: Kathryn J. Zerbe, M.D., Mae S. Sokol, M.D.

COURSE 102 9:00 a.m.-4:00 p.m.
Balcony L, Fourth Floor, Marriott

HOW TO PRACTICE EVIDENCE-BASED PSYCHIATRY

Director: David R.S. Haslam, M.D.
Faculty: John Geddes, M.R.C., Elliot M. Goldner, M.D., David M. Gardner, Pharm.D.

DISCUSSION GROUPS 22-23

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

22 Silvia Hafliger, M.D., on Hepatitis C: What Every Psychiatrist Needs to Know
Chequers Suite, Second Floor, Hilton

23 Linda L.M. Worley, M.D., on Life Balance as a Psychiatrist... Easier Said Than Done!
Trafalgar Suite, Third Floor, Hilton

LECTURES 22-23

LECTURE 22

9:00 a.m.-10:30 a.m.

Rooms 338/339, Level 3, Convention Center

Michael D. Gershon, M.D.

Gut Sensation: Serotonin and Brain-Bowel Crosstalk

Chp.: Anand Pandya, M.D.

Co-Chp.: Evaristo O. Akerele, M.D.

The enteric nervous system within the gut contains primary afferent neurons and complex microcircuits that allow it to function independently of input from the brain or spinal cord while also communicating bidirectionally with the central nervous system. Michael D. Gershon, M.D., discusses the cellular basis of the interaction between the enteric and central nervous systems, including the critical role of serotonin as an enteric transmitter. Dr. Gershon is Chair of the Department of Anatomy and Cell Biology at Columbia University College of Physicians and Surgeons in New York City. His research, described in his more than 300 publications, has focused on the neuronal control of behavior on a cellular level, the molecular basis of the development of the enteric nervous system, and the mechanisms by which the varicella zoster virus infects enteric neurons. A Fellow of the American Association for the Advancement of Science, Dr. Gershon has received the Jacob Javits Award from the National Institutes of Health and the Henry Grey Award, the highest honor conferred by the American Association of Anatomists. Dr. Gershon graduated from Cornell University Medical College in New York City and completed postdoctoral training in neuroscience at Cornell University and in pharmacology at Oxford University, England.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 23

9:00 a.m.-10:30 a.m.

Rooms 353-355, Level 3, Convention Center

Ray Kurzweil

Why We Will Spend Most of Our Time in Virtual Reality in the 21st Century

Chp.: Ronnie S. Stangler, M.D.

The expansion of computing power, the increase in the human life span, and the growth in technologies for communication, brain and genome scanning, and miniaturization of machines are likely to continue and accelerate in the 21st century. Ray Kurzweil explores how these developments may profoundly alter our experience in the century ahead. Over the past 30 years, Mr. Kurzweil has been at the forefront in the development of several products based on artificial intelligence and pattern recognition technologies, including print-to-speech reading machines for the blind, optical character recognition systems, the flat-bed scanner, text-to-speech and music synthesizers, and speech recognition systems. He is the author of three books, including *The Age of Intelligent Machines*, named the Most Outstanding Computer Science Book of 1990 by the Association of American Publishers, and *The Age of Spiritual Machines: When Computers Exceed Human Intelligence*. His national and international awards include the Dickson Prize (Carnegie Mellon University's top science prize), Engineer of the Year from *Design News*, Inventor of the Year from the Massachusetts Institute of Technology, the Grace Murray Hopper Award from the Association for Computing Machinery, and the National Medal of Technology. He is a graduate of the Massachusetts Institute of Technology in Cambridge.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 18-20

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

18 Howard J. Osofsky, M.D., on BPD: Considerations of the Cultural Context in Evaluation and Treatment
Room 337, Level 3, Convention Center

19 Don R. Lipsitt, M.D., on Patients Who Somatize
Room 340, Level 3, Convention Center

20 Nyapati R. Rao, M.D., on Crucial Issues in Training of International Medical Graduates as Psychiatrists
Room 341, Level 3, Convention Center

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSION 28

9:00 a.m.-11:00 a.m.

Versailles Ballroom, Third Floor, Hilton

THE SECRETS OF LONGEVITY

Chp.: Cheryl A. Kennedy, M.D.

49 How to Live to Be 100

(52 minutes)

Distributor: Filmmakers Library
Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

People are living longer and healthier lives and centenarians are no longer a rarity. This film presents us with the latest research on the elderly in the U.S., China, and Denmark. James Vopel of the Max Planck Institute in Germany, and a senior scientist at Duke University leads a team of scientists seeking to unravel the secrets of longevity. It has been observed that every decade the number of centenarians double. Once people reach 80, the mortality rate seems to reach a plateau. Why do some people survive past 80? Through studying factors such as lifestyles, heredity, and nutrition, the film provides insights into the elusive secrets of long life. At the same time it challenges stereotypes about the extreme elderly.

WORKSHOPS

COMPONENTS 46-52

COMPONENT WORKSHOP 46 9:00 a.m.-10:30 a.m.
Room 264, Level 2, Convention Center

RESPONSES TO THE SURGEON GENERAL'S REPORT ON MENTAL HEALTH

APA Council on Psychiatric Services, American Association for Social Psychiatry, American Association of Community Psychiatrists, and American Orthopsychiatric Association

Co-Chps.: Zebulon C. Taintor, M.D., Kenneth S. Thompson, M.D.
Participants: Howard H. Goldman, M.D., Altha J. Stewart, M.D., Joel S. Feiner, M.D.

COMPONENT WORKSHOP 47 9:00 a.m.-10:30 a.m.
Rooms 265/266, Level 2, Convention Center

FINDING COMMON GROUND: GAYS AND LESBIANS TOGETHER

APA New York County District Branch's Committee on Gay and Lesbian Issues

Co-Chps.: Steven T. Wozniak, M.D., Julie K. Schulman, M.D.
Participants: Mary E. Barber, M.D., Serena Y. Volpp, M.D., Lisa R. Fortuna, M.D.

COMPONENT WORKSHOP 48 - CANCELLED

COMPONENT WORKSHOP 49 9:00 a.m.-10:30 a.m.
Room 342, Level 3, Convention Center

THE USE OF ANABOLIC AND ANDROGENIC STEROIDS IN HIV DISEASE

APA Commission on AIDS

Chp.: Marshall Forstein, M.D.

Participant: Stephen J. Ferrando, M.D.

COMPONENT WORKSHOP 50 9:00 a.m.-10:30 a.m.
Rooms 346/347, Level 3, Convention Center

TREATMENT OF CHILD AND ADOLESCENT VICTIMS OF CRIME: NEW GUIDELINES FROM CALIFORNIA

APA Committee on Family Violence and Sexual Abuse

Co-Chps.: Graeme Hanson, M.D., Michele Winterstein, Ph.D.

Participant: Bradley D. Stein, M.D.

COMPONENT WORKSHOP 51 9:00 a.m.-10:30 a.m.
Grand Salon Section 4, Street Level, Hilton

PRACTICE GUIDELINES, STANDARDS, AND QUALITY INDICATORS: APA INITIATIVES

APA Council on Quality Improvement

Chp.: Sara C. Charles, M.D.

Participants: John M. Oldham, M.D., Charles E. Riordan, M.D., John S. McIntyre, M.D., Rhonda J.R. Beale, M.D., James C. MacIntyre, M.D.

COMPONENT WORKSHOP 52 9:00 a.m.-10:30 a.m.
Prince of Wales Suite, Second Floor, Hilton

PSYCHIATRIC DISCHARGE IN THE CRIMINAL JUSTICE SYSTEM

APA Consortium on Special Delivery Settings

Chp.: Cassandra F. Newkirk, M.D.

Participants: Ludwik S. Szymanski, M.D., Heather Barr, J.D., Erik J. Roskes, M.D., Hunter L. McQuiston, M.D.

ISSUES 97-120

ISSUE WORKSHOP 97 9:00 a.m.-10:30 a.m.
Rooms 260/261, Level 2, Convention Center

MOBILE COMPUTING IN PSYCHIATRY WITH PERSONAL DIGITAL ASSISTANTS

Chp.: John Luo, M.D.

ISSUE WORKSHOP 98 9:00 a.m.-10:30 a.m.
Rooms 267-268, Level 2, Convention Center

DOMESTIC VIOLENCE IN THE PSYCHIATRIC EMERGENCY DEPARTMENT

Chp.: Satyanarayana Chandragiri, M.D.

Participants: Satyajit Satpathy, M.D., Brigid B. Bautista, M.D.

ISSUE WORKSHOP 99 9:00 a.m.-10:30 a.m.
Room 270, Level 2, Convention Center

MENTAL HEALTH IN A JAIL

Chp.: Ole J. Thienhaus, M.D.

Participants: Joan Williamson, R.N., Melissa P. Piasecki, M.D.

ISSUE WORKSHOP 100 9:00 a.m.-10:30 a.m.
Room 271, Level 2, Convention Center

PROSPERING: MARKET DYNAMICS IN THE NEW POLITICAL CRUCIBLE

Chp.: Stuart B. Silver, M.D.

Participants: Dave M. Davis, M.D., Gary E. Miller, M.D., W. Walter Menninger, M.D., Philip E. Veenhuis, M.D.

ISSUE WORKSHOP 101 9:00 a.m.-10:30 a.m.
Room 272, Level 2, Convention Center

TEACHING PSYCHOPHARMACOLOGY TO RESIDENTS USING EVIDENCE-BASED ALGORITHMS

Chp.: David N. Osser, M.D.

Participants: Dan O. Ioanimescu, M.D., Jessica R. Oesterheld, M.D., James J. Levitt, M.D.

ISSUE WORKSHOP 102 9:00 a.m.-10:30 a.m.
Room 273, Level 2, Convention Center

IF THERAPY IS NEEDED BUT NOT AVAILABLE, WHAT SHOULD WE DO?

Chp.: Theodor Bonstedt, M.D.

Participants: Janet W. Eustis, M.S.W., Raymond A. Johnson, M.D., Debra M. Patterson, M.A.

ISSUE WORKSHOP 103 9:00 a.m.-10:30 a.m.
Rooms 333/334, Level 3, Convention Center

IMPLEMENTING OUTPATIENT COMMITMENT IN NEW YORK CITY: A FORENSIC PERSPECTIVE

Co-Chps.: A. Sasha Bardey, M.D., Deborah S. Rose, Psy.D.

Participant: Gary R. Collins, M.D.

ISSUE WORKSHOP 104 9:00 a.m.-10:30 a.m.
Rooms 335/336, Level 3, Convention Center

MEMORY SCREENING PROGRAM FOR COMMUNITY-DWELLING ELDERS: A PRACTICAL APPROACH

Co-Chps.: Janet M. Lawrence, M.D., Donald A. Davidoff, Ph.D.

Participant: Debra Katt-Lloyd, B.S.

ISSUE WORKSHOP 105 9:00 a.m.-10:30 a.m.

Rooms 348/349, Level 3, Convention Center

ADMINISTRATIVE PSYCHIATRY: HOW TO PREPARE TO MEET THE CHALLENGE

Chp.: Paul Rodenhauser, M.D.

ISSUE WORKSHOP 106 9:00 a.m.-10:30 a.m.

Rooms 350/351, Level 3, Convention Center

COGNITIVE-BEHAVIORAL THERAPY TRAINING FOR RESIDENTS: HOW TO TEACH, MEASURE, AND ATTAIN RESIDENT COMPETENCY

Chp.: Donna M. Sudak, M.D.

Participants: Judith S. Beck, Ph.D., Hinda F. Dubin, M.D., Jesse H. Wright, M.D.

ISSUE WORKSHOP 107 9:00 a.m.-10:30 a.m.

Room 352, Level 3, Convention Center

HOW TO GIVE A MORE EFFECTIVE LECTURE: PITH, PUNCH, AND POLISH

Chp.: Phillip J. Resnick, M.D.

ISSUE WORKSHOP 108 9:00 a.m.-10:30 a.m.

Room 357, Level 3, Convention Center

BIOBEHAVIORAL INTEGRATION OF ADDICTION TREATMENT

Chp.: Richard J. Frances, M.D.

Participants: Sheldon I. Miller, M.D., Robert B. Millman, M.D., Sheila B. Blume, M.D., Marc Galanter, M.D., Lionel P. Solursh, M.D., Frances R. Levin, M.D.

ISSUE WORKSHOP 109 9:00 a.m.-10:30 a.m.

Grand Salon Sections 7 & 10, Street Level, Hilton

ACHIEVING COMPREHENSIVE CARE FOR CHRONICALLY SUICIDAL INDIVIDUALS

Chp.: Ian C. Dawe, M.D.

Participants: Paul S. Links, M.D., Yvonne Bergmans, M.S.W.

ISSUE WORKSHOP 110 9:00 a.m.-10:30 a.m.

Grand Salon Sections 9 & 12, Street Level, Hilton

TEACHING THE CLINICAL ESSENTIALS: THE ROLE OF THE PSYCHIATRIST

Chp.: David C. Lindy, M.D.

Participants: Neil Pessin, Ph.D., Howard W. Telson, M.D., Christina Fragola, C.S.W., Annette Cutrino, C.S.W., Stephanie Moeller, M.A.

ISSUE WORKSHOP 111 9:00 a.m.-10:30 a.m.

Grand Salon Sections 13 & 16, Street Level, Hilton

THE IMPORTANCE OF PSYCHIATRIC MANAGEMENT FOR INPATIENT CARE AND TREATMENT

Chp.: Roger Peele, M.D.

Participants: Barbara Rosenblum, M.D., Joseph M. Jeral, M.D.

ISSUE WORKSHOP 112 9:00 a.m.-10:30 a.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

GROUP PSYCHOTHERAPY WITH SUBSTANCE ABUSERS*American Group Psychotherapy Association*

Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.

Participant: Philip J. Flores, Ph.D.

ISSUE WORKSHOP 113 9:00 a.m.-10:30 a.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

ASPERGER'S DISORDER: FROM QUANDARY TO QUAGMIRE

Chp.: Donna L. Londino, M.D.

Participants: Robert Kaltenbach, Ph.D., Elizabeth Sirota, M.D.

ISSUE WORKSHOP 114 9:00 a.m.-10:30 a.m.

Grand Salon Sections 21 & 24, Street Level, Hilton

PSYCHIATRIC DISABILITY: THE ROLE OF PSYCHIATRIC ASSESSMENT

Chp.: Edward A. Volkman, M.D.

Participants: Janice Volkman, J.D., Deborah Bailey, V.E.

ISSUE WORKSHOP 115 9:00 a.m.-10:30 a.m.

Melrose Room, Third Floor, Hilton

PERSONAL AND INTERPERSONAL DIFFICULTIES IN ORGANIZATIONAL SETTINGS

Chp.: Stewart Gabel, M.D.

ISSUE WORKSHOP 116 9:00 a.m.-10:30 a.m.

Rosedown Room, Third Floor, Hilton

STRESS DISABILITY ASSESSMENT AND COMPENSATION SEEKING: ELUSIVE TRUTH

Chp.: Landy F. Sparr, M.D.

Participants: Neil A. Matteucci, M.D., Michael Maxwell, M.S., Nina P. Sparr

ISSUE WORKSHOP 117 9:00 a.m.-10:30 a.m.
Magnolia Room, Third Floor, Hilton

**STRATEGIES FOR PROMOTING COLLABORATIVE
RESEARCH IN DEVELOPING COUNTRIES**

Co-Chps.: Victoria E. Wells, M.D., Lawson R. Wulsin, M.D.
Participants: Pius A. Kigamwa, M.D., Athanase
Hagengimana, M.D.

ISSUE WORKSHOP 118 9:00 a.m.-10:30 a.m.
Jasperwood Room, Third Floor, Hilton

**OXYMORON: FINE UNIVERSITY AND SO-SO
PUBLIC CARE**

Co-Chps.: Karl S. Burgoyne, M.D., Milton H. Miller, M.D.
Participants: Peter C. Whybrow, M.D., Marvin Southard, D.S.W.,
Norman Sartorius, M.D., James Allen, M.B.A.

ISSUE WORKSHOP 119 9:00 a.m.-10:30 a.m.
Oak Alley Room, Third Floor, Hilton

**MULTISYSTEMIC THERAPY: INTEGRATING
PSYCHIATRY**

Co-Chps.: Debbie R. Carter, M.D., Erica Viggiano, M.S.W.
Participant: Lori Gorshow, M.S.W.

ISSUE WORKSHOP 120 9:00 a.m.-10:30 a.m.
Belle Chasse Room, Third Floor, Hilton

**COMMUNITY REINTEGRATION FOR SEVERELY
MENTALLY ILL PATIENTS LEAVING JAIL**

Co-Chps.: Thomas A. Klotz, M.D., Brock H. Summers, M.D.
Participants: Linda Richardson, Ph.D., Debbie Innes
Gomberg, Ph.D., Michael Maloney, Ph.D.

11:00 a.m. Sessions

DISCUSSION GROUPS 24-25

11:00 a.m.-12:30 p.m.

**These sessions are limited to 25 participants on a first-
come, first-served basis.**

**24 Laura W. Roberts, M.D., on Evidence-Based Ethics Issues
in Psychiatry**
Chequers Suite, Second Floor, Hilton

**25 Ann E. Norwood, M.D., on My Experiences as a Military
Psychiatrist (For Residents Only)**
Trafalgar Suite, Third Floor, Hilton

**MASTER EDUCATOR CLINICAL
CONSULTATION**

11:00 a.m.-12:30 p.m.

21 CANCELLED

MEDIA SESSION 29

11:00 a.m.-12:30 p.m.

Versailles Ballroom, Third Floor, Hilton

LIVING AND DYING

Chp.: Sudha Prathikanti, M.D.

50 The Andre Show
(43 minutes)

Distributor: Fanlight Productions
4196 Washington Street, Suite 2
Boston, MA 02131

When filmmaker Beverly Peterson was invited into the lives of Andre, an HIV-positive child and his mother, Vilma, it was the beginning of an extraordinary friendship, which eventually reshaped the lives of everyone around them. As she became friends with the family, Peterson and her husband Farrell became more and more involved, inviting Andre to stay with them while Vilma was in the hospital or in drug rehabilitation programs. When Vilma realized that she did not have long to live, she asked the Petersons to adopt Andre and, after considerable struggle, they agreed. *The Andre Show* is a poignant documentary where viewers will accompany the Petersons on their journey of adoption as they move from ambivalence and conflict to increasing mutual trust and resolution.

51 At Death's Door
(30 minutes)

Distributor: Aquarius Healthcare Videos
5 Powderhouse Lane, P.O. Box 1159
Sherborn, MA 01770

A young mother is told the devastating news, her three-year-old daughter has leukemia; a young husband receives a shocking phone call, his 53-year-old father has stomach cancer; and a 68-year-old woman's gnawing fears are confirmed, her husband has Lou Gehrig's disease. Through these experiences and others, *At Death's Door* will help you acknowledge your emotions about the terminal illness to someone you love, and will guide you in living fully with your loved one through the last months, weeks, or days of your time together.

MEDICAL UPDATE 4

11:00 a.m.-12:30 p.m.

Grand Salon Sections 3 & 6, Street Level, Hilton

BRINGING THE SPACE STATION TO THE CLINICAL BEDSIDE: NEXT GENERATION BIO-PRODUCTS AND DRUG TESTING MODALITIES DEVELOPED USING STUDIES IN SPACE

Chp.: Patricia I. Ordorica, M.D.

Presenter: Timothy G. Hammond, M.B.

THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 3 Anita L.H. Clayton, M.D., on Sexual Dysfunction
Cambridge Suite, Second Floor, Hilton

SCIENTIFIC AND CLINICAL REPORT SESSIONS 33-40**SCIENTIFIC AND CLINICAL REPORT SESSION 33**

11:00 a.m.-12:30 p.m.

Room 264, Level 2, Convention Center

PROMOTION OF MENTAL HEALTH

Chp.: Mary H. Davis, M.D.

Co-Chp.: Harvey L. Ruben, M.D.

11:00 a.m.

- 98 Popular Health Advice: A Historical Survey
Laura D. Hirshbein, M.D.

11:30 a.m.

- 99 A Systematic Review of Screening for Depression in Primary Care
Bradley N. Gaynes, M.D., Michael P. Pignone, M.D.,
C. Tracy Orleans, Ph.D., Jerry L. Rushton, M.D., Cynthia D. Mulrow, M.D., Catherine Mills, M.A., Kathleen N. Lohr, Ph.D.

12 noon

- 100 Medical Students' Mental and Physical Health Promotion: A North American School Survey
S. Evelyn Stewart, M.D., Paul K. Dagg, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34

11:00 a.m.-12:30 p.m.

Room 270, Level 2, Convention Center

PSYCHIC AND SOMATIC ISSUES IN PSYCHIATRY

Chp.: Daniel K. Winstead, M.D.

Co-Chp.: Angelica J. Long-Harrell, M.D.

11:00 a.m.

- 101 Overweight Status of Parents: A Longitudinal Study of Offspring Adiposity
Debra L. Safer, M.D., W. Stewart Agras, M.D., Sue Bryson, M.S., Lawrence Hammer, M.D.

11:30 a.m.

- 102 Integrating Psychoanalysis and Neurobiology in the Treatment of Migraines
Scott M. Davis, M.D.

12 noon

- 103 Unremitting Depression: Cingulate Dysfunction and the Cleft-Self on Trial
Leo I. Jacobs, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35

11:00 a.m.-12:30 p.m.

Rooms 335/336, Level 3, Convention Center

ISSUES IN PSYCHOPHARMACOLOGY

Chp.: Alan C. Swann, M.D.

Co-Chp.: Frederick G. Moeller, M.D.

11:00 a.m.

- 104 Prolactin Levels in Patients Taking Risperidone and Ziprasodone
Jambur V. Ananth, M.D., Karl S. Burgoyne, M.D.,
Michael W. Smith, M.D., Rangaesh Gadasalli, M.D., Monica Walia, B.S., Aswin Suri, M.H.A., Andrew P. Ho, M.D.

105 CANCELLED

11:45 a.m.

- 106 Use of Intravenous Lorazepam in Patients with Catatonia-Like Syndromes
Ramaswamy Viswanathan, M.D., Olivera J. Bogunovic, M.D.,
Allan L. Tusher, M.D., Marek D. Karpinski, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 36

11:00 a.m.-12:30 p.m.

Rooms 348/349, Level 3, Convention Center

FORENSICS

Chp.: Rahn K. Bailey, M.D.

Co-Chp.: Michael R. Harris, M.D.

(Continued on next page)

11:00 a.m.

- 107 **Schizophrenia and Mass Homicide: Who, What, and Why from Case Histories**
Michael M. Welner, M.D.

11:30 a.m.

- 108 **Behavioral Treatment of the Aggressive Mentally Ill Inmate**
Robert L. Trestman, M.D., Kathy Coleman, M.S., Clyde McDonald, B.S., Tod Bogdanoff, Psy.D., Giovanni Gomez, Aqil Hashim, M.S.W.

12 noon

- 109 **Disability Evaluations in the U.S. Air Force**
David M. Walker, M.D., Matthew D. Faubion, M.D., Joseph P. Chozinski, M.D., James A. Bourgeois, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 37

11:00 a.m.-12:30 p.m.

Grand Salon Sections 15 & 18, Street Level, Hilton

MOOD DISORDERS AND REPRODUCTIVE ISSUES

Chp.: Marian I. Butterfield, M.D.

Co-Chp.: Vladimir Coric, M.D.

11:00 a.m.

- 110 **A Simple Screen to Identify Postpartum Major Depression**
Kathleen S. Peindl, Ph.D., Katherine L. Wisner, M.D., Barbara Hanusa, Ph.D.

11:30 a.m.

- 111 **Interpersonal Psychotherapy for Antepartum Depression: A Controlled Trial**
Margaret G. Spinelli, M.D.

12 noon

- 112 **Diminished Prolactin Secretion and Response to Fluoxetine Treatment**
Roy H. Perlis, M.D., Timothy J. Petersen, Ph.D., Karen E. Kelly, B.A., Megan M. Smith, B.A., Shamsah B. Sonawalla, M.D., Amy Farabaugh, M.A., Jerrold F. Rosenbaum, M.D., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 38

11:00 a.m.-12:30 p.m.

Rosedown Room, Third Floor, Hilton

SUICIDE AND THE LIFE CYCLE

Chp.: Edward F. Foulks, M.D.

Co-Chp.: Marcia K. Goin, M.D.

11:00 a.m.

- 113 **Childhood Sexual Abuse and Suicidal Behavior in BPD**
Paul H. Soloff, M.D., Kevin G. Lynch, Ph.D., Thomas M. Kelly, Ph.D.

11:30 a.m.

- 114 **Multiplicity of Suicide Attempts in Bipolar Disorder**
Joseph F. Goldberg, M.D., Tara M. Singer, M.A., Jessica L. Garno, B.S., Mallay Charters, A.B., Miki Hertz, B.S.

12 noon

- 115 **Suicidal Youth with First Emergency Room Presentations: Six-Month Outcome Predictions**
Ian G. Manion, Ph.D., S. Evelyn Stewart, M.D., Simon Davidson, M.B., Paula F. Cloutier, M.A.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 39

11:00 a.m.-12:30 p.m.

Magnolia Room, Third Floor, Hilton

PATIENT AND PHYSICIAN AUTONOMY

Chp.: Carol L. Alter, M.D.

Co-Chp.: Mercedes M. Rodriguez, M.D.

11:00 a.m.

- 116 **Managed Care and Malpractice Liability Today**
Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

11:30 a.m.

- 117 **Parity Disparity: Mental Health Insurance Coverage Decision Making**
Bentson H. McFarland, M.D., Walter K. Lierman, Ph.D., Norman R. Penner, M.P.H., Lynn E. McCamant, M.A.

12 noon

- 118 **The Doctor-Patient Relationship: Autonomy, Gender, and Preferred Physician Style**
Kalman J. Kaplan, Ph.D., Mark E. Schneiderman, Ph.D., Martin Harrow, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 40

11:00 a.m.-12:30 p.m.

Jasperwood Room, Third Floor, Hilton

WOMEN'S HEALTH ISSUES

Chp.: Valerie Raskin, M.D.

Co-Chp.: Nada L. Stotland, M.D.

11:00 a.m.

- 119 **Mood and Anxiety Disorders and Health of Multi-Ethnic Midlife Women**
Joyce T. Bromberger, Ph.D., Howard M. Kravitz, M.P.H., Adriana Cordal, M.D., Linda Jansen-McWilliams, M.S., Karen S. Matthews, Ph.D.

11:30 a.m.

- 120 **Topiramate in PMDD**
Mohammad Z. Hussain, M.D., Zubaida Chaudhry, M.D., Seema Hussain, M.D.

12 noon

121 Verapamil Effectiveness in Women with Bipolar Disorder

Katherine L. Wisner, M.D., James M. Perel, Ph.D.,
Kathleen S. Peindl, Ph.D., Catherine M. Piontek, M.D.,
Susan W. Baab, M.S.N.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS**COMPONENTS 53-54**

COMPONENT WORKSHOP 53 11:00 a.m.-12:30 p.m.
Room 269, Level 2, Convention Center

COPING WITH MEDICAL ILLNESS

APA Committee on Consultation-Liaison Psychiatry and Primary Care Education

Chp.: Francisco Fernandez, M.D.

Participants: James L. Griffith, M.D., Karl Goodkin, M.D.

COMPONENT WORKSHOP 54 11:00 a.m.-12:30 p.m.
Room 273, Level 2, Convention Center

MORE ALIVE THAN DEAD: CHANGING STRATEGIES IN HIV PSYCHOTHERAPY

APA New York County District Branch's AIDS Committee

Co-Chps.: Kristina Jones, M.D., Kenneth B. Ashley, M.D.

Participants: David B. Goldenberg, M.D., Kyle S. Kato, M.D.

ISSUES 121-131

ISSUE WORKSHOP 121 11:00 a.m.-12:30 p.m.
Rooms 265/266, Level 2, Convention Center

SHOULD SUBSTANCE ABUSE TREATMENT BE COERCED?

Chp.: Mitchell S. Rosenthal, M.D.

Participants: Sally L. Satel, M.D., James R. McDonough

ISSUE WORKSHOP 122 11:00 a.m.-12:30 p.m.
Rooms 267-268, Level 2, Convention Center

MIND MEETS BRAIN IN PRACTICE: THE MCLEAN MULTIDISCIPLINARY NEUROPSYCHIATRIC CONSULTATION SERVICE

Chp.: Bruce Price, M.D.

Participants: Miles Cunningham, M.D., Alonso Montoya-Pulido, M.D., Julie Brody, D.P., JoAnne Savoie, Ph.D., Jennifer Woehr, Psy.D., Martin A. Goldstein, M.D.

ISSUE WORKSHOP 123 11:00 a.m.-12:30 p.m.
Rooms 333/334, Level 3, Convention Center

COMMUNITY MEETINGS ON AN INPATIENT PSYCHIATRIC UNIT

Co-Chps.: Christopher L. Lange, M.D., John C. Bradley, M.D.

ISSUE WORKSHOP 124 11:00 a.m.-12:30 p.m.
Room 342, Level 3, Convention Center

INTEGRATING BEHAVIORAL HEALTH WITH PRIMARY CARE THROUGH DISEASE MANAGEMENT

Co-Chps.: Arthur L. Lazarus, M.D., David S. Brody, M.D.

ISSUE WORKSHOP 125 11:00 a.m.-12:30 p.m.
Rooms 350/351, Level 3, Convention Center

CAREER ADVANCEMENT FOR WOMEN PSYCHIATRISTS: THE ROLE OF MENTORSHIP

Co-Chps.: Anu A. Matorin, M.D., Sandra Sexson, M.D.

Participants: Cynthia W. Santos, M.D., Donna M. Mancuso, M.D., Pedro Ruiz, M.D.

ISSUE WORKSHOP 126 11:00 a.m.-12:30 p.m.
Grand Salon Section 4, Street Level, Hilton

SUBJECTIVITY: CRUCIAL KEY TO THE THERAPEUTIC ALLIANCE

Chp.: Vincenzo R. Sanguineti, M.D.

ISSUE WORKSHOP 127 11:00 a.m.-12:30 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

LEADERSHIP IN ORGANIZATIONAL TRANSITIONS

Chp.: Stewart Gabel, M.D.

ISSUE WORKSHOP 128 11:00 a.m.-12:30 p.m.
Grand Salon Sections 19 & 22, Street Level, Hilton

MIND AND BRAIN DO NOT NEED TO BE INTEGRATED IF WE DON'T SEGREGATE THEM IN THE FIRST PLACE

Chp.: Michael A. Schwartz, M.D.

Participant: Elena B. Bezzubova, M.D.

ISSUE WORKSHOP 129 11:00 a.m.-12:30 p.m.
Prince of Wales Suite, Second Floor, Hilton

HALLUCINOGENS: ILLICIT USE, RELIGIOUS USE, AND CURRENT PSYCHIATRIC RESEARCH

Co-Chps.: Charles S. Grob, M.D., John H. Halpern, M.D.

ISSUE WORKSHOP 130 11:00 a.m.-12:30 p.m.
Marlborough Suite A/B, Second Floor, Hilton

REHABILITATION EDUCATION: INTERNATIONAL COMPARISONS

Chp.: Zebulon C. Taintor, M.D.
Participants: Michael Stark, M.D., Ida Kosza, M.D., Jacques M. Dubuis, M.D., Robert Cancro, M.D.

ISSUE WORKSHOP 131 11:00 a.m.-12:30 p.m.
Elmwood Room, Third Floor, Hilton

CRIMES OF INFAMY: PERSONAL INSIGHTS

Chp.: Phillip J. Resnick, M.D.

12 noon Sessions

FORUMS 10-11

FORUM 10 12 noon-1:30 p.m.
Room 263, Level 2, Convention Center

MENTAL ILLNESS: SURGEON GENERAL'S REPORT ON CULTURE, RACE, AND ETHNICITY

Chp.: Carl C. Bell, M.D.
Participants: James W. Thompson, M.D., Francis G. Lu, M.D., Pablo D. Hernandez, M.D.

FORUM 11 12 noon-1:30 p.m.
Room 252, Level 3, Convention Center

VIRTUAL PSYCHIATRY: FROM HUMANOID TO CYBERSPACE, THE FUTURE OF PSYCHIATRY AND VIRTUAL REALITY

Chp.: David M. McDowell, M.D.
Participants: Norman E. Alessi, M.D., Randall D. Marshall, M.D., Doug Wright, Milton Huang, M.D.

NEW RESEARCH POSTER SESSION 10
12 noon-2:00 p.m.
Exhibition Center, Second Floor, Hilton

BIOLOGICAL PSYCHIATRY, CHILD AND ADOLESCENT PSYCHIATRY, GERIATRICS, WOMEN'S HEALTH, COGNITIVE DISORDERS, MENTAL RETARDATION, EPIDEMIOLOGY, ETHICS, AND CROSS-CULTURAL AND MINORITY ISSUES

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

12:30 p.m. Session

MEDIA SESSION 30
12:30 p.m.-2:00 p.m.
Versailles Ballroom, Third Floor, Hilton

COMING OUT: A STRUGGLE FOR ACCEPTANCE

Chp.: Dan H. Karasic, M.D.

52 Looking for Common Ground
(30 minutes)

Distributor: Filmmakers Library
For V52 & V53 Attn: Linda Gottesman
124 East 40th Street
New York, NY 10016

When Massachusetts enacted an antidiscrimination law establishing the rights of gay and lesbian high school students, the citizens of Westhampton were embroiled in controversy. Parents, students, school committee members, and local citizens were polarized. *Looking for Common Ground* gives voice to the gay and lesbian students who talk about their struggle or acceptance. It also allows us to hear articulate and passionate testimony from all sides to the controversy, both in interviews and community meetings. Among the issues raised are parents versus governments in determining the education of minors; community values versus the rights of the individual; and nature versus nurture in determining sexual orientation.

53 Summer in My Veins
(41 minutes)

It would be wrong to classify this remarkable film as simply a "coming out" film; it is also a look at family dynamics, at the nuances of another culture, and a most unusual "road" movie. Harvard graduate Nish Saran, a gay Indian filmmaker, travels across America with his family who is visiting from India. He was recently tested for HIV after an unsafe encounter with an HIV-positive man. As he will not know the outcome for several weeks, the threat of terminal illness shadows the trip. In addition, Nish is planning to reveal his gayness to his mother during this journey, but finds it difficult to say the words. The unsuspecting mother and her sisters are enjoying the vacation. When Nish finally comes out to his mom, her reaction is powerful and moving.

2:00 p.m. Sessions

SYMPOSIA 90-106

SYMPOSIUM 90 2:00 p.m.-5:00 p.m.
Room 262, Level 2, Convention Center

MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID DISORDERS

Chp.: Michael Y. Hwang, M.D.
Co-Chp.: Javier I. Escobar, M.D.

A Management of Schizophrenia with Depression
Samuel G. Siris, M.D.

B Management of Schizophrenia with Anxiety Disorders
Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.

C Schizophrenia and Substance Abuse
Douglas M. Ziedonis, M.D.

D Clinical Management of Persistent Aggressive Behavior in Schizophrenia

Leslie L. Citrome, M.D., Jan Volavka, M.D.

E Long-Term Outcome: Influence of Comorbid Conditions

Nina R. Schooler, Ph.D.

Discussants: Lewis A. Opler, M.D., Javier I. Escobar, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 91**

2:00 p.m.-5:00 p.m.

Room 264, Level 2, Convention Center

WHEN A SUBSTANCE ABUSER PRESENTS IN YOUR OFFICE: WHAT DO YOU DO?

Chp.: Marc Galanter, M.D.

Co-Chp.: Jonathan I. Ritvo, M.D.

A Inpatient Versus Outpatient Treatment for Abuse: A Reexamination

Laura F. McNicholas, M.D., James R. McKay, Ph.D., A. Thomas McLellan, Ph.D.

B The Dually Diagnosed Patient

Richard N. Rosenthal, M.D.

C Evaluation and Treatment of the Cocaine-Dependent Patient

Roger D. Weiss, M.D.

D The Initial Evaluation of Substance Use in Adolescents

Joyce A. Tinsley, M.D.

E Family and Social Support: Network Therapy

Marc Galanter, M.D.

Discussants: Jonathan I. Ritvo, M.D., Kathleen T. Brady, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 92**

2:00 p.m.-5:00 p.m.

Room 269, Level 2, Convention Center

TREATMENTS REDUCING PERSONALITY DYSFUNCTION*Association for Research in Personality Disorders*

Chp.: James H. Reich, M.D.

A Drug Treatment of Personality Disorder Traits

James H. Reich, M.D.

B The Interrupted Career Group

Elsa F. Ronningstam, Ph.D., David Anik, M.D.

C Treating Emotional Dysregulation

John Livesley, M.D.

D Treatment of a Personality Disorder Associated with Trauma

David P. Bernstein, Ph.D.

E An Independent, Randomized, Controlled Trial of Dialectical Behavior

Clive J. Robins, Ph.D., Cedar Koons, M.S.W.

Discussant: Giovanni de Girolamo, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 93**

2:00 p.m.-5:00 p.m.

Room 271, Level 2, Convention Center

SOCIAL ANXIETY IN SCHIZOPHRENIA ASSESSMENT AND TREATMENT

Chp.: Robert G. Stern, M.D.

Co-Chp.: William E. Narrow, M.D.

A A Comparison of Social Anxiety Symptom Patterns in Schizophrenia and Social Anxiety Disorder

Robert G. Stern, M.D., Jane Luterek, Ph.D., Richard G. Heimberg, Ph.D.

B Schizophrenia with Comorbid Social Phobia: Epidemiology and Service Use

William E. Narrow, M.D., Donald S. Rae, M.A., Robert G. Stern, M.D.

C Treating Social Anxiety in Schizophrenia: A Group-Based Cognitive-Behavior Therapy Approach

David Castle, M.D., Paula Nathan, Patrick Kingser, Steven Halperin, Peter Drummond, Ledley Jeffreys

D Social Anxiety and Premorbid Personality in Schizophrenic Patients Treated with Clozapine

Stefano Pallanti, M.D., Leonardo Quercioli, M.D., Adolfo Passagli, Ph.D.

E Interpersonal Sensitivity, Social Anxiety Disorder, and Insight into Illness in Psychotic Patients

Stefano Pini, M.D., Liliana Dell'osso, M.D., Marco Sacttoni, M.D., Alessandra Papasogli, M.D., Xavier Amador, Ph.D., Paola Rucci, D.Stat., Giovanni B. Cassano, M.D.

Discussant: John M. Davis, M.D.

THIS SESSION WILL BE AUDIOTAPED.**SYMPOSIUM 94**

2:00 p.m.-5:00 p.m.

Room 272, Level 2, Convention Center

CLINICAL APPLICATIONS OF CULTURAL PSYCHIATRY

Chp.: Wen-Shing Tseng, M.D.

Co-Chp.: Jon M. Streltzer, M.D.

A Cultural Issues in Consultation-Liaison Psychiatry

Jon M. Streltzer, M.D.

(Continued on next page)

B Culture and Addiction

Joseph J. Westermeyer, M.D.

C Cultural Aspects of Geriatric Psychiatry

Iqbal Ahmed, M.D.

D Cultural Psychiatry on Inpatient Units: The Ethnic/Minority Programs at the University of California at San Francisco/San Francisco General Hospital

Francis G. Lu, M.D., Kenneth K. Gee, M.D., Jo Ellen Branin-Rodriguez, M.D., J. Charles Ndlela, M.D., Alastair Donald, M.D., Mark Leary, M.D., Robert L. Okin, M.D.

E Ethnic/Cultural Considerations for Psychopharmacotherapy

Keh-Ming Lin, M.D.

F Culture and Practice of Psychotherapy

Wen-Shing Tseng, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95

2:00 p.m.-5:00 p.m.

Rooms 335/336, Level 3, Convention Center

THE DIFFICULT-TO-TREAT PSYCHIATRIC PATIENT

Chp.: Mantosh J. Dewan, M.D.

A The Difficult-to-Treat Patient with Eating Disorders
Katherine A. Halmi, M.D., Wendy A. Harris, M.D., Claire Wiseman, Ph.D.

B The Difficult-to-Treat Patient with PTSD
Randall D. Marshall, M.D., Elizabeth A. Hembree, Ph.D., Lee A. Fitzgibbons, Ph.D., Edna B. Foa, Ph.D.

C The Difficult-to-Treat Patient with Bipolar Disorder
Frederick K. Goodwin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96

2:00 p.m.-5:00 p.m.

Rooms 346/347, Level 3, Convention Center

BIPOLAR DEPRESSION

Chp.: Russell T. Joffe, M.D.

Co-Chp.: L. Trevor Young, M.D.

A Bipolar Depression: Phenomenology and Diagnosis
Hagop S. Akiskal, M.D.

B The Neurobiology of Bipolar Disorder
L. Trevor Young, M.D.

C Pharmacological Treatment of Bipolar Depression
Russell T. Joffe, M.D., L. Trevor Young, M.D., Glenda M. MacQueen, M.D.

D ECT in Bipolar Disorders

Charles H. Kellner, M.D.

Discussant: Robert M. Post, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97

2:00 p.m.-5:00 p.m.

Rooms 348/349, Level 3, Convention Center

PSYCHIATRIC PRACTICE IN PRISON

Chp.: Lee H. Rome, M.D.

Co-Chp.: James E. Dillon, M.D.

A Psychiatrists Inside Prison: The Lay of the Land
Lee H. Rome, M.D.

B Do Mentally Ill Criminals Belong in Prison?
James E. Dillon, M.D.

C Existential and Spiritual Issues for People in Prison
Fleet W. Maull, M.A.

D Correctional Health Care Standards: A Historical Review and Recent Developments
Jeffrey L. Metzner, M.D.

E Treatment, Training, and Clinical Studies in a Prison-Based Mental Health Unit
Richard S. Jackson, M.D.

Discussant: Henry C. Weinstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 98

2:00 p.m.-5:00 p.m.

Room 352, Level 3, Convention Center

REDUCING DURATION OF UNTREATED FIRST PSYCHOSIS: THE TREATMENT AND INTERVENTION IN PSYCHOSIS STUDY (TIPS)

Chp.: Thomas H. McGlashan, M.D.

A Early Detection and Intervention: Rationale
Thomas H. McGlashan, M.D., Per Vaglum, M.D., Svein Friis, M.D., Erik Simonsen, M.D., Jan O. Johannessen, M.D., Ingrid Melle, M.D., Tor K. Larsen, M.D.

B Does Duration of Untreated Psychosis Bias Schizophrenia Study Samples?
Per Vaglum, M.D., Svein Friis, M.D., Ingrid Melle, M.D., Stein Opjordsmoen, M.D., Tor K. Larsen, M.D., Erik Simonsen, M.D., Thomas H. McGlashan, M.D.

C Reducing Duration of Untreated Psychosis: The TIPS Historical Control Study
Tor K. Larsen, M.D., Jan O. Johannessen, M.D., Erik Simonsen, M.D., Ingrid Melle, M.D., Svein Friis, M.D., Per Vaglum, M.D., Thomas H. McGlashan, M.D.

- D TIPS Study: Duration of Untreated Psychosis and Baseline Clinical Severity in First-Episode Psychosis**
Ingrid Melle, M.D., Stein Opjordsmoen, M.D., Tor K. Larsen, M.D., Svein Friis, M.D., Thomas H. McGlashan, M.D., Ulrik Haahr, M.D., Per Vaglum, M.D.
- E TIPS: Stability of Cognitive Functioning in Patients with First-Episode Psychosis**
Stein Opjordsmoen, M.D., Bjorn Rund, Ph.D., Ingrid Melle, M.D., Svein Friis, M.D., Per Vaglum, M.D., Tor K. Larsen, M.D., Thomas H. McGlashan, M.D.
- F TIPS: First-Episode Psychosis Diagnostic Stability Over One Year**
Ulrik Haahr, M.D., Erik Simonsen, M.D., Ingrid Melle, M.D., Tor K. Larsen, M.D., Svein Friis, M.D., Per Vaglum, M.D., Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 99 2:00 p.m.-5:00 p.m.
Room 356, Level 3, Convention Center

TOWARD A NEUROBIOLOGY OF DISSOCIATION

Chp.: Daphne Simeon, M.D.

- A Dissociation and Child Development**
Frank W. Putnam, Jr., M.D., Jennie Noll, Ph.D., Lisa Horowitz, Ph.D., Penelope Trickett, Ph.D., George Bonann, Ph.D.
- B Dissociation, Childhood Abuse, and Heart Rate in Delinquent Youths**
Cheryl Koopman, Ph.D., Victor G. Carrion, M.D., Shiv Sudhaker, B.A., Hans Steiner, M.D.
- C Depersonalization: HPA Axis Dysregulation and Association Cortex Dysfunction**
Daphne Simeon, M.D., Orna Guralnik, Psy.D., Erin A. Hazlett, Ph.D., Eric Hollander, M.D., Monte S. Buchsbaum, M.D.
- D Neural Responses to Emotional Expressions in Depersonalization**
Mary L. Phillips, M.D., Anthony S. David, M.D., Kate Pietura, M.D., Kathryl Abel, M.D., Nicholas Medford, M.D., Matt Allen, M.D., Mauricio Sierra, M.D.
- E Psychopharmacologic Insights into Dissociation**
John H. Krystal, M.D., Steven M. Southwick, M.D., Dennis S. Charney, M.D., Amit Anand, M.D., D. Cyril D'Souza, J. Douglas Bremner, M.D.

Discussant: Rachel Yehuda, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 100 2:00 p.m.-5:00 p.m.
Room 357, Level 3, Convention Center

STABILITY VERSUS CHANGE IN PERSONALITY TRAITS AND DISORDERS: A DEVELOPMENTAL VIEW

Chp.: Andrew E. Skodol II, M.D.
Co-Chp.: Jeffrey G. Johnson, Ph.D.

- A Linking Childhood Personality with Maladaptation Across Time**
Rebecca L. Shiner, Ph.D.
- B Change in Personality Disorder Symptoms Between Adolescence and Adulthood**
Jeffrey G. Johnson, Ph.D., Patricia R. Cohen, Ph.D., Andrew E. Skodol II, M.D.
- C The Longitudinal Study of Personality Disorders: Predictors of Change, Hints About Mechanism**
Mark F. Lenzenweger, Ph.D.
- D Two-Year Stability of Personality Disorder Criteria**
M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Shirley Yen, Ph.D., Andrew E. Skodol II, M.D., Leslie C. Morey, Ph.D., Mary C. Zanarini, Ed.D., Charles A. Sanislow, Ph.D.
- E Personality Stability/Change and the Natural Course of Axis II Personality Disorders**
Paul T. Costa, Ph.D.

Discussant: John C. Perry, M.D.

SYMPOSIUM 101 2:00 p.m.-5:00 p.m.
Grand Salon Sections 7 & 10, Street Level, Hilton

BULIMIA NERVOSA: RECENT RESEARCH FINDINGS IN BIOLOGY AND TREATMENT

Chp.: Allan S. Kaplan, M.D.
Co-Chp.: David C. Jimerson, M.D.

- A Binge Eating, Mood Regulation, and 5HT Function in Bulimia Nervosa**
David C. Jimerson, M.D., Barbara E. Wolfe, Ph.D., Erand Metzger, M.D.
- B Eating Disorders: Genes or Jeans?**
Walter H. Kaye, M.D., Guido Frank, M.D.
- C Psychobiology of Satiety in Bulimia Nervosa**
B. Timothy Walsh, M.D.
- D Cognitive-Behavior Therapy and Pharmacotherapy in the Treatment of Bulimia Nervosa**
Allan S. Kaplan, M.D.
- E New Treatment Approaches for Bulimia Nervosa**
James E. Mitchell, M.D.
- THIS SESSION WILL BE AUDIOTAPED.**

SYMPOSIUM 102 2:00 p.m.-5:00 p.m.
Grand Salon Sections 9 & 12, Street Level, Hilton

BPD: INTEGRATING MIND AND BODY

Chp.: Marcia K. Goin, M.D.

- A Heterogeneity Within BPD**
John M. Oldham, M.D., Andrew E. Skodol II, M.D., Donna S. Bender, Ph.D.

(Continued on next page)

B Emotion, Motivation, and the Borderline Personality: A Neurobiology Perspective
Regina Pally, M.D.

C Psychoanalytic Perspectives on BPD
John F. Clarkin, Ph.D.

D Cultural Perspectives on the Borderline Personality
Leslie A. Horton, M.D.

Discussants: Sherwyn M. Woods, M.D., C. Robert Cloninger, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 103 2:00 p.m.-5:00 p.m.

Grand Salon Sections 13 & 16, Street Level, Hilton

INTEGRATING CLINICAL RESEARCH WITH CLINICAL PRACTICE: NATIONAL INSTITUTE OF MENTAL HEALTH EFFECTIVENESS TRIALS

Chp.: Gary S. Sachs, M.D.

Co-Chp.: Michael E. Thase, M.D.

A National Institute of Mental Health Approaches to Intervention Trials
Barry D. Lebowitz, Ph.D.

B The Systematic Treatment Enhancement Program for Bipolar Disorder
Gary S. Sachs, M.D., Michael E. Thase, M.D., Leslie F. Leahy, Ph.D., Jennifer Conley, M.A., Andrew A. Nierenberg, M.D., Phillip Lavori, Ph.D., Michael H. Allen, M.D.

C Sequenced Treatment Alternatives to Relieve Depression (STAR * D)
A. John Rush, M.D.

D Effectiveness Trials of Antipsychotic Drugs
Jeffrey A. Lieberman, M.D., Lon S. Schneider, M.D., Joseph McEroy, M.D., Pierre Pariot, M.D., Scott Stroup, M.D., John Adiao, M.D., Barry D. Lebowitz, Ph.D.

Discussants: Barry D. Lebowitz, Ph.D., Kenneth Z. Altshuler, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 104 2:00 p.m.-5:00 p.m.

Grand Salon Sections 19 & 22, Street Level, Hilton

NEW ANTIDEPRESSANTS: LIGHT AT THE END OF THE TUNNEL?

Chp.: Mark A. Demitrack, M.D.

Co-Chp.: John F. Greden, M.D.

A Unmet Need: What Justifies the Search for a New Antidepressant?
John F. Greden, M.D.

B Methodological Challenges in the Study of New Antidepressants
John H. Greist, M.D.

C Is There Room to Improve Monoamine-Based Therapies?
Mark A. Demitrack, M.D.

D Beyond Monoamine-Based Therapies: Clues to New Approaches
Phil Skolnick, Ph.D.

Discussant: David J. Kupfer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 105 2:00 p.m.-5:00 p.m.

Elmwood Room, Third Floor, Hilton

CHANGING PERSPECTIVES FOR PSYCHIATRIC DIAGNOSIS: IMPLICATIONS FOR THERAPEUTIC INNOVATION

Chp.: Eric D. Caine, M.D.

A Alzheimer Disease Subsyndromes
Peter V. Rabins, M.D.

B Psychiatric Syndromes in Alzheimer's Disease: Cause or Effect?
Brian Lalor, M.D.

C FDA Perspective: Psychiatric Syndromes in Alzheimer's Disease
Thomas P. Laughren, M.D.

D Development of Psychiatric Treatments: Industry Challenges and Opportunities
Alan F. Breier, M.D., Jamie S. Street, M.D.

E Policy and Psychopharmacology: A Collaboration Paradigm That Meets Public Health Needs
Rick A. Martinez, M.D.

F Shifting Paradigms: Promoting Research
Jason T. Olin, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 106 2:00 p.m.-5:00 p.m.

Belle Chasse Room, Third Floor, Hilton

HOW PSYCHIATRY DEFINES EVIL

Chp.: Michael M. Welner, M.D.

A Psychiatry's Efforts to Define and Understand Evil
Michael M. Welner, M.D.

B Personality and Evil: Psychiatric Understanding
Michael H. Stone, M.D.

C Psychological Testing and Evil

Bruce Ebert, Ph.D.

D The Depravity Scale: Development and Potential in Assessment

Michael M. Welner, M.D.

E Determining Evil: Psychiatry, Theology, or Both?

Reverend James LeBar

Discussants: Laurence R. Tancredi, M.D., Ralph Slovenko, L.L.B.

THIS SESSION WILL BE AUDIOTAPED.



Photo courtesy of Alex Demyan NOMCVB

2001 ANNUAL MEETING

TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS

1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
5. Dissociative Disorders
6. Eating Disorders
7. Mental Retardation (Child/Adolescent/Adult)
8. Mood Disorders
9. Personality Disorders
10. Schizophrenia and Other Psychotic Disorders
11. Sexual and Gender Identity Disorders
12. Sleep Disorders
13. Somatoform Disorders
14. Other Disorders Not Listed Above

PRACTICE AREAS/SETTINGS

15. Psychiatric Administration and Services: Public, Private, and University
16. Other

SUBSPECIALTY AREAS OR SPECIAL INTERESTS

17. Addiction Psychiatry
18. Biological Psychiatry and Neuroscience
19. Brain Imaging
20. Child and Adolescent Psychiatry and Disorders
21. Consultation-Liaison and Emergency Psychiatry
22. Cross-Cultural and Minority Psychiatry
23. Diagnostic Issues
24. Epidemiology
25. Ethics and Human Rights
26. Forensic Psychiatry
27. Genetics
28. Geriatric Psychiatry
29. Neuropsychiatry
30. Psychiatric Education
31. Psychiatric Rehabilitation

32. Psychoanalysis
33. Psychoimmunology
34. Research Issues
35. Social and Community Psychiatry
36. Stress
37. Suicide
38. Violence, Trauma, and Victimization

TREATMENTS

39. Behavior and Cognitive Therapies
40. Combined Pharmacotherapy and Psychotherapy
41. Couple and Family Therapies
42. Group Therapy
43. Individual Psychotherapies
44. Psychopharmacology
45. Other Somatic Therapies
46. Treatment Techniques and Outcome Studies

OTHER ISSUES

47. Computers
48. Creativity and the Arts
49. Electronic Medical Records
50. Gender Issues
51. Health Services Research
52. Information Technology
53. Internet
54. Lesbian/Gay/Bisexual/Transgender Issues
55. Managed Care and Health Care Funding
56. Men's Health Issues
57. Political Questions
58. Professional and Personal Issues
59. Religion, Spirituality, and Psychiatry
60. Resident and Medical Student Concerns
61. Presidential Theme: Mind Meets Brain: Integrating Psychiatry, Psychoanalysis, Neuroscience
62. Stigma/Advocacy
63. Telepsychiatry
64. Virtual Reality
65. Women's Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this *Program Book* to obtain further details about the session.

DISORDERS	Page #
TOPIC 1: AIDS AND HIV-RELATED DISORDERS	
MEDIA PROGRAM	
50 The Andre Show	98
SCIENTIFIC AND CLINICAL REPORT	
51 Seriously Mentally Ill Persons Who Are HIV Positive	49
SYMPOSIA	
10 Treating the Psychiatrically Ill HIV Patient	31
52 Psychotherapeutic Aspects of HIV	60
WORKSHOPS - COMPONENTS	
49 The Use of Anabolic and Androgenic Steroids in HIV Disease	96
54 More Alive than Dead: Changing Strategies in HIV Psychotherapy	101
TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS	
CLINICAL CASE CONFERENCE	
4 Assessment of Prognostic Factors in the Alcoholic Patient	68
COURSES	
24 Office-Based Treatment of Opiate Dependent Patients	7
28 Dual Diagnosis: Basic Principles of Successful Intervention	8
62 Dealing with Resistance in Addiction Patients	40
INDUSTRY-SUPPORTED SYMPOSIUM	
14 Alcoholism and Bipolar Disorder: Treatment Options Circa 2001	6
LECTURE	
12 Imaging Brain Dysfunction in Substance Abuse	46
MEDIA PROGRAMS	
16 Methamphetamine: From the Streets of San Diego	42
17 Drinking Apart: Families Under the Influence	43
SCIENTIFIC AND CLINICAL REPORTS	
23 Longitudinal Predictors of Adolescent Alcohol Disorder Onset	23
24 Delirium Tremens: Diagnosis, Misdiagnosis, and Terminology	23
SYMPOSIA	
82 Update on Treatment of Stimulant Abuse	87
91 When a Substance Abuser Presents in Your Office: What Do You Do?	103
WORKSHOP - COMPONENT	
41 How to Enhance Motivation in Patients with Substance Abuse Problems	79
WORKSHOPS - ISSUES	
9 Sleep Problems in Dual-Diagnosis Patients: Physiology and Management	19
23 Alcoholism Pharmacotherapy: A Case-Based Review for Clinicians	25
43 Ecstasy and the Rave Scene: A Canadian Perspective	45
50 Psychiatric Adverse Events During Rebatron Treatment of Hepatitis-C	46
121 Should Substance Abuse Treatment Be Coerced?	101

TOPIC 3: ANXIETY DISORDERS	Page #
COURSE	
31 Shame and Social Anxiety Disorder	8
FORUM	
7 Trauma, PTSD, and Personality Disorders: Understanding the Connections	52
INDUSTRY-SUPPORTED SYMPOSIA	
7 PTSD: Clinical Characteristics and Treatment Options	3
21 Critical Questions in Anxiety Disorders	10
22 Management of Anxiety: An International Perspective	11
37 Images of Anxiety: A New Look at GAD and PTSD	64
40 Clinical Challenges in Anxiety, Part 1	67
40 Clinical Challenges in Anxiety, Part 2	93
SCIENTIFIC AND CLINICAL REPORTS	
17 PTSD Versus Panic Disorder: Differences in HPA Axis/Noradrenergic Functioning	23
18 Beyond One-Year Imipramine Maintenance in Panic Disorder with Agoraphobia	23
19 Social Phobia Treatment Survey	23
25 Cigarette Smoking and Risk for Anxiety Disorders	23
SYMPOSIA	
4 PTSD: A Biopsychosocial Approach	30
63 The Psychiatric Consequences of Stress	62
TOPIC 4: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)	
COURSES	
47 Dementia: Advanced Diagnosis and Treatment	15
80 Psychiatric Aspects of Epilepsy	68
MEDIA PROGRAMS	
34 Grace	75
36 Something Should Be Done About Grandma Ruthie	75
TOPIC 5: DISSOCIATIVE DISORDERS	
SYMPOSIUM	
99 Toward a Neurobiology of Dissociation	105
TOPIC 6: EATING DISORDERS	
COURSES	
21 Therapeutic Interventions in Eating Disorders	7
101 Multimodal Treatment of Eating Disorders	94
SYMPOSIA	
8 Eating Disorders: New Features and New Treatments	31
32 Physiology and Behavior: The Connection in Eating Disorders	55
45 Feeding, Eating, and Eating Disorders: The Development of Disordered Eating	58
68 State Versus Trait Disturbances Found in Eating Disorders: Recent Findings	84
101 Bulimia Nervosa: Recent Research Findings in Biology and Treatment	105

TOPIC 7: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)

COURSE

- 88 Assessment and Treatment of Patients with Mental Retardation 68

WORKSHOP - ISSUE

- 8 Towards a Rational, Integrated Treatment Approach to Mentally Retarded and Developmentally Disabled Patients 19

TOPIC 8: MOOD DISORDERS

COURSES

- 27 Evidence-Based Treatment of SAD: Focus on Light Therapy 8
42 Using Humanities to Understand Mood Disorders 14
54 Anticonvulsants in Bipolar Disorder 27
93 Understanding and Treating Bipolar Disorder Today: An Update of Goodwin and Jamison's Manic-Depressive Illness 81

DISCUSSION GROUPS

- 8 Screening and Treating Depression in Primary Care: Let's Be Realistic! 41
14 Bipolar Disorder in Children and Adults: Clinical and Research Issues 69

INDUSTRY-SUPPORTED SYMPOSIA

- 2 Advances in the Treatment of Depression in Women: Beyond Clinical Lore 2
4 To Switch or Augment? Contemporary Approaches to Resistant Depression 3
8 Symptomatic and Functional Recovery: Attainable Goals in Treating Depression? 5
10 To Work and to Love: Focus on Quality of Life in Mood and Anxiety Disorders 5
13 Issues in the Long-Term Treatment of Depression 6
16 Providing Complete Treatment for Patients with Bipolar Disorder 8
23 Treatment-Resistant Depression Across the Life Span 11
24 Neurobiology, Depression, and the Specificity of Treatment Response 11
27 Optimizing Treatment Outcomes in Patients with Chronic Depression, Part 1 13
27 Optimizing Treatment Outcomes in Patients with Chronic Depression, Part 2 39
30 Mood and Anxiety Disorders in Understudied Populations, Part 1 13
30 Mood and Anxiety Disorders in Understudied Populations, Part 2 39
31 Weighing the Options for Managing Bipolar Depression, Part 1 13
31 Weighing the Options for Managing Bipolar Depression, Part 2 39
38 Responding to the Challenge of Treating Bipolar Disorder 64
42 Treatment of Depression in Women: From Acute Remission to Sustained Recovery, Part 1 67
42 Treatment of Depression in Women: From Acute Remission to Sustained Recovery, Part 2 93
43 Depression: Gender, Age, and Special Populations, Part 1 67
43 Depression: Gender, Age, and Special Populations, Part 2 93
45 Bipolar Spectrum Disorders: U.S. and European Perspectives 90

MASTER EDUCATOR CLINICAL CONSULTATIONS

- 7 Adult Patients with Comorbid Mood and Personality Disorders 42
14 Depression, Antidepressants, and Sexual Dysfunction: Differential Diagnosis, Avoiding, Treating 70

RESEARCH CONSULTATION

- 1 Mood Disorders 48

REVIEW OF PSYCHIATRY: SECTION 1

- Treatment of Recurrent Depression: A Call to Arms 29

SCIENTIFIC AND CLINICAL REPORTS

- 3 Sildenafil Citrate Effectively Treats Erectile Dysfunction in Men Who Have Been Successfully Treated for Depression 22
7 Dreaming Contributes to Adaptation in the Depressed: A Review 22
9 Training Primary Care Physicians in the Diagnosis and Treatment of Depression 22
26 Does Medical Comorbidity Impact the Severity of Depression and Its Treatment? 23
27 Treatment-Resistant Depression and Axis I Comorbidity 24
28 The Complex Comorbidity Between Bipolar Illness and OCD: Clinical Implications and Treatment Outcome 24
59 Perceptions and Impact of Bipolar Disorder: How Far Have We Really Come? 50
60 Unipolar Compared with Bipolar Depression: Similar Depressive Subtypes 50
61 Cognitive Function in Euthymic Bipolar Patients, Schizophrenics, and Controls 50
69 Illness Beliefs of Depressed Chinese Americans in Primary Care 76
70 Depression in College Students in Bombay 76
86 The Response of Psychotic-Like Symptoms to Fluoxetine in Nonpsychotic MDD 77
87 Predictors of Stable Personality Disorders in Remitted Depressed Outpatients 77
88 Personality Disorders in Psychotic Major Depression 78
110 A Simple Screen to Identify Postpartum Major Depression 100
111 Interpersonal Psychotherapy for Antepartum Depression: A Controlled Trial 100
112 Diminished Prolactin Secretion and Response to Fluoxetine Treatment 100

SYMPOSIA

- 23 Results from the Texas Medication Algorithm Project (TMAP) 34
31 The Role of Antidepressants in the Treatment of Bipolar Disorder: Pro and Con 55
34 Clinical Issues in Bipolar Disorder: The Stanley Foundation Bipolar Network 55
41 Bipolar Disorder: Current Guidelines, Practices, and Effectiveness Research 57
47 Treatment Pathways (Algorithms) in Managing Depression 59

WORKSHOP - ISSUE

- 15 A University Depression-Management Program 19

TOPIC 9: PERSONALITY DISORDERS

COURSES

- 5 Disorders of the Self: Differential Diagnosis and Treatment 1
6 The Practical Management of Personality Disorder 1
55 Personality Disorders in the Workplace 27
83 Dialectical Behavior Therapy and Partial Hospital in the Difficult-to-Treat Patient 68
87 Partial Hospitalization for Patients with BPD 68
89 Psychotherapy of Borderline Personality 69

MASTER EDUCATOR CLINICAL CONSULTATION

- 18 BPD: Considerations of the Cultural Context in Evaluation and Treatment 95

MEDIA PROGRAMS

- 11 Girl, Interrupted: The Film and the Book 28
38 Between the Lines 76

SCIENTIFIC AND CLINICAL REPORTS

- 20 Psychiatric Treatment of Borderline Patients Followed for Four Years 23
21 Predictors of Outcome in a 27-Year Follow-Up of BPD 23
22 Confirmatory Factor Analysis of DSM-IV Schizotypal Personality Disorder Criteria 23

SYMPOSIA

	Page #
24 Field Testing Dimensional Models for DSM-V Axis II	35
64 Findings from Multisite Collaborative Longitudinal Study of Personality	83
72 European Perspectives on the Biology of Personality Disorders	85
79 Psychobiology and Pharmacotherapy of BPD	87
92 Treatments Reducing Personality Dysfunction	103
96 Bipolar Depression	104
100 Stability Versus Change in Personality Traits and Disorders: A Developmental View	105
102 BPD: Integrating Mind and Body	105

WORKSHOPS - ISSUES

36 Cognitive Therapy for Personality Disorders	45
79 International Problems with Personality Disorders in the Workplace	73
92 Update on the Practice Guideline on BPD	79

TOPIC 10: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

INDUSTRY-SUPPORTED SYMPOSIA

9 Critical Decisions in the Lifetime Treatment of Schizophrenia	5
11 Meeting the Challenge of Schizophrenia and Co-Occurring Addictions	5
15 Treating Psychotic Disorders: What Is the State of the Art?	8
26 Moving Towards a More Comprehensive Management of Patients with Schizophrenia	11
36 Men, Women, and Schizophrenia: Does Anatomy Determine Destiny?	63
41 A New Era for Managing Psychosis: Rebuilding Lives for Patients and Families, Part 1	67
41 A New Era for Managing Psychosis: Rebuilding Lives for Patients and Families, Part 2	93

MEDIA PROGRAMS

4 Out of My Mind	17
6 Means of Grace	17
37 Through Madness	76
47 The Talented Mr. Ripley	91

RESEARCH ADVANCES IN MEDICINE

Schizophrenia and the Thalamus: A New Paradigm	43
--	----

SCIENTIFIC AND CLINICAL REPORTS

35 What Predicts Functioning Across 10 Years of Schizophrenic Illness?	24
36 Perinatal Brain Damages and Slower Development Interact as Risks for Psychosis	24
37 Social Sequels of Mental Disorders in the 1966 North Finland Birth Cohort	24
53 Placebo-Controlled Trial of Omega-3 Fatty Acid in Schizophrenia	49
54 Atypical Antipsychotics and Hostility in Schizophrenia: A Double-Blind Study	49
55 Factors Associated with Medication Adherence in Persons with Schizophrenia	49

SYMPOSIA

2 Risk Factors for Schizophrenia and Prevention	29
3 New Approaches to Improve Long-Term Treatment Adherence in Schizophrenia	29
65 Update on Deficit Schizophrenia	83
85 Quality of Life in Patients with Schizophrenia: Research In Europe and the Americas	88
90 Management of Schizophrenia with Comorbid Disorders	102
93 Social Anxiety in Schizophrenia Assessment and Treatment	103
98 Reducing Duration of Untreated First Psychosis: The Treatment and Intervention in Psychosis Study (TIPS)	104

WORKSHOP - ISSUE

12 Clozapine Augmentation in Refractory Schizophrenia	19
---	----

TOPIC 11: SEXUAL AND GENDER IDENTITY DISORDERS

COURSE

90 The Assessment and Treatment of Child Molesters	69
--	----

DISCUSSION GROUP

10 Treating Sexual Dysfunction in the 21st Century	46
--	----

MEDIA PROGRAM

14 The Remarkable Story of John/Joan	28
--------------------------------------	----

RESEARCH CONSULTATION

3 Sexual Dysfunction	99
----------------------	----

SCIENTIFIC AND CLINICAL REPORTS

2 Correlation Between Patient Self-Assessment of Erectile Function and the International Index of Erectile Function (IIEF-5)	22
4 Psychotropic-Induced Sexual Dysfunction Among Outpatients	22

SYMPOSIUM

33 Evidence-Based Management of SSRI Antidepressant-Associated Sexual Dysfunction	55
---	----

WORKSHOP - ISSUE

20 Recent Advances in Female Sexual Medicine	20
--	----

TOPIC 12: SLEEP DISORDERS

COURSE

13 Irresistible Sleep: Narcolepsy Update	2
--	---

INDUSTRY-SUPPORTED SYMPOSIA

1 Sleep: A Window on Mind and Brain	2
39 Current and Future Management of Insomnia and Psychiatric Illnesses	64
47 Excessive Daytime Sleepiness: Evaluation and Management in Psychiatry	90

TOPIC 13: SOMATOFORM DISORDERS

COURSE

76 The Evaluation and Management of Pain	53
--	----

MASTER EDUCATOR CLINICAL CONSULTATION

19 Patients Who Somatize	95
--------------------------	----

REVIEW OF PSYCHIATRY: SECTION 5

Psychiatry Update: Somatoform and Factitious Disorders	83
--	----

SYMPOSIUM

88 Psychocutaneous Medicine	89
-----------------------------	----

TOPIC 14: OTHER DISORDERS NOT LISTED ABOVE

COURSES

53 ADD in Adults	27
63 Advanced Assessment and Treatment of ADD	40

(Continued on next page)

TOPIC INDEX

SYMPOSIA		Page #
25	ADHD: A Life Cycle Perspective	35
57	Voyeurism in the New Millennium: A Prime-Time Obsession?	61

WORKSHOP - ISSUE

113	Asperger's Disorder: From Quandary to Quagmire	97
-----	--	----

PRACTICE AREAS/SETTINGS

TOPIC 15: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY

COURSES

16	Current Coding and Documentation Requirements	6
45	Personnel Management for Clinicians/Managers	15
70	Outcomes: Use of Rating Scales	41

DISCUSSION GROUPS

9	Academic-Public Psychiatry: Thriving and/or Surviving	41
11	The Psychiatrist as an Administrator/Manager	46
16	Administrative Psychiatry: Leaderless Leadership	69

INDUSTRY-SUPPORTED SYMPOSIUM

19	Chemical Restraints: Clinical, Research, and Ethical Implications	9
----	---	---

LECTURE

16	Surviving Organizational Change	69
----	---------------------------------	----

SCIENTIFIC AND CLINICAL REPORTS

11	Reducing Restraint and Seclusion: One Hospital's Experience	22
12	Reducing Restraint Use in a Public Psychiatric Hospital	22
13	Factors Influencing the Psychiatric Emergency Room	22
50	College Students' Perceptions of Self and Others' Risk for HIV	49

SYMPOSIA

6	A Department of Psychiatry's Extensions into the Community	30
40	The Use of Force in Psychiatry: When Is It Helpful and When Is It Not? Part I	57
83	Politics of Administrative Relationships in Psychiatry	87
89	The Use of Force in Psychiatry: When Is It Helpful and When Is It Not? Part II	89

WORKSHOPS - COMPONENTS

14	RBRVS Coding and Documentation Update	25
33	Developing a Statewide Psychiatric Disaster Plan	71
40	New Regulatory Requirements for Seclusion and Restraints	78
45	The Administrative Psychiatry Credential	79
51	Practice Guidelines, Standards, and Quality Indicators: APA Initiatives	96
52	Psychiatric Discharge in the Criminal Justice System	96

WORKSHOPS - ISSUES

65	Crisis-Stabilization Units: Alternative to Hospital or de facto Hospital?	72
91	Private Practice and the World Psychiatric Association	79
100	Prospering: Market Dynamics in the New Political Crucible	96
105	Administrative Psychiatry: How to Prepare to Meet the Challenge	97
111	The Importance of Psychiatric Management for Inpatient Care and Treatment	97
115	Personal and Interpersonal Difficulties in Organizational Settings	97
118	Oxymoron: Fine University and So-So Public Care	98
127	Leadership in Organizational Transitions	101

TOPIC 16: OTHER		Page #
-----------------	--	--------

CLINICAL CASE CONFERENCE

3	Vocal Cord Dyskinesia: A Dynamic Interchange Between Medicine and Psychiatry	68
---	--	----

FORUMS

2	Why Harry? Why Now? Understanding the Harry Potter Phenomenon	26
3	Daycare: Impact on Kids	26
6	Presidential Forum: Confidentiality and Medical Record Privacy in the 21st Century	52
9	The Pharmaceutical Industry and the APA: Controversies and Approaches	80
11	Virtual Psychiatry: From Humanoid to Cyberspace, the Future of Psychiatry, and Virtual Reality	102

ROUND TABLE DISCUSSION

The Future of Behavioral Healthcare	17
-------------------------------------	----

SYMPOSIUM

50	How to Launch a Successful Private Practice: Part III	59
----	---	----

WORKSHOPS - COMPONENTS

26	How to Launch a Successful Private Practice: Part I	44
31	How to Launch a Successful Private Practice: Part II	51

SUBSPECIALTY AREAS OR SPECIAL INTERESTS

TOPIC 17: ADDICTION PSYCHIATRY

COURSE

73	Achieving Effective Dual Diagnosis Treatment	52
----	--	----

DISCUSSION GROUP

18	Treating Addicted Patients with Psychiatric Comorbidity	74
----	---	----

FORUM

4	Substance Abuse in the Severely Mentally Ill	51
---	--	----

SCIENTIFIC AND CLINICAL REPORTS

32	Polymorphisms in the 5HT Transporter Gene and Cocaine Dependence	24
33	Addictions Psychiatry and Treatment Outcomes in a Therapeutic Community	24

SYMPOSIA

15	Addictions: Gambling and Substance Abuse: Cutting-Edge Treatment	32
60	Reduction of Chronic Benzodiazepine Use: A Myth and Reality	61

WORKSHOPS - COMPONENTS

15	XTC and K, Etc.: The New ABC's of Adolescent Substance Use	25
25	Novel Career Developments in Addiction Psychiatry	44

WORKSHOPS - ISSUES

74	Marijuana and Psychiatry: Dilemmas for the Clinician	73
108	Biobehavioral Integration of Addiction Treatment	97
129	Hallucinogens: Illicit Use, Religious Use, and Current Psychiatric Research	101

TOPIC 18: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

COURSES

- | | |
|---|----|
| 1 Behavioral Neuroanatomy: An Introduction | 1 |
| 82 Behavioral Neuroanatomy: An Introduction | 68 |

INDUSTRY-SUPPORTED SYMPOSIUM

- | | |
|--|---|
| 5 The New Biology of Depression and Antidepressant Treatment | 3 |
|--|---|

LECTURES

- | | |
|--|----|
| 2 Genes, Synapses, and Long-Term Memory | 16 |
| 6 Bipolar Disorder: Using Affective Neuroscience to Bridge the Gap Between Children and Adults | 27 |
| 9 Gene Therapy and Its Potential Applications to Psychiatry | 41 |
| 15 How Matter Becomes Imagination: From Brain Dynamics to Consciousness | 69 |
| 22 Gut Sensation: Serotonin and Brain-Bowel Crosstalk | 94 |

MEDICAL UPDATE

- | | |
|---|----|
| 1 Can Stem Cells from Bone Marrow Serve As a Fountain of Youth for the Brain? | 22 |
|---|----|

RESEARCH ADVANCES IN MEDICINE

- | | |
|--|----|
| Neurosteroids in Psychiatry | 43 |
| The Expanding Role of CNS Electrical Stimulation | 43 |

SCIENTIFIC AND CLINICAL REPORTS

- | | |
|--|----|
| 48 Cerebral Hemodynamics and Depression in the Elderly | 49 |
| 106 Use of Intravenous Lorazepam in Patients with Catatonia-Like Syndromes | 99 |

SYMPOSIUM

- | | |
|---|----|
| 5 Perimenopause, Mood, and Cognition: The Role of Reproductive Hormones | 30 |
|---|----|

TOPIC 19: BRAIN IMAGING

RESEARCH ADVANCES IN MEDICINE

- | | |
|--|----|
| New Direction in In Vivo Brain Imaging | 43 |
|--|----|

REVIEW OF PSYCHIATRY: SECTION 4

- | | |
|-------------------------------------|----|
| Brain Imaging in the New Millennium | 71 |
|-------------------------------------|----|

WORKSHOP - ISSUE

- | | |
|---|----|
| 84 Neuroimaging: Integrating Bioethics with Clinical and Basic Sciences | 74 |
|---|----|

TOPIC 20: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

COURSES

- | | |
|---|----|
| 20 ADD in Children and Adolescents | 7 |
| 59 Fundamental Knowledge Needed for Clinical Work with Infants and Toddlers | 40 |

DISCUSSION GROUP

- | | |
|---|----|
| 4 Risk Factors for Adolescent Psychotic Disorders | 20 |
|---|----|

INDUSTRY-SUPPORTED SYMPOSIA

- | | |
|--|----|
| 46 Advances in ADHD: Navigating Comorbidity | 90 |
| 48 An Evidence-Based Medicine Approach to Pediatric Psychiatry | 90 |

MEDIA PROGRAMS

- | | |
|---|----|
| 31 No Fears... No Tears: Thirteen Years Later | 70 |
| 32 In Grandma's Hands | 70 |
| 44 Come Back Jack | 82 |
| 45 Autism: A World Apart | 82 |
| 46 A Dyslexic Family Diary | 82 |

REVIEW OF PSYCHIATRY: SECTION 2

- | | |
|----------------------------------|----|
| PTSD in Children and Adolescents | 43 |
|----------------------------------|----|

SCIENTIFIC AND CLINICAL REPORTS

- | | |
|--|-----|
| 14 Some Long-Term Consequences of Orphanage Care | 23 |
| 16 Self-Comforting Strategies Used by Adolescent Males and Females | 23 |
| 41 Diagnostic Efficiency of BPD Criteria in Hospitalized Adolescents | 48 |
| 42 Overlap Between Child Depressive Inventory and Projectives in Uncovering a Child's Depression | 48 |
| 43 Comorbidity in Conduct Disorder: Gender and Age Differences | 48 |
| 83 Adderall and Methylphenidate in ADHD | 77 |
| 84 Comparison of Duration of Effect of OROS MPH with MPH TID in ADHD Children | 77 |
| 85 Once-Daily-Dosed SLI381 for Pediatric ADHD | 77 |
| 115 Suicidal Youth with First Emergency Room Presentations: Six-Month Outcome Predictions | 100 |

SYMPOSIA

- | | |
|--|----|
| 7 Arab Perspective on Child and Adolescent Psychiatry | 30 |
| 22 Frontiers of Depression in Children and Adolescents | 34 |
| 77 Childhood-Onset Depression: A Multigenerational Multidisciplinary Study | 86 |

WORKSHOPS - COMPONENTS

- | | |
|---|----|
| 10 Students and Schools at Risk: Where Is the Violence? | 18 |
| 12 A Model Infant Psychiatry Program for Abuse and Neglect Cases | 24 |
| 16 Mission Impossible: Treating the Undiagnosable Child | 25 |
| 50 Treatment of Child and Adolescent Victims of Crime: New Guidelines from California | 96 |

WORKSHOPS - ISSUES

- | | |
|---|----|
| 14 From Play Therapy to Pills and Back Again: Child Treatment in the Decade of the Mind | 19 |
| 49 The Emperor's New Clothes: Polypharmacy and Kids | 46 |
| 64 Nature and Nurture: Developing Comprehensive Services for Young Children | 72 |
| 81 Does Johnny Need Methylphenidate? | 73 |

TOPIC 21: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

COURSES

- | | |
|--|----|
| 38 Families and Medical Illness: An Integrative Treatment Approach | 14 |
| 41 Medical and Psychiatric Implications of Cytochrome P450: An Update | 14 |
| 46 Delirium and Other Acute Confusional States: Diagnosis and Management | 15 |
| 79 Innovative Therapeutics in Consultation-Liaison Psychiatry | 67 |

DISCUSSION GROUPS

- | | |
|---|----|
| 6 Why Hospitalize? | 41 |
| 12 Psychiatry in Primary Care: What Do We Want to Accomplish? | 46 |
| 17 Psychiatric Drugs in the Medically Ill | 69 |
| 20 Psychiatry at the Medical Interface: Opportunities in the New Millennium | 74 |
| 22 Hepatitis C: What Every Psychiatrist Needs to Know | 94 |

(Continued on next page)

LECTURE

- | | | |
|----|--|----|
| 21 | Psychiatry for the Medically Ill: What Is It? What Was It? What Has It Done? | 81 |
|----|--|----|

MASTER EDUCATOR CLINICAL CONSULTATION

- | | | |
|----|--|----|
| 3 | Psychiatric Problems in Medical/Surgical Patients | 16 |
| 11 | Optimizing Your Relationship with Primary Care Physicians: Ways to Maximize Your Referral Network and Satisfaction | 47 |

SCIENTIFIC AND CLINICAL REPORTS

- | | | |
|----|---|----|
| 8 | A Systematic Review of Depression as a Risk Factor for Coronary Disease | 22 |
| 10 | Screening for Depression in Head and Neck Cancer Patients | 22 |
| 31 | A Case of Ketamine Psychosis | 24 |

SYMPOSIUM

- | | | |
|----|---|----|
| 75 | Critical Issues in Early Intervention of the Psychosis Prodrome | 85 |
|----|---|----|

WORKSHOPS - COMPONENTS

- | | | |
|----|---|-----|
| 27 | Studies on Integration of Mental Health and Primary Care in the Veterans Administration | 44 |
| 53 | Coping with Medical Illness | 101 |

WORKSHOP - ISSUE

- | | | |
|-----|--|-----|
| 122 | Mind Meets Brain in Practice: The McLean Multidisciplinary Neuropsychiatric Consultation Service | 101 |
|-----|--|-----|

TOPIC 22: CROSS-CULTURAL AND MINORITY PSYCHIATRY

COURSE

- | | | |
|----|---|----|
| 74 | DSM-IV Cultural Formulations: Diagnosis and Therapy | 52 |
|----|---|----|

FORUM

- | | | |
|----|--|-----|
| 10 | Mental Illness: Surgeon General's Report on Culture, Race, and Ethnicity | 102 |
|----|--|-----|

MASTER EDUCATOR CLINICAL CONSULTATIONS

- | | | |
|----|--|----|
| 17 | Cultural Issues in Clinical Case Formulation | 75 |
| 20 | Crucial Issues in Training of International Medical Graduates As Psychiatrists | 95 |

MEDIA PROGRAMS

- | | | |
|----|---------------------------------------|----|
| 1 | The Joy Luck Club | 12 |
| 22 | The Mirror Lied | 48 |
| 23 | Struggle for Identity | 48 |
| 26 | The Italian Gardens of South Brooklyn | 54 |
| 27 | Delta Jews | 54 |
| 28 | A Wok in Progress | 54 |

SCIENTIFIC AND CLINICAL REPORTS

- | | | |
|----|---|----|
| 38 | Body Dissatisfaction and BMI Across Ethnic Groups | 48 |
| 40 | Hypersexuality in Hasidic-Jewish Inpatients | 48 |
| 68 | Depression in Chinese Primary Care Patients | 76 |

SYMPOSIA

- | | | |
|----|---|-----|
| 28 | Cultural Identity and Quality of Life | 35 |
| 44 | Cultural Influences on the Psychiatric Treatment of Women | 58 |
| 94 | Clinical Applications of Cultural Psychiatry | 103 |

WORKSHOPS - COMPONENTS

- | | | |
|----|---|----|
| 2 | Continuing the Dialogue on Racism and Psychopathology | 17 |
| 21 | The Color of Death: Suicide and Its Myths in Special Populations | 44 |
| 23 | Fear, Fantasy, and the Reality of Psychiatric Practice in the New Millennium for IMGs | 44 |
| 43 | Hispanics and Alternative Medicine | 79 |

WORKSHOPS - ISSUES

- | | | |
|----|--|----|
| 25 | Narcissism Below Sea Level: A Dutch View of Future Gay Developments | 25 |
| 47 | Clinical Paths Across Cultural and Racial Barriers: How to Do It | 45 |
| 54 | Folktales and Movies: Using the Media to Learn About Culture | 51 |
| 66 | Treating Haredi (Very Orthodox) Jews in the United States and Israel | 72 |

TOPIC 23: DIAGNOSTIC ISSUES

LECTURE

- | | | |
|----|--|----|
| 17 | Psychiatric Diagnosis: Are We Prepared for a New Millennium? | 70 |
|----|--|----|

SCIENTIFIC AND CLINICAL REPORT

- | | | |
|----|---|----|
| 81 | Post-Traumatic Spectrum Disorders: A Radical Revision of PTSD | 77 |
|----|---|----|

SYMPOSIA

- | | | |
|-----|--|-----|
| 35 | Substance Use and Psychosis: Tackling the Chicken-and-Egg Problem | 56 |
| 105 | Changing Perspectives for Psychiatric Diagnosis: Implications for Therapeutic Innovation | 106 |

WORKSHOP - ISSUE

- | | | |
|----|---|----|
| 85 | Implementing Multidisciplinary Diagnosis and Management of Pseudoseizures | 74 |
|----|---|----|

TOPIC 24: EPIDEMIOLOGY

SCIENTIFIC AND CLINICAL REPORT

- | | | |
|----|---|----|
| 89 | Lifetime and 12-Month Prevalence of Mental Illness in Chile | 78 |
|----|---|----|

TOPIC 25: ETHICS AND HUMAN RIGHTS

COURSES

- | | | |
|----|---|----|
| 26 | Medical Ethics 101 | 7 |
| 72 | Psychiatrists as Teachers of Boundaries to Physicians | 52 |

DISCUSSION GROUPS

- | | | |
|----|---|----|
| 2 | Psychiatric Aspects of End-of-Life Care | 15 |
| 5 | The Professional Ethic and Current Psychiatric Practice | 20 |
| 13 | Ethical Issues in Psychiatric Practice | 46 |
| 24 | Evidence-Based Ethics Issues in Psychiatry | 98 |

SCIENTIFIC AND CLINICAL REPORTS

- | | | |
|----|---|----|
| 77 | Willingness and Competence of Depressed Inpatients to Consent to Research | 77 |
| 90 | Race and Psychiatry in Post-Apartheid South Africa | 78 |

SYMPOSIA

- | | | |
|----|--|----|
| 42 | Teaching Ethics to Psychiatric Residents | 57 |
| 46 | National Bioethics Advisory Commission (NBAC) Revisited: Implementation of Independent Capacity Assessment | 58 |

WORKSHOP - COMPONENT

- | | | |
|----|---|----|
| 19 | The Individual Versus the State: Patients' Privacy and Abuses of Psychiatry | 44 |
|----|---|----|

WORKSHOPS - ISSUES

- | | | |
|----|--|----|
| 10 | Nonsexual Boundary Violations | 19 |
| 37 | Balancing Power in the Psychiatrist-Patient Alliance for Therapeutic Success | 45 |
| 96 | Confidentiality and Sexual History Issues in Sexual Harassment Cases | 80 |

TOPIC 26: FORENSIC PSYCHIATRY

Page #

COURSES

18	The Psychiatrist as Expert Witness	6
56	Sexual Harassment: Psychological and Legal Aspects	27
57	The Detection of Malingered Mental Illness	40
60	Introduction to Correctional Psychiatry	40
81	The Forensic Assessment of Competency to Make a Decision (In Spanish)	68
85	Insanity Defense Evaluations	68
94	Contemporary Malpractice Liability	81

FORUM

1	Along the Death Trail: Inside the Mind of an Execution Team	26
---	---	----

SCIENTIFIC AND CLINICAL REPORTS

65	Can Psychologists Help Psychiatrists in Assessing Sex Offenders?	50
66	Heterogeneity of Psychopathology Among Juvenile Sexual Offenders	50
67	Dangerous Offender Statutes: The Canadian Perspective	50
79	False Confessions: The Bane of Criminal Justice	77
107	Schizophrenia and Mass Homicide: Who, What, and Why from Case Histories	100
108	Behavioral Treatment of the Aggressive Mentally Ill Inmate	100
109	Disability Evaluations in the U.S. Air Force	100

SYMPOSIA

36	Black Rage, White Supremacists, Psychiatry, and Criminal Law	56
97	Psychiatric Practice in Prison	104
106	How Psychiatry Defines Evil	106

WORKSHOP - COMPONENT

20	Legal, Ethical, and Practice Implications of Dot-Com Psychiatry	44
----	---	----

WORKSHOPS - ISSUES

31	Current and Future Trends in Psychiatry and Employment Law	25
58	Clinical and Forensic Aspects of Sexual Harassment in Schools	51
75	How to Detect Deception	73
77	Current and Future Trends in Psychiatry and Criminal Law	73
103	Implementing Outpatient Commitment in New York City: A Forensic Perspective	96
120	Community Reintegration for Severely Mentally Ill Patients Leaving Jail	98
131	Crimes of Infamy: Personal Insights	102

TOPIC 27: GENETICS

SCIENTIFIC AND CLINICAL REPORTS

56	Schizophrenia and Bipolar Disorder: Specific and Common Susceptibility Loci	49
57	Comorbid Panic Disorder as a Marker of Genetic Heterogeneity in Bipolar Disorder	49

SYMPOSIUM

39	Personality and Psychopathology: A Behavior-Genetic Perspective	57
----	---	----

TOPIC 28: GERIATRIC PSYCHIATRY

INDUSTRY-SUPPORTED SYMPOSIA

18	Advances in the Treatment of Geriatric Depression	9
25	Psychosis in Alzheimer's Disease: New Knowledge, New Treatment Strategies	11
33	Recognition and Treatment of Alzheimer's Disease: Practical Lessons from New Research	63

MASTER EDUCATOR CLINICAL CONSULTATION

16	The Agitated Geriatric Patient	75
----	--------------------------------	----

MEDIA PROGRAMS

Page #

18	The Personals: Improvisations on Romance in the Golden Years	47
19	Bringing the Circle Together	47
20	A One and a Two	47
21	As Time Goes By	47
35	Choices and Challenge: Caring for Aggressive Adults	75
49	How to Live to Be 100	95

SCIENTIFIC AND CLINICAL REPORT

47	Antipsychotics in Geriatric Psychiatric Patients	49
----	--	----

SYMPOSIUM

38	The Use of Cholinesterase Inhibitors in Clinical Practice	56
----	---	----

WORKSHOPS - COMPONENTS

30	Genetics, Ethnicity, and Alzheimer's Disease	50
44	Successful Models of Psychiatric Care in the Nursing Home	79

WORKSHOPS - ISSUES

80	For Better or for Worse: Spouses of Patients with Dementia	73
104	Memory Screening Program for Community-Dwelling Elders: A Practical Approach	96

TOPIC 29: NEUROPSYCHIATRY

COURSES

34	Video Review of Neuropsychiatric Conditions	8
48	Traumatic Brain Injury: Neuropsychiatric Assessment	15
49	Advances in Neuropsychiatry	15
51	The Evaluation and Identification of the Major Dementias	26
58	ECT in Neurological Disorders	40

LECTURE

18	Consciousness Integrated and Differentiated	74
----	---	----

MASTER EDUCATOR CLINICAL CONSULTATION

9	Treatment of Patients with Psychiatric Symptoms Complicated with Neurologic Illness	47
---	---	----

SYMPOSIA

74	Psychiatric Management in Neurological Disease	85
78	Psychiatric Disturbances in Parkinson's Disease: Recognition and Management	86
86	Catatonia and NMS: Past, Present, and Future	88

WORKSHOPS - ISSUES

11	Neuroanatomy and Neurophysics of the Unconscious	19
34	Neuropsychotherapy	44

TOPIC 30: PSYCHIATRIC EDUCATION

COURSES

17	Balint Group: Understanding the Doctor and Patient	6
23	Advanced Interviewing Techniques	7
25	Pass the Boards! The Part II Oral Exam	7
43	Teaching Psychiatry? Let Hollywood Help!	14
52	Integrative Psychotherapy Supervision: Basic Tools	27
61	Training in the Use of the Positive and Negative Syndrome Scale	40
77	Use of the Humanities in Psychiatric Education	53
102	How to Practice Evidence-Based Psychiatry	94

LECTURE

4	Beyond DSM IV: From Appearances to Essences	20
---	---	----

(Continued on next page)

TOPIC INDEX

MASTER EDUCATOR CLINICAL CONSULTATION

- 4 Using Cinema to Enhance the Teaching of Psychiatry and Behavioral Sciences (ADMSEP Council on Education Master Teacher) 21

SCIENTIFIC AND CLINICAL REPORT

- 62 Using the "Moral Accounting" Metaphor to Teach Psychodynamic Formulations 50

SYMPOSIUM

- 61 Reform, Resident Training, Contemporary Practice, and the Public's Health 62

WORKSHOPS - COMPONENTS

- 8 Make the Media Work for You: Television Interview Tips and Techniques 18
28 Putting Your Best Foot Forward: The Art of Self-Presentation 50
29 Career Development in Academic Psychiatry for Asian Psychiatrists 50
42 A Collaborative Effort to Define and Measure Psychiatric Competencies 79

WORKSHOPS - ISSUES

- 19 How to Develop a Lecture 20
22 Teaching Behavioral Sciences to Family Doctors 20
28 Mental Health Education for the Primary Care Physician 25
42 The Use of the Mock Trial in Psychiatric Staff Education 45
48 Beyond the Lecture Hall: Integrating Educational Concepts 45
53 The Consumer Perspective in Psychiatric Education 51
93 Foundation of the World Federation of Psychiatric Trainees 80
107 How to Give a More Effective Lecture: Pith, Punch, and Polish 97
110 Teaching the Clinical Essentials: The Role of the Psychiatrist 97
130 Rehabilitation Education: International Comparisons 102

TOPIC 31: PSYCHIATRIC REHABILITATION

WORKSHOP - ISSUE

- 114 Psychiatric Disability: The Role of Psychiatric Assessment 97

TOPIC 32: PSYCHOANALYSIS

LECTURE

- 20 The Science of Psychotherapy: Legacy of Psychoanalysis 81

MEDIA PROGRAMS

- 2 The Conformist 12
24 Fat Chance 52
25 Mr. Death 54
30 Sankofa 65

SCIENTIFIC AND CLINICAL REPORT

- 102 Integrating Psychoanalysis and Neurobiology in the Treatment of Migraines 99

WORKSHOP - ISSUE

- 17 Two Dogmas of Psychoanalysis 20

TOPIC 33: PSYCHOIMMUNOLOGY

SCIENTIFIC AND CLINICAL REPORT

- 58 Antibodies to Prothrombin and Thrombin in First Psychotic Episode of Schizophrenia 49

TOPIC 34: RESEARCH ISSUES

Page #

ADVANCES IN RESEARCH

- From Clinical Trials to Clinical Practice: Can You Get There From Here? 20

COURSES

- 64 Doing Research on a Shoestring Budget 40
96 Increasing the Reliability of Outcome Measures in Psychiatric Clinical Trials 93

FORUM

- 8 Diagnostic and Statistical Manual (DSM) Research Planning Process 52

LECTURE

- 14 An Example of Neuropsychanalytic Research: The Right Hemisphere Syndrome 53

MEDICAL UPDATE

- 4 Bringing the Space Station to the Clinical Bedside: Next Generation Bioproducts and Drug Testing Modalities Developed Using Studies in Space 99

NEW RESEARCH SESSIONS

- 1 Young Investigators' Poster Session 17
2 Young Investigators' Oral/Slide Session 27
3 Young Investigators' Oral/Slide Session 27
4 Young Investigators' Oral/Slide Session 27
5 Poster Session 36
6 Poster Session 52
7 Poster Session 63
8 Poster Session 80
9 Poster Session 89
10 Poster Session 102

SCIENTIFIC AND CLINICAL REPORT

- 101 Overweight Status of Parents: A Longitudinal Study of Offspring Adiposity 99

WORKSHOPS - ISSUES

- 30 Funding Opportunities from the National Institutes of Health 25
117 Strategies for Promoting Collaborative Research in Developing Countries 98

TOPIC 35: SOCIAL AND COMMUNITY PSYCHIATRY

COURSE

- 78 Individual and Community Interventions in Disaster 53

SCIENTIFIC AND CLINICAL REPORTS

- 92 Mental Health and Stress in Highly Educated Employees 78
93 The Next Step Group: Multimodal Strategies in Group Therapy for Serious Illness 78

SYMPOSIUM

- 37 The Biopsychosocial Model: Social Perspectives 56

WORKSHOPS - COMPONENTS

- 6 Psychiatrists in the Schools: Reducing the Impact of Trauma 18
37 Mind, Brain, and Environment: How Can Clinicians Address Social Ills? 72

WORKSHOPS - ISSUES

- 56 Community Psychiatry: How to Avoid Being a Psychotech Slave Chained to the Pill Box 51
99 Mental Health in a Jail 96

TOPIC 36: STRESS

MEDIA PROGRAMS

39	Fighting Grandpa	80
40	Men Like My Father, Families Like My Own	80
41	What Do I Tell My Children?	80
51	At Death's Door	98

SCIENTIFIC AND CLINICAL REPORT

94	Psychiatric Issues in Space: Implications from the Space Shuttle/MIR Program	78
----	--	----

SYMPOSIUM

48	The Trauma of Bereavement: A New Paradigm	59
----	---	----

WORKSHOPS - ISSUES

1	Psychiatric Illness and the Workplace	18
116	Stress Disability Assessment and Compensation Seeking: Elusive Truth	97

TOPIC 37: SUICIDE

COURSE

92	Suicidal Patients in the Managed Care Era: Assessment and Risk Management	81
----	---	----

INDUSTRY-SUPPORTED SYMPOSIUM

3	Suicide Risk and Bipolar Disorder: Neurobiology and Treatment	2
---	---	---

MEDIA PROGRAM

5	A Journey Back: Coping with a Parent's Suicide	17
---	--	----

RESEARCH CONSULTATION

2	Youth Suicide Research	76
---	------------------------	----

SCIENTIFIC AND CLINICAL REPORTS

74	Suicide Mortality in the Ukraine in 1999	77
75	Decreasing Suicide Mortality in Hungary: What Are the Main Causes?	77
76	Suicide Risk Factors Among Treated Patients with BPD	77
113	Childhood Sexual Abuse and Suicidal Behavior in BPD	100
114	Multiplicity of Suicide Attempts in Bipolar Disorder	100

SYMPOSIA

19	How Can Psychiatrists Impact the Problem of Suicide at the Community Level?	33
21	Achieving Comprehensive Care for the Suicidal Individual	34

WORKSHOPS - ISSUES

18	The Impact of Suicide on Clinicians	20
109	Achieving Comprehensive Care for Chronically Suicidal Individuals	97

TOPIC 38: VIOLENCE, TRAUMA, AND VICTIMIZATION

COURSES

35	Risk Assessment for Violence	14
39	Assessment and Treatment of Traumatic Grief	14

INDUSTRY-SUPPORTED SYMPOSIA

32	The Impulsive Aggressive Spectrum: Challenging Populations, Part 1	14
32	The Impulsive Aggressive Spectrum: Challenging Populations, Part 2	39

LECTURE

1	Stalkers and Their Victims	10
---	----------------------------	----

MEDIA PROGRAMS

7	Stolen Lives	21
15	Invisible Revolution	42
42	Generations of Violence	82
43	Colors Straight Up	82

SCIENTIFIC AND CLINICAL REPORTS

39	Creativity as a Resource for Moving from Trauma Toward Connection	48
52	HIV, Health Care, and Mental Health Outcomes of Childhood Disruption	49
80	Violence and Clinical Symptoms in Different Diagnoses	77

SYMPOSIA

12	PTSD in Women: Integrating Mind and Brain in Treatment	32
14	Trauma and the Life Cycle: Multidisciplinary Perspectives	32
16	Childhood Sexual Abuse: Perpetrators and Victims	33
70	Psychopathological Pathways Following Traumatic Life Experience	84

WORKSHOPS - COMPONENTS

18	Prediction of Dangerousness in Patients	43
22	The Cost of PTSD: A Crisis We Can Prevent	44

WORKSHOPS - ISSUES

16	Disaster Psychiatry: LAPA Flight 3142	19
27	Understanding the Dynamics of Abusive Relationships	25
29	Intergenerational Aspects of Trauma and Aggressive Behavior	25
67	A Review of Patient Assaults on Staff	72
98	Domestic Violence in the Psychiatric Emergency Department	96

TREATMENTS

TOPIC 39: BEHAVIOR AND COGNITIVE THERAPIES

CONTINUOUS CLINICAL CASE CONFERENCES

1	Cognitive-Behavioral Therapy: A Case of Comorbid Major Depression, Personality Disorder, and Episodic Alcohol Abuse	15
2	Cognitive-Behavioral Therapy: A Case of Comorbid Major Depression, Personality Disorder, and Episodic Alcohol Abuse	40

COURSES

9	Cognitive-Behavior Therapy: An Overview	1
37	Cognitive Therapy for Severe Mental Disorders	14
71	Cognitive Therapy: The Basics	52

WORKSHOPS - ISSUES

41	Graphotechnology: How to Save Time and Reveal Clues in Handwriting Analysis	45
52	Cognitive-Behavioral Treatment: Prolonged Exposure for Treatment of Trauma Victims	51
106	Cognitive-Behavioral Therapy Training for Residents: How to Teach, Measure, and Attain Resident Competency	97

TOPIC 40: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

DISCUSSION GROUP

21	Integrating Pharmacotherapy and Psychotherapy in PTSD	74
----	---	----

(Continued on next page)

SCIENTIFIC AND CLINICAL REPORT

- | | | |
|----|---|----|
| 71 | A 45-Year Experience with OCD Patients Who Fear Harming Someone or Fear Harm or Humiliation to Themselves | 76 |
|----|---|----|

SYMPOSIUM

- | | | |
|----|---|----|
| 53 | A Most Common Challenge: The Dual-Diagnosed Patient | 60 |
|----|---|----|

WORKSHOP - ISSUE

- | | | |
|----|---|----|
| 63 | Psychodynamics in Treatment-Refractory Depression | 72 |
|----|---|----|

TOPIC 41: COUPLE AND FAMILY THERAPIES

COURSE

- | | | |
|----|---|----|
| 44 | The Multiple Perspectives of Couples Therapy: Skills and Techniques | 15 |
|----|---|----|

WORKSHOP - ISSUE

- | | | |
|-----|---|----|
| 119 | Multisystemic Therapy: Integrating Psychiatry | 98 |
|-----|---|----|

TOPIC 42: GROUP THERAPY

COURSE

- | | | |
|----|---|----|
| 40 | Outpatient Group Therapy for the Seriously Mentally Ill | 14 |
|----|---|----|

SYMPOSIUM

- | | | |
|----|--|----|
| 29 | Group Therapy for Breast Cancer: International Randomized Trials | 36 |
|----|--|----|

WORKSHOPS - ISSUES

- | | | |
|-----|---|-----|
| 21 | The Art of Healing: Use of Art Therapy and Group Psychotherapy for Treatment of Traumatized Immigrant Populations | 20 |
| 112 | Group Psychotherapy with Substance Abusers | 97 |
| 123 | Community Meetings on an Inpatient Psychiatric Unit | 101 |

TOPIC 43: INDIVIDUAL PSYCHOTHERAPIES

CLINICAL CASE CONFERENCES

- | | | |
|---|---|----|
| 1 | A Neuroscience Perspective on Transference in Psychotherapy | 15 |
| 2 | A Vital Role for Psychotherapy in Neuropsychiatry: Body Image Anxiety in Huntington's Disease | 40 |

COURSES

- | | | |
|----|---|----|
| 14 | Short-Term Dynamic Psychotherapy: Theories and Techniques | 2 |
| 15 | Interpersonal Psychotherapy | 6 |
| 33 | Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method | 8 |
| 68 | Working with Emotion in Psychotherapy | 41 |
| 69 | Interpersonal Psychotherapy | 41 |
| 75 | The Advanced Practice of Psychotherapy | 53 |
| 99 | Limit Setting with Psychiatric Patients | 94 |

FORUM

- | | | |
|---|---|----|
| 5 | Here's Looking at You! Self-Reflection in Psychotherapy | 51 |
|---|---|----|

LECTURE

- | | | |
|---|--|----|
| 5 | Why Play on Only Three Strings, When You Can Play on the Whole Violin? The Importance of Psychotherapy Education | 21 |
|---|--|----|

MASTER EDUCATOR CLINICAL CONSULTATIONS

- | | | |
|----|---|----|
| 10 | Psychotherapy and Therapist Self-Disclosure | 47 |
| 12 | Psychotherapy for Women | 70 |

SCIENTIFIC AND CLINICAL REPORT

- | | | |
|----|--|----|
| 72 | Solving the Riddle of Working Through in Psychotherapy | 77 |
|----|--|----|

SYMPOSIA

- | | | |
|----|--|----|
| 9 | Psychodynamic Psychotherapy: Contemporary Issues | 31 |
| 17 | Psychotherapy in the Americas | 33 |
| 49 | Psychotherapy Viewed from a Basic Science Social Brain Perspective | 59 |

WORKSHOPS - ISSUES

- | | | |
|-----|--|----|
| 3 | Working-Through in Psychotherapy | 18 |
| 45 | Dynamic Therapy with Self-Destructive BPD | 45 |
| 69 | What Ever Happened to Psychotherapy? | 73 |
| 102 | If Therapy Is Needed But Not Available, What Should We Do? | 96 |

TOPIC 44: PSYCHOPHARMACOLOGY

ADVANCES IN RESEARCH

- | | |
|---|----|
| New Molecules, New Markets: Update on Clinical Drug Development | 20 |
| Drug Discovery in the Year 2000 and Beyond | 20 |

COURSES

- | | | |
|----|--|----|
| 2 | Drug Treatment of Schizophrenia | 1 |
| 4 | Neuroleptic-Induced Movement Disorders: Assessment and Treatment | 1 |
| 91 | Melatonin and Light Treatment of SAD, Sleep and Other Body Clock Disorders | 81 |

INDUSTRY-SUPPORTED SYMPOSIA

- | | | |
|----|--|----|
| 6 | Glucose Control and Diabetes Mellitus During Antipsychotic Treatment | 3 |
| 17 | MAOIs Revisited | 9 |
| 20 | Atypical Antipsychotic Drugs: How Do They Work? | 9 |
| 29 | Comparing Atypical Antipsychotic Therapies: Making Sense of the Data, Part 1 | 13 |
| 29 | Comparing Atypical Antipsychotic Therapies: Making Sense of the Data, Part 2 | 39 |
| 34 | Everyday Challenges in Managing Patients on Psychotropic Medications | 63 |
| 35 | Off-Label on the Table: Using New Pharmacological Agents | 63 |
| 44 | Plasticity as Efficacy? Neurotrophic Effects of Mood Stabilizers | 90 |

SCIENTIFIC AND CLINICAL REPORTS

- | | | |
|-----|---|----|
| 29 | Myotoxicity and Neurotoxicity During Clozapine Treatment | 24 |
| 30 | Olanzapine and NMS: Case Report and Literature Review | 24 |
| 44 | Sildenafil Citrate in SSRI Antidepressant Treatment Emergent Sexual Dysfunction | 48 |
| 45 | Do the SSRIs Make You "Better than Well"? | 48 |
| 46 | Cholesterol Levels Decrease with Fluoxetine Treatment of MDD | 49 |
| 82 | Open Study of Nefazodone in Depression with Anger Attacks | 77 |
| 95 | Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania | 78 |
| 97 | The Rising Prevalence of Antidepressant Treatment for U.S. Youth | 78 |
| 104 | Prolactin Levels in Patients Taking Risperidone and Ziprasidone | 99 |

SYMPOSIA

- | | | |
|-----|--|-----|
| 54 | Psychopharmacology of BPD | 60 |
| 62 | Psychotropic Use During Pregnancy and Lactation: More Data and Evolving Debate | 62 |
| 73 | An Eight-Week Randomized Trial of Fluvoxamine for Pediatric Anxiety Disorder | 85 |
| 104 | New Antidepressants: Light at the End of the Tunnel? | 106 |

WORKSHOP - ISSUE

- | | | |
|----|--|----|
| 38 | Ethnicity and Psychopharmacology: Recent Research Advances | 45 |
|----|--|----|

TOPIC 45: OTHER SOMATIC THERAPIES Page #

COURSES

- 36 ECT Practice Update 14
- 67 A Practical Approach to Herbs and Nutrients in Psychiatry 41

WORKSHOPS - ISSUES

- 61 Homeopathic Medicine and Psychiatry 72
- 71 Educating Patients and Families About ECT 73

TOPIC 46: TREATMENT TECHNIQUES AND OUTCOME STUDIES

COURSES

- 10 Basic Hypnosis: Principles and Applications 2
- 29 Dream Translation: One Empirically-Based Approach 8
- 65 Advanced Hypnosis: Applications in Psychiatry 41
- 86 The Psychosocial Management of Bipolar Disorder 68

MASTER EDUCATOR CLINICAL CONSULTATIONS

- 5 Medication and Psychodynamic Therapies: Can Treatments in Conflict Be Integrated? 21
- 13 Treatments Based on the Perspectives of Psychiatry 70

MEDICAL UPDATE

- 3 Will Medicalizing Obesity Treatment Improve Outcomes? 76

REVIEW OF PSYCHIATRY: SECTION 3

- Integrated Treatment: An Overview 54

SCIENTIFIC AND CLINICAL REPORTS

- 49 Integrating End-of-Life Care with Disease Management Programs 49
- 73 Telepsychiatry for Suicidal Outpatients: Lower Morbidity, Mortality, and Cost 77

SYMPOSIA

- 13 Psychiatry, the Interview, and Medical Outcomes 32
- 87 Advance Directives in Psychiatry: Treatment Research and End of Life 88
- 95 The Difficult-to-Treat Psychiatric Patient 104
- 103 Integrating Clinical Research with Clinical Practice: National Institute of Mental Health Effectiveness Trials 106

WORKSHOPS - ISSUES

- 33 Reinventing Deinstitutionalization in the 21st Century 44
- 90 Comparative Efficacy of Antidepressants and Psychotherapy for Depression 79
- 94 Eight-Day Treatment of Panic with Moderate to Severe Agoraphobia 80
- 124 Integrating Behavioral Health with Primary Care Through Disease Management 101

OTHER ISSUES

TOPIC 47: COMPUTERS

COURSE

- 12 The Only Computer Course You Will Ever Need 2

WORKSHOPS - ISSUES

- 6 E-Supporting Clinical Practice: Guidelines and the Psychiatric Research Network 19
- 26 Computer Odyssey 2001: Updates for New Computer Purchasers 25
- 97 Mobile Computing in Psychiatry with Personal Digital Assistants 96

TOPIC 48: CREATIVITY AND THE ARTS Page #

LECTURES

- 8 A Trip to the Moon and Beyond 37
- 19 Quills: The Marquis on the Marquee 75

MEDIA PROGRAMS

- 8 A Century of Satchmo 26
- 9 The Art of Being Human 26
- 10 Faces of the Hand 26
- 29 The Matrix 64
- 48 2001: A Space Odyssey 91

SCIENTIFIC AND CLINICAL REPORT

- 15 Familial Background and Literary Creativity 23

SYMPOSIUM

- 43 Music Therapy: Integrated Art and Science in Health Care 58

WORKSHOP - COMPONENT

- 11 Music in the Lives of Psychiatrists 24

WORKSHOPS - ISSUES

- 2 Schumann, Manic-Depressive Illness, and the Creative Process 18
- 46 Healing of Spirit and Body Through Dance After Trauma 45
- 55 Poems on Psychiatry 51
- 78 Using Hamlet to Learn About Teaching, Interviewing, and Therapeutic Interaction 73
- 88 The Portrayal of Psychiatry in Recent American Film 79

TOPIC 49: ELECTRONIC MEDICAL RECORDS

COURSE

- 32 Using Open Infrastructure for Outcome: A Customizable Web-Based Clinical and Research Record System 8

TELECOMMUNICATIONS PRESENTATIONS

- 4 Electronic Medical Record: Psychiatric Survival Tool for the Decade 62
- 5 The CAPER System: Patient Assessment and Treatment Planning Software 62
- 6 Booting Up Your Practice: Computerized Record Keeping in Psychiatry 63
- 8 The Impact of Electronic Psychiatric Records on Patients and the Doctor-Patient Relationship 71

TOPIC 50: GENDER ISSUES

LECTURE

- 13 What Do Women Really Want? 53

MASTER EDUCATOR CLINICAL CONSULTATION

- 1 Unique Gender Issues in All of Psychiatric Assessment and Treatment 16

SCIENTIFIC AND CLINICAL REPORTS

- 63 A Comparison of Evaluations of Male and Female Psychiatry Supervisors 50
- 118 The Doctor-Patient Relationship: Autonomy, Gender, and Preferred Physician Style 100

(Continued on next page)

TOPIC INDEX

SYMPOSIUM	Page #
66 Women's Resiliency to Adversity	83

WORKSHOPS - ISSUES	
24 Balancing Career and Family	25
125 Career Advancement for Women Psychiatrists: The Role of Mentorship	101

TOPIC 51: HEALTH SERVICES RESEARCH

SCIENTIFIC AND CLINICAL REPORTS	
91 The World Psychiatric Association: An International Survey of Urban Mental Health	78
99 A Systematic Review of Screening for Depression in Primary Care	99

SYMPOSIA	
11 New Findings on Psychiatric Practice: Access and Patterns of Care	31
56 Closing the Efficacy/Effectiveness Gap in Psychopharmacology	61

TOPIC 52: INFORMATION TECHNOLOGY

TELECOMMUNICATIONS PRESENTATIONS	
2 Use of a CD-ROM Multimedia Interactive System to Teach Interviewing Skills	43
7 Interfaced Information Systems: Networked Office	63

WORKSHOPS - ISSUES	
73 Distance-Learning Options	73
89 Making the Media Work for You	79

TOPIC 53: INTERNET

COURSES	
3 An Introduction to Using the World Wide Web	1
19 Making a Home on the World Wide Web	7

TELECOMMUNICATIONS PRESENTATIONS	
1 Evaluation of a Web-Based Intervention for Depression in Pregnant Women	43
11 Internet Algorithms for the Pharmacotherapy of Depression: Java Version	71
12 Caught in the Web: Sex, Suicide, and Addictions on the Internet	89

TOPIC 54: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES

MEDIA SESSIONS	
3 Boys Don't Cry	17
52 Looking for Common Ground	102
53 Summer in My Veins	102

WORKSHOPS - COMPONENTS	
7 Psychiatric Views on Talking About Homosexuality to Kids	18
34 Transgender Issues: Female to Male	71
47 Finding Common Ground: Gays and Lesbians Together	95

WORKSHOP - ISSUE	
5 Hospital-Based Program for Lesbian, Gay, Bisexual, and Transgender Patients	19

TOPIC 55: MANAGED CARE AND HEALTH CARE FUNDING

COURSE	
98 How to Be More Effective with Managed Care "Doc-to-Doc" Reviews	94

SCIENTIFIC AND CLINICAL REPORTS	Page #
116 Managed Care and Malpractice Liability Today	100
117 Parity Disparity: Mental Health Insurance Coverage Decision Making	100

SYMPOSIUM	
84 Outreach to Business: The American Psychiatric Association Business Initiative	88

WORKSHOP - COMPONENT	
3 Medicare and Medicaid: Problems and Progress	18

TOPIC 56: MEN'S HEALTH ISSUES

INDUSTRY-SUPPORTED SYMPOSIUM	
12 Men Over 50: An Endangered Species	6

SYMPOSIUM	
59 Body Image Disorders in Men	61

TOPIC 57: POLITICAL QUESTIONS

COURSE	
8 Personality and Political Behavior	1

SYMPOSIUM	
67 Clinical Issues and Ethical Concerns Regarding Attempts to Change Sexual Orientation: An Update	84

WORKSHOP - COMPONENT	
46 Responses to the Surgeon General's Report on Mental Health	95

TOPIC 58: PROFESSIONAL AND PERSONAL ISSUES

COURSES	
11 Treating Medical Students and Physicians	2
22 Money Matters: Using Theory in Clinical Practice	7
100 Model Compliance Plan for Small Psychiatric Practices	94

DISCUSSION GROUP	
23 Life Balance as a Psychiatrist... Easier Said Than Done!	94

LECTURES	
10 Authentic Representation, Belonging, and the Narrative of Self-Identification	42
11 International Cooperation in Mental Health in the Americas: An Agenda for the New Millennium	46

SCIENTIFIC AND CLINICAL REPORTS	
78 Arthur Kronfeld: Professional and Personal Tragedy of a Great Psychiatrist	77
98 Popular Health Advice: A Historical Survey	99

SYMPOSIUM	
30 Professional Boundaries and Training in Psychiatry: A Comprehensive View	54

WORKSHOPS - COMPONENTS	
1 Physician Disability: Treatment, Insurance, and Conflicts	17
9 To Retire or Not to Retire, That Is the Question	18
17 Defining Boundaries in Medical Education: Ethics Applied by Role Playing	43
32 Legal Issues in Psychiatric Private Practice	51
38 Career Change for Psychiatrists and Patients Young and Old	72

WORKSHOPS - ISSUES		Page #
35	Women's Leadership and Career Development	45
39	Children of Psychiatrists	45
57	Early Career Psychiatrist: Role of Mentorship	51
62	Treating Physicians: Cutting-Edge Issues	72
70	Working with Small Businesses	73
72	Do I Need an MBA to Transform My Career?	73
76	Mid-Career Psychiatry: Staying Fresh and Creative	73

TOPIC 59: RELIGION, SPIRITUALITY AND PSYCHIATRY

COURSES

50	Issues in Transpersonal Psychiatry	15
66	Transpersonal Psychiatry: Clinical Applications	41

LECTURE

3	Existential Psychotherapy and Religious Consolation: Convergence and Divergence	16
---	---	----

SCIENTIFIC AND CLINICAL REPORT

34	Spirituality in the Detoxification Phase of Substance Abuse Treatment	24
----	---	----

SYMPOSIA

58	Beyond Mind and Brain: Considering the Patient's World View	61
69	Model Residency Programs on Religion and Spirituality	84
81	The Role of Religion in the Lives of Our Patients: Clinical Approaches	87

WORKSHOP - COMPONENT

13	The Interface Between Religion and Existential Psychotherapy	25
----	--	----

WORKSHOPS - ISSUES

60	Spiritual/Religious Assessment in Clinical Work	72
68	Spiritual Struggles: The New Priority in Treatment	73

TOPIC 60: RESIDENT AND MEDICAL STUDENT CONCERNS

DISCUSSION GROUPS

7	Consultation-Liaison Psychiatry: Career and Subspecialization Opportunities at the Medicine-Psychiatry Interface (For Residents Only)	41
15	Career Opportunities in Women's Mental Health (For Residents Only)	69
25	My Experiences as a Military Psychiatrist (For Residents Only)	98

MASTER EDUCATOR CLINICAL CONSULTATIONS

8	The Journey: Exploring Learning with Our Students (AAP Council on Education Master Teacher)	42
15	Teaching Psychopathology to Medical Students (AADPRT Council on Education Master Teacher)	75

RESIDENT'S SESSION

Meet the Experts: Sunny Side-Up	14
---------------------------------	----

SCIENTIFIC AND CLINICAL REPORTS

64	Training in Depression and Suicide: A National Survey of Primary Care	50
100	Medical Students' Mental and Physical Health Promotion: A North American School Survey	99

SYMPOSIUM

1	Residents and the Pharmaceutical Industry: How to Maintain Ethical Integrity	29
---	--	----

WORKSHOPS - COMPONENTS		Page #
4	The Great Beyond: Making Career Decisions at the End of Residency Training	18
5	The Interpretation of Dreams: Fantasy and Reality in Residency Training	18
24	Stalking: The Psychiatric Trainee at Risk	44
35	Using Practice Guidelines in Residency Training	72
36	Psychiatry in the Neuroscience Curriculum: Promise and Peril	72
39	Career Choices in Psychiatry	78

WORKSHOPS - ISSUES

7	ABPN Update: Requirements for ABPN Examination	19
59	Students Discussing Why They Have Chosen a Psychiatric Career in 2000	51
83	Training IMG Residents: Challenges and Opportunities	74
101	Teaching Psychopharmacology to Residents Using Evidence-Based Algorithms	96

TOPIC 61: PRESIDENTIAL THEME: "MIND MEETS BRAIN: INTEGRATING PSYCHIATRY, PSYCHOANALYSIS, NEUROSCIENCE"

COURSE

7	Subjectivity: Crucial Key to Therapy and the Uniqueness of the Human Mind	1
---	---	---

PRESIDENTIAL SYMPOSIUM

The Royal Road Revisited: Dreams in the 21st Century	29
--	----

SCIENTIFIC AND CLINICAL REPORTS

5	Self, Object, and Neurobiology	22
6	Conceptual Integration of Mind and Brain in Philosophy and Psychiatry	22
103	Unremitting Depression: Cingulate Dysfunction and the Cleft-Self on Trial	99

SYMPOSIA

18	Mind and Brain: The Concepts of Psychiatry	33
20	Thinking About Mind and Brain: Psychoanalysts and Neuroscientists Converse: Part I	34
26	Exercise, Athletic Participation, and Mental Health: When It Works and When It Doesn't	35
51	Thinking About Mind and Brain: Psychoanalysts and Neuroscientists Converse: Part II	59
55	Psychoanalysis and Psychotherapy Long-Term Outcome	60
76	Mind/Brain, Reduction, and Schizophrenia	86

WORKSHOPS - ISSUES

32	Does the Mind Meet the Brain in Residency? And What About the Body?	44
51	How the Theory of Evolution Is Fundamental to Our Biopsychosocial Model	51
82	Treating PTSD Complicated by Medical Problems: Mind and Brain Meet Body	74
86	Beyond Reductionism: Clinical Implications	74
95	Mind Meets Brain in Family Therapy: Bridges for Healing	80
126	Subjectivity: Crucial Key to the Therapeutic Alliance	101
128	Mind and Brain Do Not Need to Be Integrated If We Don't Segregate Them in the First Place	101

TOPIC 62: STIGMA/ADVOCACY

COURSE

95	How to Combat the Stigma of Mental Illness	93
----	--	----

DISCUSSION GROUP

3	Psychiatrists in Mental Health Advocacy Groups	20
---	--	----

(Continued on next page)

TOPIC INDEX

MEDIA PROGRAMS

12	King Gimp	28
13	Soop on Wheels	28
33	Twitch and Shout	71

SYMPOSIUM

71	The World Psychiatric Association Global Program to Reduce the Stigma of Schizophrenia	85
----	--	----

WORKSHOP - ISSUE

87	Psychiatric Illness in Psychiatrists: Overcoming Stigma	79
----	---	----

TOPIC 63: TELEPSYCHIATRY

TELECOMMUNICATIONS PRESENTATION

3	Prison Telepsychiatry: Realities and Prospects	43
---	--	----

WORKSHOP - ISSUE

13	Making Telepsychiatry Work for Your System	19
----	--	----

TOPIC 64: VIRTUAL REALITY

LECTURE

23	Why We Will Spend Most of Our Time in Virtual Reality in the 21st Century	94
----	---	----

TELECOMMUNICATIONS PRESENTATIONS

9	Digital Phenomenology of Depression	71
10	Using Virtual Reality to Treat Acrophobia	71

TOPIC 65: WOMEN'S HEALTH ISSUES

ADVANCES IN RESEARCH

Lead Optimization and the Role of In Vitro and In Vivo in Testing	20
---	----

COURSES

30	Psychiatric Disorders in Pregnancy and Postpartum	8
84	Treatment Issues for Women in Minority Groups	68

DISCUSSION GROUPS

1	Treating Women Patients: What Clinicians Need to Know	15
19	Medicine, Marriage, and Motherhood	74

INDUSTRY-SUPPORTED SYMPOSIA

Page #

28	Women's Mental Health: Antidepressant Therapy During the Childbearing Years, Part 1	13
28	Women's Mental Health: Antidepressant Therapy During the Childbearing Years, Part 2	39

MASTER EDUCATOR CLINICAL CONSULTATIONS

2	The Psychiatric Aspects of Breast Cancer	16
6	Use of Psychotropic Drugs in Pregnancy and Lactation	21

MEDICAL UPDATE

2	Breast Cancer Prevention: An Example of Translational Research	48
---	--	----

SCIENTIFIC AND CLINICAL REPORTS

96	Risk of Postpartum Depression in Women with Pregravid Major Depression Disorder	78
119	Mood and Anxiety Disorders and Health of Multi-Ethnic Midlife Women	100
120	Topiramate in PMDD	100
121	Verapamil Effectiveness in Women with Bipolar Disorder	101

SYMPOSIA

27	Women's Mental Health: A Current Perspective	35
80	Special Topics in Women's Mental Health	87

WORKSHOPS - ISSUES

40	Women and Suicide: Hormones and Genes	45
44	Integrated Treatment Programs for Pregnant, Mothering Women and Their Children	45

PARTICIPANT INDEX

APA 154TH ANNUAL MEETING

A

Abdool, Steve S.	45
Abel, Gene G.	69
Abel, Kathryn	105
Abercrombie, Delrita	48
Aboraya, Ahmed S.	30
Abrams, Karen M.	83
Acker, Sara	33
Adams, Joyce	51
Addario, Dominick	24
Adiao, John	106
Adkins, Derrick	35
Adli, Mazda	59
Agras, W. Stewart	7, 31, 58, 99
Aguiari, Diletta	36
Agustines, Davin A.	22
Ahmed, Iqbal	104
Aist, Reverend Clark S.	16, 25
Akahane, Akihisa	29
Akerele, Evaristo O.	94
Akiskal, Hagop S.	24, 56, 86, 90, 104
Alaimalo, Ernest P.	73
Alarcon, Renato D.	33, 44, 52, 76
Albanese, Mark J.	60
Albucher, Ronald C.	18, 24
Alessi, Norman E.	1, 7, 43, 61, 71, 102
Alexopoulos, George S.	11
Alger, Ian E.	17, 47, 74, 80
Allen, Alice T.	24
Allen, James	98
Allen, Matt	105
Allen, Michael H.	106
Allsworth, Jennifer	83
Allwood, Clifford W.	78
Almeida, Osvaldo P.	30
Alpert, Jonathan E.	6, 23, 63, 77, 78
Altchuler, Steven I.	2
Alter, Carol L.	100
Altshuler, Kenneth Z.	19, 34, 106
Altshuler, Lori L.	9, 13, 39, 55, 56
Amador, Xavier	30, 103
Aman, Michael G.	90
Amin, Abdel F.	30
Amsterdam, Jay D.	9, 55
Anand, Amit	105
Ananth, Jambur V.	22, 76, 99
Anderson, Arnold	61
Anderson, Tanya R.	26
Andrews, Gavin	84
Andrews, Linda B.	51, 84
Andrus, Jason M.	44
Anik, David	103
Ansari, Rubaba	48
Appelbaum, Paul S.	9, 57, 58, 84
Arboleda-Florez, Julio E.	68, 85
Arce, A. Anthony	88
Ardizzone, Timothy D.	3
Arduini, Luca	50
Arlinghaus, Kimberly A.	73
Armstrong, Moe	51
Armstrong, Scott C.	14
Arnold, L. Eugene	77
Arroyo, William	43, 57
Aruguete, Mara	48
Ashley, Kenneth B.	18, 60, 101
Atdjian, Sylvia	87
Attia, Evelyn	58, 84

Aupperle, Peter M.	15
Autio, Karen A.	55
Azadian, Abbas	20, 51

B

Baab, Susan W.	101
Baca-Garcia, Enrique	45
Backlar, Patricia	89
Bagnell, Alexa L.	44
Bailey, Deborah	97
Bailey, Rahn K.	77, 99
Baker, Robert W.	78
Bakker, Stef L.M.	49
Balderson, Kenneth E.	34
Baldessano, Claudia	13
Baldessarini, Ross J.	3
Ballenger, James C.	64
Balon, Richard	22, 74
Balson, Paul M.	73
Banazak, Deborah A.	79
Banon, Elisabeth	60
Baptiste, Shirn	32
Barad, Mark G.	60
Barakat, Samia	52
Barber, Mary E.	95
Bardey, A. Sasha	96
Bardey, Alexander	43
Bark, Nigel M.	29
Barnes, Victoria	28
Barnhill, Jr., L. Jarrett	91
Baron, David A.	25
Barr, Cathy L.	86
Barr, Heather	96
Barrett, Claire	58
Barry, Kristen L.	43
Bartlik, Barbara D.	20
Basco, Monica A.	14
Batki, Steven L.	87
Battaglia, Marco	85
Battista, John R.	15
Bauer, Michael	59
Baum, Antonia L.	35
Bautista, Brigid B.	96
Baxter, Elizabeth A.	79
Beahrs, John O.	59
Beale, Rhonda J.R.	96
Beck, Cornelia K.	57
Beck, Judith S.	45, 54, 97
Beck, Stephen	61
Becker, Anne E.	58
Becker, Daniel F.	48
Becker, Judith	43
Beebe, Diane	19, 72
Beites, Fabio J.	87
Beitman, Bernard D.	51
Bell, Carl C.	17, 45, 56, 69, 102
Belsasso, Guido	51
Benca, Ruth M.	64
Bender, Donna S.	23, 35, 83, 87, 105
Benedek, David	45
Benedek, Elissa P.	10, 26, 51
Benkert, Otto	22
Benn, Andrea F.	50
Beresford, Thomas P.	68
Berganza, Carlos	33
Bergmans, Yvonne	34, 97

Berman, Laura	20
Bernstein, Carol A.	7, 14, 45
Bernstein, David P.	27, 103
Berrettini, Wade H.	24
Berry, Sally A.	9
Bertrand, Joseph M.	18
Bezzubova, Elena B.	77, 101
Bhanji, Nadeem	29
Bialer, Philip A.	84
Biederman, Joseph	77, 90
Bienstock, Carol	11
Biermann, Bernard J.	18, 25
Binder, Renee L.	9, 27, 43
Bingham, C. Raymond	41
Binkley, Mark	15
Bisaga, Katarzyna	58
Bishop, Leigh C.	61
Bissonnette, Luc	49
Bitran, Stella	23, 50
Bittman, Barry B.	58
Blais, Mark A.	31, 78
Blake, Lesley M.	49
Blamphin, John	18
Blanco-Jerez, Carlos	23
Bland, Irma J.	23, 36
Blehar, Mary	29, 35
Bleiberg, Kathryn	22
Blier, Pierre	3, 9
Bloch, Andrew	44
Bloch, Sydney	36
Bloom, Sandra L.	44
Bluestone, Harvey	80
Blum, Harold P.	29
Blume, Sheila B.	25, 97
Blumenfeld, Michael	18
Blumer, Dietrich P.	8
Bobulinski, Michelle	86
Bodkin, J. Alexander	9
Boellner, Samuel	77
Bogdanoff, Tod	100
Bogdanov, Irena	49
Bogunovic, Olivera J.	99
Bohn, Michael J.	25
Bohn, Paul B.	8
Boland, Robert J.	29
Boles, Myde	78
Bonannd, George	105
Bond, Michael P.	60
Bonde-Jensen, Anders	36
Bonstedt, Theodor	96
Book, Howard E.	8
Borenstein, Daniel B.	7, 10, 14, 29, 36, 52
Boronow, John J.	49
Borowich, Abba E.	72, 87
Borson, Soo	67
Bottonari, Kathryn A.	77, 78
Bouanani, Siham	49
Bouffard, Suzanne M.	78
Bourdel, Marie-Chantal	88
Bourgeois, James A.	100
Boutros, Nashaat N.	1, 56, 68
Boverman, Joshua F.	89
Bowden, Charles L.	29
Bowers, Jr., Malcolm B.	56
Bowers, Jr., Theron C.	63
Bowman, Marilyn L.	30
Bradford, John M.W.	69
Bradley, John C.	101
Bradley, Ronald J.	3

PARTICIPANT INDEX

Brady, Kathleen T.	3, 32, 93, 103
Brambilla, Francesca	55
Brandabur, Melanie	86
Branin-Rodriguez, Jo Ellen	104
Braunig, Peter	88
Breier, Alan F.	106
Breiter, Hans C.	74
Bremner, J. Douglas	33, 105
Brendel, David H.	22
Breslau, Naomi	30
Breteler, Monique M.B.	49
Breteler, Rien M.	62
Brink-Vanden, Wim	85
Brockman, Richard M.	22, 34
Brody, David S.	101
Brody, Julie	101
Bromberger, Joyce T.	100
Bromet, Evelyn	56
Brook, David W.	49, 97
Brown, Alan S.	29
Brown, Frank W.	50
Brown, Richard P.	41
Brown, Thomas E.	7, 27, 40
Brozovich, Thomas F.	81
Brunet, Aileen S.	50
Bryson, Sue	99
Buchanan, Robert W.	83
Buchsbaum, Monte S.	105
Buckley, Peter F.	64
Bunt, Gregory C.	7, 24
Buongiovanni, Annunziata	55
Burgess, Ann	73
Burgman, Frank D.	57
Burgoyne, Karl S.	98, 99
Burt, Vivien K.	13, 69
Burton, John K.	21
Burton, Robert W.	35
Burwell, Rebecca	58
Butler, Lisa	36
Butterfield, Marian I.	32, 50, 51, 81, 100
Buwalda, Victor J.A.	80
Buyse, Daniel J.	64

C

Caine, Eric D.	106
Calabrese, Joseph R.	27, 64
Calcedo-Barba, Alfredo	43, 68
Caldas de Almeida, Jose M.	88
Califa-Rice, Patrick	71
Caligiuri, Michael	1, 8
Caligor, Eve	29
Callahan, Jr., William E.	18, 44, 51, 59
Callicott III, Joseph H.	71
Canceil, Oliver J.	88
Cancro, Robert	102
Candilis, Philip J.	88, 89
Canive, Jose M.	77
Canterbury, Randolph J.	49, 77
Cappelleri, Joseph	22
Caracci, Giovanni	48, 78
Carlson, Gabrielle	25
Carlson, Robert	36
Carlson, Scott R.	57
Carpenter, Jr., William T.	58, 83
Carrasco, Jose L.	85
Carrillo, Maria C.	86
Carrion, Victor G.	105
Carroll, Brendan T.	88
Caraskadon, Mary A.	90
Carta, Mauro G.	88
Carter, Cameron S.	71
Carter, Debbie R.	44, 89, 98
Carter, Diana	8
Carver, Larry A.	43

Casey, Daniel E.	11, 12, 39
Casey, David A.	22
Cassano, Giovanni B.	49, 83, 103
Cassem, Edwin H.	67
Castle, David	61, 103
Caton, Carol L.M.	56
Cavanagh, Sarah R.	64
Cerfolio, Nina E.	58
Chacko, Chowallur D.	44
Chakravorthy, Nabonita	76
Chambers, Michael	22
Chan, Carlyle H.	2
Chan, Raymond	76
Chandler, Mark C.	77
Chandragiri, Satyanarayana	96
Chang, Jacquelyn B.	50, 76, 80, 82
Chapman, Joab	49
Charles, Sara C.	20, 96
Charney, Dennis S.	3, 52, 62, 105
Charters, Mallay	100
Chaskel, Roberto E.	33
Chaudhry, Zubaida	100
Chen, Emmie	35
Cheng, Keith	89
Cheng, T.	83
Chengappa, K.N. Roy	9
Cheong, Josepha A.	50
Cheung, A.	83
Chihabeddine, K.H.	31
Chinen, Allan B.	15
Cho, Samson J.	18, 44
Choi, Elaine	76
Chou, James C.Y.	7
Chozinski, Joseph P.	100
Chung, Christopher K.	22
Chung, Henry	58
Ciesla, Thomas K.	51, 78
Citrome, Leslie L.	49, 103
Clair, Alicia A.	58
Clark, David L.	1, 68
Clark, H. Westley	7
Clark, Michelle O.	17, 42, 68
Clark, Jr., Gordon H.	88
Clarke, David M.	36
Clarke, Greg	34
Clarkin, John F.	69, 106
Clary, Cathryn M.	5, 20
Classen, Catherine	36
Clayton, Anita L.H.	6, 35, 99
Clayton, Paula J.	48
Clemens, Norman A.	88
Cliche, Denis	49
Cloitre, Marylene	52
Cloninger, C. Robert	29, 35, 87, 106
Cloutier, Paula F.	100
Cobb, Thomas G.	18
Coccaro, Emil F.	87
Coconcea, Cristinel M.	24
Coconcea, Nicoleta	24
Coffey, C. Edward	15, 40
Coffman, Kathy L.	68
Cohen, Bruce J.	50, 77
Cohen, Carl I.	72
Cohen, Irvin M.	18
Cohen, Lee S.	2, 30, 62, 67, 78, 87, 93
Cohen, Lisa J.	33
Cohen, Patricia R.	23, 105
Cohn, Jeffrey	86
Cole, Michael A.	14
Cole, Steven A.	32, 47
Coleman, Kathy	100
Collier, Barnard L.	45
Collins, Gary R.	96
Conley, Jennifer	57, 106
Conley, Robert R.	58

Connor, Cathelene E.	31
Cook, Michele K.	34
Cooney, Gerald A.	35
Cooper, Thomas	84
Coplan, Jeremy D.	23, 32, 64
Cora-Locatelli, Gabriela	51, 79
Corcoran, Cheryl M.	29
Cordal, Adriana	100
Coric, Vladimir	100
Corral, Maria R.	8
Cortese, Leonardo	1
Cosgrove, Victoria E.	57
Costa, Jr., Paul T.	105
Costello, Ellen	68
Cournos, Francine	31, 47, 60
Courvoisie, Helen E.	91
Cousin, F. Regis	88
Couvee, Jaap E.	62
Cox, John L.	36
Cozza, Kelly L.	14
Crismom, M. Lynn	34
Croft, Harry A.	55
Crone, Catherine A.	41
Crossett, Judith H. W.	79
Croudace, Tim J.	24, 29
Crow, Scott J.	31
Crowley, Brian	10
Cullen, Kenneth	33
Cummings, Jeffrey L.	63
Cunningham, Miles	101
Currier, Glenn W.	9
Curtis, James L.	56
Cutrino, Annette	97
Czobor, Pal	49

D

Dabney, Mary-Kay	36
Dagg, Paul K.	99
Dalfen, Ariel K.	18
D'Alli, Richard E.	28, 54, 70, 91
Daly, Kathleen A.	88
Daneluzzo, Enrico	50
Das, Amarendra	72
Dasher, Robert	53
Datta, Moitri N.	44
David, Anthony S.	105
Davidoff, Donald A.	96
Davidson, Jonathan R.T.	10
Davidson, Lawrence	86
Davidson, Simon	100
Davine, Jonathan S.	20
Davis, Amy R.	78
Davis, Dave M.	69, 79, 96
Davis, Glenn C.	19
Davis, John M.	1, 103
Davis, Mary H.	18, 99
Davis, Scott M.	99
Dawe, Ian C.	34, 60, 97
Dea, Robin A.	71
Dean, Christine	68
Deas, Deborah	25
Deaton, Rodney J.S.	50
DeBattista, Charles	3
Dececco, Lindsay M.	49, 77
Deckersbach, Thilo	31
de Cleves, Maria Clara	51
DeFelippo, Anne M.	94
de Girolamo, Giovanni	73, 103
de Groot, Janet M.	50
De La Gandara, Jose E.	44, 46
de Leon, Jose	45
Delahanty, Janine C.	49
Delgado, Pedro L.	11
Dell'osso, Liliana	49, 103

Del Zompo, Maria 83
 Demant, Jean-Claude 88
 Demitrack, Mark A. 106
 Denicoff, Kirk D. 55, 56
 Derivan, Albert T. 90
 Deutschman, Daniel A. 1, 7, 62
 Devanand, Davangere P. 63
 Devins, Gerald M. 22
 Devlin, Bernard 86
 Devlin, Michael J. 84
 Dewan, Mantosh J. 40, 104
 Dewan, Naakesh A. 1
 Diamond, Robert 50
 Diaz-Marsa, Marina 85
 Dickerson, Faith 49
 Dickson, Amy 30
 Dickstein, Daniel P. 26
 Dickstein, Leah J. 2, 16, 26, 32, 45, 51, 72, 79
 Dillon, James E. 40, 104
 Dingle, Arden D. 51
 Dixon, Lisa B. 5, 44, 49
 Dobyns, Robert F. 44
 Dohramji, Karl 90
 Dohrenwend, Bruce 32
 Dolan, Mairead 85
 Dolan, Regina T. 35, 83, 87
 Dominguez, Roberto A. 24
 Donald, Alastair 104
 Doody, Rachelle S. 63
 Doraiswamy, P. Murali 6
 Dording, Christina M. 77, 78
 Dosreis, Susan 78
 Dougherty, Darin D. 77
 Downey, Jennifer I. 31
 Downs, Susan R. 68
 Doyle, Brian B. 27
 Dracass, Sarah 76
 Drake, Robert E. 5
 Dralle, Penelope 30
 Drebing, Charles 84
 Drell, Martin J. 30, 40
 Drescher, Jack 18, 84
 Drescher, Peter J. 77
 Drevets, Wayne C. 3, 71
 Drummond, Peter 103
 Druss, Benjamin G. 44
 Dryden-Edwards, Roxanne 25
 D'Souza, D. Cyril 105
 Du, Nang 50
 Dubin, Hinda F. 97
 Dubuis, Jacques M. 88, 102
 Ducate, Susan 43
 Duckworth, Kenneth S. 51
 Duff, S. 83
 Duffy, Farifteh F. 31
 Duman, Ronald S. 3
 Dunn, Laura B. 18
 Dunner, David L. 67, 93
 Dunnigan, Joanne 19, 72
 Dupont, Randolph T. 57
 Dvorak, Ramona 27
 Dwyer, Donald S. 3
 Dyck, Ingrid R. 35, 83

E

Eberle, Andrea 89
 Ebert, Bruce 107
 Ebert, Michael H. 19
 Eddy, Kamryn T. 31
 Edell, William S. 48
 Edelman, Gerald M. 69
 Edman, Jeanne 48
 Edwards, Kimberly B. 86
 Eick, Carolyn 87

Eisendrath, Stuart J. 19
 Eist, Harold I. 35
 Ekselius, Lisa 73
 El-Defrawi, Mohamed H. 31, 85
 El-Sayed, Hesham 31
 Eling, Paul 62
 Elman, Igor 74
 Elzinga, Bernert M. 33
 Emslie, Graham J. 34, 67
 Endicott, Jean 5
 Engelhardt, Nina 93
 England, Mary Jane 62
 Erdos, Brandon Z. 72
 Eriksson, Elias 13
 Erman, Milton K. 2
 Erman, Ozlem 48
 Escobar, Javier I. 78, 102, 103
 Escott, Lauren 84
 Eth, Spencer 43
 Etkin, Mark S. 52
 Eustis, Janet W. 96
 Evaldson, John R. 51
 Evans, Dwight L. 39
 Eynan-Harvey, Rahel 60

F

Faber, Raymond A. 26, 40
 Fahmy, Magda 85
 Fahrer, Rodolfo D. 25, 33
 Faison, Warachal E. 50
 Fallon, Brian A. 83
 Farabaugh, Amy H. 77, 100
 Faraone, Stephen V. 29, 77, 90
 Faries, Douglas 35
 Farvolden, Peter 23
 Faubion, Matthew D. 100
 Faulkner, Larry R. 19
 Fava, Maurizio 6, 11, 23, 24, 48, 49, 50, 63, 76, 77, 78, 100
 Favell, Jennifer L. 14, 59
 Fawcett, Jan A. 11, 33
 Fazzio, Lydia O. 24, 44
 Feder, Adriana 34
 Feighner, John P. 24
 Feijen, Rudolf A.M. 25
 Fein, Sidney 48
 Feiner, Joel S. 56, 95
 Feinstein, Carl B. 25
 Feldman, Jacqueline M. 80, 88
 Feldman, Marc D. 83
 Felker, Bradford L. 44
 Feng, Weiwei 49
 Fenton, Wayne S. 49
 Ferguson, Yvonne B. 53
 Fernandez, Francisco 31, 67, 85, 101
 Ferrando, Stephen J. 31, 96
 Festa, Donna 19
 Fichter, Manfred M. 55
 Fichtner, Christopher G. 88
 Fidler, Donald C. 42
 Fiellin, David 7
 Finazzo, Christie 8
 Findling, Robert L. 90
 Fink, Max 40
 Fink, Paul J. 33, 43
 Fiorella, Michelle A. 74
 Fireman, Marian 79
 First, Michael B. 14, 35, 52, 56
 Fischman, Alan 77
 Fischman, Marian W. 32
 Fitek, Diana J. 31
 Fitzgerald, Louise F. 80
 Fitzgibbons, Lee A. 104
 Flaherty, Joseph A. 62

Flaherty, Lois T. 18
 Fleming, Anne M. 19
 Fleming, Candace M. 52
 Flores, Philip J. 97
 Flynn, Heather A. 29, 43, 71
 Flynn, Laurie M. 79
 Foa, Edna B. 104
 Fochtmann, Laura J. 32
 Folstein, Marshal F. 33
 Foote, William F. 25
 Foote, William W. 15, 41
 Forbes, Erika 86
 Ford, Julian 84
 Fore, Peter F. 62
 Forehand, Jr., Lyle B. 18
 Forneris, Catherine 32
 Forstein, Marshall 31, 60, 84, 96
 Fortineau, Jacques 88
 Fortuna, Lisa R. 95
 Fossati, Andrea 85
 Foti, Charles 30
 Foti, Mary E. 88, 89
 Foulks, Edward F. 10, 20, 51, 56, 100
 Fournier, Debra 84
 Fournier, Jean-Pierre 49
 Fowler, J. Christopher 61
 Fox, Nathan A. 86
 Fragola, Christina 97
 Frances, Richard J. 60, 74, 97
 Francis, Andrew J. 8, 88
 Franco, Eduardo L. 83
 Frank, Ellen 39
 Frank, Guido 31, 105
 Frank, Richard 17
 Frankenburg, Frances R. 23, 60
 Frausto, Teresa 25, 48
 Freeman, Nancy 30
 Freeman III, Arthur M. 3
 Friar, David H. 73
 Fried, Richard G. 89
 Friedman, Joseph I. 19
 Friedman, Matthew J. 62
 Friedman, Michelle E. 58
 Friedman, Richard C. 31
 Friis, Svein 104, 105
 Fritch, Margaret 19
 Frye, Mark A. 6, 9, 27, 55, 56
 Fuentes, Milton 34
 Fujii, Kumiko 29
 Fuller, Gail S. 18, 33
 Fullilove, Mindy J. 49, 62
 Fuschino, Antonio 55

G

Gabbard, Glen O. 15, 51, 61
 Gabel, Stewart 97, 101
 Gabriel, Geoffrey M. 44, 68
 Gabrieli, John D. E. 86
 Gadasalli, Rangaesh 99
 Gaebel, Wolfgang 85
 Galanter, Cathryn A. 78
 Galanter, Marc 97, 103
 Galderisi, Silvana 55, 83
 Gales, Michael A. 69, 74
 Galton, Elizabeth 28
 Galynker, Igor I. 33
 Ganime, Peter D. 19, 72
 Gans, Jerome S. 14
 Gardiner, Sara K. 50
 Gardner, David M. 94
 Gardner, James 78
 Gardner, Russell 59
 Gardner, Jr., Russell J. 45
 Garfield, David A. 72

PARTICIPANT INDEX

Garnis-Jones, Sylvia G.....	89
Garno, Jessica L.....	100
Gask, Linda.....	25
Gass, Charlie A.....	24
Gastfriend, David R.....	74, 87
Gatti, Marino.....	36
Gaviria, F. Moises.....	46, 86
Gaynes, Bradley N.....	99
Geddes, John.....	94
Gee, Kenneth K.....	104
Gelenberg, Alan J.....	48, 55
Gendel, Michael H.....	17
Gentil, Valentin.....	87
Genua, Jose A.....	45
Geokoop, Jaap G.....	85
George, Mark S.....	15
Gerbarg, Patricia L.....	41
Gershon, Michael D.....	94
Gerstein, Hertz C.....	3
Gertemian-King, Enid.....	33
Ghaemi, S. Nassir.....	33, 55, 93
Ghandi, Neel.....	30
Giannini, Carol.....	8
Giese-Davis, Janine.....	36
Gilman, Stephen E.....	58
Gilmer, William S.....	49
Gilmore, Julie A.....	78
Ginsberg, Iona.....	89
Gise, Leslie H.....	22, 50
Glancy, Graham G.....	69
Glas, Gerrit.....	86
Glass, John B.....	31
Glassman, Alexander H.....	11
Glazer, Diane.....	30
Glazer, William M.....	5, 63
Glick, Ira D.....	26, 67, 93
Goethe, John W.....	49
Goff, Donald C.....	83
Goforth, Harold W.....	88
Gogek, Edward B.....	72
Goin, Marcia K.....	31, 52, 88, 100, 105
Goisman, Robert M.....	1
Gold, Liza H.....	80
Goldberg, Joseph F.....	6, 9, 55, 100
Golden, Robert N.....	8
Goldenberg, David B.....	101
Goldfinger, Stephen M.....	80
Goldman, Charles R.....	80
Goldman, David.....	49
Goldman, Howard H.....	17, 95
Goldman, Margo P.....	52
Goldman-Rakic, Patricia S.....	9
Goldner, Elliot M.....	94
Goldschmidt, Walter.....	25
Goldsmith, R. Jeffrey.....	19, 46
Goldstein, Jill M.....	64
Goldstein, Mara S.....	23
Goldstein, Martin A.....	74, 101
Goldstein, Michael G.....	32
Gomez, Giovanni.....	100
Gonnelli, Chiara.....	49
Goode, David J.....	68
Goodkin, Karl.....	101
Goodnick, Paul J.....	23, 76
Goodwin, Frederick K.....	3, 55, 81, 104
Goodwin, Guy M.....	64, 90
Gordon, Alan L.....	78
Gordon, Edward.....	18, 25
Gordon, Geoffrey H.....	32
Gordon, Johanna A.....	24, 49
Gordy, Tracy R.....	25, 51
Gorelick, David A.....	60, 87
Gorgels, W. D. J.....	62
Gorman, Jack M.....	5, 30, 32, 64
Gorshow, Lori.....	98

Gorton, Gregg E.....	54
Gotthell, Edward.....	24
Gracia, Antonio J.....	73
Grady-Weliky, Tana A.....	32, 44
Granacher, Robert P.....	15
Granich, Annette.....	29
Grassi, Luigi.....	36
Gray, Ernestine S.....	30
Gray, Kevin F.....	26, 63
Gray, Sheila H.....	72
Greden, John F.....	16, 29, 106
Green, Alan I.....	5
Green, Jamison.....	71
Green, Michael F.....	12
Green, Ronald L.....	62
Greenberg, David.....	72
Greenberg, Harvey R.....	12, 54, 64
Greenberg, Leslie S.....	41
Greenberg, William E.....	44
Greenberg, William M.....	79
Greenblatt, David J.....	64
Greenfield, Shelly F.....	44
Greenhill, Laurence L.....	77, 85
Greenleaf, Wayne.....	30
Greenwald, Blaine S.....	78
Greiner, Carl B.....	72
Greist, John H.....	106
Gresham, Jr., Robert L.....	76, 78
Griffith, Ezra E.H.....	35, 42
Griffith, James L.....	15, 51, 67, 101
Grilo, Carlos M.....	23, 48, 83
Grimes, Wen D.....	61
Grob, Charles S.....	101
Grosch, William N.....	25
Grossman, Linda S.....	50
Grosz, Hanus J.....	77
Groves, Mark S.....	18
Gruenberg, Peter B.....	57
Grund, Ellen M.....	78
Guelfi, Julien D.....	73
Guggenheim, Frederick G.....	44
Guille, Constance.....	50
Gunderson, John G.....	83, 87
Gur, Raquel E.....	30
Guralnik, Orna.....	105
Guschwan, Marianne T.....	20, 44
Gushin, Vadim.....	78
Guss, Janet.....	84
Gutman, David A.....	77
Gyoerkoe, Kevin L.....	50

H

Haahr, Ulrik.....	105
Hackman, Ann L.....	49
Hadley, Sallie Jo.....	11
Hafliger, Silvia.....	94
Hagag, Wafaa.....	85
Hagengimana, Athanase.....	98
Hajak, Goran.....	64
Halbreich, Uriel.....	49
Hales, Robert E.....	13, 39
Hall, Sharon.....	19
Haller, Ellen.....	19, 68
Halmi, Katherine A.....	7, 31, 55, 104
Halperin, David A.....	91
Halperin, Steven.....	103
Halpern, Abraham L.....	44, 73
Halpern, John H.....	44, 101
Hamburg, Paul.....	58
Hammer, Lawrence.....	99
Hammond, Timothy G.....	99
Han, Xiaotong.....	49
Hanin, Edward.....	57
Hankins, Melissa M.....	73

Hansen, Mark R.....	2
Hansen, Thomas E.....	8
Hanson, Graeme.....	96
Hanusa, Barbara.....	100
Haponski, David.....	8
Harbin, Henry T.....	17
Harden, Cynthia L.....	74
Harding, Richard K.....	10, 14, 36, 52
Harding IV, George T.....	25
Harlow, Bernard L.....	30, 78
Harris, Michael R.....	99
Harris, Patrice A.....	42, 78
Harris, Wendy A.....	104
Harrison, Wilma M.....	48
Harrow, Martin.....	24, 100
Hartman, David E.....	73
Hartmann, Lawrence.....	28, 56
Harvey, Sharon C.....	33
Hashim, Aqil.....	100
Hasin, Deborah S.....	56
Haslam, David R.S.....	94
Hassan, Fatma.....	31
Hatterer, Charles.....	22
Hattori, Mineko.....	29
Hawkins, Keith A.....	86
Hazlett, Erin A.....	105
Heap, Joann.....	60
Heidel, Stephen H.....	72, 88
Heiligenstein, John H.....	35
Heilman, David W.....	94
Heimberg, Richard G.....	103
Heinlein, Ricardo.....	33
Hellerstein, David J.....	48
Hembree, Elizabeth A.....	104
Henderson, David C.....	3
Hendin, Herbert.....	50
Hendren, Robert L.....	25
Hendrick, Victoria.....	9, 39
Henkel, Shamina J.....	84
Hennen, John.....	3, 23
Hensley, Paula L.....	48, 55
Herbeck, Diane M.....	31, 32
Herbener, Ellen S.....	24
Hernandez, Pablo D.....	102
Hernandez-Serrano, Ruben J.....	33
Herrick, Fay.....	93
Herrman, Helen E.....	36
Hersh, Richard G.....	81
Hertz, Miki.....	100
Heru, Alison M.....	43
Herzog, David B.....	31, 58
Hester, Thomas W.....	15
Hettinga, Nicolaas F.J.....	25
Hiatt, John F.....	15, 41
Hibbeln, Joseph R.....	49
Hickey, Grace.....	19, 72
Hicks, Brian M.....	57
Hicks, Daniel W.....	18
Hilkert, Fred G.....	7
Hill, Kevin P.....	24
Hirsch, Alan R.....	73
Hirschfeld, Robert M.A.....	13, 39, 57
Hirshbein, Laura D.....	99
Ho, Andrew P.....	8, 52, 99
Hocking, Barbara.....	93
Hoffman, Ralph E.....	86
Hofman, Albert.....	49
Hoge, Michael.....	62
Holder-Perkins, Vicenzio.....	83
Holland, Jimmie C.....	36
Hollander, Annette J.....	80
Hollander, Eric.....	11, 14, 39, 105
Holman, Julie.....	23
Holzer, Jacob C.....	89
Honberg, Ron.....	25

Hooper, IV, James F.	56
Horowitz, Lisa	105
Horrigan, Joseph P.	91
Horton, Leslie A.	72, 106
Horton, Paul C.	23
Hostetter, Abram M.	18
Hostetter, Amy L.	39
Hovaguimian, Theodore	79
Howe, Edmund G.	7
Howsepian, Avak A.	20
Hsiung, Robert C.	7
Hsu, L.K. George	76
Huang, Milton	1, 7, 62, 71, 102
Hudson, Teresa J.	61
Huey, Leighton Y.	62
Huffine, Jr., Charles W.	51, 89
Hughes, Douglas H.	9, 72
Hughes, Judith A.	87
Hughes, Michael C.	79
Hunter, Bryan C.	58
Hussain, Mohammad Z.	100
Hussain, Seema	100
Hwang, Michael Y.	102
Hyler, Steven E.	14
Hyman, Steven E.	3, 70

I

Iacono, William G.	57
Ifesinachukwu, F. Ada	44
Ikeda, Debbie	30
Ikin, Jillian	36
Innes Gombert, Debbie	98
Invernizzi, Giordano	83
Ioanitescu, Dan O.	96
Iosifescu, Dan V.	23
Irigoyen-Rascon, Fructuoso R.	44
Isbell, Luisa	45
Isbey, Professor JoAnne M.	26
Ishak, Waguih W.	2
Isohanni, Irene	24
Isohanni, Matti K.	24, 29

J

Jackson, Richard S.	40, 104
Jacobs, Karl M.	25
Jacobs, Leo I.	99
Jacobs, Selby C.	59
Jaffe, Richard L.	14
Jamison, Kay R.	2, 18, 45, 81
Jang, Kerry L.	35, 57
Janicak, Philip G.	1
Jansen-McWilliams, Linda	100
Jarvelin, Marjo-Riitta	24
Jarvis, G. Eric	30
Jayaram, Geetha	20
Jeanniton, Chaneve	48
Jefferson, James W.	8, 67, 93
Jeffreys, Ledley	103
Jennings, Barbara	30
Jeral, Joseph M.	97
Jeste, Dilip V.	8, 64
Jimerson, David C.	7, 105
Joffe, Hadine	2, 30
Joffe, Russell T.	13, 104
Johannessen, Jan O.	104
Johnson, Bradley R.	43
Johnson, David R.	71
Johnson, Jeffrey G.	23, 105
Johnson, Katherine H.	45
Johnson, Kyle P.	89
Johnson, Raymond A.	96
Jokelainen, Jari	24

Jones, Billy E.	46
Jones, Kristina	101
Jones, Peter B.	24, 29
Jorge, Miguel R.	33
Jorgenson, Linda M.	19, 51, 54
Josephson, Allan M.	61
Jowsey, Sheila G.	71
Joy, Charles R.	51
Judd, Lewis L.	5, 90
Judge, Sheila	53
Jung, K. Elan	77
Jung, Yoon K.	19
Juthani, Nalini V.	35, 50, 58, 74, 87

K

Kahn, David A.	57
Kahn, Jeffrey P.	88
Kaltenbach, Robert	97
Kamenetz, Claudia	84
Kaminsky, Rami	44
Kamm, Ronald L.	35
Kan, Cornelis C.	62
Kanas, Nick A.	78
Kandel, Eric R.	16
Kane, John M.	30
Kanouse, David E.	49
Kant, Alexis	24
Kaplan, Allan S.	50, 105
Kaplan, Gabriel	94
Kaplan, Kalman J.	100
Kapoor, Vinay	51, 74
Kapur, Shitij	9
Karasic, Dan H.	71, 102
Karasu, T. Byram	25, 53
Karlinsky, Harry	19
Karlsogdt, Katherine	74
Karmaly, Wahida	84
Karpinski, Marek D.	99
Kash, Kathryn M.	36
Kasl, Stanislav	59
Kassaw, Kristin A.	73
Kastrup, Marianne C.	36
Kathol, Roger G.	16
Kato, Kyle S.	101
Kato, Tadafumi	29
Katon, Wayne J.	93
Katschnig, Heinz	36
Katt-Lloyd, Debra	96
Katz, Bernard A.	7
Katz, Ira R.	11
Katz, Mark R.	22
Katzow, Jacob J.	55
Kay, Jerald	21, 31, 51, 54, 73
Kaye, Walter H.	31, 84, 105
Keane, Terence M.	9
Keats, Matthew M.	94
Keck, Jr., Paul E.	8, 9, 56, 63
Keefe, Richard S.E.	5
Keener, Anita	86
Keitner, Gabor I.	6
Keller, Martin B.	13, 83
Kellner, Charles H.	14, 40, 104
Kelly, Karen E.	77, 100
Kelly, Thomas M.	77, 100
Kennedy, Cheryl A.	16, 42, 95
Kennedy, James L.	86
Kennedy, Lawrence L.	68
Kennedy, Robert S.	2
Kernberg, Otto F.	60, 69
Kessler, Carol L.	48
Kessler, Richard J.	44
Kessler, Ronald C.	10
Kestenbaum, Clarice J.	20, 74
Ketter, Terence A.	8, 27, 90

Khantzian, Edward J.	60
Kiesslinger, Ursula	59
Kigamwa, Pius A.	98
Killory, Erin	58, 84
Kilts, Clinton D.	33
King, Nicole A.	86
King, Steven A.	53
Kingser, Patrick	103
Kirkpatrick, Brian	83
Kimayer, Laurence J.	30
Kisiel, Cassandra	84
Kissane, David W.	36
Kissileff, Harry	84
Kleber, Herbert D.	7, 32, 60
Klein, Donald F.	23
Klein, Erik	33
Kloet, E. Ronald	85
Klotz, Thomas A.	98
Knable, Michael B.	49
Knoll IV, James L.	50
Knowles, James	49
Koblenzer, Caroline S.	89
Kochhar, Seema	24
Kocsis, James H.	22
Koegel, Paul	49
Koerselman, Frank G.	59
Kogan, Richard	18, 46, 58
Kohn, Robert	22, 78
Koons, Cedar	103
Koopman, Cheryl	36, 78, 105
Kopek, Neil	22
Korczyn, Amos D.	49
Kornbluh, Rebecca A.	18
Kornfeld, Donald S.	81
Kornstein, Susan G.	2, 35, 39
Koski, E. Greg	58
Kostaras, Xanthoula	83
Kosten, Thomas R.	7
Kosza, Ida	102
Kotler, Lisa A.	76
Kotler, Moshe	24
Kotrla, Kathryn J.	61
Koudstaal, Peter J.	49
Kovacs, Maria	34, 86
Kovess, Viviane	88
Kowatch, Robert A.	61
Kozerenko, Olga	78
Krahn, Lois E.	2
Krakowski, Menahem	77
Kramer, Michelle L.	43
Kramer, Milton	8, 22
Kramer, Thomas A.M.	19
Kravitz, Howard M.	100
Krejci, Jonathan	87
Kreyenbuhl, Julie A.	49
Krishnan, K. Ranga R.	6, 63
Krone, Julie	35
Krueger, Robert F.	57
Kruger, Stephanie	88
Kryger, Meir H.	2
Krystal, John H.	105
Kryzhanovskaya, Ludmila	77
Kubas, Steve M.	71
Kumar, Vinod	48
Kundu, Sudeep	41
Kunkel, Elisabeth J. S.	35
Kunugi, Hiroshi	29
Kupfer, David J.	52, 106
Kupka, Ralph	55
Kurtz, Sheila M.	45
Kurzweil, Ray	94
Kushon, Jr., Donald J.	89
Kyomen, Helen H.	50

L

Labbate, Lawrence A.	55
Lacro, Jonathan P.	8, 64
Lahmann, Jennifer S.	71
Lalonde, Pierre	88
Lalor, Brian	106
Lam, Raymond W.	8
Lambert, Timothy	1
Lambrinos, Angela	83
Lane, Deforia L.	58
Lane, Richard D.	41
Lang, Joan A.	51
Lange, Christopher L.	101
Langlieb, Alan	70
Langsley, Donald G.	57, 77
Lapp, Kathleen G.	43
Larrieu, Julie A.	24
Larsen, Tor K.	104, 105
Larson, David B.	72, 84
Lau, Marianne	36
Laughren, Thomas P.	106
Launay, Corinne	88
Lauriello, John	48
Lauterbach, Edward C.	1, 8, 68, 85
Lavia, Maria	31
Lavori, Phillip	106
Lawrence, Janet M.	96
Lawson, William B.	45, 62
Lazarus, Arthur L.	24, 49, 73, 101
Leahy, Leslie F.	57, 106
Leary, Mark	104
LeBar, Reverend James	107
Lebowitz, Harold E.	3
Lebowitz, Barry D.	106
Lee, Joseph W.	88
Lefer, Gary L.	56
Lehman, Anthony F.	52, 88
Lehmann, Laurent S.	44
Leibel, Rudolph	84
Leibenluft, Ellen	27, 69
Lenhart, Sharyn A.	27
Lenox, Robert H.	30
Lenzenweger, Mark F.	105
Leon-Andrade, Carlos	33
Lerner, Mark	77
Levav, Itzhak	22
Levendusky, Philip G.	1
Levenson, James L.	69
Leverich, Gabriele S.	55
Levin, Frances R.	33, 97
Levine, Ruth E.	21
Levine, Sharon S.	79
Levine, Stewart	45
Levitt, Anthony J.	8
Levitt, James J.	96
Levouinis, Petros	78
Lewis, Lydia J.	9, 50, 59
Lewis-Fernandez, Roberto	32, 52, 79
Lewy, Alfred J.	81
Li, Chiao-Ping	45
Liang, Warren M.	60
Liberto, Joseph G.	7
Lichtmacher, Jonathan E.	19
Lieberman, Jeffrey A.	5, 8, 49, 91, 106
Liebowitz, Michael R.	11, 23
Lieff, Susan	75
Lierman, Walter K.	100
Lilu, Yehezkel	22
Lim, Russell F.	52
Limoges, Richard F.	17
Lin, Keh-Ming	45, 104
Lin, Margaret T.	72
Lindamer, Laurie A.	64
Linden, Michael	59

Lindenmayer, Jean-Pierre	19, 49
Lindy, David C.	97
Link, Bruce	85
Links, Paul S.	60, 97
Lipschitz, Alan	50
Lipsitt, Don R.	32, 95
Lipsius, Steven H.	18, 77
Lipska, Barbara K.	9
Lit, Wilson M.	45
Livesley, John	1, 35, 57, 103
Loboprabhu, Sheila M.	73
Logsdon, Linda	17
Lohr, Kathleen N.	99
Lohr, Naomi	60
Lomax II, James W.	73, 84
Londino, Donna L.	97
London, Edythe	46
Long-Harrell, Angelica J.	44, 99
Longo, Lance P.	25
Lopez, Alberto G.	79
Lopez, Frank	77
Lopez, Juan F.	3
Lopez-Ibor, Maria I.	43
Lopez-Ibor, Jr., Juan J.	43, 85
Losardo, Marylee	84
Loschen, Earl L.	23
Losonczy, Miklos F.	102
Lousteau, Ben	30
Love, Anthony	36
Lowenkopf, Eugene L.	81, 100
Lowenthal, David A.	50
Loza, Nasser F.	31
Lu, Francis G.	12, 15, 45, 50, 52, 72, 75, 84, 102, 104

Luber, M. Philip	32
Luborsky, Lester	60
Lucksted, Alicia	49
Luhmann, Tanya M.	56
Lukon, Joella	86
Luo, John	1, 96
Luterek, Jane	103
Lyketsos, Constanine G.	11, 15, 20, 56, 57
Lynch, Frances	78
Lynch, Kevin G.	100

M

Machan, Jason	83
Maciejewski, Paul K.	59
MacIntyre, James C.	96
Mack, Avram H.	44, 60
Mackic-Magyar, Jasmine	53
MacLean, Alexandra	88
MacQueen, Glenda M.	104
Maffei, Cesare	85
Magnani, Katia	36
Maguire, Gerald A.	5
Mahowald, Mark W.	2
Maidman, Patrick S.	72
Maier, Gary J.	25
Maj, Mario	55, 83
Makikyro, Taru H.	29
Malaspina, Dolores	29, 83
Maldonado, Jose R.	2, 15, 41, 83
Mallory, George L.	17
Malmquist, Carl P.	19, 51
Maloney, Ann S.	59
Maloney, Michael	98
Maltsberger, John T.	50
Mancini, Catherine L.	23
Mancuso, Donna M.	101
Manion, Ian G.	100
Manji, Hussein K.	64, 90
Mann, J. John	2, 34, 77, 87
Mantoya, Ivan	22

Marangell, Lauren B.	3, 5
Marazziti, Donatella	1, 11
Marchant, Nestor F.	33
Marcus, Eric R.	42, 74
Marcus, Sheila	29, 43, 71
Marcus, Steven C.	31, 32, 57
Marder, Stephen R.	1, 30, 67, 93
Margo, Geoffrey M.	6
Margo, Katherine	6
Margolis, Philip M.	18
Markovich, Philip	86
Markowitz, John C.	6, 48
Marks, Robert C.	50
Marmar, Charles R.	3, 32, 78
Marshall, Randall D.	23, 32, 52, 53, 74, 102, 104
Marsillo, Alessandra	36
Martin, Camilo A.	24
Martinez, Rick A.	106
Marumoto, Megan T.	48
Marx, Christine E.	43
Masand, Prakash S.	11
Mason, Barbara J.	6
Massie, Mary Jane	7, 16, 53
Masterson, James F.	1
Matano, Robert A.	78
Matorin, Anu A.	51, 74, 101
Matteucci, Neil A.	97
Matthews, John D.	77, 78
Matthews, Karen S.	100
Maull, Fleet W.	104
Mavissakalian, Matig R.	23
Maxwell, Michael	97
Mayberg, Helen S.	3
Mayer, Laurel	58, 84
Maziade, Michel	49
Mazzanti, Chiara	49
McCall, W. Vaughn	14
McCamant, Lynn E.	100
McCarley, Robert W.	90
McCarthy, Richard H.	19, 44
McCartney, Cheryl F.	48
McCarty, Teresita A.	23
McCort, Emily A.	25
McCorvey, Brenda	73
McCue, Robert E.	22
McDermott, Stephen P.	15, 40
McDonald, Clyde	100
McDonald, Colm	29
McDonough, James R.	101
McDowell, David M.	32, 33, 75, 102
McDuff, David R.	79
McElroy, Susan L.	11, 56, 90
McEroy, Joseph	106
McEvoy, Joseph P.	49
McFarland, Bentson H.	100
McFarlane, Alexander	84
McGarvey, Elizabeth L.	49, 50, 77
McGlashan, Thomas H.	23, 33, 48, 83, 85, 86, 104, 105
McGorry, Patrick D.	67
McGrath, Patrick J.	11
McGregor, Jacqueline C.	48
McGregor, Victor	78
McGue, Matt	57
McHugh, Paul R.	20, 70
McInnes, L. Alison	19
McIntyre, John S.	31, 58, 72, 79, 96
McKay, James R.	103
McKenzie, Dean P.	36
McLellan, A. Thomas	103
McMeekin, Hayne D.	63
McNicholas, Laura F.	7, 103
McQuestion, M.	83
McQuiston, Hunter L.	72, 78, 96
Medford, Nicholas	105

Medina, David A. 86
 Mee-Lee, David. 40
 Meehan, Katherine G. 58
 Mega, Lesly T. 82
 Mehra, Gayatri 76
 Meier, Rosemary 20
 Melle, Ingrid. 104, 105
 Melonas, Jacqueline 44, 81
 Meltzer, Herbert Y. 3, 5
 Mendelowitz, Alan J. 12, 13
 Mendlewicz, Julien 90
 Mendoza, Ricardo P. 45, 79
 Menninger, W. Walter 79, 96
 Menza, Matthew A. 85
 Merette, Chantal 49
 Merlino, Joseph P. 25
 Merriam, Ursula 90
 Mesheda, Tatjana 84
 Mester, Roberto 24
 Metzger, Erand 105
 Metzl, Jonathan M. 42, 61, 89
 Metzner, Jeffrey L. 44, 104
 Meydan, Jakob 56
 Meyers, Nicholas 57, 78
 Mezzich, Juan E. 35, 36
 Michels, Robert 17, 26, 59
 Michelson, David 35
 Mignot, Emmanuel 2
 Mikalac, Cecilia M. 7
 Milberg, Laurel C. 6
 Miller, Alexander L. 34
 Miller, D. Jean 78
 Miller, Diana C. 18
 Miller, Gary E. 96
 Miller, Milton H. 98
 Miller, Paul R. 53
 Miller, Robert D. 43, 73
 Miller, Sheldon I. 44, 79, 97
 Miller, Tandy J. 85, 86
 Millman, Robert B. 97
 Mills, Catherine 99
 Milone, Richard D. 57
 Milton, Denai R. 78
 Miner, Lucinda 25
 Minkoff, Kenneth 8
 Mintzer, Jacobo E. 11, 15, 50, 79
 Miranda, Claudio 22
 Mirin, Steven M. 7, 10, 16, 69
 Misch, Donald A. 94
 Mischoulon, David 49, 76, 77, 87
 Mishara, Aaron L. 86
 Misri, Shaila 8, 83
 Mitchell, James E. 7, 31, 105
 Moeller, Frederick G. 99
 Moeller, Stephanie 97
 Moesse, Thomas 33
 Moffitt, Katherine 84
 Mohr, Wanda 89
 Moilanen, Kristina 24
 Mol, Audrey J. 62
 Molina, Amanda 31
 Molinari, Victor 73
 Molinoff, Perry 20
 Moltz, David A. 72
 Monteleone, Palmiero 55
 Montgomery, Stuart A. 67
 Montgrain, Noel 49
 Montoya, Ivan D. 51
 Montoya-Pulido, Alonso 101
 Mordecai, Donald J. 25
 Moreno, Francisco A. 11
 Morey, Leslie C. 23, 83, 105
 Morgan, Philip 20
 Morgan-Minott, Melodie 25
 Morihisa, John M. 71

Moring, Juha 29
 Morissette, Louis 50
 Morris, Raphael A. 45
 Morrow, Gary 36
 Morse, Edward V. 30
 Morse, Patricia 30
 Mosca, Daniel L. 19
 Mosher, Paul W. 52
 Moussaoui, Driss 31
 Mucci, Armida 55
 Mueser, Kim T. 5
 Mullen, Paul E. 10
 Muller, Betty Ann J. 18
 Mulrow, Cynthia D. 99
 Munoz, Rodrigo A. 51
 Muntaner, Carles 72
 Murro, Marcelo R. 19
 Murphy, Barbara 36
 Murphy, Greer M. 9
 Murphy, Michael D. 94
 Murray, Robin M. 29
 Murthy, Srinivasa 85
 Musacchio de Zan, Amelia E. 25, 33
 Muskin, Philip R. 10, 80, 81
 Musselman, Dominique L. 39
 Muszynski, Irvin L. 18
 Myers, Michael F. 2, 17, 27, 51, 72, 79
 Myers, Wade C. 57
 Myrick, Hugh 6, 90

N

Nadelson, Carol C. 19, 26, 32, 45, 73
 Nanko, Shinichiro 29
 Napoli, Joseph C. 71
 Narayan, Meena 33
 Narrow, William E. 31, 103
 Nasrallah, Henry A. 39, 49, 61, 63
 Nathan, Paula 103
 Ndlela, J. Charles 52, 104
 Neault, Nicole B. 50, 77
 Needell, Nancy J. 48
 Nelson, J. Craig 9
 Nemeroff, Charles B. 9, 56, 63
 Nersessian, Edward 34
 Nestler, Eric J. 3
 Neu, Peter 59
 Newcomer, John W. 3
 Newkirk, Cassandra F. 96
 Newman, Alan W. 25
 Newman, Rita R. 25, 80
 Newport, Donald J. 93
 Neylan, Thomas C. 3
 Nicholi, Jr., Armand M. 61
 Nierenberg, Andrew A. 3, 9, 23, 24, 50, 76, 77, 106
 Nikiforov, Kostantine 33
 Nix, Betsy 73
 Nodal, Raul F. 46
 Nolen, Willem A. 55
 Noll, Jennie 105
 Nonacs, Ruta M. 78
 Norquist, Grayson S. 61
 North, Carol S. 53, 79
 Northcutt, Colleen J. 79
 Northoff, Georg 88
 Norwood, Ann E. 98
 Nosariti, Chiara 29
 Notman, Malkah T. 19, 51
 Novac, Andrei 25
 Novotny, Sherie L. 11
 Noyes, William 15
 Nunes, Edward V. 33
 Nurnberg, H. George 48, 55
 Nurnberger, Jr., John I. 29
 Nusseir, Fatheia 85

O

O'Dea, Richard 57
 O'Dell, Kristin J. 72
 O'Hara, Michael W. 41
 O'Neill, Patrick T. 23
 Oakman, Jonathan 23
 Oberkirch, Ann M. 77
 Obiora-Oputa, Alexandra C. 44
 Ochoa, Elizabeth S. 44
 Oele, Bastiaan L. 25
 Oesterheld, Jessica R. 14, 96
 Okasha, Ahmed M.F. 31
 Okasha, Tarek A. 74
 Okereke, N. Kalaya 44
 Okin, Robert L. 104
 Olarte, Silvia W. 26, 58, 68
 Oldham, John M. 31, 35, 54, 79, 87, 96, 105
 Olsson, Mark 11, 34
 Olie, Jean-Pierre 88
 Olin, Jason T. 106
 Olivardia, Roberto 61
 Olvera, Rene L. 77
 Onch, Bedriye 48
 Opjordsmoen, Stein 104, 105
 Opler, Lewis A. 25, 40, 74, 103
 Oppenheimer, Joan 60
 Oquendo, Maria A. 78, 87
 Ordorica, Patricia I. 46, 60, 99
 Orleans, C. Tracy 99
 Osher, Fred C. 57
 Osofsky, Howard J. 26, 30, 40, 73, 95
 Osofsky, Joy D. 30, 40
 Osofsky, Michael J. 26
 Osser, David N. 71, 96
 Osterman, Janet E. 45, 72
 Otto, Michael W. 30, 93
 Oude Voshaar, Richard C. 62
 Ouimet, Marie-Claude 23
 Oureshi, Altamash I. 32
 Owen, Jr., Richard R. 61
 Ownby, Raymond L. 7

P

Pacheco, Antonio 33
 Painter, Albert F. 27
 Pallanti, Stefano 11, 103
 Pally, Regina 69, 74, 106
 Pandya, Anand 23
 Panksepp, Jaak 34
 Panzer, Paula G. 32
 Papasogli, Alessandra 103
 Pardes, Herbert 20
 Pardini, Lorella 49
 Parikh, Firoza R. 87
 Parikh, Rajesh M. 76, 87
 Pariot, Pierre 106
 Paris, Joel F. 23, 30, 60
 Parks, Joseph J. 15
 Parry, Barbara L. 2
 Passagli, Adolfo 103
 Passow, Emilie 14
 Patel, Smita H. 50
 Pathe, Michelle 10
 Patkar, Ashwin A. 24
 Pato, Michelle T. 40
 Patrick, Christopher 57
 Patterson, Debra M. 96
 Patterson, Robert D. 71
 Patton, Debra 46
 Pava, Joel A. 77
 Payne, Bryan 43
 Pearce, R. Michael 7

Pearlstein, Teri B. 2
 Peele, Roger 60, 97
 Peindl, Kathleen S. 100, 101
 Pellet, Jacques 88
 Penk, Walter E. 84
 Penner, Norman R. 100
 Perel, James M. 23, 101
 Perez, Oscar E. 46, 79
 Perkins, Diana O. 5, 63, 64
 Perlis, Roy H. 100
 Perry, Dana M. 61
 Perry, John C. 23, 60, 61, 105
 Perugi, Giulio 24
 Pessar, Linda F. 45, 72
 Pessin, Neil 97
 Peteet, John R. 61
 Peters, Lorna 84
 Petersen, Timothy J. 24, 100
 Peterson, Herbert W. 26
 Petitjean, Francois C. 88
 Petrides, Georgios 40
 Peyser, Shoshana 73
 Pfeffer, Cynthia R. 33
 Pfefferbaum, Betty 53
 Pflanz, Steven E. 18, 79
 Pfohl, Bruce M. 60
 Phillips, Katharine A. 21, 61, 79, 83
 Phillips, Mary L. 105
 Pi, Edmond H.T. 45, 50
 Piasecki, Melissa P. 96
 Pierson, Jr., Richard 58, 84
 Pietura, Kate 105
 Pignone, Michael P. 99
 Pilowsky, Daniel J. 34
 Pine, Daniel S. 23, 52, 71, 85
 Pini, Stefano 103
 Pinkerton, Relana C. 50, 77
 Pinkofsky, Harold B. 3
 Pinsker, Henry 45
 Piontek, Catherine M. 101
 Plakun, Eric M. 20, 45, 61, 72
 Plasky, Paul 22
 Pliszka, Steven R. 77
 Podrug, Dinko 73
 Poirier-Littre, Marie F. 88
 Polan, H. Jonathan 72
 Pollack, David A. 57, 89
 Pollack, Mark H. 5, 67, 93
 Pollock, Bruce G. 9
 Porteus, A. Jonathan 24
 Post, Jerrold M. 1
 Post, Robert M. 55, 86, 104
 Postrado, Letitia T. 49
 Prathikanti, Sudha 98
 Preda, Adrian 86
 Preven, David W. 19, 77
 Price, Bruce 101
 Price, Charles S. 77
 Price, Marilyn 43
 Price, Neil D. 72
 Prigerson, Holly G. 59
 Primeau, Francois J. 29
 Printz, David 23
 Prober, Mark A. 52
 Prockop, Darwin J. 22
 Prosen, Harry 72
 Proud, Laura 89
 Puchalski, Christina M. 84
 Pumariega, Andres J. 44, 56, 89
 Punia, Surender P. 44
 Purcell, Rosemary 10
 Purdy, Laura 83
 Putnam, Jr., Frank W. 105
 Pyne, Jeffrey M. 88
 Pynoos, Robert S. 26, 62

Q

Quercioli, Leonardo 103
 Quitkin, Frederick M. 79

R

Rabins, Peter V. 75, 106
 Racagni, Giorgio 90
 Radke, Alan Q. 19, 71
 Rae, Donald S. 103
 Raeburn, Bruce B. 26
 Rainey, Charles J. 1, 7
 Raju, Mary 32
 Ramirez, Luis F. 41
 Ramirez, Paul M. 40
 Rand, Elizabeth H. 46
 Rand, William 76
 Ranen, Neal G. 85
 Rangell, Leo 10, 81
 Rantakallio, Paula 24, 29
 Rao, Nyapati R. 79, 95
 Rapaport, Mark H. 5
 Rapoport, Judith H.L. 8, 91
 Raskin, Valerie Davis 100
 Rasmussen, Keith 40
 Rathmell, Aretta J. 22
 Ratliff, Brenda 15
 Rauch, Scott L. 31
 Rayner, Christine E. 43
 Recupero, Patricia R. 43
 Refaat, Amany 31
 Regier, Darrel A. 52, 70
 Reich, James H. 27, 73, 103
 Reichman, William E. 15, 57
 Reid, William H. 69, 79
 Reider, Ronald O. 79
 Reifler, Burton V. 19
 Reiner, William G. 28
 Reiser, Morton F. 29
 Remington, Gary J. 9
 Repasky, Phillip 19, 72
 Resnick, Phillip J. 6, 14, 40, 68, 97, 102
 Resnikoff, Roy O. 80
 Reznik, Ilya 24
 Rhodes, Anne E. 34
 Riala, Kaisa 24
 Riba, Michelle 7, 21, 45, 54, 80
 Richards, Lawrence K. 25
 Richardson, Harriet 83
 Richardson, Jarrett W. 2
 Richardson, Linda 98
 Richey, Angela L. 78
 Riddle, Mark A. 85
 Rieder, Ronald O. 75
 Rierdan, Jill 84
 Rihmer, Zoltan 77
 Rijkode, Roel 85
 Rinaldi, Osvaldo 50
 Rinne, Thomas 85
 Riordan, Charles E. 78, 96
 Rioseco, Pedro 78
 Risser, Richard C. 78
 Ritvo, Jonathan I. 44, 79, 103
 Roane, David M. 44
 Roberts, Jessica G. 44
 Roberts, Laura W. 98
 Robertson, Michael D. 41, 68
 Robinowitz, Carolyn B. 27, 45, 73
 Robins, Clive J. 103
 Robinson, Gail E. 27, 55, 83
 Robinson, Robert G. 85
 Robinson III, Charles T. 49
 Roca, Catherine A. 58, 93

Rockwell, Enid 64
 Rodenhauer, Paul 27, 79, 97
 Rodriguez, Mercedes M. 22, 100
 Rodriguez-Villa, Fernando 51
 Rody, Elizabeth J. 94
 Roelandt, Jean-Luc 88
 Rogers, Everett 85
 Roldan, Ismael 51
 Rolland, John S. 14
 Roman, Jasmin S. 74
 Rome, Lee H. 40, 61, 104
 Ronningstam, Elsa F. 27, 103
 Roose, Steven P. 6, 11, 21
 Roscoe, Clare 45
 Rose, Carsten 36
 Rose, Deborah S. 96
 Rosen, Arnold M. 62
 Rosen, Joanna 86
 Rosen, Karen J. 68
 Rosen, Raymond C. 6, 22
 Rosenbaum, Jerrold F. 3, 24, 49, 50, 63, 100
 Rosenbaum, Leonard A. 32
 Rosenbaum, Michael 84
 Rosenbaum, Milton 23
 Rosenberg, Doug 45
 Rosenberg, James E. 43
 Rosenberg, Kenneth P. 22, 43
 Rosenberger, John W. 19
 Rosenblum, Barbara 97
 Rosenstein, Donald L. 58, 89
 Rosenthal, Mitchell S. 101
 Rosenthal, Richard N. 33, 56, 87, 103
 Roskes, Erik J. 96
 Ross, David 83
 Rossi, Alessandro 50, 83
 Rossignol, Michel 23
 Rothbaum, Barbara O. 3
 Rothenberg, Albert 23
 Rotondo, Alessandro 49
 Rounsaville, Bruce J. 52
 Rovaris, Michael 30
 Roy, Alec 50
 Roy, Carmella 60
 Roy, Marc-Andre 49
 Rozenberg, Marina 20
 Ruben, Harvey L. 99
 Rubin, Howard C. 18
 Rubinow, David R. 30, 58
 Rucci, Paola 103
 Rudisill, John R. 27
 Rue, David S. 26
 Rueter, Martha A. 23
 Ruiperez, Maria A. 36
 Ruiz, Edmundo J. 73
 Ruiz, Pedro 19, 25, 33, 45, 51, 56, 74, 79, 101
 Rund, Bjorn 105
 Rush, A. John 5, 13, 34, 59, 106
 Rushton, Jerry L. 99
 Ryall, Jo-Ellyn M. 7
 Ryan, Deirdre M. 8
 Ryan, Donna H. 76
 Ryan, Neal D. 34
 Ryan, Ruth M. 68, 89
 Rychik, Abe M. 81, 100
 Rynearson, Edward K. 14, 26, 59

S

Sabato, Silvana 36
 Sacheim, Harold A. 73
 Sachs, Gary S. 13, 39, 50, 57, 106
 Sack, Lawrence C. 44
 Sackeim, Harold A. 11, 71
 Sadler, John Z. 33, 86

Sadoff, Robert L.	73	Segal, Gerald	19	Smith, Graeme C.	36
Saeed, Mohammad	81	Seidman, Stuart N.	6, 22	Smith, Megan M.	23, 100
Saettoni, Marco	103	Seli, Antonia	45	Smith, Michael W.	52, 99
Safer, Daniel J.	78	Seligman, Roslyn	23, 76	Smith, Nathan B.	84
Safer, Debra L.	99	Sernyak, Michael J.	86	Smith, Ward T.	77
Sajatovic, Martha	41	Servis, Mark E.	87	Smith, Jr., G. Richard	19
Sakaue, Kenneth M.	50	Sexson, Sandra	51, 84, 101	Smolka, Michael	59
Salem, Moheb	85	Shaffer, David	3, 76	Smoller, Jordan W.	50
Salize, Hans	88	Shafii, Mohammad	34, 87	Smurda, Joseph M.	18
Salnitskiy, Vyacheslav	78	Shah, Manoj R.	77	Smyke, Anna T.	24
Salone, Franck	88	Shalev, Arie Y.	32	Soares, Claudio N.	30, 87
Samet, Sharon	56	Shapiro, Edward R.	20, 45, 72	Soeken, Karen	78
Sampaio-Meireles, Marcos	88	Sharfstein, Steven S.	17, 25, 56	Sokol, Mae S.	94
Samuel, Steven E.	54	Sharif, Zafar	19	Solhkhah, Ramon	25
Sanchez, Homero R.	73	Sharma, Rajiv P.	1	Solms, Mark L.	29, 53
Sanchez, Liliana	19	Sharma, Tonmoy	29	Soloff, Paul H.	77, 79, 87, 100
Sanderson, Mary E.	20	Shaw, Daniel	86	Soltys, Stephen M.	15, 73
Sanguineti, Vincenzo R.	1, 19, 101	Shea, M. Tracie	105	Solursh, Lionel P.	97
Sanislow, Charles A.	23, 35, 83, 105	Shea, Shawn C.	7	Somjee, Lubnee	86
Sanlian, Natali	60	Shear, M. Katherine	59	Sonawalla, Shamsah B.	49, 76, 87, 100
Santos, Cynthia W.	23, 101	Shedler, Jonathon	35	Southard, Marvin	98
Sapolsky, Robert	41	Sheehan, David V.	10, 31, 64	Southwick, Steven M.	3, 33, 105
Sarova-Pinchas, Ida	24	Shefner-Rogers, Corinne L.	93	Sowers, Wesley E.	87
Sartorius, Norman	22, 79, 85, 98	Sheitman, Brian B.	49, 91	Sparr, Landy F.	97
Sarwer-Foner, Gerald J.	31, 56, 88	Shelton, Richard C.	93	Sparr, Nina P.	97
Satel, Sally L.	101	Sherman, Bonnie J.	31	Speanberg, Stephanie	61
Satpathy, Satyajit	96	Sherrill, Joel T.	34, 86	Spence, Sean A.	86
Satten, Neal R.	94	Shevlin, Howard	34	Spencer, Thomas J.	35, 90
Savage, Cary R.	31	Shidlo, Ariel	84	Sperry, Leonard T.	72, 88
Savoie, JoAnne	101	Shiner, Rebecca L.	105	Spiegel, David	2, 36, 41, 79
Scahill, Lawrence D.	91	Shoab, Arif M.	84	Spiegel, David A.	80
Scarf, Michael A.	18	Shon, Steven P.	34	Spinazzola, Joseph F.	84
Schaefer, Elizabeth H.	83	Shore, Miles F.	17	Spinelli, Margaret G.	100
Schaepper, Mary Ann	78	Shrier, Diane K.	35	Spitz, Deborah	41
Scharf, Bruce A.	32	Shrout, Patrick	56	Spitz, Henry I.	97
Schatzberg, Alan F.	9, 11	Shuchter, Stephen R.	24	Spitzer, Robert L.	35, 84
Scheeringa, Michael S.	24	Sickinger, Andrea H.	77	Spivak, Baruch	24
Schiff-Mayer, Morisa	58	Siegel, Alan P.	67	Stabinsky, Harvey	19, 24
Schiffer, Randolph B.	26, 85	Siegel, Edward A.	24	Stabinsky, Susan	19, 22
Schindler, Barbara A.	45	Siegel, Richard L.	22, 48	Stagno, Susan J.	46
Schmahl, Christian G.	33	Siegel, Steven J.	29, 30	Stahl, Stephen M.	20
Schmetzer, Alan D.	77	Sierra, Mauricio	105	Staib, Lawrence H.	33
Schmidt, Peter J.	30	Sigal, John J.	23	Stangler, Ronnie S.	44, 71, 94
Schmidt, Jr., Chester W.	6, 25, 51	Sikich, Linmarie	5, 91	Stanley, Jonathan A.	30
Schmitt, Harrison H.	37	Silberberg, Joel M.	23	Stark, Michael	102
Schneider, Lon S.	11, 56, 106	Silberman, Edward K.	40	Stasko, Robert S.	60
Schneiderman, Gerald	72	Silk, Kenneth R.	52, 60, 85	Stebbins, Glenn T.	86
Schneiderman, Mark E.	100	Silver, Ann-Louise S.	34, 59	Stein, Bradley D.	96
Schoener, Gary R.	55	Silver, Michael A.	78	Stein, Dan J.	32
Schoenfeld, Frank B.	3	Silver, Stuart B.	79, 96	Stein, Kira D.	44
Schofield, Hilary L.	36	Silverman, Gabriel K.	59	Stein, Murray B.	11, 57
Schonberg, Michael	86	Silverstein, Steven M.	44	Stein, Seth P.	18
Schooler, Nina R.	11, 12, 103	Simeon, Daphne	11, 105	Steinberg, Joel L.	49
Schottenfeld, Richard S.	79	Simon, Asher B.	51	Steinberg, Marc	87
Schreter, Robert K.	17	Simon, Naomi M.	93	Steinberg, Maurice D.	15
Schroeder, Michael	84	Simonsen, Erik	104, 105	Steinberg, Susanne I.	83
Schrut, Albert H.	76	Simpatico, Thomas A.	88	Steiner, Hans	39, 105
Schulman, Julie K.	22, 95	Simpson, Elizabeth B.	68	Stephens, Edward M.	18
Schuyler, Dean	52	Singal, Bonita	22	Sterling, Robert C.	24
Schwartz, Harold I.	45	Singer, Tara M.	100	Stern, Robert G.	103
Schwartz, Joseph	56	Siris, Samuel G.	102	Stevens, Marydale	68
Schwartz, Joseph M.	25	Sirota, Elizabeth	97	Stevenson, Ellen M.	56
Schwartz, Michael A.	33, 101	Sirota, Pinkhas	49	Stewart, Altha J.	58, 95
Scibilia, James P.	79	Sivertz, Kristin S.	8	Stewart, Donna E.	21, 50, 53, 83
Scimeca, Michael M.	19	Sklarew, Bruce H.	12	Stewart, Jonathan W.	11
Scott, C. Paul	6	Skodol II, Andrew E.	35, 83, 87, 105	Stewart, S. Evelyn	99, 100
Scott, Marcia	72	Skolnick, Phil	106	Stewart, Jr., Dudley M.	36
Scott, Roger	30	Sled, Aleksander	78	Stone, Alan A.	28, 79
Scott, Bruce W.	15	Slipp, Samuel	60	Stone, Clint	73
Scully, Jr., James H.	19, 41, 50, 79	Slovenko, Ralph	107	Stone, James B.	73
Sederer, Lloyd I.	18	Slovik, Lois S.	15	Stone, Michael H.	31, 60, 106
Sedler, Mark J.	56	Small, Elisabeth C.	68	Stone, Walter N.	14
Seedat, Soraya	43	Small, Gary W.	6, 63	Stonisch-Riggs, Gail	36
Seeman, Mary V.	64	Smelson, David A.	87	Stotland, Nada L.	7, 15, 26, 45, 72, 79, 100
Seeman, Philip	9	Smith, Eric L. P.	32	Stout, Robert L.	83, 105

PARTICIPANT INDEX

Stowe, Zachary N.	13, 39, 62, 93
Strader, Jr., James R.	93
Strain, Eric C.	7
Strain, James J.	44
Strakowski, Stephen M.	14
Stratta, Paolo	50
Strauss, Gordon D.	74
Street, Jamie S.	106
Streltzer, Jon M.	103
Stroup, Scott	106
Stuart, Heather	85
Stuart, Scott P.	41
Suarez, Anna P.	31
Suchinsky, Richard T.	24
Sudak, Donna M.	50, 97
Sudak, Howard S.	50
Sudhaker, Shiv	105
Sugai, Carmen	63
Sugai, Edward	63
Sugar, Max	36
Sullivan, Greer	49, 61, 88
Sultzter, David L.	15
Summers, Brock H.	98
Suppes, Patricia	6, 34, 55, 56, 57, 64
Suri, Aswin	99
Sved, Margery S.	25
Swann, Alan C.	14, 63, 99
Swanson, James M.	77
Swartz, Holly A.	5
Swedlow, Pamela	25
Sweeney, Professor Latanya	28, 52
Swift, Robert M.	25
Sysko, Robyn J.	84
Szabo, Christopher P.	78
Szarek, Bonnie L.	49
Szigethy, Eva M.	78
Szymanski, Ludwik S.	96

T

Taintor, Zebulon C.	43, 73, 95, 102
Talbott, John A.	88
Tamburrino, Marijo B.	79
Tamminga, Carol A.	43
Tanaka, Hiroshi	29
Tancredi, Laurence R.	107
Tandon, Rajiv	1, 13, 39
Tanneck, Rosemary	35
Tantany, Ashraf	85
Tapert, Susan	20
Targum, Steven D.	14
Tariot, Pierre N.	15, 63, 90
Tarriot, Pierre	56
Tausk, Francisco	89
Tavares, Hermano	87
Taylor, David H.	19, 41
Taylor, Graeme J.	34
Taylor, Stuart W.	40
Tedlow, Joyce R.	49
Tek, Cenik	83
Telson, Howard W.	77, 97
Ten, Aleksey	33
Tennison, Jr., Clifton R.	32, 87
Terry, Nicholas	44
Thase, Michael E.	5, 14, 57, 64, 106
Thaut, Michael H.	58
Thienhaus, Ole J.	96
Thomas, Jean M.	40
Thompson, James W.	80, 102
Thompson, Kenneth S.	56, 95
Thompson, Lawrence	60
Thompson II, Troy L.	70
Throckmorton, Warren	84
Tiamson, Maria L.	50
Tiemeier, Henning	49

Tignol, Jean L.	22
Tillman, Jane	20
Tinsley, Joyce A.	79, 103
Tobias, Teresa	22
Tofler, Ian R.	35
Tohen, Mauricio F.	78
Tomlinson, George	22
Tondo, Leonardo	3
Toni, Cristina	24
Tononi, Giulio	74
Torgersen, Sverre	85
Townsend, Mark H.	57
Tracy, Allison	84
Tracy, Martin G.	44
Tran, Pierre V.	93
Travin, Sheldon	19
Trestman, Robert L.	100
Tricket, Penelope	105
Trimble, Michael R.	15
Trinidad, Anton C.	15, 40
Trivedi, Madhukar H.	19, 34, 59
Trujillo, Manuel	2
Tsang, William	76
Tschan, Werner	55
Tseng, Wen-Shing	103, 104
Tsuang, John W.	52
Tsuang, Ming T.	29, 50
Tucker, Gary J.	40
Tucker, Phebe M.	53
Tucker, William M.	19, 43
Tuinebreijer, Wilco	25
Turgay, Atilla	48
Turkel, Ann R.	74
Turner, J. Blake	32
Tusher, Allan L.	99
Twyman, Andrew P.	73
Tynes, L. Lee	41

U

Ungvari, Gabor S.	88
Upadhyay, Gopalakrishna K.	44
Urcuyo, Leonel	22
Urdarevic, Verka	48
Ursano, Amy M.	18
Usdin, Gene L.	36

V

Vaccarino, L. Viola	33
Vaglum, Per	27, 104, 105
Van Ameringen, Michael A.	23
Van Balkom, Anton J.L.M.	62
Van de Lisdonk, Eloy H.	62
Van Der Kolk, Bessel A.	52, 84
Vanderplaats, Wilhelm G.W.	25
Vanderveen, Ernestine	25
Van Dooren, Hugo	18
van Gorp, Wilfred G.	43
Vanos, Jim J.	29
Varnier, Roy V.	22
Vassilis, Martiadis	55
Veenhuis, Philip E.	96
Veijola, Juha M.	29
Venkataraman, Sanjeev	40
Vergare, Michael J.	72
Vermetten, Eric	33
Verwey, Bas	62
Vicente, Benjamin	22, 78
Victor, Bruce S.	15
Viggiano, Erica	98
Viguera, Adele C.	67, 93
Vincent, Kathy M.	50
Viswanathan, Ramaswamy	99

Vita, Antonio	83
Vitiello, Benedetto	11, 85
Vogel-Scibilia, Suzanne E.	79
Volavka, Jan	49, 103
Volchek, Lior	24
Volkman, Edward A.	24, 97
Volkman, Janice	97
Volpp, Serena Y.	18, 44, 95

W

Wagner, Karen D.	13, 39, 63
Wagner, Larry R.	73
Wahl, David S.	57, 80
Wahl, Otto F.	93
Wahlstrom, Jr., Carl M.	73
Wain, Harold J.	68
Wainberg, Milton L.	31
Waite, Dennis	50
Wakefield, Jerome	84
Walaszek, Art C.	49
Wald, David	24
Waldron, John	22
Walia, Monica	99
Walker, David M.	100
Walker, Sandra C.	26, 47, 52, 65
Walkup, John T.	13, 71, 85
Wall, Barry W.	59, 78
Wallack, Joel J.	41, 48, 74
Walsh, B. Timothy	58, 84, 105
Walsh, Maralee	19
Wan, Yu M.	76
Wanat, Stanley	78
Wang, Po W.	8
Warner, Megan B.	83
Warner, Richard	85, 93
Warnock, Julia K.	35, 55
Wasyliv, Orest E.	50
Watts, Bradford	62
Wazana, Ashley D.	29
Weatherbee, Helen	61
Weaver, Carrie J.	33
Weaver, Richard	62
Webb, R. Mark	73
Wecker, Lynn	9
Weiden, Peter J.	12, 39
Weinberger, Daniel R.	9
Weiner, Joseph S.	32
Weiner, Richard D.	14
Weiner, Roy S.	48
Weinschenker, Naomi J.	80
Weinstein, Henry C.	104
Weinstein, Stephen P.	24
Weintraub, Daniel	45
Weiss, Daniel S.	78
Weiss, Margaret D.	7, 27, 40
Weiss, Roger D.	103
Weisser, Lydia E.	94
Weissman, Myrna M.	34, 79
Weizman, Abraham	24
Weller, Elizabeth B.	19
Wells, Victoria E.	98
Welner, Michael M.	25, 56, 73, 100, 106, 107
Werkman, Sidney L.	79
Wernicke, Joachim	35
West, Joyce C.	31, 32, 57
Westen, Drew	35
Westendord, Joan	36
Westmeyer, Joseph J.	104
Westrup, Darrah	78
White, Candace N.	50
White, Denise A.C.	88
Whitman, Anne	51
Whitney, Diane K.	45
Whitsell, Shelly	78

Whybrow, Peter C.	98
Wickrama, K. A. S.	23
Widiger, Thomas A.	35, 57
Wientjes, Henu	62
Wiesner, Irving S.	16, 61, 87
Wigal, Sharon	77
Wigg, Karen	86
Wilens, Timothy E.	35, 90
Williams, D. Keith	88
Williams, Mark D.	71
Williams, Richard	1
Williams, Veronica L.	18, 44
Williamson, Joan	96
Willick, Daniel H.	51
Wilson, Daniel	59
Wilson, G. Terrence	31
Wilson, Rodgers M.	73
Winey, Karen	30
Winkelman, John W.	90
Winstead, Daniel K.	19, 20, 99
Winterstein, Michele	96
Wirshing, Donna A.	13, 30
Wirshing, William C.	30
Wise, Lauren	78
Wise, Robert A.	78
Wise, Thomas N.	20
Wiseman, Claire	104
Wisner, Katherine L.	62, 83, 100, 101
Wisnewski, Steve	57
Woehr, Jennifer	101
Wolf, Charles J.	73
Wolfe, Barbara E.	105
Wolfson, Lee K.	68
Wolk, Sara	84
Wolkoff, David A.	73
Wong, Felicia	83
Wood, William G.	87
Woods, Scott W.	86
Woods, Sherwyn M.	79, 106
Woody, George E.	60
Worley, Linda L.M.	45, 94
Worthington III, John J.	23
Wozniak, Janet	11, 90
Wozniak, Steven T.	95
Wright, Doug	75, 102
Wright, Harry H.	40
Wright, Jesse H.	14, 97
Wulsin, Lawson R.	22, 98
Wynn, John D.	72

Y

Yager, Joel	7, 19, 31, 58, 73
Yalom, Irvin D.	16, 25
Yarhouse, Mark	84
Yates, Alayne	48
Yates, William R.	61
Yehuda, Rachel	25, 32, 43, 64, 105
Yen, Shirley	105
Yeomans, Frank E.	69
Yeung, Albert	76, 77
Yonkers, Kimberly A.	62, 67
York, Douglas L.	19
Yosef, Ismail	85
Young, Alexander S.	61
Young, Allan	30
Young, Keith W.	18, 44, 51, 59
Young, L. Trevor	104
Yudofsky, Stuart C.	13, 39, 44, 47

Z

Zajacka, John M.	63
Zanarini, Mary C.	23, 35, 60, 83, 105
Zarate, Jr., Carlos A.	64
Zaretsky, Ari E.	51
Zarin, Deborah A.	31, 57
Zavodnick, Jacquelyn M.	46
Zeanah, Charles H.	24, 40
Zerbe, Kathryn J.	32, 70, 94
Zhang, Wendy	30
Zheutlin, Barbara	61
Ziedonis, Douglas M.	5, 54, 87, 102
Zilberman, Monica L.	87
Zimmerli, Ellen	84
Zipursky, Robert B.	9
Zisook, Sidney	8, 59
Zitman, Frans G.	61, 62
Zito, Julie M.	78
Zolkind, Neil A.	19
Zuniga, Higinio	73
Zweig-Frank, Hallie	23

AMERICAN PSYCHIATRIC

APPI—Your Annual Meeting Bookstore

Grow professionally and increase your knowledge of psychiatric practices through the APPI Bookstore. Our extensive selection of topics and titles allows you to pick up the titles you've always wanted or find a title to complete series collections and annual reviews. We look forward to seeing you!



Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR™)

American Psychiatric Association

Since DSM-IV™ was published in 1994, we've seen many advances in our knowledge of psychiatric illness. This *Text Revision* incorporates information culled from a comprehensive literature review of research about mental disorders published since DSM-IV™ was completed in 1994. Updated information is included about the associated features, culture, age, and gender issues, prevalence; course; and familial pattern of mental disorders.

2000 • 1000 pages • ISBN 0-89042-024-6 • hardcover • \$71.95 • Item #2024

2000 • 1000 pages • ISBN 0-89042-025-4 • paperback • \$54.95 • Item #2025

Desk Reference to the Diagnostic Criteria From DSM-IV-TR™

American Psychiatric Association

Includes all the diagnostic criteria from DSM-IV-TR™ in an easy-to-use, spiralbound format. With a useful pull-out chart of the DSM-IV-TR™ Classification.

2000 • 496 pages • ISBN 0-89042-027-0 • spiralbound • \$32.50
Item #2027




Quick Reference to the Diagnostic Criteria From DSM-IV-TR™

American Psychiatric Association

Includes all the diagnostic criteria from DSM-IV-TR™ in a small paperback format.

2000 • 496 pages • ISBN 0-89042-026-2 • paperback • \$29.00 • Item #2026



A Pocket Reference for Psychiatrists, Third Edition

Susan C. Jenkins, M.D., Joyce A. Tinsley, M.D., and Jon A. Van Loon, M.D.

"A *Pocket Reference for Psychiatrists* is a compendium of tables and lists to be used by persons already familiar with the clinical practice of psychiatry. The book is designed to be a concise reference for the multitude of data needed in the practice of modern psychiatry."

—from the Preface

2001 • 336 pages • ISBN 1-58562-008-4 • paperback • \$29.50
Item #6208

Review of Psychiatry, Volume 20

Series Editors

John M. Oldham, M.D., and Michelle B. Riba, M.D.

PTSD in Children and Adolescents

Edited by Spencer Eth, M.D.

May 2001 • 208 pages • ISBN 1-58562-026-2 • paperback
\$29.95 • Item #62026

Integrated Treatment for Psychiatric Disorders

Edited by Jerald Kay, M.D.

May 2001 • 208 pages • ISBN 1-58562-027-0 • paperback
\$29.95 • Item #62027

Treatment of Recurrent Depression

Edited by John F. Greden, M.D.

May 2001 • 208 pages • ISBN 1-58562-025-4 • paperback
\$29.95 • Item #62025

Advances in Brain Imaging

Edited by John M. Murihisa, M.D.

May 2001 • 224 pages • ISBN 1-58562-028-9 • paperback
\$29.95 • Item #62028

Somatoform and Factitious Disorders

Edited by Katharine A. Phillips, M.D.

May 2001 • 208 pages • ISBN 1-58562-029-7 • paperback
\$29.95 • Item #62029

Borderline Personality Disorder

A Clinical Guide

John G. Gunderson, M.D.

"This book is a masterpiece of clinical wisdom. Gunderson is one of the world's experts in understanding and treating patients with borderline personality disorder, and he brings that expertise to these pages with a highly personal authentic style. . . This is an optimistic book, presenting how much we do now know about how to successfully help those who suffer with this condition."—John M. Oldham, M.D., Professor and Acting Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons, Director, New York State Psychiatric Institute

March 2001 • 360 pages • ISBN 1-58562-016-5 • hardcover • \$57.00
Item #62016

Visit us at the 2001 APA Annual Meeting

NEW in 2001

JANUARY

American Psychiatric Association Practice Guideline for the Treatment of Patients With HIV/AIDS

American Psychiatric Association

2001 • 128 pages • ISBN 0-89042-318-0
paperback • \$28.50 • Item #2318

The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition

(A Task Force Report of the American
Psychiatric Association)

American Psychiatric Association

2001 • 400 pages • ISBN 0-89042-206-0
hardcover • \$52.00 • Item #2206

Study Guide to The American Psychiatric Press Textbook of Geriatric Psychiatry, Second Edition

F.M. Baker, M.D., M.P.H.

2001 • 192 pages • ISBN 0-88048-697-X
paperback • \$29.50 • Item #8697

Treating Mental Illness and Behavior Disorders in Children and Adults With Mental Retardation

Edited by Anton Dorcen, M.D., Ph.D., and
Kenneth Day, M.B., C.H.B., F.R.C.Psych.,
D.P.M.

2001 • 608 pages • ISBN 0-88048-850-6
hardcover • \$79.00 • Item #8850

Treatment of Suicidal Patients in Managed Care

Edited by James M. Ellison, M.D., M.P.H.

2001 • 240 pages • ISBN 0-88048-828-X
paperback • \$39.00 • Item #8828

Schizophrenia and Comorbid Conditions: Diagnosis and Treatment

Edited by Michael Y. Hwang, M.D., and
Paul C. Bermanzohn, M.D.

2001 • 256 pages • ISBN 0-88048-771-2
hardcover • \$46.00 • Item #8771

Culture and Psychotherapy: A Guide to Clinical Practice

Edited by Wen-Shing Tseng, M.D., and
Jon Streltzer, M.D.

2001 • 320 pages • ISBN 0-88048-955-3
paperback • \$44.00 • Item #8955

Psychological Aspects of Women's Health Care: The Interface Between Psychiatry and Obstetrics and Gynecology, Second Edition

Edited by Nada L. Stotland, M.D., M.P.H.,
and Donna E. Stewart, M.D., D.Psych.,
F.R.C.P.C.

2001 • 688 pages • ISBN 0-88048-831-X
paperback • \$85.00 • Item #8831

Treatment of Depression: Bridging the 21st Century

Edited by Myrna M. Weissman, Ph.D.

2001 • 400 pages • ISBN 0-88048-397-0
hardcover • \$64.00 • Item #8397

FEBRUARY

Ethics Primer of the American Psychiatric Association

American Psychiatric Association

2001 • 128 pages • ISBN 0-89042-317-2
paperback • \$24.00 • Item #2317

School Violence: Assessment, Management, Prevention

Edited by Mohammad Shafii, M.D., and
Sharon Lee Shafii, R.N., B.S.N.

2001 • 352 pages • ISBN 1-58562-009-2
paperback • \$49.95 • Item #62009

MARCH

Self-Injurious Behaviors: Assessment and Treatment

Edited by Daphne Simeon, M.D., and Eric
Hollander, M.D.

2001 • 240 pages • ISBN 0-88048-808-5
paperback • \$34.00 • Item #8808

APRIL

Concise Guide to Cross-Cultural Psychiatry

Albert C. Gaw, M.D.

2001 • 224 pages • ISBN 0-88048-907-3
paperback • \$27.95 • Item #8907

Textbook of Administrative Psychiatry: New Concepts for a Changing Behavioral Health System, Second Edition

Edited by John A. Talbott, M.D., and
Robert E. Hales, M.D., M.B.A.

2001 • 480 pages • ISBN 0-88048-745-3
hardcover • \$74.00 • Item #8745

MAY

Concise Guide to the Cytochrome P450: Drug Interaction Principles for Medical Practice

Kelly L. Cozza, M.D., and Scott C.
Armstrong, M.D.

2001 • 272 pages • ISBN 1-58562-000-9
paperback • \$29.95 • Item #62000

Psychiatric Neuroimaging Research: Contemporary Strategies

Edited by Darin D. Dougherty, M.D., and
Scott L. Rauch, M.D.

2001 • 448 pages • ISBN 0-88048-844-1
hardcover • \$79.95 • Item #8844

Treatments of Psychiatric Disorders, Third Edition

Edited by Glen O. Gabbard, M.D.

2001 • 3088 pages • ISBN 0-88048-910-3
hardcover - 2 volumes • \$279.00
Item #8910

The Principles of Ethics with Annotations Especially Applicable to Psychiatry, 2001 Edition

American Psychiatric Association

2001 • 48 pages • ISBN 0-89042-143-9
paperback • \$10.00 • Item #2143

Opinions of the Ethics Committee on The Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry, 2001 Edition

American Psychiatric Association

2001 • 64 pages • ISBN 0-89042-144-7
paperback • \$10.00 • Item #2144

Concise Guide to Women's Mental Health, Second Edition

Vivien K. Burt, M.D., Ph.D., and
Victoria C. Hendrick, M.D.

2001 • 180 pages • ISBN 1-58562-030-0
paperback • \$27.95 • Item #62030

The Latino Psychiatric Patient: Assessment and Treatment

Edited by Ernestina Carrillo, L.C.S.W.,
and Alberto G. Lopez, M.D., M.P.H.

2001 • 240 pages • ISBN 0-88048-773-9
paperback • \$28.95 • Item #8773

Concise Guide to Treatment of Alcoholism and Addictions, Second Edition

Avram H. Mack, M.D., John E. Franklin
Jr., M.D., M.Sc., and Richard J.
Frances, M.D.

2001 • 189 pages • ISBN 0-88048-803-4
paperback • \$27.95 • Item #8803

Current Treatments of Obsessive- Compulsive Disorder, Second Edition

Edited by Michele Tortora Pato, M.D.,
and Joseph Zohar, M.D.

2001 • 336 pages • ISBN 0-88048-779-8
hardcover • \$49.95 • Item #8779

The Frontal Lobes and Neuropsychiatric Illness

Edited by Stephen P. Salloway, M.D.,
M.S., Paul F. Malloy, Ph.D., and
James D. Duffy, M.B., Ch.B.

2001 • 304 pages • ISBN 0-88048-800-X
hardcover • \$59.00 • Item #8800

Essentials of Clinical Psychopharmacology

Edited by Alan F. Schatzberg, M.D., and
Charles B. Nemeroff, M.D.

2001 • 752 pages • ISBN 1-58562-017-3
paperback • \$75.00 • Item #62017

Concise Guide to Psychiatry for Law and Clinicians, Third Edition

Robert I. Simon, M.D.

2001 • 320 pages • ISBN 1-58562-024-6
paperback • \$27.95 • Item #62024

Clinical Study Guide for the Oral Boards in Psychiatry

Nathan R. Strahl, M.D., Ph.D.

2001 • 320 pages • ISBN 0-88048-830-1
paperback • \$29.95 • Item #8830

Bookstore Hours:

Saturday, May 5
11:00 a.m. - 5:00 p.m.

Sunday, May 6
11:00 a.m. - 4:00 p.m.

Monday, May 7
10:00 a.m. - 6:00 p.m.

Tuesday, May 8
10:00 a.m. - 6:00 p.m.

Wednesday, May 9
10:00 a.m. - 3:00 p.m.



1400 K Street, N.W.,
Washington, D.C. 20005

Phone: Toll Free 1-800-368-5777,
9:00 am-5:00 pm, ET


Fax: 1-202-789-2648

Email: appi@psych.org

Internet: www.appi.org

INDUSTRY-SUPPORTED SYMPOSIUM 1
Saturday, May 5, 7:00 PM-10:00 PM
Grand Ballroom A/B, Street Level, Hilton

APA 2001 ANNUAL MEETING



*Sleep:
a Window
on Mind and
Brain*

Chair: Milton K. Erman, MD

Buffet Dinner: 6:30 pm – Symposium: 7:00 to 10:00 pm

The Pathogenesis of Narcolepsy and Hypersomnia
Emmanuel Mignot, MD
Stanford University

Influences of Light on Sleep and Mood
Barbara L. Parry, MD
University of California

Violent Behaviors Arising from the Sleep Period
Mark W. Mahowald, MD
Hennepin County Medical Center

Sleep Apnea: Why Treat It?
Meir H. Kryger, MD
University of Manitoba

New Options in the Treatment of Insomnia
Milton K. Erman, MD
University of California

There will be 45 minutes for **Questions and Answers** at the end of the symposium.


Objectives:
Better understand molecular and genetic influences on sleepiness, recognize the role that light plays in regulation of sleep and mood, understand how violent behaviors may occur in sleep, diagnose and treat sleep apnea, and use new and more effective treatments for insomnia.

Registration:
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 5, 7:00 PM-10:00 PM
Grand Ballroom C/D, Street Level, Hilton

AMERICAN PSYCHIATRIC ASSOCIATION 2001 ANNUAL MEETING



Advances in the Treatment of Depression in Women: Beyond Clinical Lore

Saturday, May 5, 2001 Hilton New Orleans Riverside • Grand Ballroom C/D, Street Level • New Orleans, Louisiana

6:30PM Dinner • 7:00PM-10:00PM Educational Program

6:30PM Dinner

7:00PM Welcome and Introduction
Teri B. Pearlstein, MD
Program Chairperson
Assistant Professor of Psychiatry and Human Behavior,
Brown University School of Medicine
Director, Women's Behavioral Health Program,
Women and Infants Hospital
Providence, Rhode Island

7:10PM Gender-Based Differences in the Treatment of Depressed Women
Susan G. Kornstein, MD
Associate Professor of Psychiatry and Obstetrics/Gynecology,
Chair, Division of Ambulatory Care Psychiatry
Director, Institute for Women's Health
Medical College of Virginia
Virginia Commonwealth University
Richmond, Virginia

7:45PM Treatment Strategies of PMS and PMDD
Teri B. Pearlstein, MD
Program Chairperson

8:20PM Challenges and Controversies in the Treatment of Childbearing Women
Lee S. Cohen, MD
Program Co-Chairperson
Director, Perinatal and Reproductive Psychiatry
Clinical Research Program
Associate Professor of Psychiatry, Harvard Medical School
Massachusetts General Hospital,
Boston, Massachusetts

8:55PM Critical Issues in Mood and Cognition for Menopausal Women
Hadine Joffe, MD
Director, Women's Center for Behavioral Endocrinology, McLean Hospital
Associate Psychiatrist, Perinatal and Reproductive Psychiatry Program,
Massachusetts General Hospital
Instructor in Psychiatry, Harvard Medical School
Boston, Massachusetts

9:25PM Question and Answer Session
There will be 5 minutes of questions and answers after each presentation.


Program Description
When treating mood disorders in women, physicians need to determine a management strategy based upon evaluation and data as opposed to clinical lore. This program will consider some of the latest advances in the treatment of depression in women by first examining gender-based differences in treatment and then treatment strategies when dealing with PMS and PMDD. Further discussions will explore the treatment of depression during pregnancy and lactation, as well as take an in-depth look at aging baby boomers with respect to critical issues in depression and cognition. The symposium will close with a comprehensive question and answer session.

Learning Objectives
At the conclusion of this symposium, participants will be able to


1. Be familiar with a range of treatments for mood disorders associated with significant female reproductive life events such as postpartum depression, premenstrual dysphoric disorder, and perimenopausal mood disturbance.
2. Demonstrate increased understanding of gender issues in the assessment and treatment of depression.
3. Compare the various treatment options available, such as nonpharmacologic and pharmacologic therapies, in the clinical management of the PMDD patient.
4. Make a thoughtful risk/benefit decision regarding the use of psychiatric medications during pregnancy and conceptualize the extent of infant exposure associated with the use of these agents during lactation.
5. Demonstrate an understanding of the effects of estrogen and other gonadal steroids on mood and cognitive disturbances in women during and after menopause.

Accreditation and Credit Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Registration
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1.888.357.7924 within the US or Canada or at 202.682.6000.



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Eli Lilly and Company

INDUSTRY-SUPPORTED SYMPOSIUM 3

Saturday, May 5, 7:00 PM-10:00 PM
Napoleon Ballroom, Third Floor, Hilton

APA 2001 ANNUAL MEETING

Suicide Risk and Bipolar Disorder: Neurobiology and Treatment

Saturday, May 5, 2001 • Napoleon Ballroom, Third Floor, Hilton Hotel • New Orleans, Louisiana

- 6:30 PM – 7:00 PM Dinner**
- 7:00 PM – 10:00 PM Symposium**
- 7:00 PM – 7:10 PM Welcome and introduction**
J. John Mann, MD—Chairperson—College of Physicians and Surgeons of Columbia University
- 7:10 PM – 7:35 PM Clinical Factors Affecting Suicide Risk in Bipolar Disorder**
Kay R. Jamison, PhD—Johns Hopkins University School of Medicine
- 7:35 PM – 8:00 PM Neurobiology of Suicide and Bipolar Disorder**
J. John Mann, MD
- 8:00 PM – 8:25 PM Efficacy of Mood Stabilizers in Suicide Prevention**
Ross J. Baldessarini, MD—Harvard Medical School
- 8:25 PM – 8:50 PM Clinical Management of the Suicidal Bipolar Patient**
Frederick K. Goodwin, MD—George Washington University School of Medicine and Health Sciences
- 8:50 PM – 9:15 PM Management of Bipolar Disorder in Youth**
David Shaffer, MD—College of Physicians and Surgeons of Columbia University
- 9:15 PM – 10:00 PM Question-and-answer session**

Educational Objectives

At the conclusion of this presentation, the participants will be better able to

- Make a better selection of the most appropriate medication and nonmedication interventions to reduce the risk of suicide attempts in bipolar adults and youth
- Increase their knowledge of the neurobiological underpinnings of mood disorders and suicide risk

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at (888) 357-7924 (within the United States or Canada) or (202) 682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit toward the Physician's Recognition Award of the American Medical Association and for the continuing medical education requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This symposium is sponsored by the American Psychiatric Association.

Supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc., and the American Foundation for Suicide Prevention.

INDUSTRY-SUPPORTED SYMPOSIUM 4

Saturday, May 5, 7:00 PM-10:00 PM
Acadia Ballroom, Third Floor, Marriott

Upon completion of this symposium, attendees should be able to:

- Describe serotonergic, hypothalamic-pituitary-adrenal, and neuroimaging changes during depression and with treatment
- Discuss antidepressant switching and augmentation strategies
- Review evidence for the use of nonpharmacologic treatments

To Switch or Augment: Contemporary Approaches to Resistant Depression

- 6:30 PM Dinner Reception**
- 7:00 PM Introduction**
Andrew A. Nierenberg, MD, Chairperson
- 7:10 PM Neurobiological Mechanisms of Treatment Resistance: The Role of Stress**
Juan F. Lopez, MD, University of Michigan Medical School
- 7:35 PM The Neural Basis of Antidepressant Response and Nonresponse**
Wayne C. Drevets, MD, National Institute of Mental Health
- 8:00 PM The Use of Switching in Depression Treatment**
Charles DeBattista, MD, Stanford University School of Medicine
- 8:25 PM When to Augment Antidepressants**
Andrew A. Nierenberg, MD, Harvard Medical School
- 8:50 PM The Role of Nonpharmacologic Interventions for Treatment-Resistant Depression**
Lauren B. Morrongiello, MD, Baylor College of Medicine
- 9:15 PM Questions and Answers**
- 10:00 PM Adjourn**

Saturday
May 5, 2001
7:00 pm - 10:00 pm
Marriott Hotel
Acadia Ballroom
New Orleans

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-serve basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Pharmacia Corporation

PHARMACIA

INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 5, 7:00 PM-10:00 PM
Carondelet Ballroom, Third Floor, Marriott



The New Biology of Depression and Antidepressant Treatment

APA 2001 Annual Meeting
Saturday, May 5, 2001
 6:30 PM – 7:00 PM Dinner
 7:00 PM – 10:00 PM Scientific Program

Marriott, Carondelet Ballroom
Third Floor
New Orleans, Louisiana


7:00 PM	Introduction <i>Jerrold F. Rosenbaum, MD-Chairman</i> Harvard Medical School	Sponsored by the American Psychiatric Association. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.
7:10 PM	The Depressed Brain Imaged <i>Helen S. Mayberg, MD</i> University of Toronto	
7:40 PM	The New Biology of Depression <i>Dennis S. Charney, MD</i> Yale University School of Medicine	
8:10 PM	What Do Antidepressants Do? Understanding Antidepressant Molecules, Neurotransmitters, and Receptors <i>Pierre Blier, MD</i> University of Florida	
8:40 PM	Healing the Depressed Brain: Signal Transduction, Gene Transcription, and Plasticity <i>Eric J. Nestler, MD</i> University of Texas	
9:10 PM	Question and Answer Session Psychiatrists using biological therapies and biological explanatory models with patients need to understand contemporary thinking about the biology of depression. In this symposium, attendees will learn new biological concepts of depression, visualize images of the depressed brain, and understand the mechanisms of action behind the treatment of depression. Attendees will also learn the differentiating pharmacodynamic properties of new antidepressant agents and their respective therapeutic implications.	

INDUSTRY-SUPPORTED SYMPOSIUM 6
Saturday, May 5, 7:00 PM-10:00 PM
Mardi Gras Ballroom, Third Floor, Marriott

Glucose Control and Diabetes Mellitus During Antipsychotic Treatment

Symposium to be held during the Year 2001 APA Annual Meeting
Saturday, May 5, 2001
 6:30 – 7:00 PM, Dinner; 7:00 – 10:00 PM, Symposium
New Orleans Marriott, Third Floor, Mardi Gras Ballroom
Chair: John W. Newcomer, MD

7:00–7:05 PM Welcome and Introduction <i>John W. Newcomer, MD (Chair)</i>	7:30–7:55 PM Cardiovascular Risk Increases With Glucose Levels Regardless of Diabetes Status <i>Hertzel C. Gerstein, MD</i> Department of Medicine McMaster University Hamilton, Ontario, Canada	8:20–8:45 PM Atypical Antipsychotic Agents: Diabetes and Bergman's Minimal Model Analysis <i>David C. Henderson, MD</i> Department of Psychiatry Massachusetts General Hospital Boston, Massachusetts	9:05–9:15 PM Discussion <i>Herbert V. Meltzer, MD</i> Department of Psychiatry Vanderbilt University School of Medicine Nashville, Tennessee
7:05–7:30 PM Diagnosis, Classification and Pathogenesis of Hyperglycemia <i>Harold E. Lebovitz, MD</i> Department of Medicine SUNY Downstate Medical Center Brooklyn, New York	7:55–8:20 PM Antipsychotic-related Change in Glucose Regulation <i>John W. Newcomer, MD</i> Department of Psychiatry Washington University School of Medicine St. Louis, Missouri	8:40–9:05 PM Inhibition of Glucose Transport by Antipsychotic Drugs <i>Donard S. Dwyer, PhD</i> Department of Psychiatry LSU Medical Center Shreveport, Louisiana	9:15–10:00 PM Question & Answer Session




Educational Objectives: On completion of this activity, participants should be able to: 1. Recognize clinical and laboratory signs of diabetes mellitus. 2. Identify antipsychotic medications that can increase the risk of hyperglycemia. 3. Review options for monitoring and initial management of plasma glucose.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The APA designates this educational activity for up to 3.0 hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or (202) 682-6000.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from



JANSSEN
PHARMACEUTICALS, L.P.


01-RS-798C

INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 5, 7:00 PM-10:00 PM
Grand Ballroom A-C, Fifth Floor, Sheraton


154th Annual Meeting of the American Psychiatric Association

Posttraumatic Stress Disorder

Clinical Characteristics and Treatment Options




<p>AGENDA</p> <p>6:30 PM Dinner</p> <p>7:00 Welcome and Introduction Kathleen T. Brady, MD, PhD Program Chairperson Professor of Psychiatry Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston, South Carolina</p> <p>7:15 Posttraumatic Stress Disorder: Diagnostic Issues and Comorbidity Kathleen T. Brady, MD, PhD</p> <p>7:45 Sympathetic Nervous System Dysregulation in Posttraumatic Stress Disorder Steven Southwick, MD Professor of Psychiatry Yale University School of Medicine New Haven, Connecticut National Center for Posttraumatic Stress Disorder VA Connecticut Healthcare System West Haven, Connecticut</p> <p align="center">May 5 2001</p> <p align="center">Grand Ballroom A-C, Fifth Floor Sheraton New Orleans Hotel New Orleans, Louisiana</p>	<p>8:15 Advances in the Pharmacotherapy of Posttraumatic Stress Disorder Charles R. Marmar, MD Professor and Vice Chair Department of Psychiatry University of California San Francisco, California</p> <p>8:45 Psychotherapy of Posttraumatic Stress Disorder Barbara O. Rothbaum, PhD Associate Professor in Psychiatry Director, Trauma and Anxiety Recovery Program Emory University School of Medicine Atlanta, Georgia</p> <p>9:15 Question and Answer Session Faculty Panel</p> <p>10:00 Adjourn</p>	<p>OBJECTIVES</p> <p>At the conclusion of this symposium, participants should be able to:</p> <ul style="list-style-type: none"> • Review recent findings concerning the neurobiology of posttraumatic stress disorder (PTSD); • Discuss how comorbidities can impact the presentation and course of PTSD; • Describe psychotherapeutic approaches for managing PTSD; • Identify new developments in the pharmacotherapeutic treatment of PTSD. <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</p>
---	--	---



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 8
Sunday, May 6, 8:00 AM-11:00 AM
Grand Ballroom A/B, Street Level, Hilton



APA 2001 Annual Meeting

Symptomatic and Functional Recovery: Attainable Goals in Treating Depression?

Buffet Breakfast: 7:30 a.m. / Symposium: 8:00 - 11:00 a.m.

Chair: A. John Rush, M.D.

Topics and Faculty

What is Remission? Why is it Important; and When Does it Occur?	Lauren B. Marangell, M.D. <i>Baylor College of Medicine</i>
Are All Antidepressant Medications Equivalent in Attaining Remission?	Michael E. Thase, M.D. <i>University of Pittsburgh</i>
Does Combining Medications or Medication Sequences Lead to Remission?	Jack M. Gorman, M.D. <i>Columbia University</i>
What is the Role of Psychotherapy in Attaining Remission?	A. John Rush, M.D. <i>University of Texas Southwestern Medical Center</i>

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

There will be 45 minutes of questions and answers at the end of the symposium.

Sponsored by the American Psychiatric Association
 Supported by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 9

Sunday, May 6, 8:00 AM-11:00 AM
Grand Ballroom C/D, Street Level, Hilton



Critical Decisions in the Lifetime Treatment of Schizophrenia

7:30AM Breakfast
Edison Institute and Introduction
Diane O. Perkins, MD, MPH
Program Chairperson
Associate Professor of Psychiatry,
Director, Schizophrenia Treatment
and Evaluation Program
University of North Carolina School of Medicine
Chapel Hill, North Carolina

8:10AM First Speaker
Establishing Neuroprotection
Diane O. Perkins, MD, MPH
Program Chairperson

**9:10AM Contemporary and
The Cost of Relapse**
Gerald A. Maguire, MD
Assistant Clinical Professor,
Director of Residency Training,
Department of Psychiatry
University of California-Irvine
Irvine, California

**9:30AM Neurobiology and the Development
of Treatment Resistance in Patients With
Schizophrenia: Strategies for Prevention**
Jeffrey A. Lieberman, MD
Program Co-Chairperson
Thad and Alice Eum Distinguished Professor
of Psychiatry, Pharmacology, and Radiology
Vice Chair of Research, Department of Psychiatry
Director, Mental Health and Neuroscience
Clinical Research Center
University of North Carolina School of Medicine
Chapel Hill, North Carolina

**9:45AM Clinical Decisions in the Treatment
of Adolescent and Adolescent Psychosis**
Linmarie Sikich, MD
Assistant Professor of Psychiatry,
Division of Child Psychiatry and TEACCH
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

10:15AM Drug Education Across the Lifetime
Richard S.E. Keefe, PhD
Associate Professor, Duke University Medical Center
Durham, North Carolina

10:30AM Question and Answer Session
There will be 5 minutes of questions and answers
after each presentation.

Program Description
The critical period of onset in schizophrenia is considered to be adolescence through the third decade of life, and its morbidity involves multiple symptoms and behavioral domains. Therefore, physicians need to address the pivotal clinical situations that call for crucial treatment decisions throughout a patient's lifetime. This program will begin by examining the first episode of schizophrenia and how physicians can establish neuroprotection for a given patient. Subsequent presentations will explore symptomatology and the cost of relapse, including prevention strategies and an analysis of neurobiology and the development of treatment resistance. Finally, there will be a look at cognition across the lifetime and a discussion of critical decisions in the treatment of adolescent and pediatric psychosis. The symposium will close with a comprehensive question and answer session.


Learning Objectives
At the conclusion of this symposium, participants will be able to:
1. Understand the early stages of the schizophrenic illness and the potential for neuroprotective treatment.
2. Discuss the recurrent nature of schizophrenic illness.
3. Discuss studies of the treatment of the chronic and treatment-resistant patient to illustrate the late stages of the illness.
4. Understand the cognitive dimension of schizophrenic illness and its relation to functional outcome.
5. Apply the research results of controlled studies of adolescent onset psychosis.

Accreditation and Credit Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Registration
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or at 202-682-6000.
Sponsored by the American Psychiatric Association.
Supported by an unrestricted educational grant from Eli Lilly and Company.

INDUSTRY-SUPPORTED SYMPOSIUM 10

Sunday, May 6, 8:00 AM-11:00 AM
Napoleon Ballroom, Third Floor, Hilton



**To Work & To Love:
Focus on QUALITY OF LIFE in
Mood and Anxiety Disorders**

A BREAKFAST SYMPOSIUM HELD AT
THE AMERICAN PSYCHIATRIC ASSOCIATION
154TH ANNUAL MEETING | SUNDAY,
MAY 6, 2001 8:00 AM — 11:00 AM Hilton
New Orleans Riverside | Napoleon Ballroom,
Third Floor

*Supported by an unrestricted educational
grant from GlaxoSmithKline.*

Program Objectives
After attending this continuing education program, the psychiatrist should be able to:

- Describe measures of quality of life that can be used to assess the impact of depression and anxiety disorders and the treatment of these disorders
- Outline management approaches that can improve the quality of life in patients with bipolar disorder
- Review the poor quality of life that occurs in patients with anxiety disorders and the benefits that can result from appropriate treatment
- Identify the impact that depression has on quality of life and measurable improvements that can occur following effective treatment.

Agenda

7:30 AM	Breakfast
8:00 AM	Welcome and Introduction Mark H. Rapaport, MD Symposium CoChair University of California San Diego Mark H. Pollack, MD Symposium CoChair Harvard Medical School
8:10 AM	Measures of Quality of Life Jean Endicott, PhD Columbia University
8:40 AM	Improving Quality of Life for Patients With Bipolar Disorder Holly A. Swartz, MD University of Pittsburgh
9:10 AM	Quality of Life in the Anxiety Disorders Mark H. Pollack, MD
9:40 AM	The Impact of Depression and Its Treatment Mark H. Rapaport, MD
10:10 AM	Panel Discussion With Questions and Answers
10:55 AM	Closing Remarks

Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 1-202-682-6000.

INDUSTRY-SUPPORTED SYMPOSIUM 11

Sunday, May 6, 8:00 AM-11:00 AM

Acadia Ballroom, Third Floor, Marriott

APA 2001
ANNUAL
MEETING

Meeting the Challenge of **Schizophrenia** and CO-OCCURRING ADDICTIONS

OBJECTIVES

- Understand the obstacles and options for effective treatment of patients with schizophrenia and co-occurring addictions.
- Recognize the role of new generation of antipsychotic medications for these conditions and learn how they can be combined with non-medication strategies.

Accreditation/Designation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Participation

Attendees must be registered for the APA Annual Meeting to attend this Symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. and Canada) or 202/882-6000.

EDUCATIONAL COUNCIL

Chairperson
Alan L. Green, MD
Harvard Medical School
Boston, Massachusetts

Co-chair:
William M. Glazer, MD
Harvard Medical School
Boston, Massachusetts

Lisa Dixon, MD, MPH
University of Maryland School of Medicine
Baltimore, Maryland

Herbert Meltzer, MD
Vanderbilt University School of Medicine
Nashville, Tennessee

Douglas M. Ziedonis, MD
Robert Wood Johnson Medical School
Piscataway, New Jersey

Robert E. Drake, MD, PhD
Dartmouth Medical School
Lebanon, New Hampshire



Sponsored by
the American
Psychiatric
Association



AGENDA Breakfast will be provided 30 minutes prior to the scheduled event. There will be a 10-minute question and answer session following each presentation.

8:00 SCHIZOPHRENIA AND CO-OCCURRING DISORDERS: THE SCOPE OF THE PROBLEM AND IMPACT ON OUTCOMES
— *Lisa B. Dixon, MD*

8:30 THE NEUROBIOLOGY OF ADDICTION AND SCHIZOPHRENIA IN RELATION TO THE ACTION OF ANTIPSCHOTIC DRUGS
— *Herbert Y. Meltzer, MD*

9:00 PHARMACOTHERAPY OF COMORBID SUBSTANCE USE DISORDERS
— *Alan I. Green, MD*

9:30 INTEGRATING PHARMACOTHERAPY AND DUAL RECOVERY THERAPY
— *Douglas M. Ziedonis, MD*

10:00 BEST SYSTEMS AND PRACTICES FOR DUAL DIAGNOSIS
— *Robert E. Drake, MD*

10:30 DISCUSSANT
— *William M. Glazer, MD*

10:40 AUDIENCE – PANEL DISCUSSION

NOTES: Supported by an unrestricted educational grant from Hoechst Pharmaceuticals Corporation

THE SYMPOSIUM WILL END AT 11:00 AM.

INDUSTRY-SUPPORTED SYMPOSIUM 12

Sunday, May 6, 8:00 AM-11:00 AM

Carondelet Ballroom, Third Floor, Marriott

Men Over 50: An Endangered Species

APA 2001 Annual Meeting

- 8:00 AM Introduction**
Steven P. Roose, MD, Chairman
- 8:10 AM Testosterone Decline in Aging Men: Does "Andropause" Exist?***
Stuart N. Seidman, MD
Columbia University
- 8:40 AM Sexual Functioning Past 50***
Raymond C. Rosen, PhD
Robert Wood Johnson University Hospital
- 9:10 AM Vascular Disease and Depression***
Ranga R. Krishnan, MD
Duke University Medical Center
- 9:40 AM Depression and Dementia in Older Men***
Gary W. Small, MD
University of California, Los Angeles
- 10:10 AM Suicide in Men Over 50: An Epidemic***
Steven P. Roose, MD
Columbia University
- 10:40 AM Question and Answer Session**

* Each presentation will be followed by a 5-minute question and answer session.

Sunday, May 6, 2001

7:30 AM – 8:00 AM Breakfast

8:00 AM – 11:00 AM Scientific Program

Marriott, Carondelet Ballroom, Third Floor
New Orleans, Louisiana

Men over 50 enter a period in life in which they must face the increasing prevalence of life-threatening illness and other conditions that can markedly impair quality of life.

Most mortality in men results from vascular disease, either stroke or myocardial infarction, and from suicide, which has become a virtual epidemic in older men. Other disorders that markedly impair quality of life in men are the increasing prevalence of sexual dysfunction, particularly erectile failure, and cognitive deterioration. These conditions may be associated with the age-associated decline in testosterone. Perhaps most striking is that vascular disease, erectile dysfunction, cognitive decline, and decreased testosterone are all strongly associated with depression. This symposium will review the conditions that contribute to morbidity and mortality in men over 50, the significance of depression as a comorbid illness, and the reciprocal benefits of treating depression as well as the medical disorders.

Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.


Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

Supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 13

Sunday, May 6, 8:00 AM-11:00 AM

Mardi Gras Ballroom, Third Floor, Marriott



*Please join us at the
APA 2001 Annual Meeting
Sponsored by the American
Psychiatric Association*

Sunday, May 6th

7:30 AM Breakfast ~ 8:00-11:00 AM Clinical Program
New Orleans Marriott ~ Mardi Gras Ballroom, 3rd Floor

Issues in the Long-Term Treatment of Depression

Anita H. Clayton, MD
Symposium Chair

Maurizio Fava, MD
Symposium Co-Chair

Weight Changes During Long-Term Antidepressant Treatment
Maurizio Fava, MD
Associate Chief of Psychiatry for Clinical Research
Director, Depression Clinical and Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Antidepressant-Induced Sexual Dysfunction
Anita H. Clayton, MD
Associate Professor and Vice Chair
Medical Director
Center for Psychiatric Clinical Research
Department of Psychiatric Medicine
University of Virginia Health System
Charlottesville, Virginia

The Role of Psychotherapy in Long-Term Treatment
Gabor I. Keitner, MD
Director of the Mood Disorders Program
Associate Psychiatrist in Chief
Rhode Island Hospital
Professor, Department of Psychiatry and Human Behavior
Brown University
Providence, Rhode Island


Identification of Relapse
P. Murali Doraiswamy, MD
Interim Head, Division of Biological Psychiatry
Director, Clinical Trials
Department of Psychiatry and Behavioral Sciences
Associate Professor of Biological Psychiatry
Duke University Medical Center
Durham, North Carolina

Management of Depressive Breakthrough During Long-Term Treatment
Jonathan E. Alpert, MD
Associate Director, Depression Clinical and Research Program
Massachusetts General Hospital
Assistant Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

Educational Objectives:
Examine depressive breakthrough during the long-term treatment of depression, and identify factors complicating maintenance treatment of major depressive disorder

Agenda
7:30 - 8:00 AM Breakfast
8:00 - 8:05 AM Introduction - A. Clayton, MD
8:05 - 10:15 AM Speaker presentations
10:15 - 11:00 AM Question and answer session
11:00 AM Program concludes


Registration:
Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for up to 3.0 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
This program is supported by an unrestricted educational grant from 

INDUSTRY-SUPPORTED SYMPOSIUM 14

Sunday, May 6, 8:00 AM-11:00 AM

Grand Ballroom A-C, Fifth Floor, Sheraton




Alcoholism and Bipolar Disorders: Treatment Options Circa 2001

Sunday, May 6, 2001
8:00 AM - 11:00 AM
Grand Ballroom A-C, 5th Floor
Sheraton New Orleans
New Orleans, Louisiana

American Psychiatric Association
154th Annual Meeting

Breakfast 7:30 AM - 8:00 AM

Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Pfizer Inc.

Symposium Objectives
Upon completion of this CME activity, the practicing clinician should be better able to:

- ◆ Assess and treat primary alcoholism and alcoholism withdrawal
- ◆ Evaluate how alcohol use affects suicidality, long-term course of bipolar illness, and mood stabilization response
- ◆ Discuss current treatment options for substance-abuse withdrawal
- ◆ Explain the rationale for use of antiepileptic drugs in treating alcohol abuse.

Scientific Program
(Each presentation is 25 minutes with 5 minutes of Q&A.)

7:30 AM - 8:00 AM **Breakfast**

8:00 AM - 8:10 AM **Welcome and Introduction**
Mark A. Frye, MD • University of California, Los Angeles

8:10 AM - 8:40 AM **New Pharmacotherapies for Alcohol Dependence**
Barbara J. Mason, PhD • University of Miami

8:40 AM - 9:10 AM **Suicidality, Impulsivity, and Alcoholism**
Joseph F. Goldberg, MD • Cornell University School of Medicine

9:10 AM - 9:40 AM **Antiepileptic Drugs in Alcohol Withdrawal and Relapse**
Hugh Myrick, MD • Medical University of South Carolina

9:40 AM - 10:10 AM **Bipolar Disorder and Comorbid Alcoholism: Course of Illness and Treatment Implications**
Mark A. Frye, MD

10:10 AM - 10:40 AM **Antiepileptic Drugs and Lithium in the Treatment of Bipolar Illness and Alcohol Use Disorders**
Patricia Suppes, MD, PhD
The University of Texas Southwestern Medical Center

10:40 AM - 11:00 AM **Q & A, Discussion and Close**
Mark A. Frye, MD

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit he/she actually spent in the educational activity.

Registration
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

INDUSTRY-SUPPORTED SYMPOSIUM 15
Sunday, May 6, 1:30 PM-4:30 PM
Grand Ballroom A/B, Street Level, Hilton

A Dinner Symposium...

Treating Psychotic Disorders: What Is the State-of-the Art?

Art courtesy of NARSAD Artworks. Art on and behalf of the mentally ill.

Sunday, May 6, 2001
1:30 PM-4:30 PM
Grand Ballrooms A & B Street Level
Hilton Hotel
New Orleans, Louisiana

OBJECTIVES
 Upon completion of this symposium, attendees should be able to:

- Discuss treatment options for managing a broad spectrum of psychotic symptoms
- Outline the pharmacological and clinical differences among conventional, atypical, and combined therapies for schizophrenia
- List treatment options for psychotic depression
- Review treatment options for bipolar disorder using anticonvulsants and atypical antipsychotics
- Review the diagnostic features of pediatric and geriatric psychosis and discuss options for their treatment

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-257-7524 (within the U.S. or Canada) or 202-662-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.

AGENDA

1:00 PM **Lunch/Reception**

1:30 PM **Introduction**
 Jeffrey A. Lieberman, MD, Chairperson
 James W. Jefferson, MD, Co-chairperson

1:40 PM **Issues in Managing Psychosis in Geriatric Patients**
 Dilip V. Jeste, MD
 University of California Medical School at San Diego

2:05 PM **Treatment of Depression with Psychosis**
 Robert N. Golden, MD
 University of North Carolina School of Medicine

2:30 PM **Emerging Treatments in Bipolar Disorder**
 Terence A. Ketter, MD
 Stanford University Medical School

2:55 PM **Treating the Spectrum of Symptoms in Schizophrenia**
 Jeffrey A. Lieberman, MD
 University of North Carolina School of Medicine

3:20 PM **Treatment of Pediatric Psychosis**
 Judith H.L. Rapoport, MD
 National Institute of Mental Health

3:45 PM **Panel Discussion**
 James W. Jefferson, MD
 University of Wisconsin Medical School

4:30 PM **Adjourn**

Bristol-Myers Squibb Company Otsuka Pharmaceutical Co., Ltd.

INDUSTRY-SUPPORTED SYMPOSIUM 16
Sunday, May 6, 1:30 PM-4:30 PM
Grand Ballroom C/D, Street Level, Hilton

American Psychiatric Association 2001 Annual Meeting

1:00PM Luncheon
1:30PM Welcome and Introduction
 Paul E. Keck, Jr, MD
 Program Chairperson
 Professor of Psychiatry and Pharmacology
 Vice Chairman for Research, Department of Psychiatry
 University of Cincinnati College of Medicine
 Cincinnati, Ohio

**1:40PM Manic and Mixed Episodes:
The Challenge of Improving
Functional Outcome**
 Paul E. Keck, Jr, MD
 Program Chairperson

**2:10PM New Horizons in the Treatment
of Bipolar Depression**
 K.R. Roy Chengappa, MD
 Associate Professor of Psychiatry, University of Pittsburgh
 Director, Special Studies Center, Mayview State Hospital
 Western Psychiatric Institute and Clinic
 Pittsburgh, Pennsylvania

2:40PM Women and Bipolar Disorder
 Lori L. Altshuler, MD
 Professor, Department of Psychiatry
 and Behavioral Sciences
 Director, Mood Disorders Research Program
 University of California-Los Angeles
 Los Angeles, California

**3:10PM Maintenance Treatment for
Patients With Bipolar Disorder**
 Joseph F. Goldberg, MD
 Assistant Professor of Psychiatry,
 Weill Medical College of Cornell University
 Director, Bipolar Disorders Research Clinic
 New York Presbyterian Hospital
 New York, New York

**3:40PM The Face of Bipolar Illness:
Results of a National Depressive and
Manic-Depressive Association Survey**
 Lydia J. Litvack
 Executive Director, National DMDA
 Chicago, Illinois

4:05PM Question and Answer Session
 There will be 5 minutes of questions and answers after each presentation.

Program Description
 In order to provide the most comprehensive care for patients with bipolar disorder, physicians need to develop a complete, data-driven treatment plan based upon identification, inspection, and understanding of the disorder. This program will first consider the challenge of improving functional outcomes with manic and mixed episodes, and will then take an in-depth look at treatment recommendations for bipolar depression. Further discussions will explore the gender-specific issues in bipolar disorder and provide an analysis of maintenance treatment with respect to bipolar disorder. A discussion of the results of a National Depressive and Manic-Depressive Association survey on the face of bipolar illness will round out the presentations. The symposium will close with a comprehensive question and answer session.

Learning Objectives
 At the conclusion of this symposium, participants will be able to:

1. Understand the challenges of identifying bipolar and nonbipolar disease.
2. Discuss the experience related to functional outcomes for the bipolar patient.
3. Apply understanding of the effects of acute mania and strategies for maintenance in their practice.
4. Discuss gender characterization of bipolar illness and the associated reproductive issues.

Accreditation and Credit Designation
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.


Registration
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-257-7524 (within the US or Canada) or at 202-662-6000.

Providing Complete Treatment for Patients With Bipolar Disorder

Sunday, May 6, 2001
1:00PM Luncheon
1:30PM-4:30PM Educational Program

Hilton New Orleans Riverside
Grand Ballroom C/D, Street Level
New Orleans, Louisiana

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Eli Lilly and Company




INDUSTRY-SUPPORTED SYMPOSIUM 17

Sunday, May 6, 1:30 PM-4:30 PM


Acadia Ballroom, Third Floor, Marriott

MAOIs Revisited




**SUNDAY,
MAY 6, 2001**
*The Acadia Ballroom
New Orleans
Marriott
New Orleans,
Louisiana*

SPONSORED BY THE AMERICAN
PSYCHIATRIC ASSOCIATION



SUPPORTED BY AN UNRESTRICTED
EDUCATIONAL GRANT FROM



OBJECTIVE
To update psychiatrists on diagnostic methods, new treatment options, and methods for managing difficult patients, including the use of MAOIs.

CONTINUING MEDICAL EDUCATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

APA 2001 ANNUAL MEETING
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

PROGRAM AGENDA

1:00 PM	LUNCH
1:30 PM	WELCOME AND INTRODUCTIONS JAY D. AMSTERDAM, MD CHAIR <i>University of Pennsylvania</i>
1:40 PM	AN UPDATE ON MONOAMINE OXIDASES & BEHAVIOR LYNN WECKER, PhD <i>University of South Florida</i>
2:05 PM	CELLULAR ANTIDEPRESSANT MECHANISM OF MAO INHIBITORS PIERRE BLIER, MD, PhD <i>University of Florida</i>
2:30 PM	CLINICAL USE OF MAO INHIBITORS JAY D. AMSTERDAM, MD
2:55 PM	NEXT GENERATION MAO INHIBITORS ANDREW NIERENBERG, MD <i>Harvard Medical School Massachusetts General Hospital</i>
3:20 PM	TRANSDERMAL SELEGILINE IN DEPRESSION ALEXANDER BODKIN, MD <i>Harvard Medical School McLean Hospital</i>
3:45 PM	QUESTION-AND-ANSWER SESSION/ PANEL DISCUSSION
4:30 PM	CLOSING REMARKS AND ADJOURNMENT

INDUSTRY-SUPPORTED SYMPOSIUM 18

Sunday, May 6, 1:30 PM-4:30 PM

Carondelet Ballroom, Third Floor, Marriott

Advances in the Treatment of Geriatric Depression

APA 154th Annual Meeting
Sunday, May 6, 2001
1:00-1:30 PM Lunch
1:30-4:30 PM Symposium
Marriott New Orleans • Third Floor • Carondelet Ballroom

Program Chair: **J. Craig Nelson, MD** • Yale University School of Medicine

1:45 PM **Diagnosis and Treatment of Depression in the Older Patient**
J. Craig Nelson, MD
Yale University School of Medicine

2:15 PM **Benefits of Different Classes of Antidepressants for Geriatric Depression**
Alan F. Schatzberg, MD
Stanford University School of Medicine

Co-Chair: **Greer M. Murphy, Jr, MD, PhD** • Stanford University School of Medicine

2:45 PM **DNA Microarray Technology and the Treatment of Depression**
Greer M. Murphy, Jr, MD, PhD
Stanford University School of Medicine


3:15 PM **Pharmacology of Antidepressants Pertinent to Older Patients**
Bruce G. Pollock, MD, PhD
University of Pittsburgh School of Medicine

3:45 PM **Questions and Answers**


Educational Objectives: At the conclusion of this symposium, participants should be able to: discuss the diagnosis and detection of depression in the elderly, including interactions between depression and concomitant medical illnesses; summarize the general treatment of depression in the geriatric patient; outline the genetics of geriatric depression; discuss the pharmacokinetics of antidepressants pertinent to elderly patients and the impact of possible drug interactions.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org, or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit actually spent in the educational activity.



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Organon Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 19
 Sunday, May 6, 1:30 PM-4:30 PM
 Mardi Gras Ballroom, Third Floor, Marriott



Chemical Restraints: Clinical, Research, and Ethical Implications

Symposium to be held during the Year 2001 APA Annual Meeting

Sunday, May 6, 2001

1:00 – 1:30 PM, Lunch; 1:30 – 4:30 PM, Symposium
 New Orleans Marriott, Third Floor, Mardi Gras Ballroom
 Chair: Douglas H. Hughes, MD

1:30–1:40 PM

Welcome and Introduction
 Douglas H. Hughes, MD (Chair)

1:40–2:00 PM

Issues Surrounding Forced Medication

Douglas H. Hughes, MD
 Department of Mental Health
 Dr. Solomon Carter Fuller Mental Health Center
 Boston, Massachusetts

2:00–2:20 PM

Atypical Antipsychotics in the Emergency Setting

Glenn W. Currier, MD
 Emergency Psychiatric Services
 University of Rochester Medical Center
 Rochester, New York

2:20–2:40 PM

Depot Antipsychotics: An Alternative to Forced Medication

Sally A. Barry, MD, PhD
 Department of Psychiatry
 Emory University School of Medicine
 Atlanta, Georgia

2:40–3:00 PM

Preventing Psychological Trauma Following Forced Medication

Terence M. Keane, PhD
 National Center for Posttraumatic Stress Disorder
 Boston University
 Boston, Massachusetts

3:00–3:20 PM

Historical Legal Trends and Civil Liberties in Forced Medications

Renée L. Binder, MD
 Langley Porter Psychiatric Institute
 University of California, San Francisco
 San Francisco, California

3:20–3:40 PM

Dealing With the New Legal Framework for Chemical Restraints

Paul S. Appelbaum, MD
 Department of Psychiatry
 University of Massachusetts Medical School
 Worcester, Massachusetts

3:40–4:30 PM

Question and Answer Session

Educational Objectives: On completion of this activity, participants should be able to: 1. Evaluate strategies for treating psychotic, aggressive, potentially violent patients in an emergency setting, taking into account the impact of using forced medications on both patients and overall treatment plans. 2. Explain the implications of new data on use of atypical antipsychotic agents in the emergency department with regard to everyday practice. 3. Review the evidence on depot formulations for long-term treatment.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3.0 hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or (202) 682-6000.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from

JANSSEN



PHARMACEUTICA
 PRODUCTS, L.P.

01-RS-798

INDUSTRY-SUPPORTED SYMPOSIUM 20
 Sunday, May 6, 1:30 PM-4:30 PM
 Grand Ballroom A-C, Fifth Floor, Sheraton

American Psychiatric Association 2001 Annual Meeting



ATYPICAL ANTIPSYCHOTIC DRUGS HOW DO THEY WORK?

SUNDAY, MAY 6, 2001
 LUNCH 1:00–1:30 PM
 SYMPOSIUM 1:30–4:30 PM

SHERATON NEW ORLEANS HOTEL
 FIFTH FLOOR
 GRAND BALLROOM A-C
 NEW ORLEANS, LOUISIANA

AGENDA

1:00 PM Lunch

1:30 PM **Welcome and Program Overview**

SHRUTI KAPUR, MD, PhD, FRCP (CHAIRPERSON)
 University of Toronto
 DANIEL R. WEINBERGER, MD, JCD-CHAIRPERSON
 National Institute of Mental Health

1:40 PM **What Really Is "Atypical" About Atypical Antipsychotics: Lessons From PET Imaging Studies**

SHRUTI KAPUR, MD, PhD, FRCP
 University of Toronto

2:05 PM **Understanding the Action of Antipsychotic Drugs at the Level of Gene Expression**

BARBARA K. LEBRA, PhD
 National Institute of Mental Health

2:30 PM **Intrinsic Circuitry in Cortex: Receptors, Drug Action, and Cognition**

PATRICIA S. GOLDMAN-RAKIC, PhD
 Yale University School of Medicine

2:55 PM **Behavioral and Neurochemical Predictors of Antipsychotic Drug Action**

CHARLES D. NEMEROFF, MD, PhD
 Emory University

3:20 PM **Therapeutic Insights From the Clinical Search for Genes**

DANIEL R. WEINBERGER, MD
 National Institute of Mental Health

3:45 PM **Question and Answer**

4:30 PM **Adjourn**

LEARNING OBJECTIVES

AFTER ATTENDING THIS SYMPOSIUM, PARTICIPANTS WILL BE ABLE TO:

- Explain the pharmacological basis of atypical antipsychotic action from a brain imaging perspective and become familiar with several leading hypotheses in this area.
- Assess recent advances in molecular mechanisms underlying antipsychotic drug action.
- Discuss the cellular mechanisms and circuit basis of drug action on cognitive functions by knowledge of localization of receptors on specific cellular compartments and specific components of cortical microcircuits.
- Assess the current status of animal models of schizophrenia and the action of antipsychotic drugs in such paradigms.
- Describe how genes related to brain function may explain some of the unique effects of atypical antipsychotic drugs.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 credit hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or (202) 682-6000.



Sponsored by the
 American Psychiatric Association

Supported by an unrestricted
 educational grant from

AstraZeneca

INDUSTRY-SUPPORTED SYMPOSIUM 21

Sunday, May 6, 7:00 PM-10:00 PM
Grand Ballroom A/B, Street Level, Hilton



APA 2001 Annual Meeting

Critical Questions in Anxiety Disorders

Buffet Dinner: 6:30 p.m. / Symposium: 7:00 - 10:00 p.m.

Chair: David V. Sheehan, M.D., M.B.A.

Topics and Faculty

Cost Burden of Anxiety Disorders

Ronald C. Kessler, Ph.D.
Harvard Medical School

Antidepressants and Anxiolytics:
Do They All Work in Social Phobia?

Jonathan R.T. Davidson, M.D.
Duke University

Should GAD be Treated Long Term?

David V. Sheehan, M.D., M.B.A.
University of South Florida

Treatment of Comorbid Anxiety
and Bipolar Disorders

Susan L. McElroy, M.D.
University of Cincinnati

Barriers to the Effective Treatment of
Anxiety Disorders

Mark Olfson, M.D., M.P.H.
Columbia University

Objective

1. Better understand the cost burden in and barriers to effective treatment in anxiety disorders.
2. Effectively apply the new treatments available for social anxiety disorder and generalized anxiety disorder.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

There will be 45 minutes of questions and answers at the end of the symposium.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 22

Sunday, May 6, 7:00 PM-10:00 PM
Grand Ballroom C/D, Street Level, Hilton

Management of Anxiety:

An International Perspective

- 7:00 PM-7:10 PM **Welcome and introduction**
Murray B. Stein, MD – Chairperson – University of California, San Diego, School of Medicine
- 7:10 PM-7:30 PM **The Functional Impact of Anxiety Disorders:
Focus on Social Phobia**
Murray B. Stein, MD
- 7:30 PM-7:50 PM **Integrating Neuroscience and Psychotherapy:
The Study of Human Emotions**
Donatella Marazziti, MD – University of Pisa
- 7:50 PM-8:10 PM **Childhood Anxiety Disorders: NIMH Initiatives**
Benedetto Vitiello, MD – NIMH
- 8:10 PM-8:30 PM **Refractory OCD: An International Perspective**
Eric Hollander, MD – Mt Sinai Medical School
- 8:30 PM-8:50 PM **Anxiety and Suicide**
Jan A. Fawcett, MD – Rush-Presbyterian-St. Luke's Medical Center
- 8:50 PM-9:10 PM **Discussant: Michael R. Liebowitz, MD – College of Physicians and Surgeons of Columbia University**
- 9:10 PM-10:00 PM **Question-and-answer session**

APA 2001 ANNUAL MEETING

Sunday, May 6, 2001

6:30 PM – 7:00 PM Dinner

7:00 PM – 10:00 PM Symposium

Grand Ballroom C/D, Street Level, Hilton Hotel
New Orleans, Louisiana

Educational Objectives

At the conclusion of this symposium, participants will be better able to

- Define contributing factors for refractory anxiety disorders, obsessive compulsive disorder, and social anxiety disorder
- Integrate psychological and neurobiological approaches
- Discuss the role of anxiety in suicide

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit toward the Physician's Recognition Award of the American Medical Association and for the continuing medical education requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This symposium is sponsored by the American Psychiatric Association.

Supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at (888) 357-7924 (within the United States or Canada) or (202) 682-6000.

INDUSTRY-SUPPORTED SYMPOSIUM 23

Sunday, May 6, 7:00 PM-10:00 PM

Acadia Ballroom, Third Floor, Marriott

Upon completion of this symposium, attendees should be able to: Discuss clinical and therapeutic issues that emerge in the treatment of depressed patients who do not respond to standard treatments

Sunday, May 6, 2001 7:00 pm – 10:00 pm
Marriott Hotel Acadia Ballroom New Orleans, LA

Treatment-Resistant Depression Across the Lifespan

Symposium to be held during the American Psychiatric Association 2001 Annual Meeting

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and is on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Pharmacia Corporation

PHARMACIA



6:30 PM Dinner Reception

7:00 PM Introduction
Maurizio Fava, MD, Chairperson

7:10 PM The Phenomenology and Course of Treatment-Resistant Depression
Patrick J. McGrath, MD, Columbia University College of Physicians and Surgeons

7:35 PM Pharmacological Treatment Options
Maurizio Fava, MD, Harvard Medical School

8:00 PM Management of Depression in the Medically Ill: Practical Approaches to Treatment
Prakash S. Masand, MD, SUNY Upstate Medical University

8:25 PM Juvenile Bipolar Disorder: An Overlooked Condition in Treatment-Resistant Depressed Children
Janet Wozniak, MD, Harvard Medical School

8:50 PM Treatment Advances in Geriatric Depression
George S. Alexopoulos, MD, Weill Medical College of Cornell University

9:15 PM Question-and-Answer Session

10:00 PM Adjourn

INDUSTRY-SUPPORTED SYMPOSIUM 24

Sunday, May 6, 7:00 PM-10:00 PM

Carondelet Ballroom, Third Floor, Marriott

Neurobiology, Depression

and the Specificity of Treatment Response

APA 154th Annual Meeting
Sunday, May 6, 2001

6:30 – 7:00 PM Dinner 7:00 – 10:00 PM Symposium
Marriott New Orleans • Third Floor • Carondelet Ballroom

Program Chair: Alexander H. Glassman, MD Columbia University Co-Chair: Pedro L. Delgado, MD Case Western Reserve University School of Medicine
Summary Speaker: Alan F. Schatzberg, MD Stanford University School of Medicine

7:15 PM

SHT and Norepinephrine in Depression

Pedro L. Delgado, MD
Case Western Reserve University School of Medicine
Francisco A. Moreno, MD
University of Arizona

7:45 PM

The Role of Dopamine in Depression and Antidepressant Treatment

Alexander H. Glassman, MD
Columbia University

OVERALL EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, participants should understand the implications and limitations of transmitter-based classifications of antidepressants. Further, it should be clear that, even though all antidepressants overlap in their actions, they have a distinct spectrum of activity that varies significantly by antidepressant class.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org, or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit actually spent in the educational activity.



Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Organon Inc.



INDUSTRY-SUPPORTED SYMPOSIUM 25
Sunday, May 6, 7:00 PM-10:00 PM
Mardi Gras Ballroom, Third Floor, Marriott



Psychosis in Alzheimer's Disease: New Knowledge, New Treatment Strategies

Symposium to be held during the Year 2001 APA Annual Meeting
Sunday, May 6, 2001
6:30 – 7:00 PM, Dinner; 7:00 – 10:00 PM, Symposium
New Orleans Marriott, Third Floor, Mardi Gras Ballroom
Chair: Ira R. Katz, MD

7:00–7:10 PM
Welcome and Introduction
 Ira R. Katz, MD (Chair)
7:10–7:40 PM
Efficacy of Antipsychotic Agents
 Ira R. Katz, MD
 Department of Geriatric Psychiatry
 University of Pennsylvania School of Medicine
 Philadelphia, Pennsylvania

7:40–8:10 PM
Practical Strategies for the Treatment of Psychoses Due to Dementia
 Jacobo E. Mintzer, MD
 Institute of Psychiatry
 Medical University of South Carolina
 Charleston, South Carolina
8:10–8:40 PM
Psychosis of Dementia
 Lon S. Schneider, MD
 Department of Psychiatry and Behavioral Sciences
 University of Southern California
 Keck School of Medicine
 Los Angeles, California

8:40–9:10 PM
Effects of Other Psychotherapeutic Medications
 Constantine Lykatsos, MD, MPH
 Neuropsychiatry Service
 The Johns Hopkins School of Medicine
 Baltimore, Maryland
9:10–10:00 PM
Question & Answer Session

Educational Objectives: On completion of this activity, participants should be able to: 1. Formulate a diagnostic approach to psychosis in Alzheimer's disease based on the latest research findings. 2. Review the efficacy and side-effect profiles of atypical and conventional neuroleptic agents. 3. Describe how to augment treatment of psychotic symptoms with other classes of psychotherapeutic agents. 4. Develop a global treatment plan that maximizes outcomes in this patient population beyond efficacy.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3.0 hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or (202) 682-6000.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from

JANSSEN  PHARMACEUTICA
PRODUCTS, L.P.

01-RS-798B

INDUSTRY-SUPPORTED SYMPOSIUM 26
Sunday, May 6, 7:00 PM-10:00 PM
Grand Ballroom A-C, Fifth Floor, Sheraton

Agenda

- 6:30 PM Dinner**
7:00 Welcome and Introduction
 Daniel E. Casey, MD, Program Co-Chairperson
 Chief, Psychiatric Research/Psychopharmacology
 Portland VA Medical Center
 Department of Mental Health
 Portland, Oregon
 Nina R. Schooler, PhD, Program Co-Chairperson
 Director of Research
 Hillside Hospital
 Psychiatric Research
 Glen Oaks, New York
7:10 Acute Psychotic Agitation: Exploring New Options
 Alan J. Mendelowitz, MD
 Unit Chief for Psychiatric Services
 Hillside Hospital
 Department of Psychiatry
 Glen Oaks, New York
7:35 Beyond the Acute Phase: Issues in Stabilization
 Peter J. Weiden, MD
 Director, Schizophrenia Research Program
 Professor of Psychiatry
 SUNY Health Sciences Center at Brooklyn
 Brooklyn, New York
8:00 Psychosocial Treatment for Schizophrenia: Strategies for the New Era
 Nina R. Schooler, PhD
8:25 Raising the Bar from Symptom Reduction to Disability Reduction
 Michael F. Green, MD
 Professor
 UCLA Neuropsychiatric Institute
 Department of Psychiatry
 Los Angeles, California
8:50 Improving the Overall Health of Patients with Schizophrenia
 Daniel E. Casey, MD
9:15 Question and Answer Session
10:00 Adjourn



Sponsored by
 the American
 Psychiatric
 Association



154th APA Annual Meeting

Moving Toward a More Comprehensive Management of Patients with **Schizophrenia**



Sunday, May 6, 2001

Objectives

At the conclusion of this symposium, participants should be able to:

- Recognize and list multiple diagnoses that can be present with psychotic agitation, describe and initiate the initial workup of psychotic agitation in an emergency room setting, and demonstrate strengths and limitations of various medical treatment options available;
- Define the concept and time course of the stabilization period and identify the key psychosocial and pharmacologic issues that arise during this period;
- Identify several psychosocial treatments that demonstrate efficacy and consider integrating such treatments into optimal clinical programs;
- Identify key determinants of functional outcome in schizophrenia including neurocognitive deficits;
- Recognize the unmet medical needs in patients with schizophrenia and implement monitoring strategies to detect physical illnesses.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 27
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
La Nouvelle Ballroom, Level 2, Convention Center

APA 2001 Annual Meeting
Optimizing Treatment Outcomes
in Patients with Chronic Depression

Monday & Tuesday, May 7 & 8, 2001
New Orleans Convention Center • Level 2, La Nouvelle Ballroom

CHAIR: ROBERT E. HALES, MD, MBA
University of California, Davis

CO-CHAIR: STUART C. YUDOFKY, MD
Baylor College of Medicine

Distinguished Faculty

Martin B. Keller, MD
Brown University Medical School

A. John Rush, MD
University of Texas Southwestern Medical Center

Robert M.A. Hirschfeld, MD
University of Texas Medical Branch


Susan G. Kornstein, MD
Medical College of Virginia

Sponsored by the **American Psychiatric Association**
Supported by an unrestricted educational grant from **Bristol-Myers Squibb**

Breakfast: 6:30 – 7:00 A.M.
Scientific Program: 7:00 – 8:30 A.M.

Agenda

7:00 – 7:05 Introduction
7:05 – 7:35 Speaker #1
7:35 – 7:45 Question & Answer
7:45 – 8:15 Speaker #2
8:15 – 8:25 Question & Answer
8:25 – 8:30 Faculty Question & Answer



Educational Objectives

After completing this activity, participants should be able to fully define the disorders that constitute "chronic depression"; outline the advantages and disadvantages of pharmacotherapy, psychotherapy, and combination treatment for chronic depression; list reasons why patients may not be completely satisfied with their treatment for chronic depression; identify strategies for achieving remission in the treatment of chronic depression; and list pharmacoeconomic and psychosocial outcomes that would be desirable to achieve when treating chronic depression.

Accreditation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

INDUSTRY-SUPPORTED SYMPOSIUM 28
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Grand Ballroom A/B, Street Level, Hilton

Women's Mental Health: Antidepressant Therapy During the Childbearing Years

APA 2001 Annual Meeting
Monday and Tuesday, May 7-8, 2001
7:00 a.m. – 8:30 a.m.

Grand Ballroom A/B
Hilton Hotel, Street Level
New Orleans, Louisiana

Monday, May 7, 2001

Breakfast 6:30 a.m.

7:00 a.m.

The Epidemiology of Depression Throughout the Female Life-Cycle
Vivien K. Burt, MD, PhD
University of California Los Angeles

7:20 a.m.

Diagnosis and Treatment of Premenstrual Dysphoric Disorder
Elias Eriksson, PhD
Göteborg University, Sweden

7:45 a.m.

Antidepressant Therapy During Pregnancy
Lori Altshuler, MD
University of California Los Angeles

8:05 a.m.

Questions & Answers

Tuesday, May 8, 2001

Breakfast 6:30 a.m.

7:00 a.m.

The Treatment of Postpartum Depression: Risks and Benefits to Mother and Child
Victoria Hendrick, MD
University of California Los Angeles

7:30 a.m.

Treatment Guidelines for Breast-Feeding Women
Zachary S. Stowe, MD
Emory University

8:05 a.m.

Questions & Answers

Learning Objectives:

- appreciate the importance of identifying and treating depression in women;
- recognize the symptoms and treatment options for PMDD;
- consider the risks and benefits of antidepressant therapy during pregnancy;
- consider the consequences of postpartum depression on both mother and child;
- and understand the association between menopause and depression

Epidemiological studies have shown that women are more susceptible to depression than men during their reproductive years, and it has been suggested this increased risk of depression may in part be related to hormonal changes. This symposium will review the presentation of depression throughout the childbearing years, addressing the safety and efficacy of antidepressant treatment of premenstrual dysphoric disorder and postpartum depression. Antidepressant safety in the setting of pregnancy and breast-feeding also will be discussed, and overall treatment guidelines will be presented.

This program is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come first served. For more information about the meeting, please visit the APA website at www.psych.org, or contact APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

This program is supported by an unrestricted educational grant from Forest Laboratories.

INDUSTRY-SUPPORTED SYMPOSIUM 29
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Grand Ballroom C/D, Street Level, Hilton

American Psychiatric Association 2001 Annual Meeting



COMPARING ATYPICAL ANTIPSYCHOTIC THERAPIES

MAKING SENSE OF THE DATA

HILTON NEW ORLEANS RIVERSIDE
STREET LEVEL
GRAND BALLROOM C/D
NEW ORLEANS, LOUISIANA

MONDAY & TUESDAY
MAY 7 & 8, 2001
BREAKFAST 6:30-7:00 AM
SYMPOSIUM 7:00-8:30 AM

MONDAY, MAY 7

6:30 AM Breakfast

7:00 AM Welcome and Program Overview
RAJIV TANDON, MD
(CHAIRPERSON)
University of Michigan Medical Center

7:10 AM Examining the Efficacy of Atypical Antipsychotics: Is There a Difference?
ALAN J. MENDELWITZ, MD
Albert Einstein College of Medicine

7:30 AM EPS and the Essence of Atypicality: Are All Atypical Antipsychotics the Same?
RAJIV TANDON, MD
University of Michigan Medical Center

7:50 AM Relative Tolerability of Novel Antipsychotics: Impact on Weight Gain and Sexual Function
DONNA A. WIRSHING, MD
University of California at Los Angeles School of Medicine

8:10 AM Questions and Answers

8:30 AM Adjourn

TUESDAY, MAY 8

6:30 AM Breakfast

7:00 AM Beyond Efficacy and Symptom Control: Effectiveness as the Best Measure of Antipsychotic Drug Therapy
HENRY A. NASRALLAH, MD
University of Mississippi School of Medicine

7:30 AM Optimizing Optimistically: Getting the Most Out of the Atypical Antipsychotics
PETER J. WEIDEN, MD
State University of New York Health Sciences Center

8:00 AM Questions and Answers/Panel Discussion

8:30 AM Adjourn


LEARNING OBJECTIVES

AFTER ATTENDING THIS SYMPOSIUM, PARTICIPANTS WILL BE ABLE TO:


- Evaluate the results of all head-to-head comparative clinical trials of various atypical antipsychotics, describe the differences and similarities in efficacy among the new generation of antipsychotic drugs, and formulate treatment decisions with the new agents based on the differing side effect profiles.
- Identify the steps to optimizing antipsychotic therapy, recognize common barriers and pitfalls in achieving optimal antipsychotic effectiveness, and discuss how to integrate medication response with the patient's recovery process.
- Discuss the "EPS advantage" of all atypical antipsychotics and how it translates into multiple relevant clinical benefits beyond EPS, as well as the important differences between the atypical agents with regard to the ease and consistency with which this advantage is realized.
- Explain the relative impact novel antipsychotic medications have on weight gain and related medical phenomena, such as diabetes and hypertriglyceridemia, as well as sexual function.
- Recognize that effectiveness of antipsychotic drug treatment—such as tolerability, compliance, relapse prevention, reduced suicidality, social rehabilitation, vocational reintegration, patient satisfaction, and quality of life—is the best measure of good outcomes after initial symptom control (i.e., efficacy).

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA sponsors this educational activity for up to 1.5 hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the symposium, please visit the APA website at www.psych.org or contact the APA office at 1-800-368-2842 (within the U.S.) or Canada at 1-202-882-6000.



Aspirin is an antiplatelet drug.



© 2001 AstraZeneca Inc. All rights reserved.

INDUSTRY-SUPPORTED SYMPOSIUM 30
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Acadia Ballroom, Third Floor, Marriott



MOOD AND ANXIETY DISORDERS IN UNDERSTUDIED POPULATIONS


A TWO-PART BREAKFAST SYMPOSIUM
 HELD AT THE AMERICAN PSYCHIATRIC ASSOCIATION 154TH ANNUAL MEETING
 MONDAY, MAY 7 & TUESDAY, MAY 8, 2001 7:00 AM - 8:30 AM New Orleans Marriott Acadia Ballroom, Third Floor

Supported by an unrestricted educational grant from GlaxoSmithKline.

Program Objectives

After attending this continuing education program, the psychiatrist should be able to:

- Recognize symptoms of depression and anxiety disorders in children and adolescents
- Discuss treatment strategies for mood and anxiety disorders in youth
- Describe the risk/benefit assessment for the mother and infant associated with treatment of psychiatric disorders in the pregnant and breast-feeding woman
- Recognize symptoms of comorbid depression and anxiety in patients with cancer
- Discuss the impact of menopause on the course and treatment of mood disorders in women.



Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates each day of this educational activity for up to 1.5 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7824 (within the US or Canada) or 1-202-882-6000.

Agenda

MONDAY, MAY 7, 2001

6:30 AM Breakfast

7:00 AM Welcome and Introduction
 Karen Dineen Wagner, MD, PhD
 Symposium Chair
University of Texas Medical Branch

7:05 AM Major Depression in Children and Adolescents
 Karen Dineen Wagner, MD, PhD

7:25 AM OCD and Social Anxiety Disorder in Children and Adolescents
 John T. Walkup, MD
Johns Hopkins University

7:45 AM Use of Antidepressants in Pregnant and Breastfeeding Women
 Zachary N. Stowe, MD
Emory University School of Medicine

8:05 AM Panel Discussion and Summary With Questions and Answers

TUESDAY, MAY 8, 2001

6:30 AM Breakfast

7:00 AM Welcome and Introduction

7:05 AM The Cancer Patient With Depression
 Dominique L. Musselman, MD, MS
Emory University School of Medicine

7:35 AM Psychiatric Implications of the Menopause
 Dwight L. Evans, MD
University of Pennsylvania

8:00 AM Panel Discussion With Questions and Answers

8:25 AM Closing Remarks

INDUSTRY-SUPPORTED SYMPOSIUM 31
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Carondelet Ballroom, Third Floor, Marriott

Please join us
at the APA 2001 Annual Meeting

Sponsored by the
American Psychiatric Association

Weighing the Options for Managing Bipolar Depression

CME Symposium – Two-Part Breakfast Program

Monday & Tuesday, May 7th-8th – Marriott Carondelet Ballroom, 3rd Floor

Part I – Monday – Part II – Tuesday – 6:30 AM Breakfast – 7:00 – 8:30 AM Clinical Program

Gary S. Sachs, MD, Symposium Chair

Initial Treatment Options for Bipolar Depression

Russell T. Joffe, MD
 Dept.
 Professor of Psychiatry
 University of Medicine and Dentistry of New Jersey
 New Jersey Medical School
 Newark, New Jersey

Alternatives for Patients Refractory to an Initial Course of Treatment

Claudia E. Baldassano, MD
 Director of the Bipolar Outpatient Clinic
 Assistant Professor of Psychiatry
 Hospital of the University of Pennsylvania
 University of Pennsylvania
 Philadelphia, Pennsylvania

Interpersonal and Social Rhythm Therapy Prevents Depressive Symptomatology in Patients with Bipolar I Disorder

Ellen Frank, PhD
 Director, Depression and Manic-Depression Prevention Program
 Professor of Psychiatry and Psychology
 Department of Psychiatry
 University of Pittsburgh School of Medicine
 Western Psychiatric Institute and Clinic
 Pittsburgh, Pennsylvania

Bipolar Depression: Continuation – Phase Options

Gary S. Sachs, MD
 Director, Harvard Bipolar Research Program
 Massachusetts General Hospital
 Assistant Professor of Psychiatry
 Harvard Medical School
 Boston, Massachusetts



Educational Objectives
 List the somatic and psychosocial interventions with efficacy for acute and prophylactic treatment of bipolar depression, evaluate the therapeutic options for refractory bipolar depression, and analyze factors that influence duration of continuation phase treatment.

Two-Part Breakfast Program Agenda

Part I – Monday, May 7th
 6:30 – 7:00 AM Breakfast
 7:00 – 7:05 AM Introduction – G. Sachs
 7:05 – 8:05 AM Presentations – R. Joffe and C. Baldassano
 8:05 – 8:30 AM Question and answer session
 8:30 AM Part I concludes

Part II – Tuesday, May 8th
 6:30 – 7:00 AM Breakfast
 7:00 – 7:05 AM Introduction – G. Sachs
 7:05 – 8:05 AM Presentations – E. Frank and G. Sachs
 8:05 – 8:30 AM Question and answer session
 8:30 AM Program concludes

Registration
 Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

Accreditation
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for up to 3.0 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
 This program is supported by an unrestricted educational grant from  GlaxoSmithKline

INDUSTRY-SUPPORTED SYMPOSIUM 32
Monday, May 7, and Tuesday, May 8, 7:00 AM-8:30 AM
Mardi Gras Ballroom, Third Floor, Marriott

A 2-Part Breakfast Symposium

THE IMPULSIVE AGGRESSIVE SPECTRUM: CHALLENGING POPULATIONS

May 7-8, 2001

MONDAY, MAY 7, 2001

7:00 am – 7:05 am
Eric Hollander, MD

7:05 am – 7:30 am
Alan C. Swann, MD

7:30 am – 7:50 am
Eric Hollander, MD

7:50 am – 8:15 am
Stephen M. Strakowski, MD

8:15 am – 8:30 am

TUESDAY, MAY 8, 2001

7:00 am – 7:05 am
Eric Hollander, MD

7:05 am – 7:30 am
Daniel E. Casey, MD

7:30 am – 8:00 am
Hans Steiner, MD

8:00 am – 8:30 am

Introduction
 Professor of Psychiatry, Mount Sinai School of Medicine

The Impulsive Affective Spectrum
 Professor of Psychiatry
 University of Texas Medical School at Houston

Very Bad Behaviors

Substance Abuse, Sensitization and Impulsivity
 Professor of Psychiatry, Psychology and Neuroscience
 University of Cincinnati College of Medicine

Panel Discussion / Q&A

Introduction

Anticonvulsants as Adjunctive Treatment in Psychosis
 Chief, Psychiatric Research/Pharmacology
 VA Medical Center-Portland

Aggression, Violence and Psychopathology: From Adolescence to Adulthood
 Professor of Psychiatry
 Stanford University School of Medicine

Panel Discussion / Q&A

**New Orleans Marriott –
Mardi Gras Room**

6:30 am – 7:00 am Breakfast
 7:00 am – 8:30 am Scientific Program

 **SPONSORED BY THE AMERICAN PSYCHIATRIC ASSOCIATION AND HELD AT THE APA 2001 ANNUAL MEETING**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000. For more information about this symposium, please call 1-888-451-4868.

PROGRAM OBJECTIVES


- Understand new scientific techniques being applied to the study of major neuropsychiatric diagnoses and the effects of mood stabilizers on specific molecular and cellular targets.
- Review current uses of mood stabilizers in psychiatry, and reconceptualize the pathogenesis and treatment of several neuropsychiatric disorders, including manic-depressive illness and Alzheimer's disease.

CREDIT DESIGNATION
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

 **THIS ACTIVITY IS SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM ABBOTT LABORATORIES.**

INDUSTRY-SUPPORTED SYMPOSIUM 33

Tuesday, May 8, 7:00 PM-10:00 PM
Hall G, Lobby Level, Convention Center



Recognition and Treatment of Alzheimer's Disease

Practical Lessons from New Research

Tuesday, May 8, 2001 • Hall G, Lobby Level, Convention Center • New Orleans, Louisiana

154th
APA
Annual
Meeting

Agenda

6:30 pm Dinner

7:00 **Welcome and Introduction**
Gary W. Small, MD, Chairperson
Director, UCLA Center on Aging
Parlow-Solomon Professor on Aging
University of California at
Los Angeles School of Medicine
Los Angeles, California

7:15 **Alzheimer's Disease: Integrating Mind and Brain**
Jeffrey L. Cummings, MD
Co-Chairperson
The Augustus S. Rose Professor
of Neurology
Professor of Psychiatry and
Biobehavioral Sciences
Director, UCLA Alzheimer's
Disease Center
University of California at
Los Angeles School of Medicine
Los Angeles, California

7:35 **An Update on Brain Imaging and Genetic Risk in Alzheimer's Disease Assessment**
Gary W. Small, MD

7:55 **Pathogenesis and Treatment Strategies in Alzheimer's Disease**
Rachelle S. Doody, MD
Effie Marie Cain Professor in Alzheimer's
Disease Research
Baylor College of Medicine
Department of Neurology
Houston, Texas

8:15 **Question and Answer Session**
Gary M. Jaggi, MD, Jeffrey L. Cummings, MD, Rachelle S. Doody, MD

8:35 **The Interface of Depression and Dementia**
Devangere P. Devanand, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
New York, New York

9:00 **Long-Term Benefits of Early Pharmacologic Treatment**
Pierre N. Tariot, MD
Professor of Psychiatry, Medicine,
and Neurology
University of Rochester Medical Center
Rochester, New York

9:25 **Rediscovering Nonpharmacologic Approaches to Behavior and Function**
Kevin F. Gray, MD
Assistant Professor of Psychiatry
University of Texas Southwestern
Medical Center
Director, Memory Disorder Clinic
Consultant, Geriatric and Neuropsychiatry
North Texas VA Health Care System
Dallas, Texas

9:40 **Question and Answer Session**
Devangere P. Devanand, MD,
Pierre N. Tariot, MD, Kevin F. Gray, MD

10:00 Adjourn

Objectives

At the conclusion of the program, the participant will be able to:

- Understand the impact of pharmacologic and nonpharmacologic approaches to Alzheimer's disease treatment.
- Describe emerging research.
- Use screening techniques to effectively assess and recognize the disease early in its course.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7524 (within the United States or Canada) or 202-462-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Eli Lilly and Pfizer Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 34


Tuesday, May 8, 7:00 PM-10:00 PM
La Nouvelle Ballroom, Level 2, Convention Center

A Dinner Symposium...

Everyday Challenges

in Managing Patients on Psychotropic Medications

Tuesday, May 8, 2001
7:00 PM-10:00 PM
La Nouvelle Orleans Ballroom, Level 2
Convention Center
New Orleans, Louisiana



OBJECTIVES

Upon completion of this symposium, attendees should be able to:

- Define successful remission of psychiatric illnesses
- List potential factors leading to remission
- Outline the safety and tolerability profiles of medications used to treat psychotic disorders
- Identify challenges in the diagnosis and treatment of psychosis in childhood, adolescent and geriatric populations

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7524 (within the U.S. or Canada) or 202-462-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.

AGENDA

6:30 pm Dinner Reception

7:00 pm **Introduction**
Charles B. Nemeroff, MD, PhD
Program Chairperson

7:15 pm **Approaches to Optimizing Therapies Across Psychiatric Diagnoses: Remission is the Goal**
Charles B. Nemeroff, MD, PhD
Emory University School of Medicine

7:45 pm **Optimizing Patient Outcomes Across Psychiatric Diagnoses: Focus on Safety and Tolerability**
John M. Zajecka, MD
Rush Medical College

8:15 pm **Special Challenges When Using Psychotropic Medications in Children and Adolescents**
Karen D. Wagner, MD, PhD
University of Texas Medical Branch at Galveston

8:45 pm **Special Challenges When Using Psychotropic Medications in the Geriatric Population**
K. Ranga R. Krishnan, MD
Duke University Medical Center

9:15 pm **Panel Discussion**
All Faculty

10:00 pm Adjourn

Art courtesy of NARSAD Artworks. Art on and behalf of the mentally ill.

Bristol-Myers Squibb Company Otsuka Pharmaceutical Co., Ltd.

INDUSTRY-SUPPORTED SYMPOSIUM 35
Tuesday, May 8, 7:00 PM-10:00 PM
Grand Ballroom A/B, Street Level, Hilton

APA 2001 ANNUAL MEETING		CHAIR: William Glazer, MD CO-CHAIR: Jerrold Rosenbaum MD
<h1>OFF-LABEL ON THE TABLE</h1> <h2>Using New Pharmacologic Agents</h2>		
<p>Sponsored by the American Psychiatric Association</p>		
OBJECTIVES	EDUCATIONAL COUNCIL	AGENDA
<p>Understand the boundaries for use of psychotropic agents.</p> <p>Weigh the importance of symptoms, diagnosis and diagnostic spectrum when selecting atypical antipsychotics, antidepressants, or mood stabilizers for individual patients.</p> <p>Accreditation/Designation The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</p> <p>Participation Attendees must be registered for the APA Annual Meeting to attend this Symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. and Canada) or 202/682-6000.</p>	<p>William M. Glazer, MD Harvard Medical School Boston, Massachusetts</p> <p>Jerrold Rosenbaum, MD Harvard Medical School Boston, Massachusetts</p> <p>Paul E. Keck, MD University of Cincinnati Cincinnati, Ohio</p> <p>Jonathon Alpert, MD Massachusetts General Hospital Boston, Massachusetts</p> <p>Alan Swann, MD University of Texas Medical School Houston, Texas</p>	<p>Dinner will be provided 30 minutes prior to the scheduled event. There will be a 10-minute question and answer session following each presentation.</p> <p>7:00 Introduction/Symptoms, Syndrome, or Spectrum: How Do We Select Medications? A Clinical Case Vignette – William M. Glazer, MD – Jerrold F. Rosenbaum, MD</p> <p>7:30 Atypical Antipsychotics in the Treatment of Aggressive Behaviors – Paul E. Keck Jr., MD</p> <p>8:00 The Role of Antidepressant Medications for Aggressive Behaviors – Jonathon E. Alpert, MD – Maurizio Fava, MD</p> <p>8:30 The Role of Mood Stabilizers for Aggressive Behavior – Alan C. Swann, MD</p> <p>9:00 Synthesis: Spectrum Versus Signal – Jerrold F. Rosenbaum, MD – William M. Glazer, MD</p> <p>9:30 Interactive Panel Discussion</p> <p>The Symposium will end at 10:00 PM.</p>

NOVARTIS Supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation


INDUSTRY-SUPPORTED SYMPOSIUM 36
Tuesday, May 8, 7:00 PM-10:00 PM
Grand Ballroom C/D, Street Level, Hilton

American Psychiatric Association 2001 Annual Meeting	
<h1>MEN, WOMEN, AND SCHIZOPHRENIA</h1> <h2>DOES ANATOMY DETERMINE DESTINY?</h2>	
<p>TUESDAY, MAY 8, 2001 DINNER 6:30-7:00 PM SYMPOSIUM 7:00-10:00 PM</p>	
<p>HILTON NEW ORLEANS RIVERVIEW STREET LEVEL GRAND BALLROOM C/D NEW ORLEANS, LOUISIANA</p>	
AGENDA	LEARNING OBJECTIVES
<p>6:30 PM Dinner</p> <p>7:00 PM Welcome and Program Overview HENRY A. NASRALLAH, MD (CHAIRPERSON) University of Mississippi School of Medicine DIANA O. PERKINS, MD, MPH (CO-CHAIRPERSON) University of North Carolina at Chapel Hill</p> <p>7:10 PM Normal Sexual Brain Dimorphism: Impact of Schizophrenia in Men and Women JILL M. GOLDSTEIN, PhD Harvard Medical School</p> <p>7:35 PM Outcome and Treatment Response in Schizophrenia: Influences of Gender PETER F. BUCKLEY, MD Medical College of London</p> <p>8:00 PM Male-Female Difference in Schizophrenia: A Biopsychosocial Perspective MARY V. SEEMAN, MD, FRCP, FACP University of Toronto</p> <p>8:25 PM Neuroendocrine Side Effects of Antipsychotic Treatment in Men and Women DIANA O. PERKINS, MD, MPH University of North Carolina at Chapel Hill</p> <p>8:50 PM Gender Differences in Late-Life Schizophrenia and Its Treatment DILIP V. JESTE, MD University of California at San Diego</p> <p>9:15 PM Questions and Answers</p> <p>10:00 PM Adjourn</p>	<p>After attending this symposium, participants will be able to:</p> <ul style="list-style-type: none"> Recognize how schizophrenia is different in men and women and clinical implications; how the brain develops differently in men and women; how one's sex has implications for the nature of the illness, and current literature on sex differences in brain abnormalities in schizophrenia. Describe how gender impacts the presentation, course, and treatment responsiveness in schizophrenia, with particular relevance to emerging information on gender and efficacy of atypical antipsychotic medications. Understand the multiple causes of male-female differences in schizophrenia expression, such as onset age, neurocognition, neuroimaging, symptoms, course of illness, and response to treatment. Discuss sex differences in vulnerability to and expression of neuroendocrine side effects; demonstrate an understanding of the clinical relevance of prolactin elevations secondary to antipsychotic drug treatment and of managing for and treatment of side effects of neuroleptic-induced hyperprolactinemia. Explain the diagnosis of late-onset schizophrenia, as well as the use of typical and atypical antipsychotics in late-life schizophrenia. Identify the risks, benefits, and use of estrogen in postmenopausal women with schizophrenia. <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for up to 3 credit hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</p> <p>Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. and Canada) or 202/682-6000.</p> <p align="right">Sponsored by the American Psychiatric Association AstraZeneca</p>

INDUSTRY-SUPPORTED SYMPOSIUM 37

Tuesday, May 8, 7:00 PM-10:00 PM

Acadia Ballroom, Third Floor, Marriott



IMAGES of Anxiety
A New Look at Generalized Anxiety Disorder and Post-traumatic Stress Disorder

A DINNER SYMPOSIUM HELD AT THE AMERICAN PSYCHIATRIC ASSOCIATION 154TH ANNUAL MEETING TUESDAY, MAY 8, 2001 7:00 PM — 10:00 PM
New Orleans Marriott Acadia Ballroom, Third Floor

Supported by an unrestricted educational grant from GlaxoSmithKline

Program Objectives

After attending this continuing education program, the psychiatrist should be able to:

- Review current knowledge of neuroimaging in posttraumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) and the correlation with clinical presentation
- Understand the rates of comorbidity in GAD and PTSD and the implications for treatment and patient outcome
- Understand why some individuals develop PTSD following trauma whereas others do not
- Identify appropriate treatment strategies for trauma survivors depending on the nature of the traumatic response
- Gain a better understanding of the diagnostic criteria for GAD and the application of these criteria in clinical practice and research settings
- Identify treatments for GAD that are more effective than earlier treatments.

Agenda

6:30 PM Dinner

7:00 PM Welcome and Introduction
Jack M. Gorman, MD
Symposium Chair
Columbia University

7:05 PM Update on Neuroimaging
Jack M. Gorman, MD

7:30 PM The Anxious Brain: GAD and PTSD
Jeremy D. Coplan, MD
Columbia University


7:55 PM The Comorbidity Factor in GAD and PTSD
James C. Ballenger, MD
Medical University of South Carolina

8:20 PM An Update on PTSD
Rachel Yehuda, PhD
Mount Sinai School of Medicine

8:45 PM Current Concepts in the Diagnosis and Treatment of GAD
David V. Sheehan, MD, MBA
University of South Florida

9:10 PM Panel Discussion With Questions and Answers

9:55 PM Closing Remarks



Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 1-202-682-6000.


INDUSTRY-SUPPORTED SYMPOSIUM 38

Tuesday, May 8, 7:00 PM-10:00 PM

Carondelet Ballroom, Third Floor, Marriott

Please join us at the APA 2001 Annual Meeting • Sponsored by the American Psychiatric Association

Responding to the Challenge of Treating Bipolar Disorder



Tuesday, May 8th
6:30 PM Dinner • 7-10 PM Clinical Program
New Orleans Marriott • Carondelet Ballroom, 3rd Floor

Agenda

6:30 - 7:00 PM Dinner
7:00 - 7:05 PM Introduction - J. Calabrese, MD
7:05 - 9:15 PM Speaker presentations
9:15 - 10 PM Question and answer session
10 PM Program concludes


Educational Objectives

Review the evidence base supporting the use of lithium in bipolar disorder, understand the potential role signaling pathways and cellular resiliency in the pathophysiology and treatment of mood disorders, examine the novel antipsychotics and proposed guidelines and algorithms for their use, and evaluate combination treatment trials in bipolar disorder.

Registration

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

Accreditation



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3.0 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This program is supported by an unrestricted educational grant from

Moderator

Joseph R. Calabrese, MD
Director, Mood Disorders Program
Department of Psychiatry
University Hospitals of Cleveland
Professor of Psychiatry
Case Western Reserve University School of Medicine
Cleveland, Ohio

Novel Aspects of Lithium Therapy in Bipolar Disorder

Guy M. Goodwin, MD
W.A. Hendley Professor of Psychiatry
University of Oxford
Head of University Department of Psychiatry
Warneford Hospital
Oxford, United Kingdom

Molecular Mechanisms Underlying Mood Stabilization in Bipolar Disorder


Hussein K. Manji, MD
Chief, Laboratory of Molecular Pathophysiology
National Institute of Mental Health
Bethesda, Maryland

Exploring Novel Treatment Strategies for Bipolar Disorder

Trisha Suppes, MD, PhD
Director, Bipolar Disorder Clinic and Research Program
Associate Professor
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas

Combination Treatment with Atypical Antipsychotic Agents in Bipolar Disorder

Carlos A. Zarate, Jr., MD
Chief, Mood Disorders Research Unit
Mood and Anxiety Disorders Program
National Institute of Mental Health
Bethesda, Maryland



INDUSTRY-SUPPORTED SYMPOSIUM 39
Tuesday, May 8, 7:00 PM-10:00 PM
Mardi Gras Ballroom, Third Floor, Marriott

Symposium to be held during the American
 Psychiatric Association 2001 Annual Meeting

CURRENT AND FUTURE MANAGEMENT OF INSOMNIA AND PSYCHIATRIC ILLNESSES

TUESDAY, MAY 8, 2001 7:00 PM TO 10:00 PM
MARRIOTT HOTEL, MARDI GRAS BALLROOM
NEW ORLEANS, LOUISIANA

Upon completion of this symposium, attendees should be able to:

- Understand the relationship between insomnia and psychiatric illnesses and the importance of addressing sleep issues within the context of treating the psychiatric disorder
- Identify normal and abnormal sleep patterns and discuss their relationship to psychiatric illnesses
- Discuss clinically relevant pharmacologic profiles of medications used to treat insomnia from a worldwide perspective
- Describe the basic properties of the human cytochromes P450, their role in drug interactions, and how this information can be applied to safe treatment of sleep disorders in patients with either medical or psychiatric illnesses

- 6:30 PM **Dinner Reception**
- 7:00 PM **Introduction**
 Michael E. Thase, MD, Chairperson
- 7:10 PM **The Correlation Between Insomnia and Psychiatric Illnesses**
 Ruth M. Benca, MD, PhD, University of Wisconsin School of Medicine
- 7:35 PM **The Neurobiology of Sleep in Health and Psychiatric Illnesses**
 Daniel J. Buysse, MD, University of Pittsburgh School of Medicine
- 8:00 PM **Safety and Tolerability Issues in the Treatment of Insomnia**
 David J. Greenblatt, MD, Tufts University School of Medicine
- 8:25 PM **Comparative Management of Insomnia: Worldwide Perspectives**
 Göran Hajak, MD, PhD, University of Regensburg
- 8:50 PM **Converging Therapies for Insomnia and Psychiatric Illnesses: Current Needs and Future Practices**
 Michael E. Thase, MD, University of Pittsburgh School of Medicine
- 9:10 PM **Question-and-Answer Session**
 Michael E. Thase, MD
- 10:00 PM **Adjourn**

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from SCHOTT AG, SCHOTT FRANKFURT, GERMANY

INDUSTRY-SUPPORTED SYMPOSIUM 40
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
Hall G, Lobby Level, Convention Center

Clinical Challenges in Anxiety

American Psychiatric Association 154th Annual Meeting

2-DAY BREAKFAST SYMPOSIUM

May 9 & 10, 2001 7:00 AM - 8:30 AM
Breakfast Available at 6:30 AM

Marial Convention Center
Hall G, Lobby Level • New Orleans, Louisiana

The American Psychiatric Association (APA) is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3.0 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1 (888) 357-7924 (within the U.S. or Canada) or (202) 682-6000.

Sponsored by the
 American Psychiatric
 Association



Supported by an
 unrestricted
 educational grant from Pfizer Inc.



A G E N D A

May 9, 2001

- 7:00 AM **Opening Remarks**
 Mark H. Pollack, MD, Program Co-Chair
 Massachusetts General Hospital
 Harvard Medical School
- 7:05 AM **Anxiety Disorders: Moving From Better to Well**
 Mark H. Pollack, MD, Program Co-Chair
- 7:20 AM **Innovative Pharmacologic Approaches to Treatment-Resistant Anxiety Disorders**
 James W. Jefferson, MD, Program Co-Chair
 Madison Institute of Medicine
 University of Wisconsin Medical School
- 7:40 AM **Novel Anxiolytics in Development and Abroad**
 Stuart A. Montgomery, MD, PhD
 Imperial College
 London, England, UK
- 8:00 AM **Panel Discussion/Questions and Answers**
- 8:25 AM **Closing Remarks**
 Mark H. Pollack, MD, Program Co-Chair

May 10, 2001

- 7:00 AM **Opening Remarks and Recap of Day 1**
 James W. Jefferson, MD, Program Co-Chair
- 7:05 AM **Clinical Challenges: Anxiety and Substance Abuse**
 Kathleen T. Brady, MD
 Medical University of South Carolina
- 7:25 AM **PTSD: Phenomenology and Treatment Approaches**
 Naomi M. Simon, MD
 Massachusetts General Hospital
 Harvard Medical School
- 7:40 AM **Integrating Psychosocial Strategies with Pharmacotherapy**
 Michael W. Otto, PhD
 Massachusetts General Hospital
 Harvard Medical School
- 8:00 AM **Panel Discussion/Questions and Answers**
- 8:25 AM **Closing Remarks**
 James W. Jefferson, MD, Program Co-Chair

LEARNING OBJECTIVE

At the conclusion of this symposium, the participants should be able to:

- Identify and discuss the challenges associated with the treatment of anxiety disorders in clinical practice and potential strategies to improve outcomes.

INDUSTRY-SUPPORTED SYMPOSIUM 41
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
La Nouvelle Ballroom, Level 2, Convention Center

A New Era for Managing Psychosis: Rebuilding Lives for Patients and Families

Symposia to be held during the Year 2001 APA Annual Meeting
Wednesday, May 9, 2001; Thursday, May 10, 2001
6:30 – 7:00 AM, Breakfast; 7:00 – 8:30 AM, Symposium
Convention Center, Level 2, La Nouvelle Ballroom
Chair: Ira D. Glick, MD • Co-Chair: Stephen R. Marder, MD



Wednesday Sessions

7:00–7:05 AM
Welcome and Introduction
 Ira D. Glick, MD (Chair)
 Stephen R. Marder, MD (Co-Chair)

7:05–7:25 AM
Integrating Pharmacological and Psychosocial Treatments: Improving Social and Vocational Outcomes
 Stephen R. Marder, MD
 Department of Psychiatry
 University of Melbourne
 Parkville, Victoria, Australia

7:25–7:45 AM
The Treatment of Juvenile-Onset Schizophrenia
 Patrick D. McGorry, PhD
 Department of Psychiatry
 University of Melbourne
 Parkville, Victoria, Australia

7:45–8:05 AM
The Older Patient and Family
 Soo Borson, MD
 Department of Psychiatry and Behavioral Sciences
 University of Washington School of Medicine
 Seattle, Washington

8:05–8:30 AM
Question and Answer Session

Thursday Sessions

7:00–7:05 AM
Welcome and Introduction
 Ira D. Glick, MD (Chair)
 Stephen R. Marder, MD (Co-Chair)

7:05–7:35 AM
Consumer Organizations Improve Medication Compliance
 Ira D. Glick, MD
 Department of Psychiatry and Behavioral Sciences
 Stanford University School of Medicine
 Stanford, California

7:35–8:05 AM
Enhancing Outcomes With Atypical Antipsychotics: Weight, Akathisia, and Insight
 S. Nassir Ghaemi, MD
 Harvard Bipolar Research Program
 Massachusetts General Hospital
 Boston, Massachusetts

8:05–8:30 AM
Question and Answer Session

Educational Objectives: On completion of this activity, participants should be able to: 1. Review data from recent trials involving atypical antipsychotic agents and cholinesterase inhibitors. 2. Identify how atypical antipsychotics and cholinesterase inhibitors fit into the treatment armamentarium for patients with psychotic disorders. 3. Describe how to augment pharmacotherapy with psychosocial intervention to improve outcomes. 4. Explain the implications of the new glutamate model of schizophrenia with regard to future treatment practice.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3.0 hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or (202) 682-6000.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from

JANSSEN  **PHARMACEUTICALS, L.P.**

01-RS-798A

INDUSTRY-SUPPORTED SYMPOSIUM 42
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
Grand Ballroom A/B, Street Level, Hilton

Treatment of Depression in Women: From Acute Remission to Sustained Recovery

BREAKFAST: 6:30 AM — SYMPOSIUM: 7:00 TO 8:30 AM

Chairs: LEE S. COHEN, MD and ADELE C. VIGUERA, MD

PART 1 WEDNESDAY, MAY 9TH

Sex-Based Differences in Mood and Anxiety Disorders

ADELE C. VIGUERA, MD
 Harvard Medical School

Postpartum Depression: From Acute Treatment Response to Functional Recovery

LEE S. COHEN, MD
 Harvard Medical School

PMDD: How it Affects Women's Lives

KIMBERLY A. YONKERS, MD
 Yale University School of Medicine

PART 2 THURSDAY, MAY 10TH

The Neuroendocrinology of Maternal Depression and Stress During Pregnancy

D. JEFFREY NEWPORT, MD
 Emory University School of Medicine

Role of Hormonal Therapies for Depressed Perimenopausal Women

CATHERINE ROCA, MD
 Bethesda, MD

There will be 25 minutes for **Questions and Answers** at the end of each day.

APA 2001 ANNUAL MEETING

Registration:

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

Objectives:

Participants in the symposium will learn practical treatment approaches for managing premenstrual dysphoric disorder, postpartum depression and perimenopausal mood disturbance as well as information regarding the significant impact of untreated depression on female reproductive endocrine function.



SPONSORED BY THE AMERICAN PSYCHIATRIC ASSOCIATION

Supported by an unrestricted educational grant from Wyeth-Ayerst Pharmaceuticals.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates each of these educational activities for up to 1.5 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 43
Wednesday, May 9, and Thursday, May 10, 7:00 AM-8:30 AM
Grand Ballroom C/D, Street Level, Hilton

Gender, Age, and Special Populations

Wednesday and Thursday, May 9 and 10, 2001

6:30AM Breakfast
7:00AM-8:30AM Educational Program

Hilton New Orleans Riverside
Grand Ballroom C/D
Street Level
New Orleans, Louisiana

**American Psychiatric Association
2001 Annual Meeting**

Program Description

Part 1
Results from multiple national surveys highlighting epidemiological findings on sex differences for major depressive episodes consistently reveal higher lifetime prevalence rates for women relative to men. Further, hazard ratios for women peak during the childbearing years. Given these results, multiple appeals for greater attention to the specific psychiatric needs of women have been made. Nevertheless, research addressing clinical considerations of pregnancy, lactation, menopause, and rapid symptom resolution is surprisingly sparse (concomitant to depression).

Part One of this symposium will discuss issues regarding treatment of depression in women, such as risk of treatment with SSRIs during pregnancy, use of antidepressants during lactation, and treatment of premenstrual dysphoric disorder. Additionally, the program will explore issues of determining ethnicity, cross-cultural issues in the diagnosis and treatment of depression, and the selection of pharmacotherapy and psychotherapy in relation to a wide range of age and ethnic backgrounds.

Part 2
Although depression affects a wide range of the population, management of the complex clinical issues for the medically ill, depressed patient deserves particular attention. Compared to the general population, the prevalence of depression is higher in patients with stroke, diabetes, myocardial infarction, and cancer. Part Two of this symposium will review the effectiveness of various treatment strategies for improving depression in this population. Additionally, this symposium will focus on one of the most common challenges facing psychiatrists today – the treatment-resistant patient with depression. Both Parts of this symposium will close with comprehensive question and answer sessions.

Learning Objectives
At the conclusion of this symposium, participants will be able to:

1. Recognize the complexity in diagnostic presentations and treatment decisions regarding depression in children and adolescents, the elderly, women, those with comorbid medical disorder, and those with varied ethnic backgrounds.
2. Understand prevalence for depression in women and older patients and its consequences.
3. Discuss various forms of the treatment of depression in older patients and the specific problems that pose.
4. Discuss treatment of depression in women, such as risk of treatment with SSRIs during pregnancy, use of antidepressants during lactation, and treatment of premenstrual dysphoric disorder.

Accreditation and Credit Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates each day of this educational activity for up to 1.5 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Registration
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or at 202-682-6000.

Part 1: Wednesday, May 9, 2001

6:30AM Breakfast
7:00AM Welcome and Introduction
David L. Dunner, MD
Professor, Department of Psychiatry and Behavioral Sciences
Director, Center for Anxiety and Depression
University of Washington Medical Center
Seattle, Washington

7:05AM Mood Disorders in the Child and Adolescent
Graham J. Emslie, MD
Professor of Pediatrics
Charles E. and Sarah M. Taylor Chair in Child Psychiatry
Director, The Bob Smith, MD Center for Research in Pediatric Psychiatry
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

7:25AM Ethnic and Gender Issues in the Treatment of Depression
David L. Dunner, MD
Program Chairperson

7:45AM The Elderly Patient: A Delicate Balance
Alan P. Siegel, MD
Associate Chief of Professor of Psychiatry
Tulsa University School of Medicine
Behavioral and Adult Psychiatry, LLC
Hawthorn, Connecticut

8:05AM Question and Answer Session

Part 2: Thursday, May 10, 2001

6:30AM Breakfast
7:00AM Welcome and Introduction
David L. Dunner, MD
Professor, Department of Psychiatry and Behavioral Sciences
Director, Center for Anxiety and Depression
University of Washington Medical Center
Seattle, Washington

7:15AM Depression and the Treatment-Resistant Patient
Richard C. Shelton, MD
Professor of Psychiatry and Pharmacology
Chief, Adult Psychiatry Division
Vanderbilt School of Medicine
Nashville, Tennessee

7:40AM The Depressed Patient With Comorbid Medical Illness
Wayne Katon, MD
University of Washington Medical Center
Seattle, Washington

8:05AM Question and Answer Session

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Eli Lilly and Company



INDUSTRY-SUPPORTED SYMPOSIUM 44
Wednesday, May 9, 7:00 PM-10:00 PM
Hall G, Lobby Level, Convention Center

DINNER SYMPOSIUM

Neuroprotective effects of Mood Stabilizers

Wednesday, May 9, 2001

PLASTICITY AS EFFICACY?

7:00 pm – 7:10 pm
Introduction
Pierre N. Tariot, MD
Professor of Psychiatry, Medicine, and Neurology
University of Rochester School of Medicine, Monroe Community Hospital

7:10 pm – 7:50 pm
Neurotrophic and Neuroprotective Effects of Mood Stabilizers
Hussein K. Manji, MD
Chief, Laboratory of Molecular Pathophysiology, National Institute of Mental Health

7:50 pm – 8:20 pm
Clinical and Neuroimaging Evidence of Illness Progression in Bipolar Disorders
Terence A. Ketter, MD
Associate Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine

8:20 pm – 8:45 pm
Implications for the Treatment of Alzheimer's Disease
Pierre N. Tariot, MD

8:45 pm – 9:15 pm
PTSD, Substance Use Disorders and Personality Disorders: Commonalities in Mechanisms and Treatment
Hugh Myrick, MD
Assistant Professor of Psychiatry, Medical University of South Carolina

9:15 pm – 10:00 pm
Panel Discussion / Q & A

New Orleans Convention Center
Hall G – Lobby Level
6:30 pm – 7:00 pm Dinner
7:00 pm – 10:00 pm Scientific Program

 **Sponsored by the American Psychiatric Association and held at the APA 2001 Annual Meeting**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000. For more information about this symposium, please call 1-800-451-4068.

Program Objectives


- Understand new scientific techniques being applied to the study of major neuropsychiatric diagnoses and the effects of mood stabilizers on specific molecular and cellular targets.
- Review current uses of mood stabilizers in psychiatry, and reconceptualize the pathogenesis and treatment of several neuropsychiatric disorders, including manic-depressive illness and Alzheimer's disease.

Credit Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

 This activity is supported by an unrestricted educational grant from Abbott Laboratories.

INDUSTRY-SUPPORTED SYMPOSIUM 45
Wednesday, May 9, 7:00 PM-10:00 PM
La Nouvelle Ballroom, Level 2, Convention Center



Objectives:

At the conclusion of the program, participants will be able to:

- Enhance their diagnostic acumen by understanding the dynamic and fluctuating nature of the longitudinal structure of bipolar spectrum disorders
- Better understand the science supporting the bipolar spectrum concept and to apply this understanding in improving the diagnosis and management of bipolar spectrum disorders.

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or (202)682-6000.

Agenda:

6:30 pm	Refreshments
7:00 pm	Welcome and Introductions Lewis L. Judd, M.D. University of CA, San Diego SOM
7:10 pm	Longitudinal Studies of Bipolar Disorders: Is There a Spectrum? Lewis L. Judd, M.D.
7:35 pm	Bipolar Spectrum: Clinical and Familial Validation Hagop Akiskal, M.D. University of CA, San Diego SOM
8:00 pm	Molecular Genetic Evidence for the Bipolar Spectrum Julien Mendlewicz, M.D., Ph.D. Erasmus Hospital, Brussels, Belgium
8:25 pm	Treatment Advances in Bipolar Spectrum Disorders: Mood Stabilizers Susan McElroy, M.D. University of Cincinnati College of Medicine
8:50 pm	Treatment Advances in Bipolar Spectrum Disorders: Atypical Antipsychotics Guy Goodwin, M.D. University College Medical School, UK
9:15 pm	Question and Answer Session Giorgio Racagni, Ph.D. University of Milan, Italy
10:00 pm	Program Ends


Sponsored by the American Psychiatric Association.



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours of Category 1 credit towards the Physician's Recognition Award of the American Medical Association and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from International Academy for Biomedical and Drug Research (IABDR).

INDUSTRY-SUPPORTED SYMPOSIUM 46
Wednesday, May 9, 7:00 PM-10:00 PM
Grand Ballroom A/B, Street Level, Hilton



**Advances in ADHD:
Navigating Comorbidity**

Wednesday, May 9, 2001
Hilton New Orleans Riverside
Grand Ballroom A/B, Street Level
Dinner will be served from 6:30 PM – 7:00 PM
Program 7:00 PM – 10:00 PM

Chair
Timothy E. Wilens, MD
Massachusetts General Hospital

Co-Chair
Joseph Biederman, MD
Massachusetts General Hospital

PROGRAM

7:00 PM – 7:05 PM
Introduction

7:05 PM – 7:30 PM
Overview of Comorbid Conditions in ADHD
Presented by Joseph Biederman, MD

7:30 PM – 7:55 PM
Patterns of Comorbidity in ADHD: Artifact or Reality
Presented by Stephen Faraone, PhD
Massachusetts General Hospital

7:55 PM – 8:20 PM
Depressive Disorders and ADHD
Presented by Thomas Spencer, MD
Massachusetts General Hospital

8:20 PM – 8:45 PM
Bipolar Disorder and ADHD: An Overlooked Comorbidity
Presented by Janet Wozniak, MD
Massachusetts General Hospital


8:45 PM – 9:10 PM
ADHD and the Substance Use Disorders
Presented by Timothy E. Wilens, MD

9:10 PM – 10:00 PM
Program Discussion

EDUCATIONAL OBJECTIVES

At the end of the symposium, each participant should be able to:

- Understand scientific and clinical issues of symptom overlap when ADHD is comorbid.
- Apply current conceptualizations regarding ADHD and bipolar disorder and depression, towards informed diagnosis and treatment.
- Link diverse research findings in ADHD and substance abuse disorder as they pertain to clinical practice.

 Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 5 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This event will take place during the APA 2001 Annual Meeting.

Attendees must be registered for the APA 2001 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

Supported by an unrestricted educational grant from ALZA Pharmaceuticals.

INDUSTRY-SUPPORTED SYMPOSIUM 47
Wednesday, May 9, 7:00 PM-10:00 PM
Grand Ballroom C/D, Street Level, Hilton

APA 2001 ANNUAL MEETING

Excessive Daytime Sleepiness

Evaluation and Management in Psychiatry

6:30 to 7:00 Dinner Reception

7:00 Welcome/Introduction
John W. Winkelman, MD, PhD
 Chairman

7:15 Neural Substrates of Arousal and Sleep: New Vistas
Robert W. McCarley, MD
 Harvard Medical School
 VA Medical Center
 Brockton, Massachusetts

7:45 Evaluation and Measurement of Daytime Sleepiness
Mary A. Carskadon, PhD
 Brown University
 Providence, Rhode Island

8:15 Disorders of Excessive Daytime Somnolence: Diagnosis and Management
Karl Dogramji, MD
 Thomas Jefferson University
 Philadelphia, Pennsylvania

8:45 Excessive Daytime Sleepiness in the Psychiatric Patient
John W. Winkelman, MD, PhD
 Brigham and Women's Hospital
 Boston, Massachusetts

9:15 Question and Answer Session

Learning objectives: 1. Identify the differential diagnosis of excessive daytime sleepiness in psychiatric patients. 2. Recognize the appropriate means of testing such hypotheses. 3. Understand the principal treatments available for excessive daytime sleepiness.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. The APA designates this educational activity for up to 3 hours of category 1 credit towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.


Wednesday, May 9
7:00 PM to 10:00 PM
Hilton Riverside
Two Poydras Street
New Orleans
Grand Ballroom C/D
Street Level

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA Website at www.psych.org or contact the APA toll free at 1-888-357-7924 (in the U.S. and Canada) or 202-682-6000.

Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Cephalon, Inc.



INDUSTRY-SUPPORTED SYMPOSIUM 48
Wednesday, May 9, 7:00 PM-10:00 PM
Grand Ballroom A-C, Fifth Floor, Sheraton

An Evidence-Based Medicine Approach to Pediatric Psychiatry

Symposium to be held during the Year 2001 APA Annual Meeting

Wednesday, May 9, 2001

6:30 – 7:00 PM, Dinner
7:00 – 10:00 PM, Symposium

New Orleans Sheraton, Fifth Floor, Grand Ballroom A-C
Chair: Robert L. Findling, MD

Educational Objectives: On completion of this activity, participants should be able to: 1. Review results of recent, well-designed studies using atypical antipsychotic agents for pediatric psychiatric conditions, including conduct disorder, schizophrenia, and Tourette syndrome. 2. Explain the clinical implications of these data with regard to treatment planning.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3.0 hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or (202) 682-6000.



Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from



01-RS-798D

7:00 – 7:10 PM
Welcome and Introduction
Robert L. Findling, MD (Chair)

7:10 – 7:35 PM
Long-Term Efficacy in Conduct Disorder: Evidence from Maintenance Trials
Robert L. Findling, MD
 Department of Psychiatry
 University Hospitals of Cleveland, Cleveland, Ohio

7:35 – 8:00 PM
Effects of Risperidone on the Behavior of Children with Subaverage IQ and Conduct Disorder or Oppositional Defiant Disorder
Michael G. Aman, PhD
 Department of Psychiatry
 Ohio State University School of Medicine, Columbus, Ohio

8:00 – 8:25 PM
A Placebo-Controlled Trial of Risperidone in Tourette Syndrome: Preliminary Results
Lawrence D. Scahill, MD
 School of Nursing
 Yale University, New Haven, Connecticut

8:25 – 8:50 PM
Comparative Use of Olanzapine and Risperidone in Psychotic Youth
Linmarie Sikich, MD
 Department of Psychiatry
 University of North Carolina School of Medicine
 Chapel Hill, North Carolina

8:50 – 9:15 PM
Discussion
Judith L. Rapoport, MD
 Child Psychiatry Branch
 National Institute of Mental Health, Bethesda, Maryland

9:15 – 10:00 PM
Question & Answer Session






APA Resource Center

Integrating the Value, Convenience, and Advantages of APA Membership

Your Annual Meeting destination for...



In short, visits to the APA Resource Center will provide much to see, hear, and take home with you. And speaking of home, you can even stay in touch with happenings on the homefront by checking your e-mail at the E-Mail Village, located within the APA Resource Center.

So stop by the APA Resource Center in the Exhibit Hall during the APA Annual Meeting. See how the APA works to advocate for patients, educate the public, and promote the profession, and how the APA can work for you.

APA Resource Center Exhibit Halls D, E, and F Lobby Level, Convention Center

Hours of Operation

Saturday, May 5: 10:00 a.m. – 5:00 p.m.
 Sunday, May 6: 8:00 a.m. – 4:30 p.m.*
 Monday, May 7: 10:00 a.m. – 6:00 p.m.
 Tuesday, May 8: 10:00 a.m. – 6:00 p.m.
 Wednesday, May 9: 10:00 a.m. – 3:00 p.m.

*Early closing for Opening Session.